

EXHIBIT 2

Page 1

IN THE UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

MDL NO. 16-2738 (MAS)(RLS)

IN RE: JOHNSON & JOHNSON :
TALCUM POWDER PRODUCTS :
MARKETING, SALES PRACTICES :
AND PRODUCTS LIABILITY :
LITIGATION :

Remote deposition of JACK
SIEMIATYCKI, MSC, Ph.D., taken in the
above-entitled matter before Suzanne J. Stotz,
a Certified Court Reporter (License No.
30XI00184500) and Notary Public of the State of
New Jersey, taken on Wednesday, March 27, 2024,
commencing at 11:14 a.m. EDT.

Page 2

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

APPEARANCES:

ATTORNEYS FOR PLAINTIFF:

(Via videoconference)

ASHCRAFT & GEREL, LLP

BY: MICHELLE A. PARFITT, ESQ., and

BY: PATRICK K. LYONS, ESQ.

4900 Seminary Road, Suite 650

Alexandria, Virginia 22311

(844) 680-0339

mparfitt@ashcraftlaw.com

plyons@ashcraftlaw.com

- and -

(Via videoconference)

LEVIN PAPANTONIO RAFFERTY, P.A.

BY: CHRISTOPHER V. TISI, ESQ.

316 South Baylen Street

Pensacola, Florida 32502

(850) 435-7000

ctisi@levinlaw.com

- and -

(Via videoconference)

GOLOMB LEGAL

BY: RICHARD GOLOMB, ESQ.

1835 Market Street, Suite 2900

Philadelphia, Pennsylvania 19103

(215) 278-4449

rgolomb@golomblegal.com

ATTORNEYS FOR THE DEFENDANT:

(Via videoconference)

SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

BY: JESSICA DAVIDSON, ESQ., and

BY: NOAH EPSTEIN, ESQ.

One Manhattan West

New York, New York 10001

(212) 735-3000

jessica.davidson@skadden.com

noah.epstein@skadden.com

Page 4

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

INDEX (Continued)

EXHIBITS (Continued)

Exhibit

Name

Description

Page No.

Defendant's

Paper entitled,

91

Exhibit D4

"Occupational environment and ovarian cancer risk," by Lisa Leung, et al.

Defendant's

Paper entitled,

95

Exhibit D5

"Genital powder use and risk of epithelial ovarian cancer in the Ovarian Cancer in Women of African Ancestry Consortium," by Colette P. Davis, et al.

Defendant's

Second Amended Expert

106

Exhibit D6

Report of Jack Siemiatycki, MSc, PhD

Defendant's

Paper entitled,

108

Exhibit D7

"Effects of risk factors for ovarian cancer in women with and without endometriosis," by Minh Tung Phung, MPH, PhD, et al.

Defendant's

Paper entitled,

123

Exhibit D8

"Douching, Talc Use, and Risk for Ovarian Cancer and Conditions Related to Genital Tract Inflammation," by Iwona M. Gabriel, et al.

Page 3

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

INDEX

EXAMINATION

Page No.

JACK SIEMIATYCKI, MSC, Ph.D.

BY MS. DAVIDSON

10

BY MS. PARFITT

208

BY MS. DAVIDSON

227

BY MS. PARFITT

241

EXHIBITS

Exhibit

Description

Page No.

Defendant's

Article entitled,

70

Exhibit D1

"Association Between the Frequent Use of Perineal Talcum Powder Products and Ovarian Cancer: A Systematic Review and Meta-analysis," by Sean A. Woolen, MD, MSc, et al.

Defendant's

Declaration of Interest for IARC/WHO Experts

82

Defendant's

Letter from Jack Siemiatycki to IARC re Talc/Acrylonitrile Monograph 136

85

Page 5

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

INDEX (Continued)

EXHIBITS (Continued)

Exhibit

Name

Description

Page No.

Defendant's

Paper entitled, "A critical review of talc and ovarian cancer," by Julie Goodman, et al.

128

Exhibit D9

Defendant's

Paper entitled, "Talc powder and ovarian cancer: What is the evidence?" By John P. Micha, et al.

142

Exhibit D10

Defendant's

Paper entitled,

162

Exhibit D11

"Douching and Genital Talc Use: Patterns of Use and Reliability of Self-reported Exposure," by Katie M. O'Brien, et al.

Defendant's

Paper entitled, "Use of personal care product mixtures and incident hormone-sensitive cancers in the Sister Study: A U.S.-wide prospective cohort," by Che-Jung Chang, et al.

168

Exhibit D12

Defendant's

Supplemental Table S4

173

Exhibit D13

<div>Page 6</div> <div>1 I N D E X (Continued)</div> <div>2</div> <div>3 E X H I B I T S (Continued)</div> <div>4 Exhibit</div> <div>5</div> <div>6</div> <div>7</div> <div>8</div> <div>9</div> <div>10</div> <div>11</div> <div>12</div> <div>13</div> <div>14</div> <div>15</div> <div>16</div> <div>17</div> <div>18</div> <div>19</div> <div>20</div> <div>21</div> <div>22</div> <div>23</div> <div>24</div> <div>25</div>	<div>Page 8</div> <div>1 MS. PARFITT: Most people don't</div> <div>2 want to see it. So there you go. Thank</div> <div>3 you, Jessica.</div> <div>4 MS. DAVIDSON: So you all are in</div> <div>5 the same room in Canada?</div> <div>6 MS. PARFITT: Yeah. We're all in a</div> <div>7 conference room.</div> <div>8 MS. DAVIDSON: In Canada?</div> <div>9 MS. PARFITT: In Canada, yes.</div> <div>10 MS. DAVIDSON: Okay. I'm just</div> <div>11 getting my bearings.</div> <div>12 MS. PARFITT: No, no. And where</div> <div>13 are you?</div> <div>14 You're on the west coast.</div> <div>15 MS. DAVIDSON: I'm on the west</div> <div>16 coast, correct. That's why we're starting</div> <div>17 late.</div> <div>18 MS. PARFITT: Okay.</div> <div>19 THE COURT REPORTER: Would you</div> <div>20 raise your hand, Doctor.</div> <div>21 THE WITNESS: (Complies with</div> <div>22 request.)</div> <div>23 J A C K S I E M I A T Y C K I, MSc, Ph.D.,</div> <div>24 having first been duly sworn, was examined and</div> <div>25 testified as follows:</div>
<div>Page 7</div> <div>1 MS. PARFITT: Michelle Parfitt and</div> <div>2 Chris Tisi are here on behalf of the</div> <div>3 plaintiff steering committee along with</div> <div>4 Patrick Lyons from my office.</div> <div>5 Richard, would you like to</div> <div>6 introduce yourself.</div> <div>7 MR. GOLOMB: Yes. Richard Golomb</div> <div>8 for the state court plaintiffs.</div> <div>9 MS. DAVIDSON: Hi, Richard.</div> <div>10 Michelle and Chris and Patrick, are</div> <div>11 you all in the same room as</div> <div>12 Dr. Siemiatycki?</div> <div>13 MS. PARFITT: We are not. Chris</div> <div>14 and I are here with Dr. Siemiatycki.</div> <div>15 Patrick is in his own office.</div> <div>16 MS. DAVIDSON: Got it. And are you</div> <div>17 going to go on the camera?</div> <div>18 MS. PARFITT: Yes, I'm happy to.</div> <div>19 Sure.</div> <div>20 MS. DAVIDSON: Usually we're all on</div> <div>21 the camera.</div> <div>22 MS. PARFITT: No problem. No</div> <div>23 problem.</div> <div>24 MS. DAVIDSON: I want to see your</div> <div>25 pretty face.</div>	<div>Page 9</div> <div>1 THE COURT REPORTER: Thank you.</div> <div>2 You may proceed.</div> <div>3 MS. PARFITT: Jessica, with your</div> <div>4 permission -- Ms. Davidson, with your</div> <div>5 permission, we would just like to make a</div> <div>6 correction to Dr. Siemiatycki's</div> <div>7 November 15th, 2023, report.</div> <div>8 It is page 40, Section 8.1.2</div> <div>9 entitled, "Results of my meta-analyses on</div> <div>10 Ever/Never exposed to talc powder for all</div> <div>11 ovarian cancer types combined."</div> <div>12 And about five lines up from the</div> <div>13 bottom on that page 40, there is a</div> <div>14 reference in the sentence that states, "As</div> <div>15 implied in Table 2, all of the RRs in</div> <div>16 Figure 1 are to be left of the null value</div> <div>17 of 1.0." Dr. Siemiatycki meant to put</div> <div>18 right.</div> <div>19 It's interesting, Jessica, if you</div> <div>20 go back to his 2021 deposition, it was</div> <div>21 corrected, and then somehow -- and a page</div> <div>22 substituted, but somehow the error found</div> <div>23 its way back into the 2023 report. So</div> <div>24 that is the correction we wish to make.</div> <div>25 MS. DAVIDSON: I still have to go</div>

<p style="text-align: right;">Page 10</p> <p>1 like this to remember what's the left and</p> <p>2 what's the right.</p> <p>3 MS. PARFITT: Okay. All right.</p> <p>4 Fair enough. Thank you. I appreciate</p> <p>5 that everyone.</p> <p>6 MS. DAVIDSON: Okay. Are you ready</p> <p>7 to get started?</p> <p>8 MS. PARFITT: Please. Thank you.</p> <p>9 EXAMINATION</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. Good morning, Dr. Siemiatycki.</p> <p>12 A. Good morning, Ms. Davidson.</p> <p>13 Q. Did I pronounce your name more Or</p> <p>14 less correctly?</p> <p>15 A. You did a very good job.</p> <p>16 Q. Okay. Great.</p> <p>17 Did you bring any materials with</p> <p>18 you to the deposition today?</p> <p>19 A. Oh, I brought some binders of all</p> <p>20 of the material that was in my bibliography and</p> <p>21 my written report. And a few scattered</p> <p>22 articles that hadn't been in the binders but</p> <p>23 that I wanted to have around, and I -- I have a</p> <p>24 few -- there are a few articles that I printed</p> <p>25 that I think are in the binders as well; so</p>	<p style="text-align: right;">Page 12</p> <p>1 BY MS. DAVIDSON:</p> <p>2 Q. Dr. Siemiatycki --</p> <p>3 MS. PARFITT: Yes.</p> <p>4 MS. DAVIDSON: Okay.</p> <p>5 BY MS. DAVIDSON:</p> <p>6 Q. Dr. Siemiatycki, do you have notes</p> <p>7 on any of these documents?</p> <p>8 A. I have scribbles on some -- some of</p> <p>9 the articles and some of the documents.</p> <p>10 Q. Okay.</p> <p>11 A. I don't have standalone handwritten</p> <p>12 documents of any sort or commentaries.</p> <p>13 MS. DAVIDSON: Michelle, we'd like</p> <p>14 to have those scribbles produced. I think</p> <p>15 we're still waiting also for the</p> <p>16 Clarke-Pearson ones that we had asked for</p> <p>17 at the end of his deposition.</p> <p>18 So if you could get those both to</p> <p>19 us together, that would be great.</p> <p>20 MS. PARFITT: I will make a note --</p> <p>21 I will make a note of that, Jessica,</p> <p>22 absolutely. What we'll do after the</p> <p>23 deposition is, if you don't mind when I</p> <p>24 get back, take them with me and we'll have</p> <p>25 copies made in DC and send them off to</p>
<p style="text-align: right;">Page 11</p> <p>1 they are duplicate copies.</p> <p>2 Otherwise, I have a copy -- copies</p> <p>3 of my report, including a version that</p> <p>4 compares -- sort of a compared documents with</p> <p>5 the previous version of my report.</p> <p>6 Q. I'm sorry. I'm not sure I</p> <p>7 understand what you're saying.</p> <p>8 MS. PARFITT: Jessica, may I help</p> <p>9 on that?</p> <p>10 MS. DAVIDSON: That would be great.</p> <p>11 MS. PARFITT: Okay. What he has is</p> <p>12 another report, which would be the date</p> <p>13 November 15, '23; but what it does, it</p> <p>14 highlights -- blue or red, I'm not sure</p> <p>15 what color. It highlights the changes</p> <p>16 from his earlier report of June 30th, '21.</p> <p>17 So what it does it --</p> <p>18 MS. DAVIDSON: It's a redline that</p> <p>19 you prepared for him?</p> <p>20 MS. PARFITT: Yes, yes.</p> <p>21 MS. DAVIDSON: But it's a</p> <p>22 computer-generated redline not like a</p> <p>23 handwritten --</p> <p>24 MS. PARFITT: Oh, no, no, no.</p> <p>25</p>	<p style="text-align: right;">Page 13</p> <p>1 you.</p> <p>2 MS. DAVIDSON: Great.</p> <p>3 BY MS. DAVIDSON:</p> <p>4 Q. Dr. Siemiatycki, did you review</p> <p>5 your prior two depositions to prepare for</p> <p>6 today?</p> <p>7 A. Yes.</p> <p>8 Q. Is there anything you would change</p> <p>9 in those two prior depositions?</p> <p>10 MS. PARFITT: Objection to form.</p> <p>11 THE WITNESS: No, not that I</p> <p>12 recall.</p> <p>13 BY MS. DAVIDSON:</p> <p>14 Q. Okay. And you met with Ms. Parfitt</p> <p>15 and Mr. Tisi to prepare?</p> <p>16 A. I'm sorry?</p> <p>17 Q. You met with Ms. Parfitt and</p> <p>18 Mr. Tisi to prepare for this deposition?</p> <p>19 A. We met yesterday.</p> <p>20 Q. Was that the only time you met to</p> <p>21 prepare for this deposition?</p> <p>22 A. We -- we had a couple of Zoom</p> <p>23 discussions in the last few weeks, I think</p> <p>24 maybe a cumulative two hours maybe or something</p> <p>25 like that of discussion mainly about the</p>

<p style="text-align: right;">Page 14</p> <p>1 process, but yeah.</p> <p>2 Q. You're not supposed to tell me what</p> <p>3 you talked about.</p> <p>4 So you had two meetings on Zoom and</p> <p>5 one live yesterday?</p> <p>6 A. That's my recollection at the</p> <p>7 moment, yeah.</p> <p>8 Q. And did they show you any documents</p> <p>9 that were not on your materials considered</p> <p>10 list?</p> <p>11 A. There was one --</p> <p>12 MS. PARFITT: Dr. Siemiatycki,</p> <p>13 you're not to identify what it is. The</p> <p>14 question is whether or not you were shown</p> <p>15 any documents not on your materials</p> <p>16 considered list.</p> <p>17 THE WITNESS: Yes, yes.</p> <p>18 BY MS. DAVIDSON:</p> <p>19 Q. Okay. Do you have any documents</p> <p>20 with you today that are not on your material</p> <p>21 considered list?</p> <p>22 A. Yes.</p> <p>23 Q. What is that?</p> <p>24 A. Am I supposed to answer that</p> <p>25 question?</p>	<p style="text-align: right;">Page 16</p> <p>1 documents he reviewed, and we didn't get</p> <p>2 an updated reliance list.</p> <p>3 So if there are new documents that</p> <p>4 he's reviewed since he's submitted his</p> <p>5 report, that's all I'm asking. I'm</p> <p>6 entitled to know what they are.</p> <p>7 Dr. Siemiatycki says he has</p> <p>8 documents in front of him that aren't on</p> <p>9 his reliance list. We have to know what</p> <p>10 those are to proceed.</p> <p>11 MS. PARFITT: What he have in front</p> <p>12 of him are not the reliance materials. He</p> <p>13 has and you were provided, I believe three</p> <p>14 days ago, a Dropbox. Patrick Lyons made</p> <p>15 sure that was secured and sent to all of</p> <p>16 you, which is a Dropbox of any materials</p> <p>17 he may have considered or not, meaning</p> <p>18 considered and read them, considered and</p> <p>19 read part of them.</p> <p>20 That was made available in advance</p> <p>21 of this deposition. So what you should</p> <p>22 have is a Dropbox; and Jessica, that</p> <p>23 should have been forwarded to you.</p> <p>24 MS. DAVIDSON: All right. Let's go</p> <p>25 off the record for a minute, and let me</p>
<p style="text-align: right;">Page 15</p> <p>1 Q. Yes.</p> <p>2 MS. PARFITT: Jessica, what we can</p> <p>3 do -- again, there's -- there's</p> <p>4 duplicative -- I guess it's a little bit</p> <p>5 more complex. Some of the ones on his</p> <p>6 materials considered are documents that he</p> <p>7 would pull out for you right now.</p> <p>8 I think it's probably going to be</p> <p>9 very difficult for him to discern sitting</p> <p>10 here today. You can -- we can make them</p> <p>11 all available to you. There's nothing new</p> <p>12 that you haven't seen.</p> <p>13 If there is during the course of</p> <p>14 this, we can talk about it, but I'm not</p> <p>15 sure he's going to be able to discern</p> <p>16 what's in the materials considered list,</p> <p>17 part of his bibliography produced prior to</p> <p>18 in a Dropbox his '21 deposition, and those</p> <p>19 that Patrick Lyons sent to all of you in a</p> <p>20 Dropbox of materials that he's continued</p> <p>21 to review but not necessarily are reliance</p> <p>22 materials because, obviously, those</p> <p>23 opinions are contained in the '23 report.</p> <p>24 MS. DAVIDSON: I think we're</p> <p>25 entitled before we depose him to know what</p>	<p style="text-align: right;">Page 17</p> <p>1 figure this out; and I'll be back in two</p> <p>2 minutes.</p> <p>3 (Discussion held off the record.)</p> <p>4 MS. DAVIDSON: Let's go back on the</p> <p>5 record.</p> <p>6 THE WITNESS: So one is the</p> <p>7 National Cancer Institute PDQ on</p> <p>8 ovarian/fallopian tumors.</p> <p>9 BY MS. DAVIDSON:</p> <p>10 Q. Okay. Uh-huh.</p> <p>11 A. I think that -- that was not on my</p> <p>12 list, but I'm not sure if it's in the Dropbox.</p> <p>13 And another is a report from EPA, I</p> <p>14 think, a news release from EPA called</p> <p>15 "Biden-Harris Administration Finalizes Ban on</p> <p>16 Ongoing Uses of Asbestos."</p> <p>17 MS. PARFITT: Yes, that one.</p> <p>18 THE WITNESS: This one? Yes.</p> <p>19 The report by Longo from 2023</p> <p>20 called, "Third MDL Supplemental Report."</p> <p>21 That's enough.</p> <p>22 Some of it's -- it's in the list.</p> <p>23 An article called -- by Kim, K-I-M,</p> <p>24 is the first author, Chang, Kwon, and</p> <p>25 Myong, called, "Asbestos Exposure and</p>

<p style="text-align: right;">Page 18</p> <p>1 Ovarian Cancer, a Meta-Analysis,"</p> <p>2 published in '23, 2023.</p> <p>3 MS. PARFITT: You have to read this</p> <p>4 into the record.</p> <p>5 THE WITNESS: Oh, okay. Sorry.</p> <p>6 I'm not sure which ones.</p> <p>7 Davis article is -- did you see the</p> <p>8 editorials in this pile?</p> <p>9 MS. PARFITT: He has also the</p> <p>10 Harlow, Cramer editorials to the O'Brien,</p> <p>11 which again should have been --</p> <p>12 THE COURT REPORTER: I'm sorry.</p> <p>13 Could you say that again?</p> <p>14 He also has...</p> <p>15 MS. DAVIDSON: The Gossett, the</p> <p>16 Gossett editorial.</p> <p>17 MS. PARFITT: That's on his list.</p> <p>18 MS. DAVIDSON: Okay.</p> <p>19 MS. PARFITT: But in addition to</p> <p>20 that, he has the -- the Harlow, Cramer</p> <p>21 editorials, letters to the editorial by</p> <p>22 O'Brien as well. I don't know whether</p> <p>23 they were in the '21 box or the '23 box,</p> <p>24 but he has those in front of him as well.</p> <p>25 MS. DAVIDSON: Okay.</p>	<p style="text-align: right;">Page 20</p> <p>1 the talc MDL litigation.</p> <p>2 Does that sound about right to you?</p> <p>3 A. I get -- if you got that</p> <p>4 information from Ms. Parfitt, then the</p> <p>5 information's correct.</p> <p>6 Q. I assume you have some general</p> <p>7 sense of what you've been paid in your mind.</p> <p>8 Is it around \$241,000?</p> <p>9 A. Yeah. I mean, we're going back a</p> <p>10 few -- about three or four years or something</p> <p>11 like that. Yes, I -- I think that is sounds</p> <p>12 about right.</p> <p>13 Q. Okay. And you also got paid for</p> <p>14 state court litigation.</p> <p>15 Do you know how much in total --</p> <p>16 you also were paid for your role in some state</p> <p>17 court talc cases.</p> <p>18 Do you know how much you have made</p> <p>19 in total from talc litigation?</p> <p>20 A. I'm not sure what that refers to,</p> <p>21 the "state court."</p> <p>22 MS. PARFITT: May -- may I help,</p> <p>23 again, Jessica, to move it along?</p> <p>24 MS. DAVIDSON: Sure.</p> <p>25 MS. PARFITT: You testified in</p>
<p style="text-align: right;">Page 19</p> <p>1 THE WITNESS: The Savant article.</p> <p>2 MS. PARFITT: The Savant article on</p> <p>3 inflammation, he has that in front of him.</p> <p>4 MS. DAVIDSON: And it's your belief</p> <p>5 that these were not in the Dropbox?</p> <p>6 MS. PARFITT: We'll check.</p> <p>7</p> <p>8 MS. DAVIDSON: We'll compare this</p> <p>9 to our list.</p> <p>10 MS. PARFITT: Yeah. We can do</p> <p>11 that. And, Jessica, if there's a question</p> <p>12 about anything, let us know. But you -- I</p> <p>13 just want to keep moving forward.</p> <p>14 MS. DAVIDSON: Is that all of them?</p> <p>15 MS. PARFITT: Yeah. Is there</p> <p>16 anything else, Doctor?</p> <p>17 THE WITNESS: That's all that I can</p> <p>18 identify quickly. I think that's all of</p> <p>19 them; otherwise, they're a binder with</p> <p>20 materials that --</p> <p>21 BY MS. DAVIDSON:</p> <p>22 Q. Have been previously disclosed?</p> <p>23 A. Yeah.</p> <p>24 Q. Dr. Siemiatycki, according to my</p> <p>25 math, you have he been paid \$241,000 to date in</p>	<p style="text-align: right;">Page 21</p> <p>1 Echeverria, a state court case, and she's</p> <p>2 asking --</p> <p>3 MS. DAVIDSON: And Oules.</p> <p>4 MS. PARFITT: -- and Oules. Thank</p> <p>5 you.</p> <p>6 And she's asking whether or not you</p> <p>7 have any recollection. If you do -- your</p> <p>8 invoices were submitted in the past.</p> <p>9 She's asking --</p> <p>10 THE WITNESS: Sorry. I -- I don't</p> <p>11 recall -- I don't recall at this time.</p> <p>12 BY MS. DAVIDSON:</p> <p>13 Q. So you have no sense of</p> <p>14 approximately how much money you have earned to</p> <p>15 date in talc litigation in total?</p> <p>16 A. I -- I don't have a point estimate,</p> <p>17 but I guess I could give a minimum/maximum kind</p> <p>18 of range.</p> <p>19 Q. What's that?</p> <p>20 A. I would say between 200,000 and</p> <p>21 400,000.</p> <p>22 Q. Well, we know you already got 241</p> <p>23 from federal court, and there's two other</p> <p>24 cases.</p> <p>25 A. Okay.</p>

<p style="text-align: right;">Page 22</p> <p>1 Q. So it would be a lot more than 200.</p> <p>2 A. I am estimating that the extra bit</p> <p>3 that you were talking about.</p> <p>4 Q. Oh. So you're saying that in</p> <p>5 total, it was somewhere between 400 and --</p> <p>6 MS. PARFITT: No. That's not --</p> <p>7 BY MS. DAVIDSON:</p> <p>8 Q. -- and 600?</p> <p>9 MS. PARFITT: No.</p> <p>10 MS. DAVIDSON: No. That is what he</p> <p>11 said. Michelle, don't interrupt.</p> <p>12 BY MS. DAVIDSON:</p> <p>13 Q. Dr. Siemiatycki, I think you were</p> <p>14 saying that was the additional.</p> <p>15 So are you estimating that in</p> <p>16 addition to 241,000, you received another</p> <p>17 200,000?</p> <p>18 A. I mean, I wouldn't contest that,</p> <p>19 but I -- I can't confirm it either.</p> <p>20 Q. Okay. Do you have an estimate of</p> <p>21 how much you have earned in total from talc</p> <p>22 litigation?</p> <p>23 A. No.</p> <p>24 Q. So whether it was 300, 400, 500,</p> <p>25 you don't know?</p>	<p style="text-align: right;">Page 24</p> <p>1 currently have full-time employment?</p> <p>2 A. I'm retired from university.</p> <p>3 Q. When did you retire?</p> <p>4 A. 2021.</p> <p>5 Q. And other than your -- do you have</p> <p>6 a pension?</p> <p>7 A. Yes, I do.</p> <p>8 Q. Other than your pension and your</p> <p>9 talc earnings, do you have any other earnings?</p> <p>10 MS. PARFITT: Objection. Form.</p> <p>11 You're not entitled to all his other</p> <p>12 sources of revenue, Jessica.</p> <p>13 MS. DAVIDSON: Well, we're trying</p> <p>14 to understand what percentage of his</p> <p>15 income is.</p> <p>16 MS. PARFITT: He has indicated he</p> <p>17 can't provide that.</p> <p>18 MS. DAVIDSON: I understand.</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. But, Dr. Siemiatycki, do you have</p> <p>21 any other source of income other than your</p> <p>22 pension and the talc earnings?</p> <p>23 MS. PARFITT: Objection. You're</p> <p>24 not entitled to other forms of his income.</p> <p>25 MS. DAVIDSON: I'm not asking for</p>
<p style="text-align: right;">Page 23</p> <p>1 A. Right now, no. I mean, I -- I</p> <p>2 would have to look it up.</p> <p>3 Q. What percentage of your income has</p> <p>4 talc litigation been over the last several</p> <p>5 years?</p> <p>6 A. I have to do some arithmetic and</p> <p>7 estimate what my total revenue income has been.</p> <p>8 So we're going back to 2015, so near eight or</p> <p>9 nine years; is that right? 2016, I think.</p> <p>10 So I'd have to figure out what is</p> <p>11 my total income and then what the talc part of</p> <p>12 it would be. It -- it would take me more than</p> <p>13 a couple of minutes to do that.</p> <p>14 Q. So you can't tell me, sitting here</p> <p>15 today, what percentage of your income this 400</p> <p>16 or so thousand dollars would have been?</p> <p>17 MS. PARFITT: Objection. Asked and</p> <p>18 answered.</p> <p>19 THE WITNESS: No, I can't. Not --</p> <p>20 not sitting here this moment. I could if</p> <p>21 I took time. I could take 15 or</p> <p>22 20 minutes, go off the record maybe, or</p> <p>23 whatever what you like.</p> <p>24 BY MS. DAVIDSON:</p> <p>25 Q. Are you currently -- are you</p>	<p style="text-align: right;">Page 25</p> <p>1 the amounts.</p> <p>2 BY MS. DAVIDSON:</p> <p>3 Q. You can answer the question.</p> <p>4 MS. PARFITT: You just asked for</p> <p>5 it. I object to him divulging other forms</p> <p>6 of income. You're not entitled to that.</p> <p>7 It's irrelevant.</p> <p>8 THE WITNESS: If I'm not obliged to</p> <p>9 divulge all of my sources of income, then</p> <p>10 I'd prefer not to.</p> <p>11 BY MS. DAVIDSON:</p> <p>12 Q. Dr. Siemiatycki, is your pension</p> <p>13 and your talc earnings the bulk of your income</p> <p>14 for the last several years?</p> <p>15 MS. PARFITT: Objection. Form.</p> <p>16 THE WITNESS: I guess it's part of</p> <p>17 the same answer.</p> <p>18 BY MS. DAVIDSON:</p> <p>19 Q. You are -- that is a legitimate</p> <p>20 question, Doctor. You can't choose what to</p> <p>21 answer and what not to answer today, with all</p> <p>22 due respect.</p> <p>23 Is your pension and your talc</p> <p>24 earnings the majority of your income over the</p> <p>25 last several of years?</p>

<p style="text-align: right;">Page 26</p> <p>1 A. By "majority, "you mean 50 percent</p> <p>2 or what?</p> <p>3 Q. Well, let's start with 50 percent.</p> <p>4 Is your pension and your talc</p> <p>5 earnings more than 50 percent of your earnings</p> <p>6 in the last several years?</p> <p>7 MS. PARFITT: Objection.</p> <p>8 THE WITNESS: Yes.</p> <p>9 BY MS. DAVIDSON:</p> <p>10 Q. Is it more than 75?</p> <p>11 MS. PARFITT: Objection.</p> <p>12 THE WITNESS: I -- yes.</p> <p>13 BY MS. DAVIDSON:</p> <p>14 Q. And despite the fact that your talc</p> <p>15 earnings are such a substantial portion of your</p> <p>16 income, you can't remember sitting here today</p> <p>17 how much you've earned from the talc</p> <p>18 litigation?</p> <p>19 MS. PARFITT: Objection. Asked and</p> <p>20 answered.</p> <p>21 Let's move on, Jessica. I think</p> <p>22 you've got your answers.</p> <p>23 THE WITNESS: No.</p> <p>24 BY MS. DAVIDSON:</p> <p>25 Q. Are you retained in any other</p>	<p style="text-align: right;">Page 28</p> <p>1 MS. PARFITT: Objection. The</p> <p>2 question -- you're entitled to ask whether</p> <p>3 he's been retained as an expert in a case,</p> <p>4 and he's answered.</p> <p>5 BY MS. DAVIDSON:</p> <p>6 Q. Have you served in some other role</p> <p>7 in litigation other than being an expert?</p> <p>8 MS. PARFITT: Objection.</p> <p>9 THE WITNESS: I'm not sure if I</p> <p>10 should answer.</p> <p>11 BY MS. DAVIDSON:</p> <p>12 Q. Yes, you should answer it. The</p> <p>13 objection's are for the record.</p> <p>14 MS. PARFITT: The objection is:</p> <p>15 You are entitled to get information about</p> <p>16 where he has been retained as an expert.</p> <p>17 That's it.</p> <p>18 If someone's talked to him, if</p> <p>19 someone's consulted with him, you're not</p> <p>20 entitled to that.</p> <p>21 BY MS. DAVIDSON:</p> <p>22 Q. Okay. I'm not asking for</p> <p>23 consulting.</p> <p>24 I'm asking if you have been</p> <p>25 retained in litigation in some other capacity</p>
<p style="text-align: right;">Page 27</p> <p>1 litigation at the time -- at the current time?</p> <p>2 MS. PARFITT: As an expert?</p> <p>3 THE WITNESS: As an expert, you</p> <p>4 mean? No.</p> <p>5 BY MS. DAVIDSON:</p> <p>6 Q. Have you been retained as an expert</p> <p>7 in any other litigation since 2021?</p> <p>8 A. There was a Canadian case, but I</p> <p>9 think that was before 2021. I think that was</p> <p>10 mentioned in my report, and I don't remember</p> <p>11 what the date was.</p> <p>12 Q. What did that case involve?</p> <p>13 A. It's a similar case. It's a</p> <p>14 litigation on behalf of women with ovarian</p> <p>15 cancer in Canada.</p> <p>16 Q. Right. I'm asking have you been</p> <p>17 retained in any litigation other than talc in</p> <p>18 the last several years?</p> <p>19 A. Oh, other than talc. Not -- I --</p> <p>20 I've --</p> <p>21 MS. PARFITT: As an expert.</p> <p>22 THE WITNESS: As an expert, no.</p> <p>23 BY MS. DAVIDSON:</p> <p>24 Q. Have you been retained in another</p> <p>25 capacity in litigation?</p>	<p style="text-align: right;">Page 29</p> <p>1 other than as an expert.</p> <p>2 A. Only as consultant or --</p> <p>3 Q. Okay.</p> <p>4 A. -- exploring possibility of</p> <p>5 participation in cases.</p> <p>6 Q. But none of that ended up in your</p> <p>7 being disclosed as an expert?</p> <p>8 A. No, not since 2021, I don't think.</p> <p>9 Q. Okay. And do you still do any work</p> <p>10 at McGill or University of Montreal?</p> <p>11 A. I do some work. I still have</p> <p>12 students in the -- sort of going through to the</p> <p>13 Ph.D. I still do research and publish and</p> <p>14 acknowledge my university affiliations when I</p> <p>15 do that, but I don't -- I don't have a presence</p> <p>16 on campus.</p> <p>17 Q. Now, were you an adjunct, or --</p> <p>18 were you an adjunct professor at McGill and</p> <p>19 University of Montreal?</p> <p>20 A. I was a full professor at</p> <p>21 University of Montreal --</p> <p>22 Q. Oh, okay.</p> <p>23 A. -- and a adjunct professor at</p> <p>24 McGill University.</p> <p>25 Q. Got it. So your -- your pension</p>

<p style="text-align: right;">Page 30</p> <p>1 comes from University of Montreal, not McGill?</p> <p>2 A. Yes.</p> <p>3 Q. Got it. Okay.</p> <p>4 Have you authored any publications</p> <p>5 concerning talc and ovarian cancer since</p> <p>6 September 2021?</p> <p>7 A. No.</p> <p>8 Q. Are you a coauthor on a paper</p> <p>9 called Leung?</p> <p>10 A. Called what?</p> <p>11 Q. L-E-U-N-G?</p> <p>12 A. Oh, yeah. Lisa Leung, yeah.</p> <p>13 Q. Was that published in September</p> <p>14 2021?</p> <p>15 A. I'd have to look that up.</p> <p>16 Q. That's okay. If you don't know,</p> <p>17 that's fine?</p> <p>18 A. Yeah. If you have it on my CV as</p> <p>19 September '21, then that's correct.</p> <p>20 Q. Did you disclose in that paper that</p> <p>21 you are plaintiff's expert in the talc</p> <p>22 litigation?</p> <p>23 A. I don't recall --</p> <p>24 MS. PARFITT: Let's get the paper</p> <p>25 in front of him.</p>	<p style="text-align: right;">Page 32</p> <p>1 A. I don't recall.</p> <p>2 Q. Did you have a policy of disclosing</p> <p>3 in any papers related to talc that you are an</p> <p>4 expert for plaintiffs in this litigation?</p> <p>5 A. I am not sure what you mean by</p> <p>6 "have a policy." I don't have any sort of</p> <p>7 strictly written, notarized policy, but I do</p> <p>8 disclose and I would disclose in any</p> <p>9 publications that concern talc and</p> <p>10 carcinogenicity that I am -- I have been an</p> <p>11 expert in litigation.</p> <p>12 Q. Do you know, sitting here today,</p> <p>13 why the Leung paper does not include such a</p> <p>14 disclosure?</p> <p>15 A. I'd have to look at the article,</p> <p>16 see what it was about, and see what the --</p> <p>17 whether it was relevant to disclose that.</p> <p>18 Q. Have you published your views --</p> <p>19 other than the Leung paper, have you written</p> <p>20 anything about talc or asbestos since September</p> <p>21 2021?</p> <p>22 A. I don't recall now. I'd have to</p> <p>23 look at my CV.</p> <p>24 Q. Have you made any public statements</p> <p>25 concerning talc and ovarian cancer since 2021?</p>
<p style="text-align: right;">Page 31</p> <p>1 THE WITNESS: Yeah. Let -- yes.</p> <p>2 Let me get the --</p> <p>3 BY MS. DAVIDSON:</p> <p>4 Q. Do you recall whether --</p> <p>5 MS. DAVIDSON: Michelle, this is my</p> <p>6 deposition.</p> <p>7 BY MS. DAVIDSON:</p> <p>8 Q. Dr. Siemiatycki, do you recall</p> <p>9 whether you disclosed in that paper that you</p> <p>10 are plaintiff's expert in the talc litigation?</p> <p>11 A. No. I --</p> <p>12 MS. PARFITT: He can answer the</p> <p>13 question when he has the article in front</p> <p>14 of him.</p> <p>15 MS. DAVIDSON: I asked if he</p> <p>16 recalls. He doesn't need the paper for</p> <p>17 that, Michelle.</p> <p>18 Michelle, I have four hours here</p> <p>19 today. Please don't interrupt this</p> <p>20 deposition, or I'll have to go to the</p> <p>21 Court and ask for more hours.</p> <p>22 BY MS. DAVIDSON:</p> <p>23 Q. Dr. Siemiatycki, do you recall</p> <p>24 whether you disclosed that you are an expert in</p> <p>25 the talc litigation in that paper?</p>	<p style="text-align: right;">Page 33</p> <p>1 A. I don't recall; but again, looking</p> <p>2 at my CV might refresh my memory about</p> <p>3 something, but I don't think I did.</p> <p>4 Q. Are you currently working on any</p> <p>5 articles or studies pertaining to talc or</p> <p>6 ovarian cancer?</p> <p>7 A. Well, there is an intention to</p> <p>8 write -- to do an analysis of perineal talc</p> <p>9 exposure in the context of a case control study</p> <p>10 that my colleague has carried out in Montreal,</p> <p>11 and I would be involved in that article. So</p> <p>12 it -- there's an intention for that to happen.</p> <p>13 It's not currently ongoing yet.</p> <p>14 Q. I'm sorry. I don't understand.</p> <p>15 You have an intention to publish a</p> <p>16 new case control study on talc and ovarian</p> <p>17 cancer?</p> <p>18 A. Yes.</p> <p>19 Q. And has the research begun on that?</p> <p>20 A. Has the research what?</p> <p>21 Q. Begun on that?</p> <p>22 A. The research began ten years ago,</p> <p>23 so this is a study that was carried out by my</p> <p>24 colleague, Anita Koushik, as the principal</p> <p>25 investigator. I was at the time involved as</p>

<p style="text-align: right;">Page 34</p> <p>1 kind of mentor in helping her get funding and</p> <p>2 designing the study and designing the fieldwork</p> <p>3 procedures.</p> <p>4 And the questionnaire that she</p> <p>5 developed included questions about perineal</p> <p>6 talc exposure, and the intention -- her</p> <p>7 intention was always to do an analysis of that</p> <p>8 data and publish it.</p> <p>9 Q. Do you know why it hasn't yet been</p> <p>10 published?</p> <p>11 A. Well --</p> <p>12 MS. PARFITT: Objection. Form.</p> <p>13 THE WITNESS: -- she had other</p> <p>14 priorities that were, in part, driven by</p> <p>15 the principal hypotheses of stated in her</p> <p>16 grant application and the funding agency.</p> <p>17 And those were sort of in chronological</p> <p>18 priority list.</p> <p>19 It started probably around 2017 or</p> <p>20 '18 that the data became available to be</p> <p>21 analyzed. It takes -- of course, a study</p> <p>22 that was funded around 2008 or '9, didn't</p> <p>23 complete the fieldwork and collection of</p> <p>24 data probably for about five years after</p> <p>25 that.</p>	<p style="text-align: right;">Page 36</p> <p>1 know how -- it'll -- whether it'll be accepted</p> <p>2 in first iteration or, you know, three</p> <p>3 iterations of comments from editors and</p> <p>4 reviewers and so on and so forth.</p> <p>5 So when it's going to come out is</p> <p>6 not under the control of the authors and the</p> <p>7 investigators. You can control when you're</p> <p>8 going to submit the paper for -- to a journal.</p> <p>9 Given that the analyses have not</p> <p>10 yet been carried out, unless she has started</p> <p>11 without my knowledge in the last couple of</p> <p>12 months, and that the writing of the manuscript</p> <p>13 has not started, I guess it wouldn't happen</p> <p>14 before manuscript wouldn't be ready for</p> <p>15 submission before the fall of this year.</p> <p>16 Q. Have you seen the data yet?</p> <p>17 MS. PARFITT: Seen what?</p> <p>18 MS. DAVIDSON: The data.</p> <p>19 THE WITNESS: No, not on talc</p> <p>20 exposure.</p> <p>21 BY MS. DAVIDSON:</p> <p>22 Q. Okay. Have you done any outreach</p> <p>23 to any health organizations, any public health</p> <p>24 organizations about talc use and ovarian cancer</p> <p>25 since 2021?</p>
<p style="text-align: right;">Page 35</p> <p>1 And then getting started with</p> <p>2 analyses and drafting of papers depended</p> <p>3 on her priorities and the interests of her</p> <p>4 students who were the, typically, the</p> <p>5 first authors of the eventual paper.</p> <p>6 So she has now -- they have now</p> <p>7 published -- I don't know -- four or five</p> <p>8 papers, I think, that have come out of</p> <p>9 that study. They haven't yet published</p> <p>10 anything about perineal talc exposure, and</p> <p>11 my understanding is that that is coming</p> <p>12 up. I don't know if it's next on the list</p> <p>13 or -- she's also recently moved from one</p> <p>14 university to another and had disruptions</p> <p>15 of that sort in her life.</p> <p>16 BY MS. DAVIDSON:</p> <p>17 Q. When is -- when is the last time</p> <p>18 you discussed this paper -- potential paper</p> <p>19 with her?</p> <p>20 A. A couple of months ago, I would</p> <p>21 say. Maybe December or January.</p> <p>22 Q. And when do you expect it to come</p> <p>23 out?</p> <p>24 A. To come out? You never know when a</p> <p>25 paper is going to come out because you never</p>	<p style="text-align: right;">Page 37</p> <p>1 A. Well, I -- I had reached out to</p> <p>2 Health Canada when they put out a call for or</p> <p>3 opinions and input on their proposed report,</p> <p>4 but I -- it might have been before 2021 or in</p> <p>5 2020 or something in that ballpark.</p> <p>6 Q. Since Health Canada, my question</p> <p>7 is: Have you reached out to any public health</p> <p>8 organizations about talc use and ovarian</p> <p>9 cancer?</p> <p>10 A. Any public health organization?</p> <p>11 No. It's -- it's not my practice</p> <p>12 to reach out to public health organizations</p> <p>13 about research issues.</p> <p>14 Q. Are you familiar with an</p> <p>15 organization called ACOG?</p> <p>16 A. I'm familiar with it. I'm not a</p> <p>17 member of it, and I haven't participated in any</p> <p>18 way.</p> <p>19 Q. Do you know whether they list talc</p> <p>20 use as a risk factor for ovarian cancer?</p> <p>21 A. No, I don't.</p> <p>22 Q. Have you looked on their website</p> <p>23 since 2021?</p> <p>24 A. No, I haven't.</p> <p>25 Q. Are you familiar with the Society</p>

<p style="text-align: right;">Page 38</p> <p>1 of Obstetricians and Gynecologists of Canada, 2 also known as SOGC? 3 A. No, I'm not familiar with it. 4 Q. You've never heard of SOGC? 5 MS. PARFITT: Objection. 6 THE WITNESS: Nope. 7 MS. PARFITT: Asked and answered. 8 THE WITNESS: With all the acronyms 9 that fly around my desk and my brain, it 10 doesn't ring a bell. It's not the top of 11 mind. I don't know if I've -- 12 BY MS. DAVIDSON: 13 Q. I gave it to you without the 14 acronym, actually: Society of Obstetricians 15 and Gynecologists of Canada. 16 A. I'm sure there is such a society. 17 So if you're asking me whether I'm surprised 18 that there is such a thing, no, I'm not at all 19 surprised. I would expect that there would be. 20 But I'm not familiar with it. I've 21 never been in touch with them. I've never read 22 any documents from them. It wouldn't be a 23 go-to place for me to find out about research 24 or risk factors. 25 Q. And you've never reached out to</p>	<p style="text-align: right;">Page 40</p> <p>1 website to see if they list talc as a risk 2 factor for ovarian cancer? 3 A. No, I haven't. 4 Q. So you're not aware that the CDC 5 does not identify talc as a risk factor for 6 ovarian cancer? 7 MS. PARFITT: Objection. Form. 8 THE WITNESS: No. I'm not aware of 9 what's on their website. 10 BY MS. DAVIDSON: 11 Q. Are you familiar with the American 12 Cancer Society? 13 A. Yes, I am. 14 Q. Are you aware that the American 15 Cancer Society has stated that the weight of 16 the evidence does not support an association 17 between ovarian cancer and general exposure to 18 talc-based powder? 19 MS. PARFITT: Objection. Form. 20 THE WITNESS: I am not aware of 21 that statement that you just read. 22 BY MS. DAVIDSON: 23 Q. Do you disagree with the American 24 Cancer Society? 25 MS. PARFITT: Objection. Form.</p>
<p style="text-align: right;">Page 39</p> <p>1 them to express your concerns about talc and 2 ovarian cancer, correct? 3 A. Correct. 4 Q. Are you familiar with the Society 5 of Gynecological Oncology in the United States, 6 also known as SGO? 7 A. Again, I'm -- I'm -- you know, I'm 8 not familiar with the particular combinations 9 of words that go into their name and the 10 acronym; but I am certain there is such a 11 society. 12 Q. That wasn't my question. 13 Doctor, you mentioned that you had 14 the NCI PDQ in front of you. 15 Have you ever reached out to NCI to 16 raise your concerns about talc and ovarian 17 cancer? 18 A. No, I haven't. 19 Q. Have you ever heard of the CDC? 20 A. Yes, I have. 21 Q. And have you ever reached out to 22 the CDC to express your concerns about talc and 23 ovarian cancer? 24 A. No, I haven't. 25 Q. Have you ever looked on the CDC</p>	<p style="text-align: right;">Page 41</p> <p>1 You may answer. 2 THE WITNESS: I would have to see 3 the entirety of their document and 4 their -- whatever they -- whatever they 5 include in their document to support that 6 conclusion before commenting on whether I 7 agree or disagree. 8 BY MS. DAVIDSON: 9 Q. So you might agree with their 10 statement -- is there a possibility that you 11 would agree with the statement that, "The 12 weight of the evidence does not support an 13 association between ovarian cancer and genital 14 exposure"? 15 MS. PARFITT: Objection. Form. 16 THE WITNESS: I would find it most 17 unlikely that I would disagree with it, 18 but I am open to being persuaded by 19 evidence. And if they have evidence that 20 I've never seen... 21 BY MS. DAVIDSON: 22 Q. Who drafted the changes to your 23 2023 report? 24 A. I'm sorry? 25 Q. Who drafted the additions in your</p>

<p style="text-align: right;">Page 42</p> <p>1 2023 report?</p> <p>2 A. The additions?</p> <p>3 Q. Uh-huh.</p> <p>4 A. What -- which additions are you --</p> <p>5 Q. Do you remember you have a redline</p> <p>6 in front of that shows what was added in '23?</p> <p>7 Who drafted those additions?</p> <p>8 A. So just to be clear, there are not</p> <p>9 additions to the 2023 report. There were</p> <p>10 changes to the 2021 report, and that's what is</p> <p>11 redlined in sort of the correction in the</p> <p>12 version that -- that I have.</p> <p>13 Who drafted them? I did.</p> <p>14 Q. Did you identify all the documents</p> <p>15 that have been added to your reliance list and</p> <p>16 put in the Dropbox and mentioned today, or were</p> <p>17 some of them provided to you by the lawyers?</p> <p>18 A. Some were provided by the lawyers,</p> <p>19 and some I found independently. And at this</p> <p>20 time I -- I mean, I've never kept a tally of</p> <p>21 how I found out about different documents or</p> <p>22 reports. So I couldn't really identify which</p> <p>23 ones I came upon and which ones were sent to me</p> <p>24 by the lawyers; but some were sent by the</p> <p>25 lawyers, and some I came upon independently.</p>	<p style="text-align: right;">Page 44</p> <p>1 I mean, I make a distinction</p> <p>2 between evidence that I look at and that I</p> <p>3 derive and that I hold. The opinions that I</p> <p>4 hold are based on my own personal evaluation of</p> <p>5 the data and the evidence as compared with</p> <p>6 opinions I hold based on the authoritative</p> <p>7 opinions of others that I accept.</p> <p>8 Q. What documents -- well, let's go</p> <p>9 back.</p> <p>10 You said -- referenced EPA.</p> <p>11 Has EPA ever stated that talc</p> <p>12 contains asbestos?</p> <p>13 A. I'm looking -- I'm looking for the</p> <p>14 document on that topic. So the recent EPA</p> <p>15 document -- it's in this, I think.</p> <p>16 Q. Is it your recollection that that</p> <p>17 document references talc?</p> <p>18 A. I'm sorry?</p> <p>19 Q. Is it your recollection that that</p> <p>20 document references talc?</p> <p>21 A. It is my recollection that there is</p> <p>22 mention of asbestos in talc.</p> <p>23 Q. Okay.</p> <p>24 MS. PARFITT: I can shorten this</p> <p>25 real quickly and point to the document. I</p>
<p style="text-align: right;">Page 43</p> <p>1 Q. You testified in 2021 that you're</p> <p>2 not offering an opinion that Johnson's Baby</p> <p>3 Powder contained asbestos.</p> <p>4 Is that still your position?</p> <p>5 MS. PARFITT: Objection. Form.</p> <p>6 Misstates his testimony.</p> <p>7 THE WITNESS: I would say that I've</p> <p>8 seen more evidence in the last couple of</p> <p>9 years that point in the direction that</p> <p>10 asbestos has been in the -- in the</p> <p>11 formulations of cosmetic talc.</p> <p>12 And so I would be much more</p> <p>13 amenable to the opinion that there has</p> <p>14 been asbestos.</p> <p>15 BY MS. DAVIDSON:</p> <p>16 Q. You would be more amenable to that</p> <p>17 opinion, or you're offering that opinion?</p> <p>18 A. I'm offering that opinion but based</p> <p>19 not on my own expertise as a mineralogist or a</p> <p>20 measurement scientist for asbestos, but the</p> <p>21 accumulation of evidence from credible sources,</p> <p>22 including EPA, FDA in the U.S. and some</p> <p>23 scientists who have measured asbestos fibers in</p> <p>24 talc, in historic talc preparations, make me --</p> <p>25 persuade me much more.</p>	<p style="text-align: right;">Page 45</p> <p>1 see it in his pile.</p> <p>2 MS. DAVIDSON: Michelle, let --</p> <p>3 let's just let us handle this.</p> <p>4 MS. PARFITT: Let me just say this,</p> <p>5 and we won't have any problems.</p> <p>6 If you ask him about a document and</p> <p>7 he says he's looking for it, he's entitled</p> <p>8 to have it in front of him.</p> <p>9 I know you're moving it along, but</p> <p>10 if you're going to ask him questions about</p> <p>11 a document --</p> <p>12 MS. DAVIDSON: Michelle, it is very</p> <p>13 clear that there is a strategy in this</p> <p>14 deposition of filibustering because, you</p> <p>15 know, I only have four hours. And if I</p> <p>16 have to, I will go to the Court and ask</p> <p>17 for more time.</p> <p>18 MS. PARFITT: You're remote. I'm</p> <p>19 here.</p> <p>20 MS. DAVIDSON: I'm telling you --</p> <p>21 MS. PARFITT: Filibuster --</p> <p>22 MS. DAVIDSON: I will go to the</p> <p>23 Court and ask for more time because</p> <p>24 Dr. Siemiatycki is answering simple</p> <p>25 questions --</p>

Page 46

1 MS. PARFITT: You're not going to
2 get more --
3 MS. DAVIDSON: You're interrupting
4 me. You're interrupting me.
5 Dr. Siemiatycki is answering simple
6 questions --
7 MS. PARFITT: Let me finish.
8 MS. DAVIDSON: You can finish after
9 I'm finished. You will finish after I am
10 finished.
11 Dr. Siemiatycki is answering very
12 simple questions with long-winded answers
13 that he was clearly coached to do, and we
14 have very limited time.
15 MS. PARFITT: Jessica --
16 MS. DAVIDSON: So --
17 MS. PARFITT: -- you do not give
18 your tenor to what Dr. Siemiatycki. He's
19 here to answer your questions. Make the
20 question so he can give a good answer.
21 And, Jack, if you need look to look
22 at the articles, just tell Ms. Davidson.
23 THE WITNESS: Thank you.
24 BY MS. DAVIDSON:
25 Q. Dr. Siemiatycki, other than EPA and

Page 47

1 FDA, what other materials are you relying on
2 for your new opinion that Johnson's Baby Powder
3 contains asbestos?
4 A. A document written by Dr. Longo,
5 William Longo, November 17, 2023, which
6 included analyses of talc products, historic
7 talc products of various origins, including
8 Chinese and that -- where he demonstrated the
9 presence of asbestos fibers.
10 Q. Are there any other documents
11 you're relying on?
12 A. Well, historically, there were
13 reports from Blount about this, relying on my
14 memory. Let me look in my report and see.
15 Q. Your report doesn't actually cite
16 anything. When you say -- when you refer to,
17 quote, "Growing evidence that talc products may
18 have contained asbestos fibers," there's no
19 cite there?
20 MS. PARFITT: Jessica, I'll also
21 remind you that this area was covered in
22 his prior deposition.
23 MS. DAVIDSON: It's a new sentence
24 in his report, Michelle.
25 MS. PARFITT: I understand. I'm

Page 48

1 just talking generally.
2 MS. DAVIDSON: I'm just telling you
3 it's a new sentence in his report.
4 MS. PARFITT: Fair enough.
5 BY MS. DAVIDSON:
6 Q. Dr. Siemiatycki, sitting here
7 today, can you recall any other documents that
8 you relied on for your opinion, which is
9 uncited in your report, that there is "growing
10 evidence that talc products may have contained
11 asbestos fibers"?
12 MS. PARFITT: Objection. Misstates
13 his testimony.
14 THE WITNESS: I am trying to
15 recall, and right now I can't recall
16 those. I'd have to spend a couple of
17 minutes looking through the documents.
18 BY MS. DAVIDSON:
19 Q. Okay. Dr. Siemiatycki, would you
20 agree with me that it's important for a
21 scientist before reaching any sort of opinions
22 on scientific issues, to consider all the
23 relevant data?
24 A. Yes.
25 Q. Dr. Siemiatycki, have you reviewed

Page 49

1 all the documents that J&J produced in this
2 litigation about its robust testing of talc for
3 asbestos?
4 MS. PARFITT: Objection. Form.
5 THE WITNESS: And I'm not sure what
6 you mean by "all the documents that J&J
7 produced." What's that --
8 BY MS. DAVIDSON:
9 Q. Have you reviewed all of J&J's
10 documents in which they address the robust
11 testing program for asbestos in its talc
12 products?
13 MS. PARFITT: Objection.
14 I'll give you a little foundation,
15 but this area was examined as well back on
16 January 31st, '19.
17 MS. DAVIDSON: We have this new
18 statement in the report, Michelle; and
19 please stop filibustering this deposition.
20 BY MS. DAVIDSON:
21 Q. Dr. Siemiatycki, do you --
22 MS. PARFITT: Stop going back in
23 history, or we will have to call the
24 judge.
25 MS. DAVIDSON: Michelle. Michelle,

<p style="text-align: right;">Page 50</p> <p>1 it's been four years. He has an opinion. 2 I need to know -- 3 MS. PARFITT: Jessica, don't 4 shriek. 5 BY MS. DAVIDSON: 6 Q. Dr. Siemiatycki, I'm going to ask 7 the question again. 8 Have you reviewed the documents 9 produced by J&J addressing its robust testing 10 program for talc products? 11 MS. PARFITT: Objection. 12 THE WITNESS: I remember reviewing 13 some documents from J&J about this, but I 14 don't know that this is -- was a 15 comprehensive list of documents. I mean, 16 if you -- if there are any new ones, I'd 17 be glad to look at them. 18 BY MS. DAVIDSON: 19 Q. Are you aware that J&J produced 20 thousands of documents in this litigation about 21 its testing of talc for asbestos? 22 MS. PARFITT: Objection. Asked and 23 answered in his deposition January '19. 24 THE WITNESS: I'm aware they 25 produced documents about this. I don't</p>	<p style="text-align: right;">Page 52</p> <p>1 November 17th, 2023, report, Jessica? 2 We need the record to be clear. 3 BY MS. DAVIDSON: 4 Q. Dr. Siemiatycki, have you reviewed 5 any reports by Mr. Matthew Sanchez? 6 A. By who? 7 Q. Mr. Matthew Sanchez. 8 A. That does not ring a bell. 9 What would the date be on that 10 report? 11 Q. There would be multiple such 12 reports. 13 A. Roughly beginning when and ending 14 when? 15 These are from 2023 and -- 16 Q. There -- over the years there have 17 been multiple reports by Mr. Matthew Sanchez. 18 Have you reviewed any of them? 19 A. I can't recall having reviewed 20 them. 21 Q. None of them -- none of them are 22 with you here today, correct? 23 A. Correct. 24 MS. DAVIDSON: Okay. I need to go 25 off the record. I have a quick call, so</p>
<p style="text-align: right;">Page 51</p> <p>1 know if -- there were thousands. I have 2 no idea how many, and I don't know what 3 they were total. 4 BY MS. DAVIDSON: 5 Q. Have you reviewed the expert report 6 of J&J's expert who responds to Dr. Longo and 7 explains the flaws in Dr. Longo's testing? 8 A. Who would the author be of that 9 report or the timing? 10 Q. Do you recall reading any such 11 report? 12 A. I recall reading reports from a -- 13 reports from experts for J&J about this, but I 14 don't know if it's the one -- the reports that 15 you have in mind. I don't know. 16 Q. Have you reviewed the expert report 17 from J&J's microscopist? 18 A. I have not recently, but I have. 19 Q. Did you review the report that 20 J&J's microscopist submitted in response to the 21 Longo report you mentioned a few minutes ago? 22 MS. PARFITT: You're talking about 23 the '23 Longo report, for clarity because 24 there's two or many actually? 25 Are you referring to the</p>	<p style="text-align: right;">Page 53</p> <p>1 let's take a five-minute break. 2 MS. PARFITT: Okay. Thank you. 3 (Whereupon, a break was taken.) 4 BY MS. DAVIDSON: 5 Q. Dr. Siemiatycki, other than the 6 materials that you were provided by plaintiff's 7 counsels, did you undertake any research on 8 your own regarding potential asbestos 9 contamination in Johnson's Baby Powder? 10 A. I'm not sure if I would 11 characterize it as having undertaken 12 independent research on my own; but when I was 13 reading the various documents that I did have, 14 I would sometimes look at references in those 15 documents that may -- that were not submitted 16 to me by -- by the plaintiff's lawyers. 17 But I can't remember if that 18 occurred with this topic, with the topic of 19 asbestos in talc products. But as a general 20 rule, I would explore, read a document; and 21 there may be sort of a stimulus there to look 22 at something else. 23 Q. Well, today you mentioned an EPA 24 document, an FDA document, Dr. Longo, and 25 Dr. Blount.</p>

<p style="text-align: right;">Page 54</p> <p>1 Fair to say all those materials</p> <p>2 were provided to you by plaintiff's counsel?</p> <p>3 MS. PARFITT: Objection. Form.</p> <p>4 Asked and answered.</p> <p>5 THE WITNESS: So the -- I think</p> <p>6 originally the Blount articles -- and I'm</p> <p>7 having trouble remembering all the names,</p> <p>8 but there was another early article from</p> <p>9 the late -- late '70s or early '80s that</p> <p>10 addressed the detection of asbestos</p> <p>11 particles in talc products. Those were</p> <p>12 provided originally by the lawyers.</p> <p>13 The FDA analyses, I'm not sure</p> <p>14 whether information about that was</p> <p>15 provided by the lawyers or if I saw that</p> <p>16 in another report. So I'm a little bit</p> <p>17 fuzzy on the historical origin of how I</p> <p>18 came to know those documents.</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. Was the EPA document provided to</p> <p>21 you by the plaintiff's lawyers?</p> <p>22 A. Yeah. So the EPA document is the</p> <p>23 recent ban on asbestos, which does not, in</p> <p>24 fact, concern talc. I just had a look at it</p> <p>25 directly. It doesn't explicitly concern talc,</p>	<p style="text-align: right;">Page 56</p> <p>1 You may answer, Dr. Siemiatycki.</p> <p>2 THE WITNESS: I -- I have read</p> <p>3 references to the to the detection of</p> <p>4 metals in talc products. I -- I can't</p> <p>5 say. It certainly not something that I'm</p> <p>6 relying upon for any opinions about talc,</p> <p>7 but it's something that I have read.</p> <p>8 BY MS. DAVIDSON:</p> <p>9 Q. Dr. Siemiatycki, did you reach out</p> <p>10 to IARC and offer yourself as a potential</p> <p>11 expert on talc issues recently?</p> <p>12 A. Yes, I did.</p> <p>13 Q. When was that?</p> <p>14 A. Probably a year ago or nine months</p> <p>15 ago. It was following a call by IARC for</p> <p>16 experts to volunteer to participate in a new</p> <p>17 monograph evaluation of talc, and I thought I</p> <p>18 might be useful to them; and I've had a long</p> <p>19 association with IARC. So I -- I did offer</p> <p>20 myself in that context.</p> <p>21 Q. Did you tell the lawyers you were</p> <p>22 going to do that?</p> <p>23 A. I don't think I told them before</p> <p>24 doing it. I can't remember at what point I</p> <p>25 informed them about it. Maybe only after I had</p>
<p style="text-align: right;">Page 55</p> <p>1 but it concerns one of the products that has</p> <p>2 been detected in talc products, one of them.</p> <p>3 Q. So, in fact, the EPA document does</p> <p>4 not support your new opinion that talc</p> <p>5 contained asbestos, correct?</p> <p>6 MS. PARFITT: Objection. Misstates</p> <p>7 his testimony entirely.</p> <p>8 THE WITNESS: That's correct. I</p> <p>9 would say that's correct, basically.</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. Okay. And the Dr. Longo documents</p> <p>12 were provided to you by plaintiff's counsel as</p> <p>13 well, of course?</p> <p>14 A. Yeah.</p> <p>15 Q. Okay. Thank you.</p> <p>16 Are you offering an opinion on</p> <p>17 heavy metals in this litigation?</p> <p>18 A. What do you mean by "an opinion on</p> <p>19 heavy metals"?</p> <p>20 Q. Are you offering an opinion that</p> <p>21 talc contained -- that Johnson's Baby Powder</p> <p>22 contained heavy metals?</p> <p>23 MS. PARFITT: Objection to the</p> <p>24 extent it's foundational. It was covered</p> <p>25 in his 2019 deposition.</p>	<p style="text-align: right;">Page 57</p> <p>1 learned that IARC was not going to invite me,</p> <p>2 but we didn't have a discussion about that.</p> <p>3 Q. And the reason -- and the reason</p> <p>4 they didn't include you is because of your</p> <p>5 conflict of interest as a plaintiff's expert,</p> <p>6 right?</p> <p>7 A. That's right, which --</p> <p>8 Q. And --</p> <p>9 A. -- I admitted to them front and</p> <p>10 center when I made my -- when I offered my</p> <p>11 services.</p> <p>12 Q. Did you provide plaintiffs to</p> <p>13 produce to us the letter you submitted to IARC</p> <p>14 with your application, so to speak?</p> <p>15 A. Can you -- can you repeat that?</p> <p>16 Q. Your application to IARC, was it</p> <p>17 some sort of letter?</p> <p>18 A. Yeah, it was a letter. And I think</p> <p>19 accompanying the letter, there was a form,</p> <p>20 actually, explicitly asking the applicant to</p> <p>21 list any potential conflicts of interest.</p> <p>22 MS. DAVIDSON: Michelle, has that</p> <p>23 been produced to us because we couldn't</p> <p>24 find it?</p> <p>25 MS. PARFITT: It was. It was. And</p>

<p style="text-align: right;">Page 58</p> <p>1 Patrick can confirm that.</p> <p>2 MS. DAVIDSON: Okay. All right.</p> <p>3 MR. LYONS: Yeah. It's in the --</p> <p>4 it's in the Dropbox.</p> <p>5 MS. DAVIDSON: Okay.</p> <p>6 MR. LYONS: It's labeled "Letter to</p> <p>7 IARC on Monograph 136."</p> <p>8 MS. DAVIDSON: Yeah. I don't know</p> <p>9 why we didn't find that it.</p> <p>10 Noah, please find that and make</p> <p>11 sure we have it.</p> <p>12 Noah will make sure we have it</p> <p>13 before the day is over.</p> <p>14 BY MS. DAVIDSON:</p> <p>15 Q. Okay. Dr. Siemiatycki, you're</p> <p>16 aware that Dr. Woolen found a 1.47 risk ratio</p> <p>17 for frequent talc use, right?</p> <p>18 A. For what?</p> <p>19 Q. Dr. Woolen found a 1.47 risk ratio</p> <p>20 between her definition of frequent talc use and</p> <p>21 the development of ovarian cancer, correct?</p> <p>22 A. Yes, that's correct.</p> <p>23 Q. Does that mean that if a woman used</p> <p>24 perineal talc frequently and developed ovarian</p> <p>25 cancer, 47 percent of the cause of that ovarian</p>	<p style="text-align: right;">Page 60</p> <p>1 chance of developing ovarian cancer was 1.47</p> <p>2 times greater than the risk for a non user.</p> <p>3 It can also be restated -- it can</p> <p>4 also be restated that her chance of getting</p> <p>5 ovarian cancer was 47 percent higher than for</p> <p>6 non users, but that's not an optimal way to</p> <p>7 actually present a risk ratio or a relative</p> <p>8 risk; but that is sometimes expressed that way.</p> <p>9 But not in the percentage terms</p> <p>10 that you indicated in your question.</p> <p>11 Q. Are you aware that IARC and NCI</p> <p>12 issued a report called "Expert Consensus on</p> <p>13 Future Directions for Ovarian Cancer Research"?</p> <p>14 A. What would be the date</p> <p>15 approximately? The year?</p> <p>16 I'm not sure what you're talking</p> <p>17 about.</p> <p>18 MS. PARFITT: And, Jessica, if you</p> <p>19 have a copy of that document, perhaps you</p> <p>20 could share it.</p> <p>21 BY MS. DAVIDSON:</p> <p>22 Q. I'm asking if you're familiar with</p> <p>23 the document entitled "IARC and NCI Expert</p> <p>24 Consensus on Future Directions for Ovarian</p> <p>25 Cancer Research."</p>
<p style="text-align: right;">Page 59</p> <p>1 cancer would have been her talc use?</p> <p>2 MS. PARFITT: Objection. Form.</p> <p>3 THE WITNESS: Sorry. I'm -- I'm</p> <p>4 not following your algebra.</p> <p>5 BY MS. DAVIDSON:</p> <p>6 Q. Well, I'm asking you if that</p> <p>7 makes -- I'm asking you.</p> <p>8 A. Yes. I understand, but I don't</p> <p>9 understand what your asking me.</p> <p>10 Q. I'm asking you if somebody is a</p> <p>11 frequent user of talc and then develops ovarian</p> <p>12 cancer, can the risk ratio in Woolen be turned</p> <p>13 into an absolute risk such that you can say</p> <p>14 that 47 percent of this woman's cancer</p> <p>15 causation relates to ex- -- perineal talc</p> <p>16 exposure?</p> <p>17 MS. PARFITT: Objection to form.</p> <p>18 THE WITNESS: No.</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. And why is that?</p> <p>21 A. Because that's not the meaning of</p> <p>22 relative risk.</p> <p>23 Q. Can you explain?</p> <p>24 A. The relative risk of 1.47 means</p> <p>25 that for a woman who was a frequent user, her</p>	<p style="text-align: right;">Page 61</p> <p>1 A. What year approximately?</p> <p>2 MS. DAVIDSON: Noah, what year is</p> <p>3 it?</p> <p>4 MR. EPSTEIN: 2021.</p> <p>5 MS. DAVIDSON: 2021.</p> <p>6 MR. EPSTEIN: Do you want me to put</p> <p>7 it in the chat?</p> <p>8 MS. DAVIDSON: Not right now.</p> <p>9 MS. PARFITT: Oh, so you don't want</p> <p>10 to put it in the chat; so you don't want</p> <p>11 the doctor to --</p> <p>12 MS. DAVIDSON: I just want to know</p> <p>13 if Dr. Siemiatycki is familiar with this</p> <p>14 document, if he read it before, if it</p> <p>15 sounds familiar.</p> <p>16 THE WITNESS: No, I haven't seen</p> <p>17 it.</p> <p>18 BY MS. DAVIDSON:</p> <p>19 Q. Okay. Thank you.</p> <p>20 How would you extrapolate from</p> <p>21 these epi studies to determine what a women's</p> <p>22 absolute risk is for ovarian cancer from</p> <p>23 perineal talc use?</p> <p>24 MS. PARFITT: Objection. Form.</p> <p>25 You can answer.</p>

<p style="text-align: right;">Page 62</p> <p>1 THE WITNESS: You mean technically,</p> <p>2 like the algebraic formula that is used to</p> <p>3 do that?</p> <p>4 BY MS. DAVIDSON:</p> <p>5 Q. How is it done?</p> <p>6 I'm just asking generally how it's</p> <p>7 done.</p> <p>8 MS. PARFITT: Objection.</p> <p>9 THE WITNESS: Well, it's sort of a</p> <p>10 combination of the relative risk and the</p> <p>11 incidence of the disease in the</p> <p>12 population. Combining those parameters,</p> <p>13 you can -- you can figure out the absolute</p> <p>14 risk due to the exposure.</p> <p>15 BY MS. DAVIDSON:</p> <p>16 Q. Have you done that for talc and</p> <p>17 ovarian cancer?</p> <p>18 A. No, I haven't.</p> <p>19 Q. Have you done a systematic review</p> <p>20 of the literature related to asbestos and</p> <p>21 ovarian cancer?</p> <p>22 A. Have I personally done one?</p> <p>23 Q. Yes.</p> <p>24 A. No, I haven't.</p> <p>25 Q. Do you know how much exposure to</p>	<p style="text-align: right;">Page 64</p> <p>1 not -- I'm not aware.</p> <p>2 BY MS. DAVIDSON:</p> <p>3 Q. Were you aware that the --</p> <p>4 MS. PARFITT: Let him finish.</p> <p>5 THE WITNESS: Maybe -- maybe if you</p> <p>6 tell me who the senior author is.</p> <p>7 BY MS. DAVIDSON:</p> <p>8 Q. Okay. Are you aware that the</p> <p>9 Woolen paper grew out of a meta-analysis that</p> <p>10 was actually done for purposes of this</p> <p>11 litigation?</p> <p>12 MS. PARFITT: Objection. Misstates</p> <p>13 the evidence in the case.</p> <p>14 THE WITNESS: No, I'm not aware of</p> <p>15 that.</p> <p>16 BY MS. DAVIDSON:</p> <p>17 Q. Do you know how the Woolen authors</p> <p>18 chose two times a week as their definition of</p> <p>19 frequent use?</p> <p>20 A. It may be mentioned in the paper.</p> <p>21 I certainly don't remember it. But</p> <p>22 establishing cutpoints for continuous variables</p> <p>23 has an element of arbitrariness always and you</p> <p>24 typically look for -- if it's a meta-analysis,</p> <p>25 which this is, you're probably looking for</p>
<p style="text-align: right;">Page 63</p> <p>1 asbestos is needed to cause ovarian cancer?</p> <p>2 MS. PARFITT: Objection. Form.</p> <p>3 THE WITNESS: No, I don't.</p> <p>4 BY MS. DAVIDSON:</p> <p>5 Q. Are you aware that one of the</p> <p>6 authors of Woolen is a plaintiff's expert in</p> <p>7 this litigation?</p> <p>8 A. Am I aware that one of the authors</p> <p>9 of the Woolen paper is an expert for the</p> <p>10 plaintiffs; is that what you're asking?</p> <p>11 Q. That is.</p> <p>12 A. Let me look at the article.</p> <p>13 Q. Without looking at the article, you</p> <p>14 can't tell me whether one of the authors is an</p> <p>15 expert?</p> <p>16 A. There are 200 articles in my piles,</p> <p>17 and each one has about ten authors; and I don't</p> <p>18 remember all the authors on all the papers.</p> <p>19 So --</p> <p>20 Q. You don't -- you don't recall</p> <p>21 whether the Woolen paper -- whether the senior</p> <p>22 author on the Woolen paper is a plaintiff's</p> <p>23 expert in this litigation?</p> <p>24 MS. PARFITT: Objection.</p> <p>25 THE WITNESS: I'm not aware -- I'm</p>	<p style="text-align: right;">Page 65</p> <p>1 cutpoints that have been used by the original</p> <p>2 authors of the original studies. And so you're</p> <p>3 a little bit at the mercy of what has been done</p> <p>4 previously, and you're also trying to look for</p> <p>5 cutpoints that make sense to you as a cutpoint</p> <p>6 for the parameter that you're looking for,</p> <p>7 which is frequency of use.</p> <p>8 But in this particular case, I</p> <p>9 don't recall.</p> <p>10 Q. Did you check -- when you reviewed</p> <p>11 Woolen, did you check whether the risk ratios</p> <p>12 the authors used were actually for</p> <p>13 two-times-a-week use?</p> <p>14 A. Sorry. Did -- was -- did I check</p> <p>15 whether --</p> <p>16 Q. Whether the risk ratios used in the</p> <p>17 Woolen paper actually reflected</p> <p>18 two-times-a-week use?</p> <p>19 A. No, I didn't. But coincidentally,</p> <p>20 I carried out an analysis myself along the</p> <p>21 lines of what's in the Woolen paper some years</p> <p>22 before they did, and it's in my report. And,</p> <p>23 in fact, there's a table in my report -- I</p> <p>24 think it's Table 8 in my report -- which</p> <p>25 describes my own meta-analysis on that topic</p>

<p style="text-align: right;">Page 66</p> <p>1 and the studies that I used that I found in the</p> <p>2 literature to address the question and the</p> <p>3 relative risk estimates that I used</p> <p>4 independently of Woolen.</p> <p>5 As I said, I did it years before</p> <p>6 they did, came out quite close to the relative</p> <p>7 risk estimates that they used in their</p> <p>8 analysis; and my bottom-line result came out</p> <p>9 very close to theirs. I think the</p> <p>10 meta-relative risk in my analysis of the high</p> <p>11 frequency users was 1.39 with a confidence</p> <p>12 interval that easily included the 1.47 relative</p> <p>13 risk estimate in the Woolen paper.</p> <p>14 So the two analyses carried out</p> <p>15 completely independently of each other,</p> <p>16 basically, found the same raw material to</p> <p>17 analyze, carried out the analysis in similar</p> <p>18 ways and found almost exactly the same</p> <p>19 bottom-line result.</p> <p>20 Q. How many of the studies overlapped</p> <p>21 between the two papers?</p> <p>22 A. I'm sorry. How many?</p> <p>23 Q. How many of the studies overlapped</p> <p>24 between your meta-analysis and hers?</p> <p>25 A. I didn't count them, but they</p>	<p style="text-align: right;">Page 68</p> <p>1 MS. PARFITT: Objection. Form.</p> <p>2 THE WITNESS: Do I know -- right</p> <p>3 now sitting here, no; but if you told me</p> <p>4 of another study, I might recognize it.</p> <p>5 BY MS. DAVIDSON:</p> <p>6 Q. And one difference between your</p> <p>7 paper and the Woolen paper is that she used</p> <p>8 NHS-1 data right they used NHS-1 data, right?</p> <p>9 MS. PARFITT: Objection. Form.</p> <p>10 THE WITNESS: I -- maybe. Maybe</p> <p>11 that's a distinction. I used O'Brien, I</p> <p>12 believe; and if they used NHS-1, then that</p> <p>13 would be a difference.</p> <p>14 I did not use NHS. I used</p> <p>15 O'Brien --</p> <p>16 MS. DAVIDSON: Turn to Table 1.</p> <p>17 MS. PARFITT: Wait, Jessica. He's</p> <p>18 finishing his statement. Let him finish.</p> <p>19 THE WITNESS: I'm just</p> <p>20 confirming --</p> <p>21 MS. DAVIDSON: He's answering a</p> <p>22 question I didn't ask.</p> <p>23 MS. PARFITT: Yes. Let him finish.</p> <p>24 THE WITNESS: So I used -- you were</p> <p>25 asking about studies that overlapped and</p>
<p style="text-align: right;">Page 67</p> <p>1 almost all do.</p> <p>2 Q. Okay.</p> <p>3 A. I think there was one --</p> <p>4 Q. Okay.</p> <p>5 MS. PARFITT: Let him finish.</p> <p>6 THE WITNESS: I think one exception</p> <p>7 was that, if I remember correctly, I</p> <p>8 included the Terry analysis -- the Terry</p> <p>9 paper as one of the components.</p> <p>10 Sorry. I'm just verifying that</p> <p>11 that is the case.</p> <p>12 Oh, no. I included the Terry</p> <p>13 analysis in my Table 6, which is an</p> <p>14 analogous meta-analysis, but for</p> <p>15 cumulative exposure not frequency of</p> <p>16 exposure.</p> <p>17 So the frequency of use, which is</p> <p>18 the same parameter that Woolen used -- I</p> <p>19 mean, I can list the studies, but they</p> <p>20 were almost identical with the ones that</p> <p>21 they used.</p> <p>22 BY MS. DAVIDSON:</p> <p>23 Q. Do you know whether there have been</p> <p>24 other meta-analyses that defined frequency of</p> <p>25 use different than two times a week?</p>	<p style="text-align: right;">Page 69</p> <p>1 whether I used NHS data, and I'm just</p> <p>2 trying to answer that question. I did not</p> <p>3 use NHS.</p> <p>4 I used the superior data, which is</p> <p>5 in the O'Brien study, which involved a</p> <p>6 longer period of follow-up and larger</p> <p>7 number of cases.</p> <p>8 BY MS. DAVIDSON:</p> <p>9 Q. Where did Woolen get the NHS data?</p> <p>10 A. I'm sorry?</p> <p>11 Q. Do you know where Woolen got her --</p> <p>12 where the Woolen authors got their NHS-1 data?</p> <p>13 A. Off the top, no. I could look up</p> <p>14 the article and try to find it, but I -- I</p> <p>15 don't recall.</p> <p>16 Q. Do you recall that they limited</p> <p>17 their NHS-1 data to patent women?</p> <p>18 A. I don't recall specifically, but it</p> <p>19 doesn't surprise me.</p> <p>20 Q. Can we look --</p> <p>21 MS. DAVIDSON: Noah, can you put up</p> <p>22 on the screen Table 1 of Woolen, which we</p> <p>23 just marked as Exhibit 1.</p> <p>24 MS. PARFITT: Let the doctor get</p> <p>25 his article.</p>

<p style="text-align: right;">Page 70</p> <p>1 MS. DAVIDSON: I'm sorry.</p> <p>2 MS. PARFITT: I've asked you to</p> <p>3 allow Dr. Siemiatycki to --</p> <p>4 MS. DAVIDSON: I can't hear you for</p> <p>5 some reason.</p> <p>6 MS. PARFITT: Oh, I'm sorry. I</p> <p>7 just simply asked if he has the article.</p> <p>8 He has it in front of him.</p> <p>9 THE WITNESS: Yeah. I have it in</p> <p>10 front of me now.</p> <p>11 BY MS. DAVIDSON:</p> <p>12 Q. We're looking at Table 1.</p> <p>13 A. Table 1.</p> <p>14 (Whereupon, Defendant's Exhibit D1,</p> <p>15 Article entitled, "Association Between the</p> <p>16 Frequent Use of Perineal Talcum Powder</p> <p>17 Products and Ovarian Cancer: A Systematic</p> <p>18 Review and Meta-analysis," by Sean A.</p> <p>19 Woolen, MD, MSc, et al., was marked for</p> <p>20 identification.)</p> <p>21 THE WITNESS: Quality assessment</p> <p>22 table, yeah.</p> <p>23 BY MS. DAVIDSON:</p> <p>24 Q. Are you familiar with the</p> <p>25 Newcastle-Ottawa Scale?</p>	<p style="text-align: right;">Page 72</p> <p>1 BY MS. DAVIDSON:</p> <p>2 Q. Do you disagree with that?</p> <p>3 A. No. I don't -- neither agree nor</p> <p>4 disagree.</p> <p>5 I thought you had said before that</p> <p>6 they used the NHS study, so I was confused --</p> <p>7 I'm a little bit confused now about which</p> <p>8 studies they used.</p> <p>9 Oh, it's the NHS component of the</p> <p>10 O'Brien, apparently. That's, I think, what</p> <p>11 this table is indicating that was used in --</p> <p>12 whereas, I used the entire O'Brien study.</p> <p>13 But it might be -- now that I think</p> <p>14 about it, it might be that the other components</p> <p>15 of the O'Brien study, the other cohorts did not</p> <p>16 include frequency questions in their</p> <p>17 questionnaire. I'm not quite sure. I'd have</p> <p>18 to read the article to see why they included</p> <p>19 only the NHS component.</p> <p>20 Q. You don't recall sitting here</p> <p>21 today?</p> <p>22 A. I'm sorry?</p> <p>23 Q. Sitting here today, you don't</p> <p>24 recall how they made that decision, correct?</p> <p>25 A. Correct.</p>
<p style="text-align: right;">Page 71</p> <p>1 A. I'm familiar with it.</p> <p>2 Q. Have you used it before?</p> <p>3 A. I'm sorry?</p> <p>4 Q. Have you used it before?</p> <p>5 A. No. I -- I don't believe that the</p> <p>6 quality of epidemiological studies can be</p> <p>7 summarized in these kind of mono-dimensional</p> <p>8 scales. So I'm skeptical about the principle,</p> <p>9 and I know that I can evaluate the quality of</p> <p>10 studies better than by using any automated</p> <p>11 tool, simplistic tool because epidemiological</p> <p>12 studies are extremely complicated. And you</p> <p>13 can't predict ahead of time which dimensions</p> <p>14 are -- might embody fatal flaws or serious</p> <p>15 flaws or flaws that are not serious, don't</p> <p>16 impact the result.</p> <p>17 But anyways, to answer your</p> <p>18 question, I'm familiar with the scale. I've</p> <p>19 never used it. I don't believe in it</p> <p>20 particularly. I've never had occasion to use</p> <p>21 it.</p> <p>22 Q. Which study does -- do the Woolen</p> <p>23 authors give the highest score to?</p> <p>24 MS. PARFITT: Objection. Form.</p> <p>25 THE WITNESS: To the O'Brien study.</p>	<p style="text-align: right;">Page 73</p> <p>1 Q. Would you agree or disagree with</p> <p>2 Woolen's decision to rate the cohort design</p> <p>3 higher than the case control designs?</p> <p>4 MS. PARFITT: Objection to form.</p> <p>5 THE WITNESS: I disagree if the</p> <p>6 implication of the question is that they</p> <p>7 did it because it was a cohort design. I</p> <p>8 would have to consider carefully all of</p> <p>9 the dimensions that go into determining</p> <p>10 the validity and quality of a result.</p> <p>11 And basically, I probably would</p> <p>12 disagree with it after I did look at all</p> <p>13 of that because cohort studies have a lot</p> <p>14 of disadvantages as well as case control</p> <p>15 studies.</p> <p>16 And depending on how the Newcastle</p> <p>17 Scale is weighted by people who developed</p> <p>18 it 20 years ago and were not familiar with</p> <p>19 these particular studies but just did it</p> <p>20 in a very generic, general way, I -- my</p> <p>21 appreciation -- my understanding of these</p> <p>22 studies is that the Nurses Health</p> <p>23 certain -- National Health Study -- so I'm</p> <p>24 not sure what the National Health Study --</p> <p>25 is that the Nurses Health Study?</p>

<p style="text-align: right;">Page 74</p> <p>1 Anyways, you're asking me</p> <p>2 questions. I'd have to spend a couple of</p> <p>3 minutes reading the paper to answer them</p> <p>4 properly because I'm a bit confused now</p> <p>5 about what was -- what they included.</p> <p>6 BY MS. DAVIDSON:</p> <p>7 Q. Dr. Siemiatycki, what was my</p> <p>8 question that you're currently answering?</p> <p>9 A. I think your question was whether I</p> <p>10 agree that the highest quality study was the</p> <p>11 cohort study among these various studies that</p> <p>12 they've listed. I think that was your</p> <p>13 question, whether I agree with that.</p> <p>14 Q. Please try to respond to the actual</p> <p>15 questions being asked because you do remember</p> <p>16 the question, but your response was not related</p> <p>17 to the question.</p> <p>18 Dr. Siemiatycki, if a woman is</p> <p>19 not --</p> <p>20 A. What -- you're saying that I</p> <p>21 already responded to it and then went off</p> <p>22 script or something.</p> <p>23 But what -- what response did you</p> <p>24 get from my first comment about it?</p> <p>25 I think --</p>	<p style="text-align: right;">Page 76</p> <p>1 Q. Correct. Thank you.</p> <p>2 And do you know the average age at</p> <p>3 which women start using talc?</p> <p>4 A. In a particular study or in</p> <p>5 general?</p> <p>6 Q. Have you seen any studies that</p> <p>7 identify the average age when women start using</p> <p>8 talc in their genital areas?</p> <p>9 A. I probably have, and I don't recall</p> <p>10 that particular factum; but I would guess it's</p> <p>11 somewhere between the ages of 13 and 25.</p> <p>12 Q. And do you know the average age at</p> <p>13 which women have a tubal ligation?</p> <p>14 A. I don't know that for a fact. I</p> <p>15 don't know that for a fact. I could -- I could</p> <p>16 guesstimate; but if you're asking me for</p> <p>17 factual information, I don't know.</p> <p>18 Q. Is it usually older than 15 to 25?</p> <p>19 MS. PARFITT: Objection.</p> <p>20 THE WITNESS: Yes.</p> <p>21 MS. DAVIDSON: All right. If we</p> <p>22 could turn to Table 2.</p> <p>23 MS. PARFITT: For the record, the</p> <p>24 Woolen article.</p> <p>25 THE WITNESS: Yes. Sorry. I'm not</p>
<p style="text-align: right;">Page 75</p> <p>1 Q. Dr. Siemiatycki --</p> <p>2 A. -- I explained --</p> <p>3 Q. Dr. Siemiatycki, if a woman does</p> <p>4 not have patent tubes at the time that she is</p> <p>5 interviewed in a -- if a woman does not have</p> <p>6 patent tubes at the time she's interviewed for</p> <p>7 an epidemiological study, does that mean she</p> <p>8 never used talc while she had patent tubes?</p> <p>9 MS. PARFITT: Objection. Form.</p> <p>10 THE WITNESS: Is this in relation</p> <p>11 to -- is this sequitur to the question</p> <p>12 that you've just been asking?</p> <p>13 I don't understand that question.</p> <p>14 BY MS. DAVIDSON:</p> <p>15 Q. Doctor, just answer the question.</p> <p>16 MS. PARFITT: I think --</p> <p>17 THE WITNESS: I'm trying to</p> <p>18 understand the question.</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. If a woman is interviewed for</p> <p>21 epidemiological study and at the time she is</p> <p>22 interviewed she no longer has patent tubes,</p> <p>23 does she mean she never used talc at the time</p> <p>24 when she had patent tubes?</p> <p>25 A. No.</p>	<p style="text-align: right;">Page 77</p> <p>1 sure if I've lost the audio.</p> <p>2 MS. PARFITT: Jessica, you went out</p> <p>3 completely, just so you know.</p> <p>4 BY MS. DAVIDSON:</p> <p>5 Q. The authors state, "We include data</p> <p>6 on women with intact fallopian tubes to</p> <p>7 harmonize with other publications."</p> <p>8 Do you see that at the bottom of</p> <p>9 Footnote 5? Doctor?</p> <p>10 A. Yeah. Sorry. I'm sorry. I'm</p> <p>11 reading the entire footnote.</p> <p>12 Q. I'm asking you about the last</p> <p>13 sentence in the footnote.</p> <p>14 Do you see it?</p> <p>15 MS. PARFITT: Jessica, he's reading</p> <p>16 the footnote.</p> <p>17 THE WITNESS: Do you want me to</p> <p>18 read only -- because my answer to the last</p> <p>19 sentence only will be I need to read the</p> <p>20 full footnote.</p> <p>21 So should I -- should we do it in</p> <p>22 two steps, or should I start reading the</p> <p>23 full --</p> <p>24 BY MS. DAVIDSON:</p> <p>25 Q. Doctor, please don't be difficult</p>

<p style="text-align: right;">Page 78</p> <p>1 here. We're trying to get through this 2 deposition. I'm asking you a question. 3 Do you see that the authors state, 4 "We include data on women with intact fallopian 5 tubes to harmonize with other publications"? 6 Do you see that sentence? 7 MS. PARFITT: I object to your 8 characterization of this witness being 9 difficult. That is unfair, and I 10 challenge that representation, Jessica. 11 Please move forward. Just ask the 12 questions not the commentary. 13 BY MS. DAVIDSON: 14 Q. Doctor, do you see that sentence, 15 for the third time? 16 A. I see -- I see that sentence, yes. 17 Q. Doctor, can you tell me which other 18 publications on this list in Table 2 were 19 limited to women with patent tubes, if any? 20 A. I don't know. I don't know. 21 Q. When you evaluated the Woolen 22 study, did you consider whether it was accurate 23 that including data on women with intact 24 fallopian tubes would harmonize this with other 25 publications?</p>	<p style="text-align: right;">Page 80</p> <p>1 Q. Right. But my question, Doctor, 2 was whether any of the other ten studies in 3 Table 2 limited -- were limited to women with 4 patent tubes. 5 A. I don't know. I'd have to look 6 through those studies. 7 Q. And then I asked: When you 8 reviewed this paper, did you look through the 9 studies to determine whether the other papers 10 were limited to women -- 11 A. No. 12 Q. -- with patent tubes? 13 A. No, no. 14 Q. That was my question. Thank you. 15 A. Okay. The answer's no. 16 Q. Doctor, if you could look at 17 Table 2, at the -- one, two, three, four, 18 five -- and the sixth column, specification of 19 talc exposure. 20 Do you see that? 21 A. Yes, I do. 22 Q. Which of these papers -- which of 23 these -- which of these relative risks used by 24 Dr. Woolen, et al., is limited -- reflects use 25 two times per week?</p>
<p style="text-align: right;">Page 79</p> <p>1 A. Well, I have some problem with the 2 formulation of that sentence because -- maybe 3 one of your previous questions hinted at 4 this -- but I think when people talk about 5 intact fallopian tubes and patent reproductive 6 tract and related to exposure to talc, there 7 should really be an appreciation of the 8 temporal relationship between those things. 9 So for sure women who used powder 10 and were -- and then had surgery, you have to 11 understand what the temporal sequence was 12 between these events to understand if there was 13 possible exposure to talc fibers, to talc 14 particles. 15 Q. Dr. Siemiatycki, what was my 16 question? 17 A. Could we have the stenographer read 18 back the question? 19 Q. You don't recall the question? 20 A. Well, I recall the theme of the 21 question, and I recall what I was trying to 22 convey, that timing is relevant to 23 understanding whether the exposure and the 24 possibility of disease are in harmony in any 25 way.</p>	<p style="text-align: right;">Page 81</p> <p>1 A. Reflects? 2 Q. Use of two times per week. 3 A. I don't know. I'd have to go 4 through them, but some of them are expressed in 5 different units; and so they are not expressed 6 in the two-times-per-week metric that you're 7 referring to. 8 Q. Do you know whether any of these 9 papers included other risk ratios for talc use 10 that more closely approximated two times per 11 week? 12 MS. PARFITT: Objection. Form. 13 THE WITNESS: No, I don't. 14 BY MS. DAVIDSON: 15 Q. Do you know how many of the papers 16 in Table 2 were not actually limited to 17 perineal talc use? 18 A. No, I don't. 19 Q. Are you aware that several of these 20 papers offered six or seven different risk 21 ratios for different specifications of talc 22 exposure? 23 MS. PARFITT: Objection. Form. 24 THE WITNESS: I would have guessed 25 that they do. Every paper usually</p>

<p style="text-align: right;">Page 82</p> <p>1 provides estimates of risk according to</p> <p>2 different parameterizations of the</p> <p>3 exposure variable. So I'm sure that these</p> <p>4 studies, most of them, would have done</p> <p>5 that.</p> <p>6 BY MS. DAVIDSON:</p> <p>7 Q. Did you determine how Woolen chose</p> <p>8 which risk ratio to use when there were</p> <p>9 multiple choices in one paper?</p> <p>10 A. No, I didn't.</p> <p>11 MS. DAVIDSON: All right. Let's go</p> <p>12 off the record.</p> <p>13 (Whereupon, a break was taken.)</p> <p>14 BY MS. DAVIDSON:</p> <p>15 Q. All right. Let's mark as Exhibit 2</p> <p>16 your Declaration of Interest that you submitted</p> <p>17 to IARC.</p> <p>18 (Whereupon, Defendant's Exhibit D2,</p> <p>19 Declaration of Interest for IARC/WHO</p> <p>20 Experts, was marked for identification.)</p> <p>21 BY MS. DAVIDSON:</p> <p>22 Q. Okay. You're familiar with this</p> <p>23 document?</p> <p>24 A. Yes.</p> <p>25 Q. And what's the date of it?</p>	<p style="text-align: right;">Page 84</p> <p>1 about it?</p> <p>2 BY MS. DAVIDSON:</p> <p>3 Q. Is it your testimony today that</p> <p>4 that's accurate?</p> <p>5 A. I'm sorry?</p> <p>6 Q. Is it your testimony today that</p> <p>7 what you wrote here was accurate?</p> <p>8 A. At the time that I wrote it, yes.</p> <p>9 Q. So at the time that you wrote it in</p> <p>10 2023, you believed that you had stopped</p> <p>11 providing paid consultation services in this</p> <p>12 litigation in 2020?</p> <p>13 MS. PARFITT: Objection. Form.</p> <p>14 THE WITNESS: I think so.</p> <p>15 BY MS. DAVIDSON:</p> <p>16 Q. When were you deposed last in this</p> <p>17 litigation, Dr. Siemiatycki?</p> <p>18 A. In 2021. Yes. Excuse me.</p> <p>19 Q. And you provided a -- did you</p> <p>20 provide a supplemental expert report in 2021?</p> <p>21 A. A supplemental?</p> <p>22 Q. Did you provide an expert report in</p> <p>23 2021?</p> <p>24 A. Yes. Yes, I did. Yes, I did.</p> <p>25 Q. Were you paid for that expert</p>
<p style="text-align: right;">Page 83</p> <p>1 A. It says July 28th, 2023.</p> <p>2 Q. And that's the same day on which</p> <p>3 you submitted you're -- that's the same day on</p> <p>4 which you submitted your letter?</p> <p>5 A. I can't say for sure. I -- if you</p> <p>6 have my letter, you -- you could show me that;</p> <p>7 or I could check my e-mail.</p> <p>8 Q. Were they submitted at</p> <p>9 approximately the same time?</p> <p>10 A. Yes, yes.</p> <p>11 Q. Okay. Great. That's my question.</p> <p>12 A. Okay.</p> <p>13 Q. If we could go to your Statement of</p> <p>14 Conflict, if you could read what you wrote</p> <p>15 there because -- at the bottom.</p> <p>16 A. Yes. Okay.</p> <p>17 It says, "From 2016 to 2020</p> <p>18 January, I provided paid consultation services</p> <p>19 to a law firm -- to law firms that were</p> <p>20 involved in litigation against companies that</p> <p>21 produced or sold talcum powder products."</p> <p>22 Q. And, Dr. Siemiatycki, that's not</p> <p>23 accurate, correct?</p> <p>24 MS. PARFITT: Objection. Form.</p> <p>25 THE WITNESS: What's inaccurate</p>	<p style="text-align: right;">Page 85</p> <p>1 report?</p> <p>2 A. Yes.</p> <p>3 Q. So, in fact --</p> <p>4 A. Okay. Yeah.</p> <p>5 Q. -- your statement of declaration is</p> <p>6 inaccurate, correct?</p> <p>7 A. That's correct.</p> <p>8 Q. All right. Can we go to your</p> <p>9 letter?</p> <p>10 MS. PARFITT: Do you want to put</p> <p>11 that in chat. I have a copy of it but --</p> <p>12 MS. DAVIDSON: We're going to mark</p> <p>13 the letter as Exhibit 3.</p> <p>14 MS. PARFITT: Okay.</p> <p>15 (Whereupon, Defendant's Exhibit D3,</p> <p>16 Letter from Jack Siemiatycki to IARC re</p> <p>17 Talc/Acrylonitrile Monograph 136, was</p> <p>18 marked for identification.)</p> <p>19 MS. DAVIDSON: Noah, are you</p> <p>20 putting it up on the screen?</p> <p>21 MR. EPSTEIN: There you go.</p> <p>22 MS. DAVIDSON: Noah, again you</p> <p>23 forget --</p> <p>24 MR. EPSTEIN: I shared it in chat.</p> <p>25 MS. DAVIDSON: Can you make it</p>

<p style="text-align: right;">Page 86</p> <p>1 bigger?</p> <p>2 MS. PARFITT: Jessica, I have a</p> <p>3 copy of it.</p> <p>4 MS. DAVIDSON: I'm sorry. I can't</p> <p>5 hear you, Michelle.</p> <p>6 MS. PARFITT: I have a copy of the</p> <p>7 letter too. I'm going to put it in front</p> <p>8 of him, unless you object. It's a little</p> <p>9 bit easier to see. It's hard on the</p> <p>10 screen.</p> <p>11 MS. DAVIDSON: Okay.</p> <p>12 MS. PARFITT: It's the same as you</p> <p>13 have it on the screen.</p> <p>14 MS. DAVIDSON: I want it on the</p> <p>15 screen as well, Noah. I don't know why</p> <p>16 you pulled it down.</p> <p>17 MR. EPSTEIN: I'm -- I'm making the</p> <p>18 bigger.</p> <p>19 MS. DAVIDSON: You can just zoom.</p> <p>20 Text Asher; ask him how to do it. He</p> <p>21 knows how. I can just zoom it on my own</p> <p>22 screen if everybody else has their --</p> <p>23 MS. PARFITT: He has a paper copy</p> <p>24 too. It may good for others that are</p> <p>25 participating, but I've given him a paper</p>	<p style="text-align: right;">Page 88</p> <p>1 the future."</p> <p>2 That's inaccurate as well correct?</p> <p>3 MS. PARFITT: Objection. Form.</p> <p>4 THE WITNESS: Yes. The three-years</p> <p>5 estimate is inaccurate. The next part of</p> <p>6 the sentence is accurate. At that time I</p> <p>7 didn't anticipate future involvement.</p> <p>8 BY MS. DAVIDSON:</p> <p>9 Q. When did plaintiff's counsel</p> <p>10 approach you about the expert report that you</p> <p>11 submitted in the fall of 2023?</p> <p>12 A. It was a few months before --</p> <p>13 before I submitted it.</p> <p>14 Q. How many months?</p> <p>15 A. I'm sorry?</p> <p>16 Q. How many months before?</p> <p>17 A. I -- I can't remember. I -- I'd</p> <p>18 have to look for evidence in emails or</p> <p>19 something like that; but off the top of my</p> <p>20 head, I don't recall. It wasn't like six</p> <p>21 months before. It was a few -- a few months</p> <p>22 before.</p> <p>23 Q. Okay. Did you have any</p> <p>24 communications with plaintiff's counsel in this</p> <p>25 litigation between 2020 and 2023?</p>
<p style="text-align: right;">Page 87</p> <p>1 copy; and I'll make sure it's provided and</p> <p>2 Xeroxed.</p> <p>3 MS. DAVIDSON: Okay.</p> <p>4 BY MS. DAVIDSON:</p> <p>5 Q. If we could go to -- it says, "In</p> <p>6 the ensuing three years, 2016 to 2019, I</p> <p>7 contributed reports to a few court cases and</p> <p>8 was deposed by the lawyers for the defense; and</p> <p>9 in one case I testified in court," right?</p> <p>10 A. Sorry. I'm not sure where</p> <p>11 you're -- where are you reading?</p> <p>12 Q. Under legal consultation related to</p> <p>13 talc --</p> <p>14 A. Oh, yes. Yeah.</p> <p>15 Q. That -- that statement, 2016 to</p> <p>16 2019, that's inaccurate as well, correct?</p> <p>17 MS. PARFITT: Objection. Form.</p> <p>18 THE WITNESS: Yes. Yes.</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. Okay. And if we could continue</p> <p>21 down, down to conflict of interest.</p> <p>22 A. Yes.</p> <p>23 Q. It says, "I have not been involved</p> <p>24 with talc litigation in the past three years,</p> <p>25 and I do not anticipate any such involvement in</p>	<p style="text-align: right;">Page 89</p> <p>1 A. Well, there was -- as you pointed</p> <p>2 out, the 2021, there was a deposition and the</p> <p>3 report; so yes.</p> <p>4 Q. And after you submitted -- after</p> <p>5 you were deposed in 2021, have you spoken --</p> <p>6 did you speak with any plaintiff's counsel</p> <p>7 between 2021 after you were deposed and the</p> <p>8 time when you submitted your expert report in</p> <p>9 the fall of 2023?</p> <p>10 A. I don't recall.</p> <p>11 Q. Okay. Let's move on.</p> <p>12 MS. DAVIDSON: Oh, Asher, can you</p> <p>13 put -- I'm sorry.</p> <p>14 Noah, can you put up that -- the</p> <p>15 table?</p> <p>16 MR. EPSTEIN: Which table?</p> <p>17 MS. DAVIDSON: On page -- the next</p> <p>18 page.</p> <p>19 MR. EPSTEIN: Right there at the</p> <p>20 bottom?</p> <p>21 MS. DAVIDSON: Uh-huh. It starts</p> <p>22 with Oules and Echeverria. Yes.</p> <p>23 BY MS. DAVIDSON:</p> <p>24 Q. Dr. Siemiatycki, is this table</p> <p>25 accurate?</p>

<p style="text-align: right;">Page 90</p> <p>1 Let me ask a different question.</p> <p>2 Is this table complete and</p> <p>3 accurate?</p> <p>4 A. Yeah. I'm looking at the paper</p> <p>5 version that Ms. Parfitt just handed me, I</p> <p>6 think.</p> <p>7 Q. I'm just looking at the table</p> <p>8 that's on the screen.</p> <p>9 I'm asking you is this table</p> <p>10 complete and accurate?</p> <p>11 It's a simple question.</p> <p>12 A. I understand, and I'm trying to</p> <p>13 rack my memory to --</p> <p>14 Q. Well, I can make it easy for you.</p> <p>15 You submitted an expert report in 2021, and you</p> <p>16 were deposed in 2021, correct?</p> <p>17 A. Correct.</p> <p>18 Q. And that's not included on this</p> <p>19 table, correct?</p> <p>20 A. That's correct.</p> <p>21 Q. So the table is not complete and</p> <p>22 accurate, correct?</p> <p>23 A. That's correct.</p> <p>24 Q. Thank you.</p> <p>25 MS. DAVIDSON: Let's mark as</p>	<p style="text-align: right;">Page 92</p> <p>1 correct?</p> <p>2 A. That's correct.</p> <p>3 Q. And the final author, Anita</p> <p>4 Koushik, is that the woman you said that you</p> <p>5 may be doing another case control paper with?</p> <p>6 A. It's another paper using the data</p> <p>7 from a case control study from this same --</p> <p>8 Q. Okay.</p> <p>9 A. -- case control study, yes.</p> <p>10 Q. Okay. It's from this very same</p> <p>11 study?</p> <p>12 A. Yes.</p> <p>13 Q. So in other words, it's from the</p> <p>14 same group of women as this?</p> <p>15 A. Yes, that's correct.</p> <p>16 Q. Okay. Looking at this paper, does</p> <p>17 it refresh your recollection as to whether you</p> <p>18 included a conflict-of-interest statement?</p> <p>19 A. Yes. I see that there were no</p> <p>20 competing interests declared.</p> <p>21 Q. Do you recall why you failed to do</p> <p>22 that?</p> <p>23 A. Because I had no competing</p> <p>24 interests with the --</p> <p>25 Q. Did this paper address --</p>
<p style="text-align: right;">Page 91</p> <p>1 Exhibit 4 the Leung paper.</p> <p>2 (Whereupon, Defendant's Exhibit D4,</p> <p>3 Paper entitled, "Occupational environment</p> <p>4 and ovarian cancer risk," by Lisa</p> <p>5 Leung, et al., was marked for</p> <p>6 identification.)</p> <p>7 MS. DAVIDSON: Noah will put it in</p> <p>8 the chat and put it on the screen.</p> <p>9 MS. PARFITT: I'll hand you a copy</p> <p>10 of that.</p> <p>11 THE WITNESS: If you have a copy.</p> <p>12 MS. DAVIDSON: I can't hear you,</p> <p>13 Michelle, for some reason.</p> <p>14 MS. PARFITT: Oh, that's all right.</p> <p>15 I said I'm just handing him a completely</p> <p>16 unedited, nothing on it, which we'll turn</p> <p>17 over to you. It's a little bit easier.</p> <p>18 MS. DAVIDSON: Noah, if you --</p> <p>19 MR. EPSTEIN: I put it on the chat,</p> <p>20 and here it is on the screen.</p> <p>21 MS. DAVIDSON: Okay.</p> <p>22 BY MS. DAVIDSON:</p> <p>23 Q. I'm marking as Exhibit 4</p> <p>24 "Occupational environment and ovarian cancer</p> <p>25 risk," on which you're the third author,</p>	<p style="text-align: right;">Page 93</p> <p>1 A. Sorry?</p> <p>2 Q. Did this paper address talc and</p> <p>3 ovarian cancer?</p> <p>4 A. It doesn't address cosmetic</p> <p>5 perineal talc, no. That -- that's -- that was</p> <p>6 the issue on which I would have had a conflict</p> <p>7 of interest.</p> <p>8 Q. Did you ask the -- did you ask the</p> <p>9 publishers whether it is accurate and proper to</p> <p>10 not include your competing interest when the</p> <p>11 paper addresses talc exposure generally rather</p> <p>12 than limited to perineal talc?</p> <p>13 MS. PARFITT: Objection. Form.</p> <p>14 THE WITNESS: No, I didn't consult</p> <p>15 anybody.</p> <p>16 BY MS. DAVIDSON:</p> <p>17 Q. Okay. Do you recall testifying in</p> <p>18 2021 that you believed it is important for a</p> <p>19 paid expert in litigation to disclose both the</p> <p>20 fact that he or she has been retained as an</p> <p>21 expert and which side he or she is retained on</p> <p>22 behalf of?</p> <p>23 A. Are you asking if I recall saying</p> <p>24 that, or if I would say --</p> <p>25 Q. Well, first, do you recall that?</p>

<p style="text-align: right;">Page 94</p> <p>1 A. No, I don't recall.</p> <p>2 Q. Do you disagree with that</p> <p>3 statement?</p> <p>4 A. No, I don't disagree with it.</p> <p>5 Q. Let's go to the Davis paper, 2021.</p> <p>6 Let's mark that as Exhibit 4.</p> <p>7 A. Sorry. The Davis paper?</p> <p>8 Q. Yes.</p> <p>9 THE COURT REPORTER: I'm sorry. I</p> <p>10 think that should be Exhibit 5.</p> <p>11 MS. DAVIDSON: Oh, okay. Great. I</p> <p>12 can never get it right. It's a running</p> <p>13 joke that I can never keep track.</p> <p>14 All right. We're marking as</p> <p>15 Exhibit 5 a paper entitled --</p> <p>16 THE WITNESS: Michelle, are you</p> <p>17 looking for that or should I --</p> <p>18 MS. PARFITT: Yeah. Give us one</p> <p>19 second.</p> <p>20 BY MS. DAVIDSON:</p> <p>21 Q. -- "Genital powder use and risk of</p> <p>22 epithelial ovarian cancer --</p> <p>23 A. Wait. Hold on. Wait. We're</p> <p>24 looking for the article.</p> <p>25 Q. Okay. That's fine. I'm marking it</p>	<p style="text-align: right;">Page 96</p> <p>1 paper --</p> <p>2 MR. TISI: What's confusing --</p> <p>3 MS. DAVIDSON: -- great. Let's go</p> <p>4 off the record.</p> <p>5 MR. TISI: Excuse me.</p> <p>6 MS. DAVIDSON: Chris, we have one</p> <p>7 person --</p> <p>8 MR. TISI: Excuse me.</p> <p>9 MS. DAVIDSON: No. We have one</p> <p>10 person defending this deposition.</p> <p>11 MR. TISI: I understand, but it's</p> <p>12 confusing. It's about 6 inches.</p> <p>13 MS. DAVIDSON: Okay.</p> <p>14 MR. TISI: 6 inches. I got to get</p> <p>15 him the copy of the paper.</p> <p>16 MS. DAVIDSON: Is it you or</p> <p>17 Michelle defending this deposition?</p> <p>18 MR. TISI: Okay. Michelle, will</p> <p>19 you tell her how big the screen is.</p> <p>20 MS. DAVIDSON: Let's go off the</p> <p>21 record while you look for the paper.</p> <p>22 MR. TISI: Fine. Thank you.</p> <p>23 (Discussion held off the record.)</p> <p>24 BY MS. DAVIDSON:</p> <p>25 Q. I'd like to read the conflict of</p>
<p style="text-align: right;">Page 95</p> <p>1 as an exhibit.</p> <p>2 A. Okay. Thank you. Sorry.</p> <p>3 Q. We're marking as Exhibit 5,</p> <p>4 "Genital powder use and risk of epithelial</p> <p>5 ovarian cancer in the ovarian cancer in women</p> <p>6 of African ancestry consortium." First author</p> <p>7 Davis, published in 2021.</p> <p>8 (Whereupon, Defendant's Exhibit D5,</p> <p>9 Paper entitled, "Genital powder use and</p> <p>10 risk of epithelial ovarian cancer in the</p> <p>11 Ovarian Cancer in Women of African</p> <p>12 Ancestry Consortium," by Colette P.</p> <p>13 Davis, et al., was marked for</p> <p>14 identification.)</p> <p>15 BY MS. DAVIDSON:</p> <p>16 Q. Can you please turn to the bottom</p> <p>17 of page 1?</p> <p>18 MR. TISI: You've got -- you've got</p> <p>19 to wait until we get the paper. Okay?</p> <p>20 It's okay for you to identify it.</p> <p>21 MS. DAVIDSON: I'm sorry. We sent</p> <p>22 it to you in the chat.</p> <p>23 MR. TISI: I understand, but --</p> <p>24 MS. DAVIDSON: Fine. If you're</p> <p>25 going to take the time to find the</p>	<p style="text-align: right;">Page 97</p> <p>1 disclosure statement. It says --</p> <p>2 A. Sorry?</p> <p>3 Q. It says, "Patricia Moorman has</p> <p>4 received compensation for work related to</p> <p>5 litigation in regard to talc and ovarian</p> <p>6 cancer. All other authors report no conflict</p> <p>7 of interest."</p> <p>8 Did I read that correctly?</p> <p>9 A. Yes.</p> <p>10 Q. Does -- does Ms. -- Dr. Moorman</p> <p>11 disclose here which side she testified on</p> <p>12 behalf of?</p> <p>13 MS. PARFITT: Objection. Form.</p> <p>14 THE WITNESS: I don't see that</p> <p>15 indicated, no.</p> <p>16 BY MS. DAVIDSON:</p> <p>17 Q. And do you recall that you</p> <p>18 testified in 2021 that a proper</p> <p>19 conflict-of-interest disclosure would say which</p> <p>20 side you're appearing on behalf of, correct?</p> <p>21 A. Yes, yes.</p> <p>22 Q. Okay. Thank you.</p> <p>23 If we could turn to Table 3.</p> <p>24 A. Of what? Of the Davis paper?</p> <p>25 Q. Yeah. We're still on the Davis</p>

25 (Pages 94 - 97)

<p style="text-align: right;">Page 98</p> <p>1 paper.</p> <p>2 A. Okay.</p> <p>3 Q. Table 3 for African American women,</p> <p>4 the OR is lower than for all participants and</p> <p>5 for white participants and also is not</p> <p>6 statistically significant, correct?</p> <p>7 A. I'm still looking for that page.</p> <p>8 Sorry.</p> <p>9 Table 3 you said?</p> <p>10 Q. Yeah. It's up on the screen.</p> <p>11 A. Yeah. I'm sorry. The screen font</p> <p>12 is too small for me to read.</p> <p>13 But I have the paper in front of</p> <p>14 me.</p> <p>15 Can you repeat your question?</p> <p>16 Q. The OR for African American women</p> <p>17 is lower than the OR for white women, correct?</p> <p>18 A. Sorry. I don't see -- where --</p> <p>19 where are the results for African American</p> <p>20 women?</p> <p>21 Oh, yes, yes. Okay. I'm</p> <p>22 reorienting myself to this particular layout.</p> <p>23 And which particular -- can you</p> <p>24 point to particular cells in this table that</p> <p>25 you are looking at?</p>	<p style="text-align: right;">Page 100</p> <p>1 women is statistically significant, correct?</p> <p>2 MS. PARFITT: Objection. Form.</p> <p>3 THE WITNESS: That's correct.</p> <p>4 BY MS. DAVIDSON:</p> <p>5 Q. Thank you.</p> <p>6 A. The term "statistically</p> <p>7 significant" has to be qualified.</p> <p>8 You mean at the .05 level, I</p> <p>9 assume.</p> <p>10 Q. Thank you.</p> <p>11 A. Is that correct?</p> <p>12 To clarify your question. Because</p> <p>13 statistical significance --</p> <p>14 MS. PARFITT: He's still talking.</p> <p>15 BY MS. DAVIDSON:</p> <p>16 Q. I understand your testimony.</p> <p>17 A. -- depends on the level of alpha</p> <p>18 error that you assume in the test.</p> <p>19 Q. The Davis paper did not find a</p> <p>20 dose-response relationship, right?</p> <p>21 A. I -- I don't know.</p> <p>22 In which -- which table would I</p> <p>23 find those results?</p> <p>24 Q. You don't recall from reviewing</p> <p>25 this paper?</p>
<p style="text-align: right;">Page 99</p> <p>1 Q. I'm just asking you,</p> <p>2 Dr. Siemiatycki, is the OR for African American</p> <p>3 women lower than the OR for white women?</p> <p>4 A. The results here for all cases,</p> <p>5 high-grade --</p> <p>6 Q. All cases. Let's look at all</p> <p>7 cases.</p> <p>8 A. Okay. Thank you for that. So --</p> <p>9 so the 1.22 for African American women and</p> <p>10 versus the 1.32 for all participants, is that</p> <p>11 what you're comparing or asking me?</p> <p>12 Q. Doctor, I asked about white women,</p> <p>13 correct?</p> <p>14 A. No. I -- I didn't remember every</p> <p>15 word that you used in your preamble.</p> <p>16 So yes. Thank you.</p> <p>17 Q. It wasn't a preamble. It was a</p> <p>18 question.</p> <p>19 And my question was: Is the OR for</p> <p>20 African American women under all cases lower</p> <p>21 than for white women?</p> <p>22 A. The point estimate is lower, yes.</p> <p>23 Q. And also, the point estimate for</p> <p>24 African American women is not statistically</p> <p>25 significant, while the point estimate for white</p>	<p style="text-align: right;">Page 101</p> <p>1 When's the last time you looked at</p> <p>2 this paper, Doctor?</p> <p>3 MS. PARFITT: Jessica, I might add</p> <p>4 that I will give you a little leeway; but</p> <p>5 back in your '21 deposition -- and I can</p> <p>6 give you the pages -- Dr. Siemiatycki was</p> <p>7 examined with regard to the Davis paper on</p> <p>8 page --</p> <p>9 MS. DAVIDSON: Michelle, I'm not</p> <p>10 going to go through this with every</p> <p>11 question. It was added to his 2021 report</p> <p>12 -- to his 2023. It wasn't in that report.</p> <p>13 I'm more than able to ask him about it.</p> <p>14 If you want to take that to the judge, go</p> <p>15 ahead because we'll win.</p> <p>16 BY MS. DAVIDSON:</p> <p>17 Q. Dr. Siemiatycki --</p> <p>18 MS. PARFITT: Well, Jessica, that's</p> <p>19 quite conclusionary. But my point being</p> <p>20 this: You examined on page 143 of his</p> <p>21 2021 deposition the Davis article. Let</p> <p>22 this record reflect that. I'll give you a</p> <p>23 little leeway, Jessica.</p> <p>24 MS. DAVIDSON: You're not giving me</p> <p>25 leeway, Michelle. That's bullshit. I</p>

<p style="text-align: right;">Page 102</p> <p>1 mean, come on.</p> <p>2 MS. PARFITT: Oh, my goodness,</p> <p>3 Jessica. You should watch your language.</p> <p>4 MS. DAVIDSON: Michelle, it's just</p> <p>5 like this entire deposition, every</p> <p>6 question I ask, either you're</p> <p>7 filibustering it or Dr. Siemiatycki's</p> <p>8 answering a question I haven't asked.</p> <p>9 It's getting very, very frustrating. It's</p> <p>10 getting very frustrating.</p> <p>11 You know very well that he added a</p> <p>12 section to his report about Davis. I'm</p> <p>13 sorry for my foul language. I'm just</p> <p>14 incredibly, incredibly frustrated because</p> <p>15 I'm asking you guys to just let me ask my</p> <p>16 questions. Let the doctor answer them.</p> <p>17 You know there's this in the</p> <p>18 report. You're not giving me leeway.</p> <p>19 It's the -- there's no need for leeway</p> <p>20 because it's added to his report. Like,</p> <p>21 to suggest that you're giving me leeway,</p> <p>22 is disingenuous.</p> <p>23 And, again, I apologize for losing</p> <p>24 my temper. I apologize for my foul mouth,</p> <p>25 but you're not giving me any leeway.</p>	<p style="text-align: right;">Page 104</p> <p>1 with Ms. Parfitt?</p> <p>2 A. No. I had 200 papers in my</p> <p>3 binders, and I didn't look at all of them in</p> <p>4 the last three days. And I looked at the ones</p> <p>5 that I considered the most important ones, not</p> <p>6 necessarily the ones -- well, so I would have</p> <p>7 to look at the paper to answer your questions</p> <p>8 about it. I can't, by memory, recall</p> <p>9 everything that's in the paper.</p> <p>10 Q. So you do not recall whether the</p> <p>11 Davis paper found a dose response?</p> <p>12 A. Not without looking at it.</p> <p>13 Q. If I were to tell you that the</p> <p>14 Davis paper stated, "Furthermore, there was not</p> <p>15 a dose-response relationship between frequency</p> <p>16 or duration of genital powder use and ovarian</p> <p>17 cancer risk or any significant differences in</p> <p>18 association by histotype," that does not</p> <p>19 refresh your recollection?</p> <p>20 MS. PARFITT: Can you point us to a</p> <p>21 page, Jessica?</p> <p>22 MS. DAVIDSON: I'm sorry, Michelle?</p> <p>23 MS. PARFITT: Maybe -- I'm sorry.</p> <p>24 If you could just point him to a page.</p> <p>25 MS. DAVIDSON: Asher -- I keep</p>
<p style="text-align: right;">Page 103</p> <p>1 This was added to his report; and</p> <p>2 obviously it's fair game for questioning,</p> <p>3 Michelle.</p> <p>4 And you and I generally get along,</p> <p>5 so let's just get along today.</p> <p>6 Again, I'm sorry I lost my temper.</p> <p>7 BY MS. DAVIDSON:</p> <p>8 Q. Dr. Siemiatycki?</p> <p>9 MS. PARFITT: Let's --</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. Dr. Siemiatycki, when is the last</p> <p>12 time you looked at the Davis paper?</p> <p>13 A. I can't recall. I certainly</p> <p>14 haven't done a sort of an in-depth forensic</p> <p>15 evaluation of it in at least a month or so or</p> <p>16 maybe longer, but I -- I probably skimmed it</p> <p>17 recently; but not -- it's not -- it's not fresh</p> <p>18 in my memory.</p> <p>19 Q. You didn't look at it when you were</p> <p>20 preparing for your deposition with Ms. --</p> <p>21 A. When I --</p> <p>22 Q. -- with Ms. Parfitt?</p> <p>23 A. When I looked at what?</p> <p>24 Q. Did you look at the Davis paper</p> <p>25 when you were preparing for your deposition</p>	<p style="text-align: right;">Page 105</p> <p>1 calling Noah Asher. Asher is on vacation.</p> <p>2 Noah, can you please put up this</p> <p>3 language?</p> <p>4 MS. PARFITT: Thank you, Jessica.</p> <p>5 We appreciate it.</p> <p>6 MS. DAVIDSON: Of course.</p> <p>7 THE WITNESS: Am I waiting for you</p> <p>8 to point out a page?</p> <p>9 MS. PARFITT: He just put it on the</p> <p>10 screen.</p> <p>11 BY MS. DAVIDSON:</p> <p>12 Q. "We observed" -- it's in the bottom</p> <p>13 paragraph there: "We observed no clear</p> <p>14 dose-response trends for frequency or duration</p> <p>15 of genital powder use and ovarian cancer risk</p> <p>16 among AA women or white women."</p> <p>17 Do you see that?</p> <p>18 A. Yes.</p> <p>19 MS. PARFITT: It's on page 8</p> <p>20 doctor.</p> <p>21 THE WITNESS: Yes, I do.</p> <p>22 BY MS. DAVIDSON:</p> <p>23 Q. Did you address that in your</p> <p>24 report?</p> <p>25 A. What do you mean by did I "address</p>

<p style="text-align: right;">Page 106</p> <p>1 that?"</p> <p>2 Q. Did you address in your report the</p> <p>3 fact that Davis did not find a dose-response</p> <p>4 relationship?</p> <p>5 A. No, I didn't.</p> <p>6 Q. Okay.</p> <p>7 A. It didn't change anything in my --</p> <p>8 it wouldn't have changed anything in my report.</p> <p>9 Q. So if we could mark your report as</p> <p>10 Exhibit 6.</p> <p>11 (Whereupon, Defendant's Exhibit D6,</p> <p>12 Second Amended Expert Report of Jack</p> <p>13 Siemiatycki, MSc, PhD, was marked for</p> <p>14 identification.)</p> <p>15 BY MS. DAVIDSON:</p> <p>16 Q. In the back of your report, Doctor,</p> <p>17 you have some tables, right?</p> <p>18 A. Yes.</p> <p>19 Q. And some of those tables address</p> <p>20 dose response, right?</p> <p>21 A. Yes.</p> <p>22 MS. PARFITT: He is still looking</p> <p>23 at the Davis paper. You've now directed</p> <p>24 him to the expert report.</p> <p>25 Jessica, I'll make comment too. I</p>	<p style="text-align: right;">Page 108</p> <p>1 tables is that it overlaps with other papers?</p> <p>2 A. Yes.</p> <p>3 Q. Okay. Let's move on.</p> <p>4 Let's look at Phung 2022.</p> <p>5 MS. PARFITT: Jessica, we're just</p> <p>6 grabbing his paper.</p> <p>7 MS. DAVIDSON: No problem. No</p> <p>8 problem. Phung 2022 is Exhibit 7.</p> <p>9 (Whereupon, Defendant's Exhibit D7,</p> <p>10 Paper entitled, "Effects of risk factors</p> <p>11 for ovarian cancer in women with and</p> <p>12 without endometriosis," by Minh Tung</p> <p>13 Phung, MPH, PhD, et al., was marked for</p> <p>14 identification.)</p> <p>15 MS. DAVIDSON: Let's -- let's mark</p> <p>16 it as, "Effects of risk factors for</p> <p>17 ovarian cancer in women with and without</p> <p>18 endometriosis." The first author is Phung</p> <p>19 2022.</p> <p>20 MR. TISI: Wait a second.</p> <p>21 MS. DAVIDSON: And I want to go</p> <p>22 down to page -- I want to -- okay. Sure.</p> <p>23 I just want to go to page 960.</p> <p>24 MR. TISI: We're not listening to</p> <p>25 you right now because he's finding the</p>
<p style="text-align: right;">Page 107</p> <p>1 know this is really hard. He's a little</p> <p>2 hard of hearing.</p> <p>3 So just -- just -- I'm being</p> <p>4 delicate, Doctor. I'll make that point.</p> <p>5 She's just told you she's gone to your</p> <p>6 expert report.</p> <p>7 THE WITNESS: Okay.</p> <p>8 MS. PARFITT: Thank you, Jessica.</p> <p>9 I appreciate it.</p> <p>10 MS. DAVIDSON: Michelle, nobody has</p> <p>11 ever complained that my voice is too soft.</p> <p>12 It's usually the opposite.</p> <p>13 BY MS. DAVIDSON:</p> <p>14 Q. Doctor, did you add the Davis paper</p> <p>15 to the tables in the back of your report?</p> <p>16 A. No, I didn't. In fact, it's coming</p> <p>17 back to me. My recollection is that the data</p> <p>18 in the Davis paper, in fact, overlaps with the</p> <p>19 data in some of the other stud- -- some of the</p> <p>20 other articles that have been written.</p> <p>21 And if you give me some time, I'll</p> <p>22 try to figure out which papers it overlaps</p> <p>23 with.</p> <p>24 Q. So, Doctor, your testimony is that</p> <p>25 the reason you didn't include Davis in your</p>	<p style="text-align: right;">Page 109</p> <p>1 paper.</p> <p>2 MS. DAVIDSON: Understood.</p> <p>3 Understood.</p> <p>4 MR. TISI: Give us a moment, and</p> <p>5 we'll see if we can find it.</p> <p>6 MS. DAVIDSON: I want to go to the</p> <p>7 authors' conflict statement.</p> <p>8 For some reason, Noah, I have</p> <p>9 different page numbers because sometimes</p> <p>10 one is the one pulled off the web, and one</p> <p>11 is the one that's not; and I think that's</p> <p>12 creating some confusion with you. But</p> <p>13 yes, this is --</p> <p>14 MR. EPSTEIN: Yeah. I'm seeing</p> <p>15 that.</p> <p>16 Am I in the right spot.</p> <p>17 MS. DAVIDSON: That was the problem</p> <p>18 with the Davis paper as well.</p> <p>19 MR. EPSTEIN: Sorry about that.</p> <p>20 MS. DAVIDSON: I have different</p> <p>21 versions. I'm sorry about that, but now</p> <p>22 you're moving --</p> <p>23 MR. EPSTEIN: Okay. Did I -- did</p> <p>24 I --</p> <p>25 MS. DAVIDSON: You've just gone to</p>

<p style="text-align: right;">Page 110</p> <p>1 the wrong page. I want to go to the</p> <p>2 disclosures.</p> <p>3 It's weird. What you have up here</p> <p>4 has some Spanish in it. Okay. So here we</p> <p>5 go. Yeah. Down there.</p> <p>6 MR. EPSTEIN: Okay.</p> <p>7 BY MS. DAVIDSON:</p> <p>8 Q. If we look at the disclosures</p> <p>9 acknowledgements, Doctor.</p> <p>10 A. I'm sorry. Look at what?</p> <p>11 Q. We're looking at the, I believe</p> <p>12 it's the very last page, acknowledgements.</p> <p>13 It says -- and I'll read to you,</p> <p>14 except it's -- you have issues with your ears.</p> <p>15 I have issues with my eyes. We're a great</p> <p>16 pair -- we're a great pair here today. But it</p> <p>17 says --</p> <p>18 A. Hear no evil. See no evil.</p> <p>19 Q. It says, "D.W.C. reports payments</p> <p>20 from expert -- for expert testimony from</p> <p>21 Ferraro Law Firm and Ashcraft and Gerel Law</p> <p>22 Firm."</p> <p>23 Do you see that?</p> <p>24 A. In the last -- in the paragraph</p> <p>25 labeled "Acknowledgements"?</p>	<p style="text-align: right;">Page 112</p> <p>1 Ashcraft and Gerel is or the Ferraro Law Firm?</p> <p>2 A. I doubt it but --</p> <p>3 Q. Okay. So -- so the average person</p> <p>4 would not -- who reads this -- who reads</p> <p>5 medical journals would not know whether</p> <p>6 Dr. Cramer was a witness for the plaintiffs or</p> <p>7 for the defense, correct?</p> <p>8 MS. PARFITT: Objection. Form.</p> <p>9 THE WITNESS: Correct. Correct.</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. Okay. Let's move on.</p> <p>12 If we could look at Table 2.</p> <p>13 A. Of which paper now?</p> <p>14 Q. We're on the same paper.</p> <p>15 A. Okay.</p> <p>16 Q. Table 2.</p> <p>17 MS. DAVIDSON: You've got to turn</p> <p>18 it right side up, Noah.</p> <p>19 MR. EPSTEIN: Yeah. Let me figure</p> <p>20 out how to do that. Sorry about that.</p> <p>21 MS. DAVIDSON: Noah has been a</p> <p>22 lawyer for three months, so let's all give</p> <p>23 him a kudos for doing a great job.</p> <p>24 MS. PARFITT: Jessica, we're fine</p> <p>25 with that.</p>
<p style="text-align: right;">Page 111</p> <p>1 Q. Yes. So the third paragraph,</p> <p>2 "Acknowledgements" on line 6.</p> <p>3 A. I must not be looking in the right</p> <p>4 place.</p> <p>5 Q. If you look up on the -- on the</p> <p>6 camera -- on the screen, I will read it to you.</p> <p>7 A. Okay. Can you blow up that about</p> <p>8 threefold?</p> <p>9 Q. Fourfold. "D.W.C. reports" --</p> <p>10 A. Are we talking about the Phung</p> <p>11 paper?</p> <p>12 Q. I'm reading you the sentence. It's</p> <p>13 really half a sentence.</p> <p>14 It says, "D.W.C. reports payment</p> <p>15 from expert testimony from Ferraro Law Firm and</p> <p>16 Ashcraft and Gerel Law Firm."</p> <p>17 Do you see that?</p> <p>18 A. Okay.</p> <p>19 MS. PARFITT: Let the record</p> <p>20 reflect I have directed the doctor to it.</p> <p>21 MS. DAVIDSON: Thank you, Michelle.</p> <p>22 THE WITNESS: Okay.</p> <p>23 BY MS. DAVIDSON:</p> <p>24 Q. Okay. Would the average person</p> <p>25 reading scientific papers know what the</p>	<p style="text-align: right;">Page 113</p> <p>1 MS. DAVIDSON: Noah, it's your</p> <p>2 first deposition?</p> <p>3 MR. EPSTEIN: Yes.</p> <p>4 MS. DAVIDSON: Your last?</p> <p>5 MR. EPSTEIN: So Table 2. I'm -- I</p> <p>6 can't get it to --</p> <p>7 MS. PARFITT: Hey, Noah, we have</p> <p>8 it.</p> <p>9 MR. LYONS: I have the paper.</p> <p>10 MR. EPSTEIN: Okay. Thank you.</p> <p>11 MR. LYONS: I'm also happy to pull</p> <p>12 it up if you want. I have the version, I</p> <p>13 believe, that Dr. Siemiatycki has, which</p> <p>14 is the final published version, rather</p> <p>15 than the author manuscript.</p> <p>16 MS. DAVIDSON: We have it as well,</p> <p>17 Noah. I'm not sure why you have the</p> <p>18 author manuscript there.</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. Okay. So, Dr. Siemiatycki, what is</p> <p>21 the reported OR for first-degree family history</p> <p>22 of ovarian cancer with endometriosis?</p> <p>23 A. With endometriosis? So we're</p> <p>24 looking sort of at the bottom right-hand area</p> <p>25 of that table, and there is an OR of 1.58.</p>

<p style="text-align: right;">Page 114</p> <p>1 Is that the one you're looking at?</p> <p>2 Q. Okay. And what is the OR for</p> <p>3 first-degree family history of ovarian cancer</p> <p>4 without endometriosis?</p> <p>5 A. It looks like it's 2.20.</p> <p>6 Q. Why would having endometriosis</p> <p>7 cause the risk factor of first-degree family</p> <p>8 history, to go down?</p> <p>9 MS. PARFITT: Objection. Form.</p> <p>10 THE WITNESS: Well, I don't know</p> <p>11 that it does.</p> <p>12 Among other things, when I -- when</p> <p>13 I look at relative risk estimates, I also</p> <p>14 look at the confidence intervals around</p> <p>15 them to see what the data really means.</p> <p>16 And if you notice, the upper</p> <p>17 confidence limit of both of those point</p> <p>18 estimates that you highlighted are</p> <p>19 identical -- that's a coincidence -- at</p> <p>20 2.57; but the important part of the</p> <p>21 message is that they don't differ very</p> <p>22 much. Statistically, they overlap</p> <p>23 greatly.</p> <p>24 And so the two point estimates of</p> <p>25 1.58 that you pointed at and 2.20 that you</p>	<p style="text-align: right;">Page 116</p> <p>1 different as the point estimates would</p> <p>2 indicate.</p> <p>3 Q. So do these -- do these two</p> <p>4 confidence intervals overlap considerably?</p> <p>5 A. They do overlap considerably.</p> <p>6 Q. And how do you define "overlap</p> <p>7 considerably"?</p> <p>8 You knew I was going to ask that.</p> <p>9 A. Yeah. So I mean, if you imagine in</p> <p>10 your mind sort of a little graphic display with</p> <p>11 one of them showing the odds ratio for women</p> <p>12 with endometriosis and one without, the middle</p> <p>13 of the two confidence intervals would be</p> <p>14 different.</p> <p>15 One goes from 1.88 to 2.57, so it</p> <p>16 is -- it covers that part of the graph. And</p> <p>17 the other one covers the part of the graph from</p> <p>18 .97 to 2.57. And, you know, just by eyeballing</p> <p>19 it, you can see that they overlap. Those two</p> <p>20 ranges overlap considerably.</p> <p>21 Now, it's possible to do</p> <p>22 statistical tests to show to what -- whether</p> <p>23 the amount of overlap is so -- the difference</p> <p>24 is so great that despite the variability,</p> <p>25 there's still significant differences between</p>
<p style="text-align: right;">Page 115</p> <p>1 pointed at, although they look different,</p> <p>2 would not be -- they're not so different</p> <p>3 that they require theorizing about.</p> <p>4 BY MS. DAVIDSON:</p> <p>5 Q. Okay. So let me make sure I</p> <p>6 understand.</p> <p>7 Are you saying that if two</p> <p>8 confidence intervals overlap, they're not so</p> <p>9 different that they suggest an actual effect</p> <p>10 difference?</p> <p>11 And forgive me if my language</p> <p>12 isn't --</p> <p>13 A. Yeah. No. I -- I -- I forgive you</p> <p>14 if you forgive me my verbal errors.</p> <p>15 I'm saying that if you look at two</p> <p>16 confidence intervals for the same parameter and</p> <p>17 you're trying to compare them, if they overlap</p> <p>18 considerably -- and I'm not going to define</p> <p>19 what I mean by "considerably" -- but if they</p> <p>20 overlap considerably, then the plausible range</p> <p>21 of true underlying relative risks for the two</p> <p>22 entities that you're comparing, the women with</p> <p>23 first-degree history and the women -- sorry,</p> <p>24 the women with endometriosis and the women</p> <p>25 without endometriosis, that they are not as</p>	<p style="text-align: right;">Page 117</p> <p>1 them.</p> <p>2 But in this case I can assure you</p> <p>3 that if you did such a test, it would show that</p> <p>4 there is no statistically significant</p> <p>5 difference between those two estimates.</p> <p>6 Q. How is that test done?</p> <p>7 A. So I -- I think it started when you</p> <p>8 asked me to speculate on possible reasons for</p> <p>9 the differences. And my answer would be that I</p> <p>10 wouldn't even go to the point of trying to find</p> <p>11 an explanation, which might not be -- for</p> <p>12 something that might not be their, namely a</p> <p>13 difference between endometri- -- with</p> <p>14 endometriosis and without endometriosis.</p> <p>15 Q. Right. My question was: Like,</p> <p>16 when you use the term "overlap considerably,"</p> <p>17 is that just sort of subjective of what you</p> <p>18 see; or is there an actual mathematical test?</p> <p>19 A. The actual mathematical test would</p> <p>20 be a test of the difference between the point</p> <p>21 estimates of 2.20 and 1.58, the difference</p> <p>22 between those two, considering the variability</p> <p>23 of those two estimates or the imprecision.</p> <p>24 Those two are imprecise estimates. The</p> <p>25 imprecision is captured by the 95-percent</p>

<p style="text-align: right;">Page 118</p> <p>1 confidence interval.</p> <p>2 And if you do the mathematics to</p> <p>3 plug in the point estimates and the confidence</p> <p>4 intervals, that's how you would test the</p> <p>5 difference between the two.</p> <p>6 And no, in the past 30 seconds, I</p> <p>7 have not done such a test; but by experience, I</p> <p>8 can tell you that it's not even close to</p> <p>9 statistically significant.</p> <p>10 Q. Got it. So you're saying the</p> <p>11 difference -- just to make sure I understand,</p> <p>12 you're saying the difference in the confidence</p> <p>13 intervals is not statistically significant?</p> <p>14 A. No. I'm saying the difference in</p> <p>15 the point estimates is -- given the confidence</p> <p>16 intervals.</p> <p>17 Q. Okay.</p> <p>18 A. The difference in the point</p> <p>19 estimates, I'm saying, is not statistically</p> <p>20 significantly different.</p> <p>21 Q. So the difference between 1.58 and</p> <p>22 2.20 is not statistically significant because</p> <p>23 there is considerable overlap in the confidence</p> <p>24 intervals --</p> <p>25 A. Yes.</p>	<p style="text-align: right;">Page 120</p> <p>1 confidence interval or not. It is pretty wide.</p> <p>2 But I'm saying that the two</p> <p>3 confidence intervals overlap considerably.</p> <p>4 Q. Okay.</p> <p>5 A. And that means that a whole range</p> <p>6 of -- what -- what you're really interested in</p> <p>7 when you're making these kind of estimates is</p> <p>8 what is the true underlying relative risk, not</p> <p>9 what is the relative risk in this sample of</p> <p>10 women in such and such a city that I happen to</p> <p>11 interview in such a year or so on.</p> <p>12 You're trying to make a generic,</p> <p>13 generalizable estimate of something. And the</p> <p>14 something is what is the relative risk among</p> <p>15 women with endometriosis.</p> <p>16 Now, you have a small sample of</p> <p>17 people in -- in these studies, small enough</p> <p>18 that the -- each -- well, no matter what the</p> <p>19 size is, each statistical estimate of point</p> <p>20 estimate embodies a certain degree of</p> <p>21 precision. And that degree of precision can be</p> <p>22 expressed in various forms.</p> <p>23 And one way of expressing it is in</p> <p>24 the width of the confidence interval. And the</p> <p>25 confidence interval can be -- you can think of</p>
<p style="text-align: right;">Page 119</p> <p>1 Q. -- is that a fair way to put it?</p> <p>2 A. That's a fair way to put it. I</p> <p>3 mean, the overlap in the confidence intervals</p> <p>4 is just another way of expressing that there's</p> <p>5 a lot of statistical imprecision in the two</p> <p>6 point estimates.</p> <p>7 Q. I'm sorry. Can you explain that</p> <p>8 again?</p> <p>9 A. Yes. Sorry. So the -- you know,</p> <p>10 what -- I use the overlap in the confidence</p> <p>11 intervals as a shorthand for me because I</p> <p>12 understand the implications that -- to indicate</p> <p>13 that the two point estimates are very unstable.</p> <p>14 They depend on small numbers and they could</p> <p>15 fluctuate.</p> <p>16 And, you know, I don't know if you</p> <p>17 want to go to examples about flipping coins;</p> <p>18 and, you know, I could sort of conjure</p> <p>19 up some --</p> <p>20 Q. Sorry, Doctor.</p> <p>21 Is 1.88 to 2.57, that's a wide</p> <p>22 confidence interval?</p> <p>23 A. 1.88 to 2.57?</p> <p>24 Q. Uh-huh.</p> <p>25 A. I'm not saying it's a wide</p>	<p style="text-align: right;">Page 121</p> <p>1 it as indicating the range of true underlying</p> <p>2 relative risks that can be -- that could</p> <p>3 hypothetically be found in the total population</p> <p>4 if you had, you know, the total population of</p> <p>5 the United States or an infinite population,</p> <p>6 even, of women who you've interviewed and you</p> <p>7 know really, you know, what is the</p> <p>8 endometriosis status and so on.</p> <p>9 But the -- you don't have that.</p> <p>10 You have an estimate from a sample. And the</p> <p>11 estimate of 2.20 is your best estimate from</p> <p>12 this sample of the true underlying relative</p> <p>13 risk.</p> <p>14 The confidence interval tells you</p> <p>15 how good your sample estimate is, how precise</p> <p>16 it is in capturing the true underlying relative</p> <p>17 risk. And it's kind of telling you that with</p> <p>18 95-percent probability, the true underlying</p> <p>19 relative risk among the women without</p> <p>20 endometriosis -- I'm just taking that as the</p> <p>21 example -- that the true underlying risk,</p> <p>22 there's a 95-percent probability that it's</p> <p>23 somewhere in the range from 1.88 to 2.57.</p> <p>24 So you could have think of the</p> <p>25 confidence interval as an expression of that</p>

<p style="text-align: right;">Page 122</p> <p>1 kind of statement. It's -- it's -- what I've 2 just said it's not strictly a hundred percent 3 accurate. It's a more complicated, slightly 4 more complicated statistical issue, but need no 5 need to get in to it. 6 At a first approximation, you can 7 think of the confidence interval as telling you 8 how close your sample -- what is the range of 9 possible underlying true relative risks that 10 are compatible with the data that you've 11 collected. 12 And this is saying that for the 13 without endometriosis women, the true relative 14 risk ranges from -- with 95-percent probability 15 from 1.88 to 2.57; whereas, for with 16 endometriosis, it ran -- the true value ranges 17 from .97 to -- to 2.57. And those two ranges 18 are -- you know, it's just common sense. They 19 overlap a lot. A lot of those two ranges, you 20 know, one -- one is largely subsumed in the 21 other. 22 Q. Okay. I think I've got it. Thank 23 you. 24 A. Thank you. 25 Q. Let's mark as Exhibit 8 the Gabriel</p>	<p style="text-align: right;">Page 124</p> <p>1 MS. PARFITT: Let the record 2 reflect, I've just handed the doctor a 3 blank copy of the Gabriel paper. 4 MS. DAVIDSON: Okay. 5 BY MS. DAVIDSON: 6 Q. Doctor, this paper was published in 7 2019. If I read your reports right and the 8 redline, you did not include it in your 2021 9 report; but you included it in your 2023 10 report. Is that correct? 11 A. I'll take your word for that. I 12 can't remember. 13 Q. Do you know why you didn't include 14 it originally and included it now? 15 A. Well, I -- I guess I included it 16 now because I came upon it at some point. And 17 I didn't include it in 2021. I don't know. It 18 might have been an oversight. I -- I can't 19 think that there would have been a -- I'm not 20 sure -- I'm not sure why. I don't see -- 21 Q. Okay. Can we go to the Disclosure 22 of Potential Conflicts of Interest. 23 A. That's at the back of the article, 24 I think. Oh, yes. I see that. 25 Q. It says here, "A.F. Vitonis has</p>
<p style="text-align: right;">Page 123</p> <p>1 2019 paper. 2 MS. PARFITT: And, Jessica, just 3 give us a moment to get that paper. I 4 appreciate it. 5 (Whereupon, Defendant's Exhibit D8, 6 Paper entitled, "Douching, Talc Use, and 7 Risk for Ovarian Cancer and Conditions 8 Related to Genital Tract Inflammation," by 9 Iwona M. Gabriel, et al., was marked for 10 identification.) 11 MS. DAVIDSON: This paper. 12 MS. PARFITT: Again, one moment. I 13 don't want to take your time. 14 BY MS. DAVIDSON: 15 Q. This paper is entitled, "Douching, 16 Talc Use, and Risk for Ovarian Cancer and 17 Conditions Related to Genital Tract 18 Inflammation." The authors are Iwona Gabriel, 19 Allison Vitonis, William Welch, Linda Titus, 20 and Daniel Cramer. 21 Do you see that? 22 A. Yeah. I'm -- 23 MS. PARFITT: One second, Jessica. 24 THE WITNESS: We're just looking 25 for it. Sorry.</p>	<p style="text-align: right;">Page 125</p> <p>1 provided statistical programming to support 2 expert testimony for Beasley Allen Law Firm. 3 D.W. Cramer has provided expert testimony for 4 Beasley Allen Law Firm." 5 Do you see that? 6 A. Yes, I do. 7 Q. And you'll agree with me that the 8 average person who is reading a journal 9 entitled "Cancer Epidemiology, Biomarkers & 10 Prevention" would not know what the Beasley 11 Allen Law Firm is, correct? 12 MS. PARFITT: Objection. Form. 13 THE WITNESS: Correct. 14 BY MS. DAVIDSON: 15 Q. So the average person reading this 16 paper would not be able to determine which side 17 Dr. Cramer and Mr. -- or Dr. Vitonis was 18 providing testimony for, right? 19 MS. PARFITT: Objection. Form. 20 THE WITNESS: Correct. 21 BY MS. DAVIDSON: 22 Q. Okay. Have you ever spoken to 23 either Dr. O'Brien or Dr. Wentzensen? 24 A. Not that I'm aware of. Not that I 25 recall.</p>

<p style="text-align: right;">Page 126</p> <p>1 Q. Are you familiar -- are you</p> <p>2 familiar with their reputations?</p> <p>3 A. I'm familiar with their</p> <p>4 publications in the -- in the talc domain that</p> <p>5 are part of the references in my report.</p> <p>6 Q. Do you know where they work?</p> <p>7 A. I think they work in North</p> <p>8 Carolina, if I'm not mistaken, at Research</p> <p>9 Triangle Park for -- maybe for NIEHS; but I'm</p> <p>10 not positive. I'm just recollecting or</p> <p>11 guessing. I'm not sure.</p> <p>12 Q. And they -- they are not expert</p> <p>13 witnesses for either side on this litigation,</p> <p>14 correct?</p> <p>15 MS. PARFITT: Objection. Form.</p> <p>16 THE WITNESS: I -- there's no way I</p> <p>17 would know that. I have no idea.</p> <p>18 BY MS. DAVIDSON:</p> <p>19 Q. Well, have they disclosed any</p> <p>20 conflicts of interest?</p> <p>21 MS. PARFITT: Objection. Form.</p> <p>22 THE WITNESS: Where?</p> <p>23 BY MS. DAVIDSON:</p> <p>24 Q. In their papers.</p> <p>25 Do you recall seeing any conflicts</p>	<p style="text-align: right;">Page 128</p> <p>1 author. I think that's the right term, the</p> <p>2 first author and the corresponding author.</p> <p>3 (Whereupon, Defendant's Exhibit D9,</p> <p>4 Paper entitled, "A critical review of talc</p> <p>5 and ovarian cancer," by Julie</p> <p>6 Goodman, et al., was marked for</p> <p>7 identification.)</p> <p>8 THE WITNESS: It's Julie?</p> <p>9 MS. PARFITT: Julie.</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. Dr. Siemiatycki, your camera is not</p> <p>12 on --</p> <p>13 A. Sorry.</p> <p>14 Q. -- which is a problem for a</p> <p>15 deposition --</p> <p>16 A. Which one is it --</p> <p>17 Q. Let's first get Dr. Siemiatycki's</p> <p>18 camera on.</p> <p>19 Do we need to go off the record for</p> <p>20 that?</p> <p>21 A. No.</p> <p>22 Q. There we go.</p> <p>23 A. Sorry about that.</p> <p>24 Q. Dr. Siemiatycki, do you have the</p> <p>25 Goodman 2020 paper?</p>
<p style="text-align: right;">Page 127</p> <p>1 of interest were disclosed in their papers?</p> <p>2 A. I haven't memorized all the</p> <p>3 conflict-of-interest paragraphs in every paper</p> <p>4 I've looked at. So I don't --</p> <p>5 Q. Do you know whether employees of</p> <p>6 the National Institutes of Health are even</p> <p>7 allowed to serve as experts in private</p> <p>8 litigation?</p> <p>9 MS. PARFITT: No. I have no idea.</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. You wouldn't be surprised to learn</p> <p>12 that ex -- that -- that scientists who work for</p> <p>13 the federal government are not allowed to serve</p> <p>14 as experts in litigation, would you?</p> <p>15 MS. PARFITT: Objection. Form.</p> <p>16 THE WITNESS: No, I wouldn't be</p> <p>17 surprised to learn that.</p> <p>18 MS. DAVIDSON: Okay. Let's go off</p> <p>19 the record.</p> <p>20 (Whereupon, a break was taken.)</p> <p>21 BY MS. DAVIDSON:</p> <p>22 Q. We're going to mark as Exhibit 9 a</p> <p>23 paper entitled, "A critical review of talc and</p> <p>24 ovarian cancer," by Julie Goodman, et al.</p> <p>25 And Julie is the corresponding</p>	<p style="text-align: right;">Page 129</p> <p>1 A. Not quite, but now I believe I do.</p> <p>2 Yes. Thank you.</p> <p>3 Q. Okay. And you address this paper</p> <p>4 in your new report, correct?</p> <p>5 A. That's correct.</p> <p>6 Q. And you did not address it in your</p> <p>7 2021 report, correct?</p> <p>8 A. That's correct.</p> <p>9 Q. Did -- were you aware of this paper</p> <p>10 when you wrote your 2021 report?</p> <p>11 A. I may have been aware of it and not</p> <p>12 considered that it would influence my opinion</p> <p>13 one way or the other, but I probably adopted a</p> <p>14 more generous attitude to being inclusive of</p> <p>15 articles this time than I did before.</p> <p>16 Q. Did you do any research as to</p> <p>17 Dr. Goodman's credentials?</p> <p>18 A. I don't recall having done that.</p> <p>19 Q. You mentioned in your paper -- in</p> <p>20 your report that this paper was carried out by</p> <p>21 a private research firm.</p> <p>22 Do you recall saying that?</p> <p>23 A. I now have my report in front of me</p> <p>24 as well. And yes, I recall saying that --</p> <p>25 well, writing it, yes.</p>

<p style="text-align: right;">Page 130</p> <p>1 Q. Were you suggesting anything with 2 that language?</p> <p>3 A. Yeah. I can't say that I'm 4 completely naive about the use of that 5 language; so I guess it -- in my mind, reading 6 the article, it felt like it would have been a 7 solicited paper to defend a point of view.</p> <p>8 Q. Did you feel that way about 9 Dr. Egilman's letter to the editor responding 10 to other papers?</p> <p>11 MS. PARFITT: Objection. Form.</p> <p>12 THE WITNESS: You know, I didn't 13 feel exactly the same way about it.</p> <p>14 BY MS. DAVIDSON:</p> <p>15 Q. And why is that?</p> <p>16 A. Sorry?</p> <p>17 Q. Why is that?</p> <p>18 A. Well, because for one thing, he was 19 on a completely -- he took a completely 20 different editorial opinion to the issues at 21 hand; but I -- I don't know -- I don't know for 22 a fact -- I suspect that Egilman was more of a 23 self-initiated intervenor in this matter. 24 Whereas, a private contract firm would more 25 likely be responding to a request.</p>	<p style="text-align: right;">Page 132</p> <p>1 kinds of issues, including female cancer risks 2 from various hormonal factors. But -- so I'm 3 not sure if it's the same person. I didn't 4 look her up specifically when I saw the name on 5 this article.</p> <p>6 Q. So your opinions about the validity 7 of this article are -- are not based on any 8 actual knowledge of Dr. Goodman's background, 9 correct?</p> <p>10 A. I guess not.</p> <p>11 Q. Is Johns Hopkins --</p> <p>12 A. I don't know which Dr. Goodman it 13 was. I didn't look -- as I said, I didn't look 14 her up to see if it was the one that I recall 15 from previous experience.</p> <p>16 Q. Do you know if Johns Hopkins has a 17 strong epidemiology program?</p> <p>18 A. Yes. Quite --</p> <p>19 MS. PARFITT: Objection. Form.</p> <p>20 THE WITNESS: Quite strong.</p> <p>21 BY MS. DAVIDSON:</p> <p>22 Q. And do you know whether Dr. Goodman 23 is a fellow of the American College of 24 Epidemiology?</p> <p>25 A. If it's the one -- if it's the</p>
<p style="text-align: right;">Page 131</p> <p>1 Q. Do you have any objective basis for 2 that assumption?</p> <p>3 A. Which part of it?</p> <p>4 Q. The part about Dr. Egilman and the 5 part about this paper?</p> <p>6 A. I know Egilman a little bit, and I 7 know that he is a very energetic, active 8 proponent of his scientific beliefs and 9 theories; and he doesn't really -- in my 10 experience, he doesn't need a solicitation from 11 a law firm or a company or an intervenor to -- 12 to put forth his opinions.</p> <p>13 So that would be, you know, the 14 basis for my prejudiced or, you know, 15 subjective view about the motivations. In that 16 I'm not implying the validity or the quality of 17 either of the points of view.</p> <p>18 Q. Does Dr. Egilman have a degree in 19 epidemiology?</p> <p>20 A. I'm not sure. I don't know.</p> <p>21 Q. Does Dr. Goodman have a degree in 22 epidemiology?</p> <p>23 A. I think -- you know, I'm not sure 24 if it's the one that I remember from sort of a 25 career at Harvard doing epidemiology on various</p>	<p style="text-align: right;">Page 133</p> <p>1 person I'm thinking of, then I would be 2 surprised if she doesn't have that.</p> <p>3 Q. Is Dr. Egilman a fellow of the 4 American College of Epidemiology?</p> <p>5 A. I have no idea.</p> <p>6 Q. Has Dr. Egilman ever taught 7 epidemiology?</p> <p>8 A. I have no idea.</p> <p>9 Q. Has Dr. Egilman ever been a cancer 10 prevention fellow at NCI?</p> <p>11 A. I -- I'm not aware of it.</p> <p>12 Q. Does Dr. Egilman have any 13 professional experience in gynecological 14 cancers prior to being a witness in this 15 litigation?</p> <p>16 A. I'm unaware.</p> <p>17 Q. Are you aware that Dr. Goodman was 18 a cancer prevention fellow at NCI?</p> <p>19 A. If it's the person that I'm 20 thinking of, then it wouldn't surprise me if 21 she had all of those pieces on her CV, yeah.</p> <p>22 Q. NCI is the National Cancer 23 Institute, right?</p> <p>24 A. That's correct.</p> <p>25 Q. Are you familiar with that</p>

Page 134

1 organization?

2 A. Yes, I have some familiarity with

3 it.

4 Q. Is it a respected organization?

5 MS. PARFITT: Objection. Asked and

6 answered.

7 THE WITNESS: Well, it's an

8 enormous beast. It's like asking if the

9 United States has any respect.

10 Yes, NCI is a respected

11 organization; and it's main job is to do

12 research and to fund research.

13 MS. DAVIDSON: Okay. We can take

14 this paper down.

15 BY MS. DAVIDSON:

16 Q. Dr. Siemiatycki, are you aware that

17 ovarian cancer rates have fallen significantly

18 over the last 20 to 30 years?

19 A. I'm aware that they've declined.

20 Q. Do you --

21 A. But I don't know about

22 significantly. I don't know what you mean by

23 that, but they've -- yes.

24 Q. How much did they decline?

25 A. Sorry?

Page 135

1 Q. Do you know how much they declined?

2 A. I don't.

3 Q. Are you aware that the incidence

4 rate for new cases of ovarian cancer fell from

5 14.9 per 100,000 people to 9.6 between 1992 and

6 2019?

7 MS. PARFITT: Objection. Asked and

8 answered.

9 THE WITNESS: I'm not aware of

10 those numbers.

11 BY MS. DAVIDSON:

12 Q. Do you have an opinion as to why

13 those numbers have fallen?

14 A. Whenever there are changes in

15 incidence of a disease, one of the first

16 questions that should be asked is whether there

17 have been any changes in diagnostic habits of

18 physicians or pathologists in regard to the

19 disease in question.

20 So -- but having said that, I have

21 no idea and no reason to believe that there

22 have been changes in diagnostic practices or

23 criteria over that period of time that would

24 explain such an apparent decline.

25 Q. You would agree that's good news

Page 136

1 for public health that the incidence of ovarian

2 cancer fell precipitously over 30 years, right?

3 A. Yes. If it's completely true, then

4 I think it's great.

5 Q. During the 30 years when ovarian

6 cancer rates declined precipitously, did that

7 follow a precipitous decline in talcum powder

8 use?

9 MS. PARFITT: Objection. Form.

10 THE WITNESS: I don't know. You

11 know, I guess -- I don't know if anyone

12 has done an analysis of time trends in

13 talcum powder use and in talcum powder

14 composition, and that's what would be

15 required.

16 I believe -- I hope I'm not making

17 this up, but I believe there has been some

18 decline in use of talcum powder by women.

19 And there have certainly been changes in

20 composition of talcum powder since the

21 1980s. There's been less mineral and more

22 of other products that have the same

23 effect.

24 So there's a possibility that some

25 of that has played in to changing

Page 137

1 incidence rates of ovarian cancer, but I

2 wouldn't affirm that.

3 BY MS. DAVIDSON:

4 Q. What's your basis for saying that

5 the composition of talcum powder has changed

6 since the 1980s?

7 A. Well, I believe that the companies,

8 I think Johnson & Johnson and other companies,

9 have proclaimed and offered alternatives to the

10 mineral talc in their products and more of

11 the -- what's it called -- corn -- sorry,

12 sometimes words fall out of my vocabulary

13 box -- corn starch -- no. It's corn starch,

14 yeah.

15 So that there's been an increase

16 since about the 1980s -- at least that's what I

17 read. I mean, I haven't done the research into

18 this firsthand research; but everything I've

19 read -- and I don't think it's contested -- is

20 that there's been a shift away from the mineral

21 talc to corn starch and maybe other products as

22 well, other substances as well that have

23 similar cosmetic effects as talc does.

24 Q. What's the latency period for

25 ovarian cancer?

<p style="text-align: right;">Page 138</p> <p>1 A. Well, as with any cancer, there's</p> <p>2 no single number; but I think the range -- and</p> <p>3 there -- it's hard to -- especially when you</p> <p>4 don't have a good grasp on the important risk</p> <p>5 factors for the disease, it's difficult to</p> <p>6 affirm with any degree of certainty what the</p> <p>7 latency period is.</p> <p>8 But the general feeling is that for</p> <p>9 epithelial solid tumors, a range from 10 to 20</p> <p>10 or 25 years is a reasonable estimate of what</p> <p>11 the latency period is.</p> <p>12 But with cancer's, there may be</p> <p>13 early-stage risk factors, later-stage risk</p> <p>14 factors that -- that come into play. And these</p> <p>15 influence latency periods in different ways.</p> <p>16 But --</p> <p>17 Q. Have you done any sort of analysis</p> <p>18 to determine whether there was a drop in the</p> <p>19 use of talcum powder with the appropriate</p> <p>20 latency that it would have affected the drop in</p> <p>21 ovarian cancer rates over the last 30 years, or</p> <p>22 are you just speculating?</p> <p>23 MS. PARFITT: Objection. Form.</p> <p>24 THE WITNESS: I have not done an</p> <p>25 analysis of this topic.</p>	<p style="text-align: right;">Page 140</p> <p>1 You speculated, correct?</p> <p>2 You were talking about how women</p> <p>3 have moved away -- possibly have moved away</p> <p>4 from talcum powder toward other compositions.</p> <p>5 At first, you said it was other compositions of</p> <p>6 talc, but now I think you mean other products</p> <p>7 all together; and maybe that relates to the</p> <p>8 precipitous decline in ovarian cancer.</p> <p>9 My question is: You don't have any</p> <p>10 actual evidence for that, correct?</p> <p>11 MS. PARFITT: Objection. Form.</p> <p>12 THE WITNESS: I mean, I think there</p> <p>13 are pieces -- I haven't produced any</p> <p>14 evidence of that, but I've read that</p> <p>15 there's -- I've seen evidence that there's</p> <p>16 a decline in usage of talcum powder.</p> <p>17 I've seen that there have been</p> <p>18 changes over time in composition of the</p> <p>19 products that are commonly called talcum</p> <p>20 powder.</p> <p>21 And so but -- and there -- it's</p> <p>22 widely accepted that there is the latency</p> <p>23 period roughly between 10 and 20 years or</p> <p>24 so, maybe 5 to 25 years if you want to</p> <p>25 broaden it, which -- and for between</p>
<p style="text-align: right;">Page 139</p> <p>1 BY MS. DAVIDSON:</p> <p>2 Q. So fair to say that you're</p> <p>3 speculating?</p> <p>4 MS. PARFITT: Objection. Form.</p> <p>5 THE WITNESS: Sorry. I spoke for</p> <p>6 about five minutes. I'm not sure which</p> <p>7 part of it you are addressing.</p> <p>8 You're saying it's all --</p> <p>9 everything I've said is speculation?</p> <p>10 Is that what your -- asking me?</p> <p>11 BY MS. DAVIDSON:</p> <p>12 Q. You speculated that maybe -- well,</p> <p>13 first you said changes in talcum powder</p> <p>14 composition, but then I think you said a move</p> <p>15 away from talcum powder could have affected</p> <p>16 precipitous decline in ovarian cancer rates.</p> <p>17 I'm asking you: Is that</p> <p>18 speculation?</p> <p>19 MS. PARFITT: Objection. Form.</p> <p>20 THE WITNESS: If it's speculation</p> <p>21 that there's been a drop -- a decline in</p> <p>22 talcum powder use?</p> <p>23 BY MS. DAVIDSON:</p> <p>24 Q. That would -- Doctor, it's not a</p> <p>25 difficult question.</p>	<p style="text-align: right;">Page 141</p> <p>1 exposure and onset of disease.</p> <p>2 Latency period is a very</p> <p>3 complicated -- it's an easy term to use,</p> <p>4 but what it actually means is not obvious.</p> <p>5 So I don't want to -- I hesitate answering</p> <p>6 your question about latency period partly</p> <p>7 for that question. But if you want me to,</p> <p>8 I'll get into why it is so complicated.</p> <p>9 BY MS. DAVIDSON:</p> <p>10 Q. Dr. Siemiatycki, could you try to</p> <p>11 stick to the question.</p> <p>12 My question is: Sitting here</p> <p>13 today, do you have any evidence that the</p> <p>14 decline between 1990 and 2020 in ovarian cancer</p> <p>15 rates relates to a decline in talcum powder</p> <p>16 use?</p> <p>17 A. Okay.</p> <p>18 MS. PARFITT: Objection. Form.</p> <p>19 THE WITNESS: If that -- if that is</p> <p>20 your question, then the answer is: I</p> <p>21 don't have evidence for that.</p> <p>22 BY MS. DAVIDSON:</p> <p>23 Q. Thank you.</p> <p>24 Doctor, you criticize in your</p> <p>25 report a paper called Micha 2022.</p>

<p style="text-align: right;">Page 142</p> <p>1 Do you recall that?</p> <p>2 A. Yes. Let's -- let's find it.</p> <p>3 MS. PARFITT: Page 78, just to move</p> <p>4 this along.</p> <p>5 MS. DAVIDSON: Micha '22, what --</p> <p>6 Noah, we're marking that as exhibit what?</p> <p>7 MR. EPSTEIN: That would be</p> <p>8 Exhibit 10.</p> <p>9 MS. DAVIDSON: Okay.</p> <p>10 (Whereupon, Defendant's</p> <p>11 Exhibit D10, Paper entitled, "Talc powder</p> <p>12 and ovarian cancer: What is the</p> <p>13 evidence?" By John P. Micha, et al., was</p> <p>14 marked for identification.)</p> <p>15 MR. EPSTEIN: I'll put that in chat</p> <p>16 right you.</p> <p>17 MS. DAVIDSON: Great. With that</p> <p>18 new heading.</p> <p>19 MR. EPSTEIN: Yes.</p> <p>20 BY MS. DAVIDSON:</p> <p>21 Q. "Talc powder and ovarian cancer:</p> <p>22 What is the evidence?" John Micha.</p> <p>23 Dr. Siemiatycki, do you know who</p> <p>24 John Micha is?</p> <p>25 MS. PARFITT: We are just trying</p>	<p style="text-align: right;">Page 144</p> <p>1 disclose."</p> <p>2 Do you see that?</p> <p>3 A. I see that.</p> <p>4 Q. Are you aware that Susan Berg,</p> <p>5 whose family sponsored this paper, was actually</p> <p>6 a plaintiff in talc litigation?</p> <p>7 MS. PARFITT: Objection.</p> <p>8 Completely misstates the evidence who</p> <p>9 Susan Berg was.</p> <p>10 THE WITNESS: I'm unaware of any of</p> <p>11 this.</p> <p>12 BY MS. DAVIDSON:</p> <p>13 Q. Okay. And in contrast to</p> <p>14 Dr. Micha, Dr. Egilman who responded to this</p> <p>15 paper does have a conflict of interest,</p> <p>16 correct?</p> <p>17 MS. PARFITT: Objection. Form.</p> <p>18 THE WITNESS: I'm not aware of</p> <p>19 that.</p> <p>20 BY MS. DAVIDSON:</p> <p>21 Q. You're not aware that Dr. Egilman</p> <p>22 has a conflict of interest?</p> <p>23 A. Correct. Unless it's -- I'm not</p> <p>24 aware of it. It might have been in the paper.</p> <p>25 He might have stated it. I'll look at the</p>
<p style="text-align: right;">Page 143</p> <p>1 to grab --</p> <p>2 MS. DAVIDSON: While you're looking</p> <p>3 for the paper, I'm just asking if he knows</p> <p>4 who John Micha is.</p> <p>5 THE WITNESS: I don't know.</p> <p>6 BY MS. DAVIDSON:</p> <p>7 Q. Did you do any investigation as to</p> <p>8 whether Dr. Micha had any conflicts of interest</p> <p>9 here?</p> <p>10 A. I don't know who he is, and I</p> <p>11 didn't do any investigations.</p> <p>12 Q. Got it. Did you read who funded</p> <p>13 the paper?</p> <p>14 A. No, I didn't.</p> <p>15 Q. I'll read it to you. "This study</p> <p>16 was funded by the Women's Cancer Research</p> <p>17 Foundation, the family of Susan Berg, and the</p> <p>18 family of Joan and Len Rullo in memory of</p> <p>19 Elizabeth Johnson."</p> <p>20 Do you see that?</p> <p>21 That's on the last page, funding.</p> <p>22 A. Yes, I see -- on the last page --</p> <p>23 oh, yes.</p> <p>24 Q. "The authors have no relevant</p> <p>25 financial or nonfinancial interests to</p>	<p style="text-align: right;">Page 145</p> <p>1 paper if you'd like.</p> <p>2 Q. Dr. Siemiatycki, is serving in this</p> <p>3 litigation a conflict of interest that should</p> <p>4 be disclosed in the letter?</p> <p>5 A. It depends what the letter is</p> <p>6 about.</p> <p>7 Q. I don't understand. When you say</p> <p>8 Dr. Egilman didn't have a conflict of interest,</p> <p>9 are you aware that Dr. Egilman is a plaintiff's</p> <p>10 expert in talc litigation?</p> <p>11 A. I'm -- I'm unaware of that.</p> <p>12 Q. I see. Okay. We can continue.</p> <p>13 I'd like to turn to -- back to</p> <p>14 Exhibit 6, which is your expert report, and I'd</p> <p>15 like to go to your discussion of Wentzensen</p> <p>16 paper.</p> <p>17 MS. PARFITT: One moment.</p> <p>18 THE WITNESS: Which one is it?</p> <p>19 MS. PARFITT: The Wentzensen 2021.</p> <p>20 Right, Jessica?</p> <p>21 MS. DAVIDSON: I'm just talking</p> <p>22 about -- let's -- Noah, can you please put</p> <p>23 up Exhibit 5 on the screen, page 76 of</p> <p>24 Dr. Siemiatycki's Second Amended Expert</p> <p>25 Report?</p>

<p style="text-align: right;">Page 146</p> <p>1 MR. EPSTEIN: Yes. That's</p> <p>2 Exhibit 6, correct, Jessica?</p> <p>3 MS. DAVIDSON: Oh, sorry. Sorry.</p> <p>4 Exhibit 6. Confusion.</p> <p>5 MR. EPSTEIN: It should be up now.</p> <p>6 THE WITNESS: I have -- I have the</p> <p>7 report in front of me.</p> <p>8 BY MS. DAVIDSON:</p> <p>9 Q. I'd like to ask you a question</p> <p>10 about your report.</p> <p>11 You say here, quote, "They debunked</p> <p>12 the notion expressed by Goodman 2020, Lynch</p> <p>13 2023, and others that cohorts studies as a</p> <p>14 class are more valid than case control</p> <p>15 studies."</p> <p>16 Do you see that?</p> <p>17 A. I see that.</p> <p>18 Q. Can you show me where in the paper</p> <p>19 they debunk that?</p> <p>20 A. I'll have to look at the paper.</p> <p>21 It'll take me a few minutes.</p> <p>22 So I'm looking at the article --</p> <p>23 Q. Uh-huh.</p> <p>24 A. -- and on page 4 of the version</p> <p>25 that I have, but it would be on the -- can you</p>	<p style="text-align: right;">Page 148</p> <p>1 which is not true.</p> <p>2 And that's the point I was trying</p> <p>3 to make only that they made -- they</p> <p>4 debunked the notions that these are</p> <p>5 generic general truths that cohort studies</p> <p>6 are superior to case control studies.</p> <p>7 It's the specifics of each type of</p> <p>8 study -- of each study that determines</p> <p>9 it's quality, not whether it fits under</p> <p>10 the umbrella of cohort or case control.</p> <p>11 BY MS. DAVIDSON:</p> <p>12 Q. Do Goodman 2020 and Lynch 2023</p> <p>13 state that cohort studies have no limitations?</p> <p>14 A. Do they state what?</p> <p>15 Q. That cohort studies have no</p> <p>16 limitations.</p> <p>17 A. I'll have to go through the two</p> <p>18 studies to see where -- what I'm contrasting</p> <p>19 where --</p> <p>20 Q. I'm just asking you whether you</p> <p>21 recall. Obviously we don't have time to go</p> <p>22 through those two studies.</p> <p>23 Do you recall whether these two</p> <p>24 papers state that cohort studies have no</p> <p>25 limitations?</p>
<p style="text-align: right;">Page 147</p> <p>1 find page 4?</p> <p>2 Q. Sure.</p> <p>3 A. It's 4.2 called "Study Designs."</p> <p>4 Q. Uh-huh.</p> <p>5 A. There are a few paragraphs there</p> <p>6 that contrast the strengths and weaknesses of</p> <p>7 case control versus cohort studies.</p> <p>8 Q. Uh-huh.</p> <p>9 A. And the --</p> <p>10 Q. Can you just point me to the</p> <p>11 sentence that, quote, "debunks the notion that</p> <p>12 cohort studies as a class are more valid"?</p> <p>13 MS. PARFITT: Objection to the</p> <p>14 question. I think he was in the middle of</p> <p>15 trying to deliver a response.</p> <p>16 THE WITNESS: Yeah, yeah. I don't</p> <p>17 think I said there is a sentence that</p> <p>18 debunks it. It's this entire section.</p> <p>19 The entire section, the effect of</p> <p>20 itself to show that there are strengths</p> <p>21 and weaknesses of both types of designs.</p> <p>22 And that's -- and by contrast with some</p> <p>23 other opinions that make the blanket</p> <p>24 statement that cohort studies as a class</p> <p>25 are superior to case control studies,</p>	<p style="text-align: right;">Page 149</p> <p>1 A. I don't recall such statements; but</p> <p>2 if I put this --</p> <p>3 Q. Okay.</p> <p>4 A. -- into this report I probably --</p> <p>5 it was probably based on the impression that I</p> <p>6 got by reading the entirety of the article that</p> <p>7 they were downplaying the validity of case</p> <p>8 control studies by contrast with cohort</p> <p>9 studies. So it's based on an impression of the</p> <p>10 entire articles, not a specific sentence.</p> <p>11 Q. In fact, O'Brien and Wentzensen</p> <p>12 published the most comprehensive meta-analysis</p> <p>13 of cohort studies, correct?</p> <p>14 MS. PARFITT: Objection. Form.</p> <p>15 THE WITNESS: Sorry. O'Brien</p> <p>16 published the most comprehensive -- sorry.</p> <p>17 Can you repeat that.</p> <p>18 BY MS. DAVIDSON:</p> <p>19 Q. Isn't it true that O'Brien and</p> <p>20 Wentzensen themselves published the most</p> <p>21 comprehensive meta-analysis of cohort studies?</p> <p>22 A. Of the available cohort studies on</p> <p>23 talc and ovarian cancer, correct.</p> <p>24 Q. That's what we're discussing today.</p> <p>25 Thank you.</p>

<p style="text-align: right;">Page 150</p> <p>1 If you go few lines down in your</p> <p>2 report, you say that, "Women with intact</p> <p>3 reproductive systems and used -- that the</p> <p>4 authors found that women with intact</p> <p>5 reproductive systems and used talcum powder had</p> <p>6 particularly high risks of ovarian cancer."</p> <p>7 Do you see that language?</p> <p>8 MS. PARFITT: And, again, he was</p> <p>9 going to the article.</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. We're on page 76 of your report.</p> <p>12 MS. PARFITT: 76.</p> <p>13 BY MS. DAVIDSON:</p> <p>14 Q. It says, "Women with intact</p> <p>15 reproductive systems and used talcum powder had</p> <p>16 particularly high risks of ovarian cancer."</p> <p>17 Do you see that language,</p> <p>18 "particularly high"?</p> <p>19 A. Oh, yes. I see that now.</p> <p>20 Q. Can you show me where in the</p> <p>21 Wentzensen paper it says that, "Women with</p> <p>22 intact reproductive systems had particularly</p> <p>23 high risks of ovarian cancer"?</p> <p>24 THE WITNESS: Wentzensen study.</p> <p>25 MS. PARFITT: I'm handing him the</p>	<p style="text-align: right;">Page 152</p> <p>1 A. No.</p> <p>2 Q. That sentence says that</p> <p>3 epidemiological studies have found that women</p> <p>4 with talc -- with intact reproductive systems</p> <p>5 and who used talcum powder have particularly</p> <p>6 high risks of ovarian cancer?</p> <p>7 MS. PARFITT: He was trying to</p> <p>8 answer.</p> <p>9 Go ahead, Doctor.</p> <p>10 THE WITNESS: So if I carry on</p> <p>11 reading in the Wentzensen paper, it says,</p> <p>12 "As described below, many of these</p> <p>13 existing studies have attempted to look at</p> <p>14 this in some way. However, most were</p> <p>15 unable to do so with a clear temporal</p> <p>16 sequence between hysterectomy, tubal</p> <p>17 ligation, and powder use. For example, it</p> <p>18 may not be possible to know whether talc</p> <p>19 was used prior to hysterectomy and tubal</p> <p>20 ligation or what a women's combined talc</p> <p>21 use status was."</p> <p>22 So that's indicating that the --</p> <p>23 that there's been insufficient research</p> <p>24 to -- to sort of lock up this topic,</p> <p>25 but --</p>
<p style="text-align: right;">Page 151</p> <p>1 Wentzensen study.</p> <p>2 THE WITNESS: So in -- on page --</p> <p>3 I'm looking for a page number. I think</p> <p>4 page 7 --</p> <p>5 BY MS. DAVIDSON:</p> <p>6 Q. Uh-huh.</p> <p>7 A. -- above Table 3 --</p> <p>8 Q. Uh-huh.</p> <p>9 A. -- there's a Section 5.3. It says,</p> <p>10 "Patients of genital powder use and ovarian</p> <p>11 cancer by tubal ligation and hysterectomy</p> <p>12 and" --</p> <p>13 Q. I'm there.</p> <p>14 A. Okay. So a few lines down it</p> <p>15 says -- well, "As such, it would make sense</p> <p>16 that women who did not have uteri, either i.e.,</p> <p>17 hysterectomy or those who had blocked fallopian</p> <p>18 tubes, would have a markedly reduced risk of</p> <p>19 developing the disease as a direct consequence</p> <p>20 of talc use."</p> <p>21 There are a few other sentences</p> <p>22 around it, but that sentence captures, I think,</p> <p>23 the meaning of my sentence that you --</p> <p>24 Q. So that sentence says that the</p> <p>25 studies have found --</p>	<p style="text-align: right;">Page 153</p> <p>1 BY MS. DAVIDSON:</p> <p>2 Q. But that's not what you say,</p> <p>3 Doctor.</p> <p>4 What you say in your report is</p> <p>5 that, "The data tend to show that women with</p> <p>6 intact reproductive systems and used talcum</p> <p>7 powder have particularly high risks of ovarian</p> <p>8 cancer."</p> <p>9 I'm trying to understand -- I've</p> <p>10 got the report in front of me, the papers at --</p> <p>11 the paper in front of me too.</p> <p>12 I'm trying to understand where from</p> <p>13 Wentzensen do you drive that the authors</p> <p>14 believed the data show that women who used</p> <p>15 talcum powder and have intact reproductive</p> <p>16 systems have particularly high risks?</p> <p>17 MS. PARFITT: Jessica, you may not</p> <p>18 have heard. He was still talking when you</p> <p>19 started to talk again. So please, let him</p> <p>20 finish.</p> <p>21 And I realize this is very</p> <p>22 difficult and challenging being remote,</p> <p>23 but he was actually talking.</p> <p>24 You're going to have to raise your</p> <p>25 voice as well, Doctor.</p>

<p style="text-align: right;">Page 154</p> <p>1 THE WITNESS: Yeah.</p> <p>2 MS. PARFITT: But please continue</p> <p>3 your thought and opinion.</p> <p>4 THE WITNESS: So as such, it would</p> <p>5 make sense they say that women who did not</p> <p>6 have intact reproductive systems would --</p> <p>7 would have a reduced risk of developing.</p> <p>8 So if it was blocked, there would</p> <p>9 be a reduced risk of talc particles</p> <p>10 reaching the ovaries. And my sentence</p> <p>11 says -- so with the intact reproductive</p> <p>12 systems and the lack of blockage from --</p> <p>13 from any surgical interventions, that</p> <p>14 there would be -- oh, particularly high</p> <p>15 risks.</p> <p>16 Yes. So with intact reproductive</p> <p>17 systems, there would be greater chance of</p> <p>18 particles reaching the ovaries.</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. What you say here is that, "The few</p> <p>21 studies that have data tend to show that women</p> <p>22 with intact reproductive systems had</p> <p>23 particularly high risks."</p> <p>24 "The few studies that had data."</p> <p>25 Where do Wentzensen and O'Brien say</p>	<p style="text-align: right;">Page 156</p> <p>1 right?</p> <p>2 A. Sorry. Can you -- can you show me</p> <p>3 where -- where is that last -- yes. I'm in the</p> <p>4 conclusions section, which is --</p> <p>5 MS. DAVIDSON: Noah, can you put</p> <p>6 the conclusion of Wentzensen up?</p> <p>7 MR. EPSTEIN: Yes. I'm on it right</p> <p>8 now.</p> <p>9 MS. PARFITT: Thanks, Noah.</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. Okay. We're in the second</p> <p>12 paragraph of the conclusion.</p> <p>13 MS. DAVIDSON: Blow it up, the</p> <p>14 paragraph that starts with "Taken</p> <p>15 together. Blow it up, Noah.</p> <p>16 MR. EPSTEIN: I don't know how to</p> <p>17 do it through Zoom. I'm sorry.</p> <p>18 MS. DAVIDSON: Okay.</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. Anyway the authors say, "Taken</p> <p>21 together, the epidemiological data from case</p> <p>22 control studies and cohort studies suggests</p> <p>23 that there may be a small positive association</p> <p>24 between genital powder use and ovarian cancer</p> <p>25 which may be limited to women with patent</p>
<p style="text-align: right;">Page 155</p> <p>1 that the few studies that had data tend to show</p> <p>2 particularly high risks of ovarian cancer?</p> <p>3 A. So the article says they were</p> <p>4 unable to demonstrate this with a clear</p> <p>5 temporal sequence. This article is not -- does</p> <p>6 not make the bold statement that I make in</p> <p>7 describing the Wentzensen article.</p> <p>8 Q. Doctor --</p> <p>9 A. Yes.</p> <p>10 Q. -- in fact, don't they say only</p> <p>11 there may be a small positive association</p> <p>12 between genital powder use and ovarian cancer,</p> <p>13 which may be limited to women with patent</p> <p>14 reproductive tracts?</p> <p>15 Isn't that what they say on page 8?</p> <p>16 A. Sorry. Can you --</p> <p>17 MS. PARFITT: Page 8.</p> <p>18 THE WITNESS: Yeah.</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. In their conclusion, the authors</p> <p>21 state, "There may be a small positive</p> <p>22 association between genital powder use and</p> <p>23 ovarian cancer, which may be limited to women</p> <p>24 with patent reproductive tracts."</p> <p>25 That's what they actually say,</p>	<p style="text-align: right;">Page 157</p> <p>1 reproductive tracts."</p> <p>2 I read that correctly, right,</p> <p>3 Dr. Siemiatycki?</p> <p>4 A. Yes.</p> <p>5 Q. So rather than saying anything</p> <p>6 about a particularly high risk, the authors</p> <p>7 actually say "small positive association,"</p> <p>8 right?</p> <p>9 MS. PARFITT: Objection. Form.</p> <p>10 THE WITNESS: So terms like "small"</p> <p>11 and "high" are not technically defined. I</p> <p>12 mean, they don't have -- carry with them</p> <p>13 any implication of what exactly that means</p> <p>14 in terms of the magnitude. And whether</p> <p>15 you call something -- an effect large or</p> <p>16 small is rather subjective, and it doesn't</p> <p>17 mean the same thing in all contexts.</p> <p>18 So yes, they use the words "small</p> <p>19 positive association" here; but for many</p> <p>20 associations that we have in biomedicine</p> <p>21 and epidemiology and even in talc -- in</p> <p>22 ovarian cancer epidemiology, there are</p> <p>23 effects which have relative risks much</p> <p>24 smaller than the relative risks shown for</p> <p>25 ovarian -- for talc and ovarian cancer</p>

<p style="text-align: right;">Page 158</p> <p>1 that are considered quite strong effects. 2 There are very genetic markers that 3 have associations with ovarian cancer 4 where the relative risks are in the order 5 of 1.05 or something like that. And, you 6 know, air pollution has that affect on 7 lung cancer. 8 And so the descriptor, the word 9 that you use to describe the magnitude of 10 a relative risk is somewhat subjective and 11 context dependent. 12 So if I understand your question 13 correctly, you are trying to show that 14 whereas they use the word "small" to 15 describe the association, I used the 16 word -- let me find it again. 17 BY MS. DAVIDSON: 18 Q. "Particularly high risk," Doctor. 19 I'm trying to -- 20 A. Yeah. 21 MS. PARFITT: Let him finish. 22 THE WITNESS: What I mentally 23 "particularly high" was particularly high 24 compared with women with surgical 25 interventions to interrupt the -- the</p>	<p style="text-align: right;">Page 160</p> <p>1 BY MS. DAVIDSON: 2 Q. The authors did not note that, 3 correct? 4 MS. PARFITT: Objection. Asked and 5 answered. 6 THE WITNESS: Well, I'll look 7 through the article again to see what 8 triggered my interpretation that they had 9 made such an inference. 10 BY MS. DAVIDSON: 11 Q. Okay. Doctor, if you look at the 12 top of page 9 of Wentzensen, the authors state, 13 "Independent of the underlying cause, this 14 association between powder use and ovarian 15 cancer risk is weak. The low relative risk 16 translates to a very low risk increase." 17 Do you see that? 18 A. I see that. 19 Do you want me to comment on it? 20 Q. No. I'm just asking if you see 21 that language. 22 A. I see it. 23 Q. This paragraph 2 does not have any 24 reference or notation to a particularly high 25 risk, correct?</p>
<p style="text-align: right;">Page 159</p> <p>1 potential entry of talc particles. 2 And so in the contrast, I can't 3 remember what it is; but if I remember, if 4 the overall relative risk is, you know, in 5 the order of 1.3 for talc and ovarian 6 cancer, it might be that that -- that 7 combines a relative risk of 1.4 or 1.5 for 8 women with intact reproductive tracts 9 compared to maybe 1.1 or 1.2 for women 10 without. 11 And so that's the contrast -- 12 that's what I meant by "particularly," by 13 contrast with women without intact 14 reproductive tracts, and that's -- so the 15 descriptor "high" was in the comparison of 16 the two groups of women. 17 BY MS. DAVIDSON: 18 Q. Dr. Siemiatycki, in fact, the 19 authors did not note that women with intact 20 reproductive systems who used talcum powder had 21 particularly high risks of ovarian cancer, 22 right? 23 MS. PARFITT: Objection. Asked and 24 answered. 25</p>	<p style="text-align: right;">Page 161</p> <p>1 MS. PARFITT: Objection. Asked and 2 answered. 3 THE WITNESS: Correct. 4 MS. DAVIDSON: Thank you. Let's go 5 off the record. 6 (Whereupon, a lunch was taken.) 7 MS. DAVIDSON: Let's mark as 8 Exhibit 11 "Douching and Genital Talc Use: 9 Patterns of Use and Reliability of 10 Self-reported Exposure," first author 11 O'Brien. 12 MS. PARFITT: It was hard to hear 13 you, Jessica. I'm sorry. 14 MS. DAVIDSON: It's called 15 "Douching and Genital Talc Use: Patterns 16 of Use and Reliability of Self-reported 17 Exposure," first author O'Brien. 18 MS. PARFITT: Give us one moment. 19 MS. DAVIDSON: I'm sorry? 20 MS. PARFITT: Give us one moment. 21 MS. DAVIDSON: No problem. We'll 22 put it up on the screen. 23 24 25</p>

<p style="text-align: right;">Page 162</p> <p>1 (Whereupon, Defendant's 2 Exhibit D11, Paper entitled, "Douching and 3 Genital Talc Use: Patterns of Use and 4 Reliability of Self-reported Exposure," by 5 Katie M. O'Brien, et al., was marked for 6 identification.) 7 MR. TISI: I'm just trying to give 8 him -- 9 MS. PARFITT: Jessica, it's the 10 "Perineal talc use and" -- 11 MR. TISI: No. It's the Patterns 12 and Reliability the self-exposure. 13 MS. DAVIDSON: "Douching and 14 Genital Talc Use: Patterns of Use and 15 Reliability of Self-reported Exposure." 16 MR. TISI: Hold on. Let me see if 17 I can get another copy. All I have is the 18 preprint. Let me see if I have another 19 copy. 20 BY MS. DAVIDSON: 21 Q. Dr. Wentzensen [sic], have you read 22 this article before? 23 MS. PARFITT: You mean 24 Dr. Siemiatycki. 25 MS. DAVIDSON: Oh, I'm sorry.</p>	<p style="text-align: right;">Page 164</p> <p>1 parameters of talc use and douching in 2 that population. 3 BY MS. DAVIDSON: 4 Q. Do you recall that the authors were 5 looking at questions of recall bias? 6 A. Yes. It's in the title, so I 7 recall that. 8 Q. And what do the authors determine; 9 do you recall? 10 A. I don't recall. 11 Q. Okay. Dr. Siemiatycki -- 12 A. Yes. 13 Q. -- the authors state, "If historic 14 use cannot be accurately recalled, measurement 15 error can bias effect estimates, especially if 16 recall reliability differs by outcome status." 17 Do you agree with that statement? 18 A. So I didn't catch all of what you 19 said. 20 Could you -- 21 Q. It's right here on page 1. 22 A. Okay. 23 Q. It's up on the screen. 24 A. Yeah. 25 Q. On the right-hand, the last</p>
<p style="text-align: right;">Page 163</p> <p>1 Yeah. I'm definitely running out of steam 2 here. I'm so sorry. 3 MS. PARFITT: No worries. No 4 worries. No worries. 5 MS. DAVIDSON: Fortunately, no 6 contagion on Zoom. 7 BY MS. DAVIDSON: 8 Q. Dr. Siemiatycki, have you read this 9 article before? 10 A. I think I have. 11 Q. What is does this article address? 12 A. Well, patterns of use and 13 reliability of self-reported exposure of 14 douching and genital talc use by women. 15 Q. Do you know what the paper looks 16 at? 17 MS. PARFITT: Objection. Form. 18 THE WITNESS: I'm just -- I'm just 19 starting to look at the preprint version. 20 It's not one that I've looked at recently, 21 so it will just take me a minute to 22 refresh my memory about this one. 23 Oh, yes. It's from the 24 Sister Study. And it's kind of a 25 descriptive presentation of various</p>	<p style="text-align: right;">Page 165</p> <p>1 sentence of the second paragraph on the right. 2 I'll read it again. 3 "If historic use cannot be 4 accurately recalled, measurement error can bias 5 effect estimates, especially if recall 6 reliability differs by outcome status." 7 Do you agree with that statement? 8 A. Yes. I still haven't found the 9 sentence on the page, but I agree with that 10 statement. 11 Q. This study looked at recall bias 12 with respect to ever use and never use, 13 correct? 14 A. I guess so. Again, this article is 15 not fresh in my memory and -- 16 Q. Okay. 17 A. -- I'm -- I'm just looking at -- 18 Q. Could -- my question is: Could 19 recall bias also affect reporting of the 20 frequency of use of a product? 21 A. Yes, it could. 22 Q. So if you -- do you recall whether 23 O'Brien's paper found that there may be 24 over-reporting of talc use among those with a 25 history of ovarian cancer?</p>

<p style="text-align: right;">Page 166</p> <p>1 MS. PARFITT: And, Jessica, for 2 clarity, are you still talking about this 3 douching paper or a different O'Brien 4 paper, just for clarity? 5 MS. DAVIDSON: I'm talking about 6 this paper, I believe. 7 MS. PARFITT: Okay. No. That's 8 fine. That's fine. 9 It was really faint, Jessica. I'm 10 sorry. I know you don't -- you're not 11 feeling well, but you're really faint. 12 Okay. 13 BY MS. DAVIDSON: 14 Q. Dr. Siemiatycki? 15 A. Yes. 16 Q. Do the authors of this paper find 17 that there may be over-reporting of talc use 18 among those with a history of ovarian cancer? 19 A. You know, I -- I can't -- I can't 20 remember, to be honest. I can't remember 21 this -- 22 Q. Okay. 23 A. -- particularly well. 24 Q. Okay. That's fair. 25 Do you recall the author saying</p>	<p style="text-align: right;">Page 168</p> <p>1 bias in that; and I had a discussion of the 2 possible impact that it might have. 3 So I felt -- I feel like I already 4 dealt with this issue in my report. I -- I 5 don't know that this -- this publication 6 changed anything for my report. 7 MS. DAVIDSON: Okay. I'd like to 8 mark as Exhibit 12 a paper entitled, "Use 9 of personal care product mixtures and 10 incident hormone-sensitive cancers in the 11 Sister Study: A U.S.-wide prospective 12 cohort," first author Chang. 13 (Whereupon, Defendant's 14 Exhibit D12, Paper entitled, "Use of 15 personal care product mixtures and 16 incident hormone-sensitive cancers in the 17 Sister Study: A U.S.-wide prospective 18 cohort," by Che-Jung Chang, et al., was 19 marked for identification.) 20 THE WITNESS: C-H-I-A-N-G-E. 21 BY MS. DAVIDSON: 22 Q. C-H-A-N-G. 23 A. I'm getting it. It will just take 24 a second before we find it. 25 Q. Does the paper name sound familiar</p>
<p style="text-align: right;">Page 167</p> <p>1 that, "Recall bias is potentially driving some 2 of the previous observed differences in effect 3 estimates between studies collecting genital 4 powder exposure status retrospectively versus 5 prospectively"? 6 A. So I don't recall that. 7 Q. Okay. 8 A. But I don't disagree that it's 9 potentially true. 10 Q. Okay. 11 A. The qualifier potentially's the key 12 word in -- in that sentence. 13 Q. Did you include a discussion of 14 this paper in your -- in your report? 15 A. Of this paper? 16 Q. Uh-huh. 17 A. You know, I don't remember if I did 18 or not. 19 Q. Okay. 20 A. I didn't think that it moved of the 21 dial in any way compared to what I already had 22 in the paper. You know, I had a section in my 23 paper -- in my report about different kinds of 24 biases that can affect different kinds of 25 epidemiologic studies, and I included reporting</p>	<p style="text-align: right;">Page 169</p> <p>1 to you? 2 A. I'm sorry? 3 Q. Does the paper name sound familiar 4 to you? 5 A. Yes, vaguely; but again, not fresh 6 in my mind. 7 Q. Do you recall when you read it? 8 A. Sorry. Did you say -- did you ask 9 something? 10 Q. Do you recall when you read this 11 paper? 12 A. No, I don't, not right now. Not 13 before having seen it. If you can hang on for 14 a couple of minutes, I think we're looking for 15 it. 16 THE WITNESS: Is it missing? 17 MS. DAVIDSON: We'll put it up on 18 the screen, Noah. 19 MS. PARFITT: If you can go -- if 20 you could go ahead and -- thank you very 21 much -- put it up. 22 MS. DAVIDSON: I believe this paper 23 was in the materials you sent us in the 24 Dropbox, Michelle, correct? 25 MS. PARFITT: Correct. That's</p>

<p style="text-align: right;">Page 170</p> <p>1 correct, yes.</p> <p>2 MS. DAVIDSON: So I'm asking the</p> <p>3 doctor when he read it.</p> <p>4 MS. PARFITT: Yes. The distinction</p> <p>5 we were making, he's got three binders of</p> <p>6 articles here; and it is not in his</p> <p>7 binder. I don't know if it's in the</p> <p>8 miscellaneous materials that we got.</p> <p>9 THE WITNESS: I don't remember when</p> <p>10 I looked at this. It wasn't an important</p> <p>11 paper in my evaluation.</p> <p>12 BY MS. DAVIDSON:</p> <p>13 Q. Does this paper report a risk</p> <p>14 estimate for exposure to perineal talc use and</p> <p>15 the development of ovarian cancer?</p> <p>16 MS. PARFITT: Objection. Form.</p> <p>17 If you want to show him what</p> <p>18 you're --</p> <p>19 THE WITNESS: I have to read it. I</p> <p>20 have to read it. I'm sorry. I just</p> <p>21 don't -- I'm not familiar enough with the</p> <p>22 article, and I don't remember it very</p> <p>23 well.</p> <p>24 BY MS. DAVIDSON:</p> <p>25 Q. Okay. It was on your reliance</p>	<p style="text-align: right;">Page 172</p> <p>1 And if you can point me to where</p> <p>2 this is an important article with important</p> <p>3 results, I will certainly consider it if I'm</p> <p>4 called upon to comment on this again.</p> <p>5 Q. So your testimony is that it's in</p> <p>6 your materials considered list, but you never</p> <p>7 actually read it?</p> <p>8 A. I looked at it in some form, maybe</p> <p>9 looked at the abstract; but, you know, of the</p> <p>10 hundreds and hundreds of articles I've looked</p> <p>11 at in abstracts on this topic and other topics</p> <p>12 in the past year, I can't say that this one</p> <p>13 stuck out in any way.</p> <p>14 Q. All right. Let's turn to Table S4.</p> <p>15 A. To where?</p> <p>16 Q. Table S4.</p> <p>17 A. Of this article, okay.</p> <p>18 Q. Correct.</p> <p>19 A. I don't have the article in front</p> <p>20 of me so --</p> <p>21 Q. We're going to put it up on the</p> <p>22 screen. Don't worry.</p> <p>23 A. Yeah.</p> <p>24 MS. DAVIDSON: We're going to mark</p> <p>25 Table S4 as Exhibit 13.</p>
<p style="text-align: right;">Page 171</p> <p>1 list, and it came out in 2024.</p> <p>2 So you read it pretty recently,</p> <p>3 correct?</p> <p>4 MS. PARFITT: It was on materials</p> <p>5 considered, Jessica, not on reliance.</p> <p>6 BY MS. DAVIDSON:</p> <p>7 Q. Dr. Siemiatycki, this was on your</p> <p>8 materials considered list and it came out in</p> <p>9 2024.</p> <p>10 So you read it pretty recently,</p> <p>11 correct?</p> <p>12 MS. PARFITT: Objection.</p> <p>13 THE WITNESS: Not correct.</p> <p>14 BY MS. DAVIDSON:</p> <p>15 Q. Well, when did you read it?</p> <p>16 A. Well, I don't think I read it. I</p> <p>17 think I glanced at it, decided it was not</p> <p>18 important to write up or review. So I --</p> <p>19 Q. How do you decide that a paper's</p> <p>20 not important to review just by glancing it</p> <p>21 without reading it in full?</p> <p>22 A. You have to make such decisions</p> <p>23 when you're reviewing, you know, an enormous</p> <p>24 volume of material, which ones to go further</p> <p>25 and dig into and which ones to set aside.</p>	<p style="text-align: right;">Page 173</p> <p>1 Noah, it is the Supplemental</p> <p>2 Table S4.</p> <p>3 MR. EPSTEIN: Yeah. Sorry about</p> <p>4 that. Let me pull that up.</p> <p>5 MS. DAVIDSON: Let's mark that as</p> <p>6 Exhibit 13.</p> <p>7 (Whereupon, Defendant's Exhibit</p> <p>8 D13, Supplemental Table S4, was marked for</p> <p>9 identification.)</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. Table S4, which we're putting up on</p> <p>12 the screen, is titled --</p> <p>13 MS. PARFITT: Jessica, it's not up</p> <p>14 yet, just so you know.</p> <p>15 MS. DAVIDSON: I know. I know.</p> <p>16 I'm just -- I'm not asking any questions</p> <p>17 yet. I'm just telling you.</p> <p>18 Table S4, which is being put up on</p> <p>19 the screen is entitled, "Associations</p> <p>20 between one-frequency category increase in</p> <p>21 use of single personal care product and</p> <p>22 breast, ovarian, and uterine cancer using</p> <p>23 Cox proportional hazards models."</p> <p>24 Noah, I would like to look at the</p> <p>25 middle column, which is ovarian cancer.</p>

<p style="text-align: right;">Page 174</p> <p>1 So can you below that up and focus on</p> <p>2 that.</p> <p>3 MR. EPSTEIN: I've looked. I don't</p> <p>4 see a way to blow it up.</p> <p>5 MS. DAVIDSON: There is a way, but</p> <p>6 okay.</p> <p>7 MR. EPSTEIN: Sorry about that.</p> <p>8 MS. DAVIDSON: Did you ask -- do</p> <p>9 you ask someone?</p> <p>10 MR. EPSTEIN: I've reached out to</p> <p>11 Asher. I haven't heard back.</p> <p>12 MS. DAVIDSON: Okay. Ask a</p> <p>13 paralegal.</p> <p>14 MR. EPSTEIN: Okay.</p> <p>15 BY MS. DAVIDSON:</p> <p>16 Q. Looking at the bottom -- we'll all</p> <p>17 just have to strain our eyes a little.</p> <p>18 In the bottom middle column, it</p> <p>19 lists for several hygiene products an adjusted</p> <p>20 hazard ratio for ovarian cancer.</p> <p>21 Do you see that?</p> <p>22 It's also been e-mailed to you in</p> <p>23 the chat if you want to open it up there.</p> <p>24 MS. PARFITT: Jessica, I would just</p> <p>25 object to the extent the doctor has</p>	<p style="text-align: right;">Page 176</p> <p>1 Can you -- are you able to increase</p> <p>2 it?</p> <p>3 MR. LYONS: I mean, if you want me</p> <p>4 to share, I can zoom. So I've got the</p> <p>5 document if you want me to share.</p> <p>6 MS. DAVIDSON: Patrick, do you know</p> <p>7 how to do it?</p> <p>8 MR. LYONS: Yes.</p> <p>9 MS. DAVIDSON: Great. Let's have</p> <p>10 Patrick do it.</p> <p>11 MR. LYONS: If that will be</p> <p>12 helpful.</p> <p>13 MS. DAVIDSON: Yes. That would be</p> <p>14 amazing, Patrick.</p> <p>15 So you're going to put -- Patrick,</p> <p>16 you're going to put up Table S4, the</p> <p>17 middle table on ovarian cancer.</p> <p>18 Thank you so much.</p> <p>19 Michelle, he's useful. You're</p> <p>20 lucky.</p> <p>21 Okay. Patrick, we want to go to</p> <p>22 the bottom. Okay. And then we're looking</p> <p>23 at -- right. We're looking at adjusted</p> <p>24 hazard ratios for bath gel, deodorant,</p> <p>25 douche, mouthwash, shaving cream.</p>
<p style="text-align: right;">Page 175</p> <p>1 already testified. He looked at an</p> <p>2 abstract. He has not reviewed this</p> <p>3 article --</p> <p>4 MS. DAVIDSON: I understand, but</p> <p>5 I'm -- I'm showing you --</p> <p>6 MR. TISI: Do you mind if I can go</p> <p>7 behind him and see if I can download --</p> <p>8 MS. DAVIDSON: Well, do you guys</p> <p>9 want to just print -- do you want to go</p> <p>10 off the record and print this?</p> <p>11 MR. TISI: We're not in a place</p> <p>12 where we can do that, Jessica.</p> <p>13 MS. DAVIDSON: Oh, okay.</p> <p>14 MR. TISI: I'm seeing if I go to</p> <p>15 the chat --</p> <p>16 MS. DAVIDSON: On my computer I'm</p> <p>17 able to just -- to zoom in.</p> <p>18 MR. TISI: Yeah. He can't do that</p> <p>19 unless he downloads the document.</p> <p>20 MS. DAVIDSON: On my table I can</p> <p>21 just go on my Zoom, interestingly enough,</p> <p>22 and just -- on my computer, I can increase</p> <p>23 it.</p> <p>24 MR. TISI: Let's see if we can do</p> <p>25 that.</p>	<p style="text-align: right;">Page 177</p> <p>1 And then if you turn to the next</p> <p>2 page, talc underarm, talc vaginal, and</p> <p>3 talc other.</p> <p>4 BY MS. DAVIDSON:</p> <p>5 Q. So I'd like to ask you,</p> <p>6 Dr. Siemiatycki, of these hygiene products,</p> <p>7 bath gel, deodorant, douche, mouthwash, shaving</p> <p>8 cream, talc underarm, and talc vaginal, do any</p> <p>9 show an age-adjusted hazard ratio that's</p> <p>10 statistically significant with ovarian cancer?</p> <p>11 MS. PARFITT: Objection to the</p> <p>12 question.</p> <p>13 The doctor's testified he has not</p> <p>14 had a chance to review the entire article,</p> <p>15 and he has not relied on it for the</p> <p>16 purposes of this --</p> <p>17 MS. DAVIDSON: I understand. We're</p> <p>18 just looking at this table, Michelle.</p> <p>19 THE WITNESS: Well, from just the</p> <p>20 table, I wouldn't venture a guess as to</p> <p>21 how -- what I would think if I saw the</p> <p>22 whole paper.</p> <p>23 Just as an example -- this is from</p> <p>24 the Sister Study, correct?</p> <p>25 In the original publication of the</p>

<p style="text-align: right;">Page 178</p> <p>1 Sister Study, the published result on</p> <p>2 perineal use of talc and ovarian cancer</p> <p>3 showed a relative risk of .73.</p> <p>4 In the analysis of the Sister Study</p> <p>5 data by the O'Brien team, they found that</p> <p>6 the Sister Study data actually showed a</p> <p>7 relative risk of 1.05.</p> <p>8 So depending on who did the</p> <p>9 analysis and how they did the analysis,</p> <p>10 there's an enormous change in the point</p> <p>11 estimate.</p> <p>12 I don't know what this data was</p> <p>13 based on that you're showing me here in</p> <p>14 this article. I would need to look at it</p> <p>15 and understand what -- what subjects it</p> <p>16 was based on, what subsets of the</p> <p>17 Sister Study cohort it was based on, what</p> <p>18 the methods were. So I really can't</p> <p>19 answer the questions about it.</p> <p>20 BY MS. DAVIDSON:</p> <p>21 Q. Dr. Siemiatycki, you're refusing to</p> <p>22 tell me which of the risk ratios that are</p> <p>23 listed here are statistically significant?</p> <p>24 MS. PARFITT: Objection. Form.</p> <p>25 THE WITNESS: I could -- I could --</p>	<p style="text-align: right;">Page 180</p> <p>1 A. I see that.</p> <p>2 Q. Okay. Let's go back down.</p> <p>3 The adjusted hazard ratio for bath</p> <p>4 gel is not statistically significant at the</p> <p>5 95-percent confidence interval, correct?</p> <p>6 MS. PARFITT: Objection. Form.</p> <p>7 THE WITNESS: That's correct.</p> <p>8 BY MS. DAVIDSON:</p> <p>9 Q. And the same is true for deodorant</p> <p>10 mouthwash, shaving cream, talc underarm, and</p> <p>11 talc vaginal, correct?</p> <p>12 MS. PARFITT: Objection. Form.</p> <p>13 THE WITNESS: That's correct.</p> <p>14 BY MS. DAVIDSON:</p> <p>15 Q. And the only -- the only</p> <p>16 statistically significant --</p> <p>17 MS. PARFITT: Jessica, let me --</p> <p>18 THE WITNESS: I don't endorse that</p> <p>19 those are valid statements.</p> <p>20 BY MS. DAVIDSON:</p> <p>21 Q. I understand. But, you know,</p> <p>22 that's not my question, with all due respect.</p> <p>23 And you're happy -- I'm happy for</p> <p>24 you. When Ms. Parfitt questions you, you can</p> <p>25 go on and on why you don't endorse this paper,</p>
<p style="text-align: right;">Page 179</p> <p>1 BY MS. DAVIDSON:</p> <p>2 Q. If you're refusing, just tell me</p> <p>3 that.</p> <p>4 MS. PARFITT: Objection to the</p> <p>5 response.</p> <p>6 BY MS. DAVIDSON:</p> <p>7 Q. I asked you in this paper do the</p> <p>8 authors -- well, let's start with bath gel.</p> <p>9 Is the adjusted hazard ratio for</p> <p>10 bath gel and ovarian cancer statistically</p> <p>11 significant?</p> <p>12 A. Well, one thing, I don't know which</p> <p>13 is the adjusted.</p> <p>14 Q. Right here, it says it, 1.06.</p> <p>15 There's --</p> <p>16 A. It doesn't say it on my screen.</p> <p>17 Q. It's at the top of the page,</p> <p>18 Doctor.</p> <p>19 A. Well, the top of the page is not</p> <p>20 visible.</p> <p>21 Q. We're happy to show it to you</p> <p>22 again. We showed it to you already.</p> <p>23 It says, "Adjusted -- age-adjusted</p> <p>24 hazard ratio 95 percent confidence interval."</p> <p>25 Do you see that, Doctor?</p>	<p style="text-align: right;">Page 181</p> <p>1 but my question is very simple.</p> <p>2 The only statistically significant</p> <p>3 hazard ratio in this column is for douching,</p> <p>4 correct?</p> <p>5 MS. PARFITT: Objection. Form.</p> <p>6 And you aren't letting him finish the</p> <p>7 answer.</p> <p>8 MS. DAVIDSON: Okay. I understand.</p> <p>9 BY MS. DAVIDSON:</p> <p>10 Q. Dr. Siemiatycki, the only adjusted</p> <p>11 hazard ratio that is statistically significant</p> <p>12 is for douching, correct?</p> <p>13 MS. PARFITT: Objection. Form.</p> <p>14 THE WITNESS: If by "statistically</p> <p>15 significant," you mean the confidence</p> <p>16 interval -- the 95-percent confidence</p> <p>17 interval does not include one, then that's</p> <p>18 correct.</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. For douching it shows a 1.37;</p> <p>21 whereas, for talc vaginal, it shows 1.07</p> <p>22 correct?</p> <p>23 MS. PARFITT: Objection. Form.</p> <p>24 He's already testified. He cannot --</p> <p>25 MS. DAVIDSON: Okay. I understand,</p>

<p style="text-align: right;">Page 182</p> <p>1 Michelle. You can have a standing 2 objection to this document. 3 BY MS. DAVIDSON: 4 Q. For douching shows 1.37 compared to 5 talc vaginal at 1.07, correct? 6 MS. PARFITT: Objection. Form. 7 THE WITNESS: That's what this 8 table -- these numbers in this table show. 9 BY MS. DAVIDSON: 10 Q. Correct. And I'm asking you about 11 this table. That's all I'm asking you about. 12 And for bath and -- 13 MS. PARFITT: Jessica, I don't want 14 to talk over you. 15 MS. DAVIDSON: No. I'm not having 16 speeches about this. I'm asking questions 17 about this document. 18 You can ask him all the questions 19 you want about -- about this paper. 20 MS. PARFITT: He's -- 21 BY MS. DAVIDSON: 22 Q. Dr. Siemiatycki, am I correct 23 that -- am I correct that the adjusted hazard 24 ratio for bath gel is 1.06 and for talc is 25 1.07; is that correct?</p>	<p style="text-align: right;">Page 184</p> <p>1 MS. PARFITT: Objection. Form. 2 THE WITNESS: Yes. 3 BY MS. DAVIDSON: 4 Q. Okay. Let's go back to the 5 Wentzensen, O'Brien paper 2021. 6 MR. EPSTEIN: I can take over from 7 here. Thank you. I figured out the 8 zooming. I apologize. 9 BY MS. DAVIDSON: 10 Q. Oh, Dr. Siemiatycki, you noted 11 earlier that O'Brien had a different risk ratio 12 for the Sister Study than was originally 13 reported in Gonzalez, right? 14 A. Yes. 15 Q. And one reason for that is that 16 O'Brien had more years of data, right? 17 A. Yes. 18 Q. And the 1.05 risk ratio for the 19 Sister -- for the Sister Study reported in 20 O'Brien was not statistically significant at 21 the 95-percent confidence interval, correct? 22 A. Correct. 23 Q. Okay. If we could look at 24 Wentzensen, O'Brien, going back to -- 25 MR. TISI: I'm trying to get it, so</p>
<p style="text-align: right;">Page 183</p> <p>1 MS. PARFITT: Dr. Siemiatycki, 2 would you answer the in the fashion you 3 have been attempting to answer it but have 4 been obstructed by counsel from giving 5 your answer. 6 BY MS. DAVIDSON: 7 Q. Dr. Siemiatycki, am I correct that 8 in this table the adjusted hazard ratio for 9 bath gel is not statistically significant at 10 1.06, and the adjusted hazard ratio for vaginal 11 talc is not statistically significant at 1.07, 12 correct? 13 MS. PARFITT: Objection. Form. 14 Answer as in fulsome a manner as 15 you need to answer the question 16 accurately. 17 THE WITNESS: Yes. 18 BY MS. DAVIDSON: 19 Q. Thank you. And the confidence 20 intervals for bath gel and for vaginal talc 21 use, the confidence intervals listed on this 22 table overlap significantly, right -- or 23 considerably, to use the language you used 24 before? 25 They overlap considerably, right?</p>	<p style="text-align: right;">Page 185</p> <p>1 just give him a second. 2 MS. DAVIDSON: Okay. 3 MR. TISI: Thank you. 4 BY MS. DAVIDSON: 5 Q. I just have one question on this 6 paper. 7 Dr. Siemiatycki, did the confidence 8 intervals in O'Brien 2021 for the risk ratio 9 for women with patent tubes versus women with 10 non patent tubes, did those confidence 11 intervals overlap considerably? 12 MS. PARFITT: Objection. Form. 13 THE WITNESS: Sorry. I don't know 14 which paper we're talking about or which 15 table we're talking about. 16 BY MS. DAVIDSON: 17 Q. In the Wentzensen and O'Brien paper 18 2021, that's what we've been talking about. 19 I'm asking you: Did the confidence 20 intervals reported by those authors for women 21 with patent tubes and women who didn't have 22 patent tubes, did they overlap considerably? 23 MS. PARFITT: Jessica, which table 24 are you referring to? 25 He's trying to orient himself.</p>

<p style="text-align: right;">Page 186</p> <p>1 THE WITNESS: Are you waiting for</p> <p>2 me to answer a question?</p> <p>3 BY MS. DAVIDSON:</p> <p>4 Q. Yes, of course.</p> <p>5 MS. PARFITT: All right. We</p> <p>6 thought --</p> <p>7 BY MS. DAVIDSON:</p> <p>8 Q. There's a question pending.</p> <p>9 Have you forgotten the question?</p> <p>10 MS. PARFITT: He did.</p> <p>11 Suzanne, could you read that.</p> <p>12 MS. DAVIDSON: I'm sorry. I'm</p> <p>13 talking to him, Michelle.</p> <p>14 BY MS. DAVIDSON:</p> <p>15 Q. Dr. Siemiatycki, have you forgotten</p> <p>16 my question?</p> <p>17 A. I thought that you were going to</p> <p>18 point me to a table. I don't know which data</p> <p>19 you are -- the question pertains to. I thought</p> <p>20 you were going to indicate --</p> <p>21 Q. Doctor, you -- you included the</p> <p>22 Wentzensen paper in your report, right?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. I assume you read it,</p> <p>25 correct?</p>	<p style="text-align: right;">Page 188</p> <p>1 immunological data from case control</p> <p>2 studies and cohort studies suggests that</p> <p>3 there may be a small positive association</p> <p>4 between genital powder use and ovarian</p> <p>5 cancer. The causal factors underlying the</p> <p>6 association are not clear. Proposed</p> <p>7 factors include talc, other minerals."</p> <p>8 Do you want me to continue reading</p> <p>9 their conclusion?</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. I didn't ask you to read the</p> <p>12 conclusions.</p> <p>13 I asked you whether the confidence</p> <p>14 intervals reported in this paper for patent</p> <p>15 women overlap with the confidence interval</p> <p>16 reported in this paper for non patent women.</p> <p>17 A. I don't see --</p> <p>18 Q. It is a simple question.</p> <p>19 A. I don't see the results that you're</p> <p>20 alluding to. I don't see results for patent --</p> <p>21 I think we're talking about different papers.</p> <p>22 MR. TISI: Which paper are you</p> <p>23 talking about?</p> <p>24 We have the Wentzensen 2021.</p> <p>25 THE WITNESS: Wentzensen,</p>
<p style="text-align: right;">Page 187</p> <p>1 A. Correct.</p> <p>2 Q. And you're aware that it provides</p> <p>3 risk ratios for patent women and non patent</p> <p>4 women, right?</p> <p>5 A. Can you show me which table you're</p> <p>6 referring to?</p> <p>7 Q. I'm not referring to a table. I'm</p> <p>8 asking you what the results are of the study.</p> <p>9 A. I'm asking you which table you are</p> <p>10 referring to. You're talking about relative</p> <p>11 risks and overlapping confidence intervals. I</p> <p>12 don't know what to look at.</p> <p>13 Q. Do you know what the results were</p> <p>14 of the Wentzensen study?</p> <p>15 MS. PARFITT: Different question.</p> <p>16 THE WITNESS: Okay.</p> <p>17 MS. PARFITT: New question, Doctor.</p> <p>18 THE WITNESS: Okay. Well, I'll</p> <p>19 look at the final conclusion of their</p> <p>20 paper, and we went through this paper</p> <p>21 15 minutes ago. And -- let me go to the</p> <p>22 abstract, which often has a concise</p> <p>23 statement of the findings or the</p> <p>24 conclusions.</p> <p>25 So they say, "Taken together via</p>	<p style="text-align: right;">Page 189</p> <p>1 O'Brien --</p> <p>2 BY MS. DAVIDSON:</p> <p>3 Q. Excuse me. I don't know who's</p> <p>4 talking to you, but we don't have lawyers</p> <p>5 talking to witnesses during a deposition.</p> <p>6 MR. TISI: Well, no. I'm actually</p> <p>7 talking to you. I'm trying to figure</p> <p>8 out --</p> <p>9 MS. DAVIDSON: Hey, don't talk to</p> <p>10 me because Michelle's defending this</p> <p>11 deposition.</p> <p>12 MR. TISI: Fine. Michelle, would</p> <p>13 you ask --</p> <p>14 BY MS. DAVIDSON:</p> <p>15 Q. Dr. Siemiatycki --</p> <p>16 MR. TISI: -- what she's referring</p> <p>17 to?</p> <p>18 MS. DAVIDSON: Okay. Hold on.</p> <p>19 Guys --</p> <p>20 MR. TISI: I'm trying -- I'm trying</p> <p>21 to help you.</p> <p>22 MS. DAVIDSON: Cut.</p> <p>23 MR. TISI: I'm trying to help you.</p> <p>24 MS. DAVIDSON: You're not helping</p> <p>25 me.</p>

<p style="text-align: right;">Page 190</p> <p>1 MR. TISI: Okay.</p> <p>2 MS. DAVIDSON: Thanks for your</p> <p>3 help. I don't want it.</p> <p>4 BY MS. DAVIDSON:</p> <p>5 Q. Dr. Siemiatycki, can you tell me,</p> <p>6 sitting here, what the -- what the risk ratio</p> <p>7 reported in this paper was for patent women</p> <p>8 versus non patent women and whether the</p> <p>9 confidence intervals overlapped?</p> <p>10 If you can't, just say you can't.</p> <p>11 MS. PARFITT: Jessica, I think</p> <p>12 there's a little confusion because they're</p> <p>13 not marked.</p> <p>14 MS. DAVIDSON: Excuse me. There's</p> <p>15 no confusion. I've asked the same</p> <p>16 question --</p> <p>17 MS. PARFITT: There actually is.</p> <p>18 MS. DAVIDSON: -- six times.</p> <p>19 MS. PARFITT: He's -- we're making</p> <p>20 sure you are talking about the Wentzensen,</p> <p>21 O'Brien because the one in his hand is</p> <p>22 Wentzensen, O'Brien, "Talc, body powder,</p> <p>23 and ovarian cancer: a summary of the</p> <p>24 epidemiologic evidence."</p> <p>25 Are we on the same article.</p>	<p style="text-align: right;">Page 192</p> <p>1 Q. You don't see it in here?</p> <p>2 Would you like to look at</p> <p>3 Wentzensen 2020 for that information?</p> <p>4 A. Well, I'll look at whatever you</p> <p>5 think I should look at, but I'm looking at the</p> <p>6 one you pointed me at five minutes ago; and I</p> <p>7 can't find that -- those results.</p> <p>8 So just point me to the results,</p> <p>9 and I'm happy to look at it.</p> <p>10 Q. If you look on page 8, the authors</p> <p>11 state --</p> <p>12 A. Which -- which paper? Which paper?</p> <p>13 Q. The same one we've been on.</p> <p>14 A. Okay, okay. Because you just</p> <p>15 switched papers. But now you're back to the</p> <p>16 one we've been talking about. That's fine.</p> <p>17 Q. No, I didn't switch papers, Doctor.</p> <p>18 It says, "A history of genital</p> <p>19 powder use was associated with an increase of</p> <p>20 developing incident ovarian cancer. Hazard</p> <p>21 ratio 1.13. Confidence interval 1.01 to 1.26.</p> <p>22 This association was null among women who did</p> <p>23 not have patent tubes, 0.99 confidence interval</p> <p>24 .86 to 1.15."</p> <p>25 Do those confidence intervals</p>
<p style="text-align: right;">Page 191</p> <p>1 MS. DAVIDSON: We are on the same</p> <p>2 article, Michelle.</p> <p>3 MS. PARFITT: Okay. That's good.</p> <p>4 Okay. That's all. That's good.</p> <p>5 Here you go.</p> <p>6 THE WITNESS: And are you claiming</p> <p>7 that there are results here showing the</p> <p>8 association for women with patent</p> <p>9 reproductive tracts and non patent; is</p> <p>10 that what you're saying?</p> <p>11 BY MS. DAVIDSON:</p> <p>12 Q. Well, you testified earlier that</p> <p>13 you wrote in your paper that these authors</p> <p>14 reported particularly high risk for patent</p> <p>15 women.</p> <p>16 So do you not recall whether</p> <p>17 there -- this study actually has results for</p> <p>18 patent and non patent women?</p> <p>19 A. Well, as -- as this is a review</p> <p>20 article, it doesn't necessarily show numerical</p> <p>21 results for each study that they took into</p> <p>22 account. And I'm just looking to see whether</p> <p>23 they have any numeric -- because you're asking</p> <p>24 about numerical results, overlaps of confidence</p> <p>25 intervals and things. And I at first glance --</p>	<p style="text-align: right;">Page 193</p> <p>1 overlap?</p> <p>2 A. I'm now looking for that sentence.</p> <p>3 So page 8, the first column, I assume; and</p> <p>4 you're talking about the first full paragraph</p> <p>5 on that -- in that column; is that where you're</p> <p>6 looking, or the second?</p> <p>7 Q. Can we make this easier?</p> <p>8 Do the -- does the confidence</p> <p>9 interval of 1.01 to 1.26 overlap with a</p> <p>10 confidence interval of .86 to 1.15?</p> <p>11 A. Okay. Repeat that question.</p> <p>12 Q. Does the confidence interval of</p> <p>13 1.01 to 1.26 overlap with the confidence</p> <p>14 interval of .86 to 1.15?</p> <p>15 A. Yes.</p> <p>16 Q. Okay.</p> <p>17 MS. DAVIDSON: Now, let's go to</p> <p>18 O'Brien 2020, and let's mark that as</p> <p>19 Exhibit --</p> <p>20 MR. EPSTEIN: 14.</p> <p>21 MS. DAVIDSON: -- 14.</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>

<p style="text-align: right;">Page 194</p> <p>1 (Whereupon, Defendant's</p> <p>2 Exhibit D14, Paper entitled, "Association</p> <p>3 of Powder Use in the Genital Area With</p> <p>4 Risk of Ovarian Cancer," by Katie M.</p> <p>5 O'Brien, PhD, et al., was marked for</p> <p>6 identification.)</p> <p>7 MS. DAVIDSON: Do you guys have</p> <p>8 that paper in front of you?</p> <p>9 THE WITNESS: We're getting it.</p> <p>10 MS. PARFITT: And, Jessica, for</p> <p>11 accuracy, you're talking about the O'Brien</p> <p>12 paper entitled, "Association of Powder Use</p> <p>13 in the Genital Area with Risk" --</p> <p>14 MS. DAVIDSON: I'm going to --</p> <p>15 yeah. I'm going to -- I'm going to mark</p> <p>16 it as soon as Noah puts it up.</p> <p>17 Okay. So, Noah, what number are we</p> <p>18 on?</p> <p>19 MR. EPSTEIN: This is Exhibit 14.</p> <p>20 MS. DAVIDSON: Okay. You have it</p> <p>21 right up there. This is great.</p> <p>22 Chris, you have to credit me with</p> <p>23 this PDF naming idea.</p> <p>24 BY MS. DAVIDSON:</p> <p>25 Q. Exhibit 14 is, "Association of</p>	<p style="text-align: right;">Page 196</p> <p>1 A. Correct.</p> <p>2 MS. PARFITT: He does.</p> <p>3 MS. DAVIDSON: We can go to the</p> <p>4 conclusion.</p> <p>5 BY MS. DAVIDSON:</p> <p>6 Q. Dr. Siemiatycki, are you looking</p> <p>7 for -- for this in a hard copy?</p> <p>8 A. Yeah. I have the hard copy of this</p> <p>9 page that's on the screen.</p> <p>10 So I don't see any -- I don't see</p> <p>11 any tables. This is not a --</p> <p>12 Q. Okay. Doctor, you're -- I assume</p> <p>13 that you know how to read an epidemiological</p> <p>14 paper, correct?</p> <p>15 MS. PARFITT: Objection. Form.</p> <p>16 THE WITNESS: I'm not sure how to</p> <p>17 answer that, but yes.</p> <p>18 BY MS. DAVIDSON:</p> <p>19 Q. Okay. Can you tell me where in</p> <p>20 this paper it reports confidence intervals for</p> <p>21 patent and non patent women and whether those</p> <p>22 confidence intervals overlap?</p> <p>23 A. I didn't hear that whole sentence.</p> <p>24 Can I tell you where they are?</p> <p>25 Q. Uh-huh. You can't find the</p>
<p style="text-align: right;">Page 195</p> <p>1 Powder Use in the Genital Area With Risk of</p> <p>2 Ovarian Cancer," published in JAMA by O'Brien.</p> <p>3 You're familiar with this paper,</p> <p>4 right, Doctor?</p> <p>5 A. Yes.</p> <p>6 Q. And you've testified about this</p> <p>7 before, and I just have one question for you on</p> <p>8 this paper.</p> <p>9 On this paper do the confidence</p> <p>10 intervals for patent women and non patent women</p> <p>11 reported by this paper overlap?</p> <p>12 A. I'm sorry. Do they what?</p> <p>13 Q. Overlap. Do the confidence</p> <p>14 intervals overlap?</p> <p>15 The same question I've been asking.</p> <p>16 A. You want to -- you want to point me</p> <p>17 specifically to the results in the table, or</p> <p>18 should I try to find them myself?</p> <p>19 Do you know in which table those</p> <p>20 results are found?</p> <p>21 MS. PARFITT: We're scrolling to</p> <p>22 them right now.</p> <p>23 BY MS. DAVIDSON:</p> <p>24 Q. We're scrolling through -- you do</p> <p>25 have the paper in front of you, correct?</p>	<p style="text-align: right;">Page 197</p> <p>1 confidence intervals and the reported --</p> <p>2 MS. PARFITT: We're having a hard</p> <p>3 time hearing you between the remote nature</p> <p>4 and his hearing issue, he is having a hard</p> <p>5 time hearing you.</p> <p>6 I'm sorry. If you want to read it</p> <p>7 back to him.</p> <p>8 MS. DAVIDSON: I don't know. He's</p> <p>9 heard me all day.</p> <p>10 MS. PARFITT: No, no. Actually, he</p> <p>11 hasn't. That's why I keep interrupting.</p> <p>12 He hasn't, and my apologies for that; but</p> <p>13 we are having an issue here.</p> <p>14 THE WITNESS: So you want me to</p> <p>15 read through this page and find the</p> <p>16 results that you are referring to?</p> <p>17 It will take me a minute to read</p> <p>18 through the page, or do you want to say</p> <p>19 specifically --</p> <p>20 BY MS. DAVIDSON:</p> <p>21 Q. I am asking you: What are the</p> <p>22 point estimates in confidence intervals</p> <p>23 reported in this paper perineal talc use and</p> <p>24 the development of ovarian cancer for patent</p> <p>25 women versus non patent women?</p>

<p style="text-align: right;">Page 198</p> <p>1 A. And it's on this page?</p> <p>2 Q. It's in this paper.</p> <p>3 A. It's in the paper. So it will take</p> <p>4 me about 10 or 15 minutes to read --</p> <p>5 Q. It's going to take you 10 or</p> <p>6 15 minutes to identify the risk ratios in this</p> <p>7 paper?</p> <p>8 A. To read -- because I would have</p> <p>9 to -- unless you point me to a specific paper</p> <p>10 or a page or a specific table and call them, I</p> <p>11 will read from the beginning the entire paper</p> <p>12 to try to find what is the nature of the</p> <p>13 question.</p> <p>14 I still don't understand the</p> <p>15 question. You're asking me to find some</p> <p>16 results in a paper, in an eight-page paper.</p> <p>17 Q. I just want to make sure I</p> <p>18 understand.</p> <p>19 It would take you 10 or 15 minutes</p> <p>20 to find the -- to find the risk -- the point</p> <p>21 estimates reported by these authors?</p> <p>22 A. Yes, or the ones that you are</p> <p>23 referring to.</p> <p>24 Q. Do you recall whether this paper --</p> <p>25 A. I'm sorry?</p>	<p style="text-align: right;">Page 200</p> <p>1 know --</p> <p>2 Q. I'm not asking you to read my mind.</p> <p>3 I'm asking you to read the paper.</p> <p>4 A. Is the data that you're referring</p> <p>5 to in Table 2?</p> <p>6 Q. Doctor, I'm asking you to tell me</p> <p>7 what this paper reports in terms of hazard</p> <p>8 ratio for patent versus non patent women. I</p> <p>9 don't care where in the paper you find it.</p> <p>10 I'm just asking you: What does it</p> <p>11 report, and do the confidence intervals</p> <p>12 overlap?</p> <p>13 A. Okay.</p> <p>14 Q. Is that too hard?</p> <p>15 MS. PARFITT: Objection. Form.</p> <p>16 THE WITNESS: It's hard if I've got</p> <p>17 to guess where the information is; but if</p> <p>18 you have time, I'll read through the paper</p> <p>19 and try to find that information.</p> <p>20 BY MS. DAVIDSON:</p> <p>21 Q. You would have to read this entire</p> <p>22 paper in order to answer that question?</p> <p>23 MS. PARFITT: Objection. Form.</p> <p>24 THE WITNESS: To know which results</p> <p>25 you're talking about, yes. I would have</p>
<p style="text-align: right;">Page 199</p> <p>1 Q. Do you recall whether this paper</p> <p>2 provided risk estimates for patent women versus</p> <p>3 non patent women?</p> <p>4 Do you recall that sitting here</p> <p>5 today?</p> <p>6 A. Well, I believe -- I believe it</p> <p>7 did. I believe it did. I'm just looking</p> <p>8 because this group published several papers in</p> <p>9 a few years, and I'm not sure which results</p> <p>10 were presented in which papers. So I'm just</p> <p>11 going to look to see if I can find something in</p> <p>12 this.</p> <p>13 So I see in Figure -- in the figure</p> <p>14 on page 54 some results separately by patent</p> <p>15 and non patent women.</p> <p>16 Q. Uh-huh. Are you looking at</p> <p>17 Table 2?</p> <p>18 A. No. I'm looking at the figure.</p> <p>19 But if you --</p> <p>20 Q. Okay.</p> <p>21 A. -- want me to look at Table 2 --</p> <p>22 Q. I don't care where you look,</p> <p>23 Doctor. I just want the answer to my question.</p> <p>24 I don't care where you look.</p> <p>25 A. So I'm not a mind reader. I don't</p>	<p style="text-align: right;">Page 201</p> <p>1 to at least skim through the entire paper</p> <p>2 to know what you're talking about.</p> <p>3 BY MS. DAVIDSON:</p> <p>4 Q. Doctor, when you read an</p> <p>5 epidemiological paper, is that -- you're not --</p> <p>6 you're not familiar with how to identify risk</p> <p>7 ratios from tables?</p> <p>8 MS. PARFITT: Objection. Form.</p> <p>9 Misstates his testimony.</p> <p>10 BY MS. DAVIDSON:</p> <p>11 Q. I'm just trying to understand why</p> <p>12 it would take you 15 minutes to tell me what</p> <p>13 the hazard ratios are reported in this paper --</p> <p>14 A. Because --</p> <p>15 Q. -- which you covered in your</p> <p>16 report.</p> <p>17 A. Because a paper of three or four</p> <p>18 thousand words with several paragraphs and</p> <p>19 sections and sentences may have that</p> <p>20 information that you are interested in buried</p> <p>21 anywhere in the paper. So to find it, I need</p> <p>22 to go through it.</p> <p>23 Q. All right. Well --</p> <p>24 A. I don't understand why you can't</p> <p>25 tell me on which page or table the numbers are</p>

<p style="text-align: right;">Page 202</p> <p>1 that you are asking me to comment on.</p> <p>2 Q. I can point you to it if you really</p> <p>3 cannot find it on your own.</p> <p>4 MR. GOLOMB: Suzanne, how much time</p> <p>5 is left? How much time is left?</p> <p>6 THE COURT REPORTER: Okay. One</p> <p>7 second.</p> <p>8 MS. DAVIDSON: Suzanne, let's go</p> <p>9 off the record.</p> <p>10 THE COURT REPORTER: We're off the</p> <p>11 record.</p> <p>12 (Discussion held off the record.)</p> <p>13 MS. DAVIDSON: Let's go back on the</p> <p>14 record and let's turn to page 54 of</p> <p>15 O'Brien.</p> <p>16 THE WITNESS: 54?</p> <p>17 MS. DAVIDSON: Uh-huh.</p> <p>18 THE WITNESS: Okay.</p> <p>19 MS. PARFITT: There was a question</p> <p>20 pending, Jessica, when he went off camera</p> <p>21 is that -- when you went off camera.</p> <p>22 Is that question still pending are,</p> <p>23 or are we starting over?</p> <p>24 BY MS. DAVIDSON:</p> <p>25 Q. Dr. Siemiatycki, do you remember</p>	<p style="text-align: right;">Page 204</p> <p>1 I read to you five minutes ago from the other</p> <p>2 paper, aren't they?</p> <p>3 A. I don't remember.</p> <p>4 MS. PARFITT: Objection. Form.</p> <p>5 BY MS. DAVIDSON:</p> <p>6 Q. Okay. And these two confidence</p> <p>7 intervals overlap considerably, correct?</p> <p>8 A. Correct.</p> <p>9 Q. Okay. Let's move on.</p> <p>10 Dr. Siemiatycki, I wanted to mark</p> <p>11 as our final exhibit a paper entitled,</p> <p>12 "Quantitative recall bias analysis of the talc</p> <p>13 and ovarian cancer association." First author</p> <p>14 is Goodman.</p> <p>15 (Whereupon, Defendant's Exhibit</p> <p>16 D15, Paper entitled, "Quantitative recall</p> <p>17 bias analysis of the talc and ovarian</p> <p>18 cancer association," by Julie E.</p> <p>19 Goodman, et al., was marked for</p> <p>20 identification.)</p> <p>21 MS. DAVIDSON: Noah, would you be</p> <p>22 so kind as to put that in the chat and on</p> <p>23 the screen.</p> <p>24 MR. EPSTEIN: On it.</p> <p>25 MS. PARFITT: Give us one moment</p>
<p style="text-align: right;">Page 203</p> <p>1 the question?</p> <p>2 A. I think you asked -- were asking if</p> <p>3 I could describe and comment on the risk</p> <p>4 estimates, the relative risk estimates for</p> <p>5 women with patent reproductive tracts and women</p> <p>6 without, not patent.</p> <p>7 Q. Correct. And the answer is on</p> <p>8 page 54, right?</p> <p>9 A. Well, that's one of the places</p> <p>10 where the answer -- an answer can be found to</p> <p>11 that question.</p> <p>12 Q. And as I read to you from the last</p> <p>13 Wentzensen paper, it's actually the same. The</p> <p>14 same numbers are reported here, right?</p> <p>15 1.13 hazard ratio for patent woman</p> <p>16 with a 1.01 to 1.26 confidence interval; and</p> <p>17 for non patent women .99 with a .86 to a 1.15</p> <p>18 confidence interval, correct?</p> <p>19 MS. PARFITT: Objection. Form.</p> <p>20 THE WITNESS: So I -- I don't</p> <p>21 recall the question you asked before about</p> <p>22 this; but yeah, those are the two numbers</p> <p>23 that are in this table.</p> <p>24 BY MS. DAVIDSON:</p> <p>25 Q. And those are the same numbers that</p>	<p style="text-align: right;">Page 205</p> <p>1 please.</p> <p>2 MS. DAVIDSON: Sure.</p> <p>3 MS. PARFITT: It's a different</p> <p>4 article than the one talked about earlier,</p> <p>5 and we'll have to look at the screen. He</p> <p>6 doesn't have a copy of it.</p> <p>7 THE WITNESS: This -- this is</p> <p>8 very --</p> <p>9 BY MS. DAVIDSON:</p> <p>10 Q. We're marking this paper as</p> <p>11 Exhibit 15, I believe.</p> <p>12 Have you seen this paper before,</p> <p>13 Dr. Siemiatycki?</p> <p>14 A. I don't think I have. It looks</p> <p>15 like it's a very new -- newly published one.</p> <p>16 Q. Dr. Siemiatycki, have you ever</p> <p>17 done -- I'm sorry. I didn't turn my camera on.</p> <p>18 That's not on purpose.</p> <p>19 Have you ever done any analysis of</p> <p>20 how much recall bias would be necessary to</p> <p>21 attenuate the results of the talc ovarian</p> <p>22 cancer studies to the null?</p> <p>23 A. No.</p> <p>24 Q. Have you ever seen any papers</p> <p>25 analyzing that question?</p>

<p style="text-align: right;">Page 206</p> <p>1 A. To attenuate to the null?</p> <p>2 Have I seen any papers?</p> <p>3 I -- I don't recall any -- seeing</p> <p>4 it, but it may be that I did; but I don't</p> <p>5 recall.</p> <p>6 Q. Okay.</p> <p>7 MS. DAVIDSON: I believe I'm done,</p> <p>8 but let's just go off the record for three</p> <p>9 minutes for me to check my notes; and then</p> <p>10 I'll turn you over to Michelle.</p> <p>11 MS. PARFITT: Thank you, Jessica.</p> <p>12 MS. DAVIDSON: Okay.</p> <p>13 (Whereupon, a break was taken.)</p> <p>14 BY MS. DAVIDSON:</p> <p>15 Q. Dr. Siemiatycki, are you aware that</p> <p>16 your testimony today is on behalf of six</p> <p>17 specific Bellwether plaintiffs who've been</p> <p>18 chosen for trial in the MDL proceeding?</p> <p>19 A. No, I am not aware.</p> <p>20 Q. Have you ever heard the names</p> <p>21 Ms. Converse, Ms. Newsome, or Ms. Rausa?</p> <p>22 A. No, I haven't.</p> <p>23 Q. Have you ever heard the names</p> <p>24 Ms. Carl or Ms. Balderrama?</p> <p>25 A. No, I haven't.</p>	<p style="text-align: right;">Page 208</p> <p>1 So I do want to apologize and thank you</p> <p>2 for your time today.</p> <p>3 MS. PARFITT: Oh, thank you,</p> <p>4 Jessica. I appreciate that. We</p> <p>5 understand you're not feeling well.</p> <p>6 THE WITNESS: Thank you.</p> <p>7 MS. PARFITT: Okay. I'm ready to</p> <p>8 go, so why don't we --</p> <p>9 MS. DAVIDSON: Go ahead.</p> <p>10 MS. PARFITT: All right.</p> <p>11 MS. DAVIDSON: Michelle, can I ask</p> <p>12 a favor?</p> <p>13 MS. PARFITT: Of course.</p> <p>14 MS. DAVIDSON: Could we switch</p> <p>15 the -- could we switch the microphone to</p> <p>16 you because you are really hard to hear.</p> <p>17 (Discussion held off the record.)</p> <p>18 EXAMINATION</p> <p>19 BY MS. PARFITT:</p> <p>20 Q. Dr. Siemiatycki, you'll recall that</p> <p>21 several hours ago counsel for J&J asked you</p> <p>22 some questions with regard to an EPA document</p> <p>23 that recently came out banning chrysotile</p> <p>24 asbestos.</p> <p>25 Do you recall that series of</p>
<p style="text-align: right;">Page 207</p> <p>1 Q. Have you looked at any records --</p> <p>2 any medical records or other documents related</p> <p>3 to the plaintiffs in this -- in these cases?</p> <p>4 A. No, I haven't.</p> <p>5 Q. Do you know anything about the</p> <p>6 plaintiff's in these cases usage of talcum</p> <p>7 powder?</p> <p>8 A. No, I don't.</p> <p>9 Q. Do you know what other risk factors</p> <p>10 any of these plaintiffs had for ovarian cancer?</p> <p>11 A. No, I don't.</p> <p>12 Q. Are you offering an opinion that</p> <p>13 talcum powder use caused any specific women to</p> <p>14 develop ovarian cancer?</p> <p>15 MS. PARFITT: Objection. Form.</p> <p>16 THE WITNESS: No. That's not what</p> <p>17 I'm --</p> <p>18 MS. DAVIDSON: Okay. Subject to</p> <p>19 any questions Michelle has, I have no more</p> <p>20 questions at this time.</p> <p>21 I do just want to before I turn</p> <p>22 this over to Michelle, as I said earlier,</p> <p>23 I'm not feeling well; and I did get very</p> <p>24 frustrated this morning. I did not think</p> <p>25 my outburst was particularly professional.</p>	<p style="text-align: right;">Page 209</p> <p>1 questions?</p> <p>2 A. Yes, I do.</p> <p>3 Q. Okay. Let me show you what's been</p> <p>4 entitled, "Environmental Protection Agency."</p> <p>5 It's 40 CFR, Part 751.</p> <p>6 And specifically, I'd like you to</p> <p>7 turn to page 14 of that document. Here you go,</p> <p>8 Doctor.</p> <p>9 A. Thank you.</p> <p>10 Q. And if you'll turn to page 14.</p> <p>11 MS. DAVIDSON: Can we put that up</p> <p>12 on the screen as well?</p> <p>13 MS. PARFITT: Okay.</p> <p>14 MS. DAVIDSON: And should we mark</p> <p>15 it as an exhibit?</p> <p>16 MS. PARFITT: Sure. We certainly</p> <p>17 can. We'll mark it as plaintiff's Exhibit</p> <p>18 Number 1.</p> <p>19 (Whereupon, Plaintiff's Exhibit P1,</p> <p>20 Pre-Publication Notice, was marked for</p> <p>21 identification.)</p> <p>22 MS. PARFITT: And, Patrick, if you</p> <p>23 have a copy of the -- perfect. Thank you,</p> <p>24 Patrick. And that will be marked as</p> <p>25 plaintiff's Exhibit Number 1.</p>

<p style="text-align: right;">Page 210</p> <p>1 And page 14, Patrick. Can you</p> <p>2 share with us page 14?</p> <p>3 Thank you so much.</p> <p>4 BY MS. PARFITT:</p> <p>5 Q. Okay. And, Dr. Siemiatycki, at the</p> <p>6 bottom of page 14, specifically, the document</p> <p>7 says, "Additionally, some talc deposits and</p> <p>8 articles containing talc have been shown to</p> <p>9 contain asbestos. Thus, EPA recognizes that</p> <p>10 certain uses of talc may present the potential</p> <p>11 for asbestos exposure."</p> <p>12 Did I read that correctly?</p> <p>13 A. Yes.</p> <p>14 Q. All right. What is the</p> <p>15 significance of that statement concerning the</p> <p>16 fact that talc deposits and articles containing</p> <p>17 talc have been shown to contain asbestos?</p> <p>18 What significance does that</p> <p>19 statement have to your opinions with regard to</p> <p>20 the relationship of asbestos to the biological</p> <p>21 plausibility that talc can cause ovarian</p> <p>22 cancer?</p> <p>23 A. Well, my main take away from this</p> <p>24 is that if the epidemiological evidence</p> <p>25 demonstrates an association between women's use</p>	<p style="text-align: right;">Page 212</p> <p>1 statistical analyses; and the credibility of</p> <p>2 that meta-analysis is persuasive to me.</p> <p>3 I've also seen a recent report -- I</p> <p>4 can't remember now -- from a Korean group that</p> <p>5 updated the Camargo analysis because the</p> <p>6 Camargo analysis only included papers published</p> <p>7 until about 2010 or 2011; and the new paper,</p> <p>8 relatively new paper publishes additional</p> <p>9 papers. And it goes in exactly the same</p> <p>10 direction. It reinforces the same conclusion.</p> <p>11 Q. Did you also review the IARC</p> <p>12 monograph 2012?</p> <p>13 A. Well, I didn't need to review it</p> <p>14 because I was on the panel.</p> <p>15 Q. Does the IARC monograph 2012, does</p> <p>16 it address talcum powder as a cause of</p> <p>17 ovarian -- or talc as a cause of ovarian</p> <p>18 cancer?</p> <p>19 A. There is a mention of talc because,</p> <p>20 although this particular IARC monograph meeting</p> <p>21 did not include talc as one of the primary</p> <p>22 exposures to be reevaluated, it did include</p> <p>23 asbestos.</p> <p>24 And as part of the asbestos</p> <p>25 evaluation, there was an evaluation of talc</p>
<p style="text-align: right;">Page 211</p> <p>1 of talc and ovarian cancer, this information</p> <p>2 provides some potential avenues for biological</p> <p>3 plausibility that the asbestos might be</p> <p>4 responsible for excess risks for</p> <p>5 epidemiologically demonstrated excess risks of</p> <p>6 ovarian cancer.</p> <p>7 Q. Dr. Siemiatycki, some time ago you</p> <p>8 were also asked whether or not you had done a</p> <p>9 systematic review of the literature regarding</p> <p>10 asbestos and ovarian cancer.</p> <p>11 Do you remember those questions?</p> <p>12 A. Yes.</p> <p>13 Q. All right. Does the fact that you</p> <p>14 did not do a complete systematic review of</p> <p>15 asbestos prevent you from opining on a</p> <p>16 relationship of asbestos to be biological</p> <p>17 plausibility of talcum powder causing ovarian</p> <p>18 cancer?</p> <p>19 A. Not at all.</p> <p>20 Q. Why not?</p> <p>21 A. Well, there have been now a couple</p> <p>22 of reviews of the topic. One, the main one by</p> <p>23 Camargo and colleagues, was carried out by very</p> <p>24 a competent team. They describe their methods</p> <p>25 of searching for data of carrying out the</p>	<p style="text-align: right;">Page 213</p> <p>1 containing asbestos form fibers. And so there</p> <p>2 was an evaluation, which concluded that talc</p> <p>3 containing asbestiform fibers was carcinogenic.</p> <p>4 Q. You were asked questions about</p> <p>5 reaching out to SGO, ACOG, the NCI PDQ, and</p> <p>6 other medical and scientific organizations.</p> <p>7 Do you remember that series of</p> <p>8 questions?</p> <p>9 A. Yes, I do.</p> <p>10 Q. Why haven't you, as an</p> <p>11 epidemiologist, reached out to speak to SGO and</p> <p>12 ACOG and -- excuse me, the PDQ?</p> <p>13 A. Well, that's not the way scientific</p> <p>14 communication works. I never in my career</p> <p>15 reached out to organizations like that to give</p> <p>16 them my opinions or to tell them about my</p> <p>17 results because they don't really have the</p> <p>18 capacity to intake opinions and information</p> <p>19 from every researcher who studies all of the</p> <p>20 topics in their purview. So it's just not</p> <p>21 done. I've never heard of researchers doing</p> <p>22 things like that.</p> <p>23 The normal and natural and</p> <p>24 efficient way is to communicate through</p> <p>25 scientific publications and scientific</p>

<p style="text-align: right;">Page 214</p> <p>1 meetings. And information, once it -- which it 2 gets into such forums, then gets assimilated 3 into the general medical research community and 4 it ends up influencing those organizations if 5 they have responsibility for communicating 6 information like this to the public. 7 But in my experience -- and I've 8 been president of Association of 9 Epidemiologists. I was on the board of the 10 American College of Epidemiology. And these 11 organizations are not equipped to -- to carry 12 out evaluations of all possible research topics 13 and to communicate all of the possible research 14 issues to the public. 15 Q. Do scientists like yourself in the 16 epidemiologic community rely on groups like the 17 NCI PDQ and other -- SGO, ACOG, and others for 18 scientific literature as part of their bases 19 for their opinions? 20 A. No. I've -- I have never seen any 21 of those organizations or NCI PDQ cited as a 22 reference in a scientific journal. I've never 23 heard scientists communicate that some 24 important result is reported in such media as 25 NCI PDQ or some of the websites of</p>	<p style="text-align: right;">Page 216</p> <p>1 specifically at column of questions Numbers 1 2 through 4 and 7 -- and I'll show it to you, and 3 specifically, I'm referencing Number 5 and 6. 4 And in that you stated, "From 2016 5 to 2020 January, I provided, A) consultation 6 services to law firms that were involved in 7 litigation against companies that produced or 8 sold talcum powder products." 9 Do you remember that series of 10 questions? 11 A. Yes, I do. 12 Q. Okay. And you represented to 13 counsel that you were incorrect with regard to 14 that -- those dates. All right. 15 How did you prepare this document, 16 and what documents did you rely on for purposes 17 of that statement? 18 A. I didn't rely on any documents. I 19 did it by memory, and I did it hastily because 20 I didn't think it was important document any of 21 this. 22 I understand how the IARC system 23 works, having been part of it for a period of 24 time. And I -- I sort of wrote things down 25 hastily without carrying out any verifications</p>
<p style="text-align: right;">Page 215</p> <p>1 organizations like this. It's just not part of 2 the infrastructure of knowledge transmission 3 within the scientific community. 4 Q. I can't recall the precise 5 question, Dr. Siemiatycki, but you were asked 6 specifically whether or not you agreed or 7 disagreed with the American Cancer Society. 8 If, in fact, it was the 9 representation the American Cancer Society that 10 talcum powder was not associated with ovarian 11 cancer and/or there was insufficient evidence 12 to support that talcum powder could cause 13 ovarian cancer or associated with ovarian 14 cancer, would you agree or disagree with that? 15 A. I would disagree with that. 16 Q. Doctor, you were asked several 17 questions with regard to a declaration of 18 interest that you filed with IARC as well as a 19 letter that you sent to IARC anticipating their 20 re- review of the talcum powder in 2024. 21 Do you remember those questions? 22 A. Yes, I do. 23 Q. And do you remember counsel 24 addressing I believe it's Exhibit 3, 2 or 3, 25 the actual Declaration of Interest,</p>	<p style="text-align: right;">Page 217</p> <p>1 of the dates. I didn't think the dates were 2 important. I put them in here. I'm not sure 3 why, but at that -- when I did this in the 4 summer of 2023, I was recollecting when these 5 things happened; and I got it wrong. 6 Q. Do you have an understanding that 7 this litigation was in bankruptcy for a period 8 of time? 9 A. I -- I heard about that. 10 Q. Okay. What was the nature of your 11 work in this case during the period of 12 bankruptcy, if any? 13 A. I didn't do any during that period. 14 Q. Is it fair to say that there was a 15 period of a few years where you did no work at 16 all because the case was being stayed in 17 bankruptcy? 18 A. Yes, that's true. 19 Q. You were asked about the Goodman 20 article, and specifically the Goodman article 21 that's entitled, "A critical review of talc and 22 ovarian cancer." 23 Do you remember that question? Do 24 you remember that question? 25 A. Yes, I do.</p>

<p style="text-align: right;">Page 218</p> <p>1 Q. Okay. And specifically, you</p> <p>2 addressed the Goodman article in your report?</p> <p>3 A. Yes, I do.</p> <p>4 Q. All right. Would you turn to your</p> <p>5 report. I believe it's page 76.</p> <p>6 Tell me when you're ready.</p> <p>7 A. Yes.</p> <p>8 Q. What, if any, methodological flaws</p> <p>9 did you observe based upon your review and</p> <p>10 analysis of the Goodman study entitled, "A</p> <p>11 critical review of talc and ovarian cancer"?</p> <p>12 A. Well, I found it methodologically</p> <p>13 quite flawed, and I didn't take the resulting</p> <p>14 opinions that they gave very seriously. I</p> <p>15 could list some of the problems that -- that I</p> <p>16 pointed out.</p> <p>17 Q. What were they?</p> <p>18 A. First, it's curious that they did</p> <p>19 not conduct a meta-analysis to estimate the</p> <p>20 relative risk from the unsong of epidemiologic</p> <p>21 studies that they considered of good quality.</p> <p>22 That would be a natural thing to do if they</p> <p>23 had -- they had all the material they needed.</p> <p>24 Instead, they rely on a fatally</p> <p>25 flawed method of using statistical significance</p>	<p style="text-align: right;">Page 220</p> <p>1 done that, and you produce a meta-analysis; and</p> <p>2 they -- you don't produce a meta-analysis. You</p> <p>3 produce a count of how many studies are</p> <p>4 individually significant or nonsignificance,</p> <p>5 and you find that most are them or all of them</p> <p>6 are not significant.</p> <p>7 Well, that is a hopeless distortion</p> <p>8 of what statistical significance is about. But</p> <p>9 this is what they did in this -- in this paper.</p> <p>10 Q. In this Goodman paper?</p> <p>11 A. In this Goodman paper.</p> <p>12 Q. Any other?</p> <p>13 A. They make basic error of asserting</p> <p>14 that cohort studies across the board are</p> <p>15 superior in validity to case control studies.</p> <p>16 This is completely false. There is</p> <p>17 no credible epidemiological literature that</p> <p>18 demonstrates or proves such a proposition.</p> <p>19 Each study has strengths and weaknesses, and it</p> <p>20 requires sophistication to tally up the</p> <p>21 strengths and weaknesses of each study and to</p> <p>22 find what the results mean. Whether it's a</p> <p>23 case control or a cohort study is not a</p> <p>24 determinant of the quality of and the validity</p> <p>25 of the results.</p>
<p style="text-align: right;">Page 219</p> <p>1 of individual studies and tallying up how many</p> <p>2 studies are individually statistically</p> <p>3 significant to guide their overall conclusion.</p> <p>4 Q. And what did you mean by that?</p> <p>5 A. Well, in the old days, people used</p> <p>6 to do that. People used to count up -- do a</p> <p>7 literature review and count how many studies</p> <p>8 show a statistically significant association</p> <p>9 with something and how many don't and use that</p> <p>10 as a kind of an indicator of whether there's an</p> <p>11 overall trend that shows an association.</p> <p>12 And it was painfully clear to</p> <p>13 sophisticated statisticians and other</p> <p>14 researchers, clinical as well as</p> <p>15 epidemiological, that it's hopelessly flawed to</p> <p>16 count statistical significance studies as a</p> <p>17 measure of anything. Statistical significance</p> <p>18 does not -- is not something that can be</p> <p>19 counted up between -- among studies.</p> <p>20 The best way to guarantee that</p> <p>21 you'll never find an association is to conduct</p> <p>22 studies with small numbers -- small enough</p> <p>23 numbers of subjects that none of the results</p> <p>24 will be statistically significant. And then</p> <p>25 you gather together all the studies that have</p>	<p style="text-align: right;">Page 221</p> <p>1 The third problem with the Goodman</p> <p>2 study -- well, they -- they present a bunch of</p> <p>3 studies in their list, but some of them are</p> <p>4 actually subsumed in other -- some of the</p> <p>5 papers are subsumed in other studies, which</p> <p>6 were follow-ups and analyses done later. And</p> <p>7 this is not how to -- how to do a review of a</p> <p>8 topic. It's sort of a double-counting problem.</p> <p>9 And the next problem was their</p> <p>10 interpretation of the conformity of the results</p> <p>11 with Bradford Hill's considerations. It's</p> <p>12 their interpretation and their evaluation,</p> <p>13 their description of how the Bradford Hill</p> <p>14 considerations apply to the literature. The</p> <p>15 studies that they have considered is very</p> <p>16 subjective, and it's unreliable. It's not</p> <p>17 objective and fact-based.</p> <p>18 Well, and the next point -- my last</p> <p>19 point was while the they point out many gaps in</p> <p>20 knowledge regarding the transport of fibers and</p> <p>21 the mechanisms of carcinogeneses, they tend to</p> <p>22 interpret the absence of evidence as evidence</p> <p>23 against an association. So --</p> <p>24 Q. And what does that mean?</p> <p>25 A. Well, when -- you know, there are</p>


<p style="text-align: right;">Page 222</p> <p>1 some areas where there just hasn't been 2 definitive research to demonstrate that certain 3 mechanisms of translocation of -- transport of 4 fibers in the body would support the hypothesis 5 of talc fibers causing ovarian cancer. 6 It's -- it's fine to present data 7 and make an argument that there are gaps in 8 knowledge. But their conclusion from the gaps 9 of knowledge is that this is evidence against 10 the hypothesis that the particles can be 11 transported to the ovaries, and that's a 12 logical flaw. 13 Q. Any others that you wish to 14 express? 15 A. No others that I would express now. 16 Q. Okay. Jumping around, let me 17 direct your attention to the -- you can hold on 18 to the report -- direct your attention to the 19 Wentzensen and O'Brien article entitled, "Talc 20 body powder and ovarian cancer: A summary of 21 an epidemiological test." 22 Do you have that? 23 A. I have that. 24 Q. Okay. Specifically, if you would 25 turn to the conclusions section, which is</p>	<p style="text-align: right;">Page 224</p> <p>1 performed and documented in now several 2 reports? 3 A. I think the associations is of 4 moderate magnitude compared to other cancer 5 risk factors if you look -- or disease risk 6 factors. And there are well-established cancer 7 risk factors that have relative risks well in 8 the range of 1.3, which is what we're talking 9 about for talc and ovarian cancer or even much 10 lower. Even for ovarian cancer there are 11 well-established risk factors that have -- that 12 have relative risks in the order of 1.3. 13 So that is certainly not -- you 14 know, these terms "weak, strong, moderate" are 15 not scientifically designed. There's no 16 convention about what constitutes strong 17 evidence or weak evidence. 18 The -- the original development of 19 risk factor -- modern risk factor epidemiology 20 occurred in the 1950s around the issue of 21 tobacco and lung cancer, and it so happened 22 that the relative risk of that association was 23 about 10 or 15. And that became kind of a 24 marker for relative risks between risk factors 25 and disease.</p>
<p style="text-align: right;">Page 223</p> <p>1 Section 6. And it spans to the front of 2 page 9 -- the top of page 9. 3 Are you there? 4 A. Yes, I am. 5 Q. The sentence starts, "Independent 6 of the underlying cause" -- 7 A. I have it. 8 Q. "Independent of the underlying 9 cause, the association between powder use and 10 ovarian cancer is weak. The low relative risk 11 translates to a very low risk increase given 12 the rarity of ovarian cancer." 13 Do you remember that question being 14 asked of you? 15 A. Yes, I do. 16 Q. Okay. And do you agree or disagree 17 with that statement? 18 A. With the statement that the 19 evidence is weak? 20 Q. Correct. 21 A. No, I don't agree with that. 22 Q. Okay. How would you describe the 23 evidence in the talcum powder and ovarian 24 cancer based upon the literature review -- 25 systematic literature review that you have</p>	<p style="text-align: right;">Page 225</p> <p>1 We -- people didn't know at the 2 time that hardly any chance of risk factor 3 would ever be shown to have such strong and 4 high relative risk. So having that as the 5 first thing that the discipline discovered and 6 latched on to and started developing 7 terminology around and conventions around in a 8 way distorted how subsequent epidemiology of 9 other risk factors was described in the 10 literature and described even in public. 11 But certainly there is -- there are 12 many examples now of risk factors which are in 13 the same range as the talc ovarian cancer 14 relative risk, which are considered strongly 15 supported evidence in epidemiology. 16 Q. You have stated in your report that 17 the evidence in the talcum powder and ovarian 18 cancer case, based upon your systematic review, 19 is significant. 20 When said "the evidence regarding 21 consistency and strength is significant," what 22 do you mean by that? 23 A. I'm not sure. If you could point 24 me to a page. 25 That the evidence is significant?</p>

<p style="text-align: right;">Page 226</p> <p>1 Q. Generally, the strength of the 2 evidence and the association of the evidence is 3 significant. 4 A. Well, I don't remember using that 5 word in that context. But, you know, I'd say 6 the evidence is persuasive and persuasive 7 because of some of the concepts that we 8 associate with the Bradford Hill 9 considerations; but it's not because it's 10 Bradford Hill, but the strength, the magnitude 11 and the -- especially the consistency of the 12 results from different studies carried out in 13 different countries of different populations of 14 women by different teams of investigators and 15 over a 30-year span by -- published over a 30- 16 or 40-year span; and almost all of them 17 indicate that there is an excess risk. 18 Whether the individual studies are 19 statistically significant at point .05 level or 20 not is moot. It's not the important thing. 21 But putting all of that together and carrying 22 out appropriate meta-analyses shows that there 23 is incontrovertible evidence that there is a 24 strong association. 25 Going to causality requires a few</p>	<p style="text-align: right;">Page 228</p> <p>1 description -- 2 BY MS. DAVIDSON: 3 Q. That describe an association 4 between 1.1 and 1.3 as "strong." 5 MS. PARFITT: You're referring to 6 talc articles or anything? 7 MS. DAVIDSON: I think my question 8 stands for itself, Michelle. 9 THE WITNESS: Well, I assume that 10 your question refers to anything, not just 11 talc. 12 BY MS. DAVIDSON: 13 Q. Have you ever read a publication 14 that described an association between 1.1 and 15 1.3 as, quote, "strong"? 16 MS. PARFITT: Objection. Form. 17 THE WITNESS: I can't really recall 18 because, you know, that's not how I 19 process and categorize information about 20 associations. 21 But in my report there are 22 several -- there are some examples of 23 associations that have such relative risks 24 that are well accepted as being causal and 25 there are many more.</p>
<p style="text-align: right;">Page 227</p> <p>1 more hoops to demonstrate. 2 Q. And you have done that in your 3 report, correct? 4 A. Yes. 5 MS. PARFITT: All right. Give 6 me -- Jessica, if you will give me about 7 30 seconds just to make sure -- we can go 8 off real quick to see if I have any 9 further questions, and I think we'll be 10 good. 11 MS. DAVIDSON: Sure. 12 MS. PARFITT: Thank you. 13 (Whereupon, a break was taken.) 14 MS. PARFITT: Thank you. I have no 15 further questions at this time. 16 EXAMINATION 17 BY MS. DAVIDSON: 18 Q. I just have a few, Dr. Siemiatycki. 19 Can you point me to any publication 20 that refers to an association between 1.1 and 21 1.3 as, quote, "strong"? 22 MS. PARFITT: Objection. Form. 23 THE WITNESS: I'm sorry. Are you 24 asking me to point to publications that 25 report such associations or that</p>	<p style="text-align: right;">Page 229</p> <p>1 But having the authors or somebody 2 using the word "strong," I don't recall. 3 It would require me to have an incredible 4 memory to remember every paper I've ever 5 heard about, you know, cardiovascular 6 disease and hyperlipidemia; and, you know, 7 I just can't recall every single paper 8 I've ever seen and which words they used 9 to categorize an association. 10 BY MS. DAVIDSON: 11 Q. Would it surprise you to know that 12 I have looked high and low and have never been 13 able to find a published epidemiological paper 14 that uses the word "strong" to describe an 15 association in the one to two -- between in the 16 1 to 2 -- with one- to two-point estimates? 17 MS. PARFITT: Objection. Form. 18 THE WITNESS: Would it surprise me? 19 No, it wouldn't surprise me. 20 BY MS. DAVIDSON: 21 Q. Okay. 22 MS. PARFITT: Wait, wait. 23 Do you have anymore. 24 THE WITNESS: I would start 25 probably by finding a little bit more</p>

<p style="text-align: right;">Page 230</p> <p>1 about how you did your search; but even if</p> <p>2 your search was conducted in the most</p> <p>3 thorough and rigorous way, it wouldn't</p> <p>4 surprise me.</p> <p>5 As I indicated, I don't recall</p> <p>6 every paper I've read and whether which</p> <p>7 descriptors people use.</p> <p>8 BY MS. DAVIDSON:</p> <p>9 Q. Can we go back to Plaintiff's</p> <p>10 Exhibit 1?</p> <p>11 MS. PARFITT: To help us out with</p> <p>12 one.</p> <p>13 MS. DAVIDSON: Plaintiff's Exhibit</p> <p>14 1. I believe it was page 14.</p> <p>15 MS. PARFITT: Yeah.</p> <p>16 MS. DAVIDSON: Maybe Patrick could</p> <p>17 put it up since he put it up last time.</p> <p>18 Is Patrick still here?</p> <p>19 There he is. Thank you, Patrick.</p> <p>20 BY MS. DAVIDSON:</p> <p>21 Q. Ms. Parfitt read to you from</p> <p>22 page 14, and at the bottom of page 14, I</p> <p>23 believe it was.</p> <p>24 A. Yeah.</p> <p>25 Q. It says, "Some talc deposits in</p>	<p style="text-align: right;">Page 232</p> <p>1 MS. PARFITT: Objection. It has</p> <p>2 been covered in the first deposition.</p> <p>3 MS. DAVIDSON: Michelle, you asked</p> <p>4 about it in your redirect?</p> <p>5 MS. PARFITT: That is -- that is</p> <p>6 fair.</p> <p>7 BY MS. DAVIDSON:</p> <p>8 Q. Are you offering such an opinion,</p> <p>9 Doctor?</p> <p>10 A. Well, I'm hesitating because I</p> <p>11 don't know how much to say about this. In my</p> <p>12 report --</p> <p>13 Q. It's a yes-or-no question.</p> <p>14 MS. PARFITT: Wait. Let him</p> <p>15 finish. He said in his report.</p> <p>16 THE WITNESS: I'm happy to give a</p> <p>17 yes-or-no answer, but what is the</p> <p>18 question?</p> <p>19 BY MS. DAVIDSON:</p> <p>20 Q. Are you planning to testify at</p> <p>21 trial that you know the way by which talc</p> <p>22 allegedly causes ovarian cancer?</p> <p>23 MS. PARFITT: Objection. Form.</p> <p>24 THE WITNESS: Do I know the way</p> <p>25 it -- the way talc causes ovarian cancer</p>
<p style="text-align: right;">Page 231</p> <p>1 articles containing talc have been shown to</p> <p>2 contain asbestos."</p> <p>3 Do you see that?</p> <p>4 A. I see that.</p> <p>5 Q. Does the paper specify what</p> <p>6 deposits?</p> <p>7 A. I haven't read the rest of this</p> <p>8 paper, so I don't know if the -- anything in</p> <p>9 the paper -- this sentence doesn't specify. I</p> <p>10 don't know if there's anything else in the</p> <p>11 paper that would specify.</p> <p>12 Q. Does this sentence specify whether</p> <p>13 they're talking about industrial talc versus</p> <p>14 cosmetic talc?</p> <p>15 A. This sentence does not specify.</p> <p>16 Q. And you have no idea whether the</p> <p>17 deposits and products they're talking about</p> <p>18 are -- have anything to do with Johnson's Baby</p> <p>19 Powder, correct?</p> <p>20 MS. PARFITT: Objection. Form.</p> <p>21 THE WITNESS: That's correct.</p> <p>22 BY MS. DAVIDSON:</p> <p>23 Q. Do you have an opinion on the</p> <p>24 biological pathway by which talc causes ovarian</p> <p>25 cancer allegedly?</p>	<p style="text-align: right;">Page 233</p> <p>1 is that the question?</p> <p>2 Do I know the way.</p> <p>3 BY MS. DAVIDSON:</p> <p>4 Q. Do you plan to testify at trial as</p> <p>5 to how you believe talc allegedly causes</p> <p>6 ovarian cancer, how, the mechanism, the</p> <p>7 biological pathway?</p> <p>8 A. No, I don't -- I don't plan to</p> <p>9 testify --</p> <p>10 Q. Okay.</p> <p>11 A. -- that I know the way.</p> <p>12 Q. You testified earlier that you</p> <p>13 don't typically speak to public health groups.</p> <p>14 You did, however, speak to Health</p> <p>15 Canada, correct?</p> <p>16 A. I spoke to a Health Canada</p> <p>17 scientist.</p> <p>18 Q. Who is what the scientist?</p> <p>19 A. What is his name? Hancock.</p> <p>20 Q. Did you research his credentials?</p> <p>21 MS. PARFITT: Objection to the</p> <p>22 extent --</p> <p>23 THE WITNESS: No, I didn't --</p> <p>24 MS. PARFITT: -- it was covered in</p> <p>25 his '21 report.</p>

<p style="text-align: right;">Page 234</p> <p>1 THE WITNESS: -- research his</p> <p>2 credentials.</p> <p>3 BY MS. DAVIDSON:</p> <p>4 Q. You said no?</p> <p>5 A. I didn't research his credentials.</p> <p>6 Q. Did you research the credentials of</p> <p>7 any of the authors of the Health Canada paper?</p> <p>8 MS. PARFITT: Objection. Asked and</p> <p>9 answered and covered in the '21</p> <p>10 deposition.</p> <p>11 THE WITNESS: No.</p> <p>12 BY MS. DAVIDSON:</p> <p>13 Q. Are you aware that another</p> <p>14 plaintiff's expert has reached out multiple</p> <p>15 times to ACOG and SGO?</p> <p>16 MS. PARFITT: Objection. Form.</p> <p>17 THE WITNESS: No, I'm not aware.</p> <p>18 BY MS. DAVIDSON:</p> <p>19 Q. Have plaintiffs shared with you --</p> <p>20 plaintiff's counsel shared with you the</p> <p>21 discovery that they sought from ACOG and SGO</p> <p>22 about their communications with a plaintiff's</p> <p>23 expert?</p> <p>24 MS. PARFITT: Objection. Form.</p> <p>25 THE WITNESS: Sorry. I didn't -- I</p>	<p style="text-align: right;">Page 236</p> <p>1 colleague with a student a study of lung cancer</p> <p>2 risks among women who resided in the towns of</p> <p>3 Quebec where asbestos had been mined and milled</p> <p>4 in order to get an idea of whether</p> <p>5 environmental exposure to asbestos dust caused</p> <p>6 an increase in lung cancer risk.</p> <p>7 Q. I take it none of those papers</p> <p>8 related to ovarian cancer?</p> <p>9 A. No.</p> <p>10 Q. Have you ever published anything in</p> <p>11 the peer-reviewed literature about asbestos and</p> <p>12 ovarian cancer?</p> <p>13 A. No.</p> <p>14 MS. PARFITT: Objection. Form.</p> <p>15 Asked and answered in the '21 deposition.</p> <p>16 BY MS. DAVIDSON:</p> <p>17 Q. Did you ever consider a potential</p> <p>18 association between asbestos and ovarian cancer</p> <p>19 before you were hired as an expert in this</p> <p>20 litigation?</p> <p>21 MS. PARFITT: Objection.</p> <p>22 THE WITNESS: Yes, I -- because I</p> <p>23 was invited to participate in an IARC</p> <p>24 expert panel that evaluated talc among</p> <p>25 some other substances in 2006. And as a</p>
<p style="text-align: right;">Page 235</p> <p>1 didn't quite understand the question.</p> <p>2 BY MS. DAVIDSON:</p> <p>3 Q. Are you aware that plaintiff's</p> <p>4 counsel have subpoenaed SGO and ACOG for</p> <p>5 documents related to talc?</p> <p>6 A. No.</p> <p>7 MS. PARFITT: Objection. Form.</p> <p>8 BY MS. DAVIDSON:</p> <p>9 Q. Did they share those documents with</p> <p>10 you?</p> <p>11 A. No.</p> <p>12 Q. Have you ever published any paper</p> <p>13 in the peer-reviewed literature about asbestos?</p> <p>14 A. Yes.</p> <p>15 Q. What was that paper?</p> <p>16 A. I think there were a few that I was</p> <p>17 on. I -- I was involved as a research</p> <p>18 assistant when I started out in a team that was</p> <p>19 studying cancer risks among asbestos miners and</p> <p>20 millers in Quebec, and I was included in as a</p> <p>21 coauthor on a couple of publications that came</p> <p>22 out of that. It concerned mill workers and</p> <p>23 occupational exposure and lung cancer and</p> <p>24 mesothelioma as the possible outcomes.</p> <p>25 I also carried out or with a</p>	<p style="text-align: right;">Page 237</p> <p>1 member -- in fact, as the chairman of that</p> <p>2 review committee, I had occasion to become</p> <p>3 familiar with talc and ovarian cancer</p> <p>4 epidemiology.</p> <p>5 MS. DAVIDSON: Let's go off the</p> <p>6 record for a minute.</p> <p>7 (Discussion held off the record.)</p> <p>8 (Whereupon, a break was taken.)</p> <p>9 BY MS. DAVIDSON:</p> <p>10 Q. Dr. Siemiatycki, you testified in</p> <p>11 this litigation in 2019 that the cell phone and</p> <p>12 brain cancer literature is not affected by</p> <p>13 recall bias.</p> <p>14 Is that still your position?</p> <p>15 THE WITNESS: Sorry?</p> <p>16 MS. PARFITT: Objection. Form.</p> <p>17 THE WITNESS: Which literature?</p> <p>18 BY MS. DAVIDSON:</p> <p>19 Q. Cell phones and brain cancer.</p> <p>20 A. Cell phones and brain cancer?</p> <p>21 MS. PARFITT: Objection. Form.</p> <p>22 BY MS. DAVIDSON:</p> <p>23 Q. You testified in 2019 that it's not</p> <p>24 affected by recall bias, that literature. I'm</p> <p>25 wondering if that's still your position today.</p>

<p style="text-align: right;">Page 238</p> <p>1 A. Sorry. I'm trying to resituate my 2 thoughts. 3 So this is in a deposition about 4 talc, right, and ovarian cancer, not in a -- 5 not in any litigation around cell phones; is 6 that correct? 7 Q. Were you ever in litigation around 8 cell phones? 9 A. No. 10 MS. PARFITT: Objection. Form. 11 THE WITNESS: No. That's why -- 12 BY MS. DAVIDSON: 13 Q. You couldn't have testified to it, 14 right? 15 A. I don't -- at first glance, I 16 couldn't understand why I would be testifying 17 about cell phones and brain cancer in talc. 18 Okay. So can you restate the 19 question? 20 Q. What needs to be restated? 21 A. In a -- so in a deposition in -- 22 Q. Dr. Siemiatycki, let me make it 23 simpler for you. 24 Do you believe that the cell phone 25 cancer literature is affected by recall bias?</p>	<p style="text-align: right;">Page 240</p> <p>1 Q. I'm fine. 2 A. Do -- are you alleging that in 3 2019 -- 4 Q. I'm not alleging anything, Doctor. 5 I'm asking a question. "Alleging" I don't 6 think is a fair word. 7 A. Is the premise of your question 8 that in 2019 I stated that I believe that there 9 is recall bias in studies of cell phones and 10 brain cancer or there is not recall bias in 11 those studies? 12 What are you saying that I said at 13 the time? 14 Q. Dr. Siemiatycki, I just want to 15 know whether you currently believe that the 16 cell phone brain cancer literature is affected 17 by recall bias? 18 MS. PARFITT: Objection. Form. 19 THE WITNESS: I think it is 20 potentially affected by it, but I'm not 21 confirming or denying anything that you 22 say I said or that you're implying that I 23 said in 2019. 24 BY MS. DAVIDSON: 25 Q. Do you agree that recall bias</p>
<p style="text-align: right;">Page 239</p> <p>1 MS. PARFITT: Objection. Form. 2 THE WITNESS: I have to think about 3 that because -- for a minute because any 4 evaluation of recall bias is 5 context-specific. And so I'm trying to 6 resituate myself in the context of the 7 evidence around cell phones and brain 8 cancer. 9 And so I think there's a 10 possibility that it could be affected by 11 recall bias, yes. 12 BY MS. DAVIDSON: 13 Q. So your opinion on that has changed 14 since 2019, correct? 15 MS. PARFITT: Objection. Form. If 16 you can direct us to his prior opinion and 17 testimony, that would be helpful. Right 18 now it's a guess. 19 BY MS. DAVIDSON: 20 Q. Dr. Siemiatycki? 21 A. No. I don't understand -- 22 understand the question because are you stating 23 or are you alleging that the in 2019 -- sorry. 24 Do you need to go off the record? 25 Are you okay?</p>	<p style="text-align: right;">Page 241</p> <p>1 should be assessed and evaluated when there's a 2 discrepancy between case control studies and 3 cohort studies on a specific exposure? 4 MS. PARFITT: Objection. The topic 5 of recall bias was exhaustively examined 6 in his 2021 deposition prior. 7 BY MS. DAVIDSON: 8 Q. Go ahead, Doctor. 9 MS. PARFITT: Move on. 10 BY MS. DAVIDSON: 11 Q. Go ahead, Doctor. 12 A. I think all sources of bias should 13 be considered when examining any possible 14 association. 15 MS. DAVIDSON: Okay. I have no 16 further questions. 17 MS. PARFITT: I just have one quick 18 one. 19 EXAMINATION 20 BY MS. PARFITT: 21 Q. Dr. Siemiatycki, you were asked 22 with regard to literature that you had 23 published on the topic of talc and ovarian 24 cancer. Do. 25 You remember question by counsel?</p>

<p style="text-align: right;">Page 242</p> <p>1 MS. DAVIDSON: He was not. He was</p> <p>2 not asked that.</p> <p>3 THE WITNESS: Asbestos.</p> <p>4 MS. DAVIDSON: I didn't ask that.</p> <p>5 I asked about asbestos, Michelle.</p> <p>6 MS. PARFITT: Oh, asbestos.</p> <p>7 MS. DAVIDSON: I didn't ask about</p> <p>8 talc.</p> <p>9 MS. PARFITT: I have no further</p> <p>10 questions.</p> <p>11 MS. DAVIDSON: Great. Have a good</p> <p>12 day everybody.</p> <p>13 MS. PARFITT: Suzanne, we are going</p> <p>14 to read and sign. Thank you.</p> <p>15 MS. DAVIDSON: We just want</p> <p>16 expedited, but not -- we just want</p> <p>17 expedited, but not rough. We're looking</p> <p>18 for expedites, but not roughs.</p> <p>19 THE COURT REPORTER: That's fine.</p> <p>20 When do you need that by.</p> <p>21 MS. DAVIDSON: Monday.</p> <p>22 THE COURT REPORTER: Okay. Thank</p> <p>23 you.</p> <p>24 MS. PARFITT: We'll take one as</p> <p>25 well. Thank you.</p>	<p style="text-align: right;">Page 244</p> <p>1 C E R T I F I C A T E</p> <p>2</p> <p>3</p> <p>4 I, SUZANNE J. STOTZ, a Certified</p> <p>5 Court Reporter, Registered Professional</p> <p>6 Reporter, Certified Realtime Reporter, and</p> <p>7 Notary Public in and for the State of New</p> <p>8 Jersey, do hereby certify that the foregoing is</p> <p>9 a true and accurate transcript of the</p> <p>10 stenographic above-captioned matter.</p> <p>11</p> <p>12 </p> <p>13</p> <p>14 SUZANNE J. STOTZ, CCR, RPR, CRR</p> <p>15 LICENSE NO. 30XI00184500</p> <p>16</p> <p>17</p> <p>18 DATED: March 31, 2024</p> <p>19</p> <p>20</p> <p>21 NOTE: THE CERTIFICATE APPENDED TO THIS</p> <p>22 TRANSCRIPT DOES NOT APPLY TO ANY REPRODUCTION</p> <p>23 OF THE SAME BY ANY MEANS, UNLESS UNDER THE</p> <p>24 DIRECT CONTROL AND/OR DIRECTION OF THE</p> <p>25 CERTIFYING COURT REPORTER.</p>
<p style="text-align: right;">Page 243</p> <p>1 THE COURT REPORTER: Expedited too</p> <p>2 or regular delivery, Ms. Parfitt?</p> <p>3 MS. PARFITT: When you deliver</p> <p>4 hers, you can deliver mine.</p> <p>5 (The witness is excused.)</p> <p>6 (Deposition of Jack Siemiatycki,</p> <p>7 MSC, Ph.D, concluded at 5:35 p.m. EDT.)</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>	<p style="text-align: right;">Page 245</p> <p>1 E R R A T A S H E E T</p> <p>2 I have read my testimony in the foregoing</p> <p>3 transcript and believe it to be true and</p> <p>4 correct to the best of my knowledge and belief</p> <p>5 with the following changes:</p> <p>6 PAGE LINE CHANGE</p> <p>7 _____</p> <p>8 _____</p> <p>9 _____</p> <p>10 _____</p> <p>11 _____</p> <p>12 _____</p> <p>13 _____</p> <p>14 _____</p> <p>15 _____</p> <p>16 _____</p> <p>17 _____</p> <p>18 _____</p> <p>19 WITNESS SIGNATURE DATE</p> <p>20</p> <p>21 Sworn and subscribed to before me this</p> <p>22 ____ day of _____, 2024.</p> <p>23</p> <p>24 Notary Public of the</p> <p>25 State of _____.</p>

[& - 2011]

Page 1

&	1.15 193:10,14 203:17	11 161:8	1950s 224:20
& 1:3 2:4,21 125:9 137:8	1.15. 192:24	11:14 1:14	1980s 136:21 137:6,16
0	1.2 159:9	12 168:8	1990 141:14
0.99 192:23	1.22 99:9	12203 244:12	1992 135:5
05 100:8 226:19	1.26 193:9,13 203:16	123 4:20	2
1	1.26. 192:21	128 5:5	2 9:15 76:22 78:18 80:3,17 81:16 82:15 112:12,16 113:5 160:23 199:17,21 200:5 215:24 229:16
1 9:16 68:8,8,12 68:16 69:12,17 69:22,23 70:12 70:13 95:17 164:21 209:18 209:25 216:1 229:16 230:10 230:14	1.3 159:5 224:8 227:21 228:4 228:15	13 76:11 172:25 173:6	2.20 114:25 117:21 118:22 121:11
1.0. 9:17	1.3. 224:12	136 3:23 58:7 85:17	2.20. 114:5
1.01 192:21 193:9,13 203:16	1.32 99:10	14 193:20,21 194:19,25 209:7,10 210:1 210:2,6 230:14 230:22,22	2.57 114:20 116:15 119:21 119:23 122:15
1.05 158:5 184:18	1.37 181:20 182:4	14.9 135:5	2.57. 116:18 121:23 122:17
1.05. 178:7	1.39 66:11	142 5:8	20 23:22 73:18 134:18 138:9 140:23
1.06 182:24 183:10	1.4 159:7	143 101:20	200 22:1 63:16 104:2
1.06. 179:14	1.47 58:16,19 59:24 60:1 66:12	15 11:13 23:21 76:18 187:21 198:4,6,19 201:12 205:11 224:23	200,000 21:20 22:17
1.07 181:21 182:5,25 183:11	1.5 159:7	15th 9:7	2006 236:25
1.1 159:9 227:20 228:4 228:14	1.58 114:25 117:21 118:21	16-2738 1:2	2008 34:22
1.13 203:15	1.58. 113:25	162 5:11	2010 212:7
1.13. 192:21	1.88 116:15 119:21,23 121:23 122:15	168 5:15	2011 212:7
	10 3:5 138:9 140:23 142:8 198:4,5,19 224:23	17 47:5	
	100,000 135:5	173 5:21	
	10001 2:23	17th 52:1	
	106 4:13	18 34:20	
	108 4:15	1835 2:16	
		19 49:16 50:23	
		19103 2:17	
		194 6:5	

[2012 - 8]

Page 2

2012 212:12,15 2015 23:8 2016 23:9 83:17 87:6,15 216:4 2017 34:19 2019 55:25 87:6 87:16 123:1 124:7 135:6 237:11,23 239:14,23 240:3,8,23 2020 37:5 83:17 84:12 88:25 128:25 141:14 146:12 148:12 192:3 193:18 216:5 2021 9:20 24:4 27:7,9 29:8 30:6,14 32:21 32:25 36:25 37:4,23 42:10 43:1 61:4,5 84:18,20,23 89:2,5,7 90:15 90:16 93:18 94:5 95:7 97:18 101:11,21 124:8,17 129:7 129:10 145:19 184:5 185:8,18 188:24 241:6 2022 108:4,8,19 141:25 2023 9:7,23 17:19 18:2	41:23 42:1,9 47:5 52:1,15 83:1 84:10 88:11,25 89:9 101:12 124:9 146:13 148:12 217:4 2024 1:13 171:1 171:9 215:20 244:18 245:22 204 6:9 208 3:6 209 6:13 21 11:16 15:18 18:23 30:19 101:5 233:25 234:9 236:15 212 2:24 215 2:17 22 142:5 22311 2:6 227 3:7 23 11:13 15:23 18:2,23 42:6 51:23 241 3:8 21:22 241,000 19:25 20:8 22:16 25 76:11,18 138:10 140:24 27 1:13 278-4449 2:17 28th 83:1 2900 2:16	3	5.3. 151:9 50 26:1,3,5 500 22:24 54 199:14 202:14,16 203:8 5:35 243:7
		3 85:13 97:23 98:3,9 151:7 215:24,24 30 118:6 134:18 136:2,5 138:21 226:15,15 227:7 300 22:24 30th 11:16 30xi00184500 1:12 244:15 31 244:18 316 2:11 31st 49:16 32502 2:12	6 6 67:13 96:12 96:14 106:10 111:2 145:14 146:2,4 216:3 223:1 600 22:8 650 2:6 680-0339 2:7
		4	7
		4 91:1,23 94:6 146:24 147:1 216:2 4.2 147:3 40 9:8,13 209:5 226:16 400 22:5,24 23:15 400,000 21:21 435-7000 2:12 47 58:25 59:14 60:5 4900 2:6	7 108:8 151:4 216:2 70 3:14 70s 54:9 73 178:3 735-3000 2:24 75 26:10 751 209:5 76 145:23 150:11,12 218:5 78 142:3
		5	8
		5 77:9 94:10,15 95:3 140:24 145:23 216:3	8 65:24 105:19 122:25 155:15 155:17 192:10 193:3

[8.1.2 - african]

Page 3

8.1.2 9:8 80s 54:9 82 3:20 844 2:7 85 3:22 850 2:12 86 192:24 193:10,14 203:17	absolute 59:13 61:22 62:13 absolutely 12:22 abstract 172:9 175:2 187:22 abstracts 172:11 accept 44:7 accepted 36:1 140:22 228:24 accompanying 57:19 account 191:22 accumulation 43:21 accuracy 194:11 accurate 78:22 83:23 84:4,7 88:6 89:25 90:3 90:10,22 93:9 122:3 244:9 accurately 164:14 165:4 183:16 acknowledge 29:14 acknowledge... 110:9,12,25 111:2 acog 37:15 213:5,12 214:17 234:15 234:21 235:4	acronym 38:14 39:10 acronyms 38:8 acrylonitrile 3:23 85:17 active 131:7 actual 74:14 115:9 117:18 117:19 132:8 140:10 215:25 actually 38:14 47:15 51:24 57:20 60:7 64:10 65:12,17 81:16 141:4 144:5 153:23 155:25 157:7 172:7 178:6 189:6 190:17 191:17 197:10 203:13 221:4 add 101:3 107:14 added 42:6,15 101:11 102:11 102:20 103:1 addition 18:19 22:16 additional 22:14 212:8 additionally 210:7 additions 41:25 42:2,4,7,9 address 49:10 66:2 92:25 93:2	93:4 105:23,25 106:2,19 129:3 129:6 163:11 212:16 addressed 54:10 218:2 addresses 93:11 addressing 50:9 139:7 215:24 adjunct 29:17 29:18,23 adjusted 174:19 176:23 177:9 179:9,13 179:23,23 180:3 181:10 182:23 183:8 183:10 administration 17:15 admitted 57:9 adopted 129:13 advance 16:20 affect 158:6 165:19 167:24 affected 138:20 139:15 237:12 237:24 238:25 239:10 240:16 240:20 affiliations 29:14 affirm 137:2 138:6 african 4:11 95:6,11 98:3,16
9			
9 34:22 127:22 160:12 223:2,2 9.6 135:5 91 4:5 95 4:8 117:25 121:18,22 122:14 179:24 180:5 181:16 184:21 960 108:23 97 116:18 122:17 99 203:17			
a			
a.f. 124:25 a.m. 1:14 aa 105:16 able 15:15 101:13 125:16 175:17 176:1 229:13 above 1:10 151:7 244:10 absence 221:22			

[african - apparent]

Page 4

98:19 99:2,9,20 99:24 age 76:2,7,12 177:9 179:23 agency 34:16 209:4 ages 76:11 ago 16:14 33:22 35:20 51:21 56:14,15 73:18 187:21 192:6 204:1 208:21 211:7 agree 41:7,9,11 48:20 72:3 73:1 74:10,13 125:7 135:25 164:17 165:7,9 215:14 223:16,21 240:25 agreed 215:6 ahead 71:13 101:15 152:9 169:20 208:9 241:8,11 air 158:6 al 3:19 4:7,12 4:19,24 5:7,10 5:14,20 6:8,12 70:19 80:24 91:5 95:13 108:13 123:9 127:24 128:6 142:13 162:5 168:18 194:5 204:19	alexandria 2:6 algebra 59:4 algebraic 62:2 allegedly 231:25 232:22 233:5 alleging 239:23 240:2,4,5 allen 125:2,4,11 allison 123:19 allow 70:3 allowed 127:7 127:13 alluding 188:20 alpha 100:17 alternatives 137:9 amazing 176:14 amenable 43:13,16 amended 4:13 106:12 145:24 american 40:11 40:14,23 98:3 98:16,19 99:2,9 99:20,24 132:23 133:4 214:10 215:7,9 amount 116:23 amounts 25:1 analogous 67:14 analyses 9:9 35:2 36:9 47:6 54:13 66:14	67:24 212:1 221:6 226:22 analysis 3:17 6:10 18:1 33:8 34:7 64:9,24 65:20,25 66:8 66:10,17,24 67:8,13,14 70:18 136:12 138:17,25 149:12,21 178:4,9,9 204:12,17 205:19 212:2,5 212:6 218:10 218:19 220:1,2 analyze 66:17 analyzed 34:21 analyzing 205:25 ancestry 4:11 95:6,12 anita 33:24 92:3 answer 14:24 25:3,17,21,21 28:10,12 31:12 41:1 46:19,20 56:1 61:25 69:2 71:17 74:3 75:15 77:18 102:16 104:7 117:9 141:20 152:8 178:19 181:7 183:2,3,5 183:14,15	186:2 196:17 199:23 200:22 203:7,10,10 232:17 answer's 80:15 answered 23:18 26:20 28:4 38:7 50:23 54:4 134:6 135:8 159:24 160:5 161:2 234:9 236:15 answering 45:24 46:5,11 68:21 74:8 102:8 141:5 answers 26:22 46:12 anticipate 87:25 88:7 anticipating 215:19 anybody 93:15 anymore 229:23 anyway 156:20 anyways 71:17 74:1 apologies 197:12 apologize 102:23,24 184:8 208:1 apparent 135:24
---	--	--	---

[apparently - assimilated]

Page 5

apparently 72:10	arithmetic 23:6	43:23 44:12,22	208:21 211:8
appearing 97:20	arps 2:21	47:3,9,18 48:11	213:4 215:5,16
appended 244:21	article 3:14	49:3,11 50:21	217:19 223:14
applicant 57:20	17:23 18:7 19:1	53:8,19 54:10	232:3 234:8
application 34:16 57:14,16	19:2 31:13	54:23 55:5	236:15 241:21
apply 221:14	32:15 33:11	62:20 63:1	242:2,5
244:22	54:8 63:12,13	208:24 210:9	asking 16:5
appreciate 10:4	69:14,25 70:7	210:11,17,20	21:2,6,9 24:25
105:5 107:9	70:15 72:18	211:3,10,15,16	27:16 28:22,24
123:4 208:4	76:24 94:24	212:23,24	38:17 57:20
appreciation 73:21 79:7	101:21 124:23	213:1 231:2	59:6,7,9,10
approach 88:10	130:6 132:5,7	235:13,19	60:22 62:6
appropriate 138:19 226:22	146:22 149:6	236:3,5,11,18	63:10 68:25
approximated 81:10	150:9 155:3,5,7	242:3,5,6	74:1 75:12
approximately 21:14 60:15	160:7 162:22	ashcarft 110:21	76:16 77:12
61:1 83:9	163:9,11	111:16	78:2 90:9 93:23
approximation 122:6	165:14 170:22	ashcraft 2:4	99:1,11 102:15
arbitrariness 64:23	172:2,17,19	112:1	134:8 139:10
area 6:7 47:21	175:3 177:14	ashcraftlaw.c...	139:17 143:3
49:15 113:24	178:14 190:25	2:7,8	148:20 160:20
194:3,13 195:1	191:2,20 205:4	asher 86:20	170:2 173:16
areas 76:8	217:20,20	89:12 104:25	182:10,11,16
222:1	218:2 222:19	105:1,1 174:11	185:19 187:8,9
argument 222:7	articles 10:22	aside 171:25	191:23 195:15
	10:24 12:9 33:5	asked 12:16	197:21 198:15
	46:22 54:6	23:17 25:4	200:2,3,6,10
	63:16 107:20	26:19 31:15	202:1 203:2
	129:15 149:10	38:7 50:22 54:4	227:24 240:5
	170:6 172:10	70:2,7 74:15	asserting
	210:8,16 228:6	80:7 99:12	220:13
	231:1	102:8 117:8	assessed 241:1
	asbestiform	134:5 135:7,16	assessment
	213:3	159:23 160:4	70:21
	asbestos 17:16	161:1 179:7	assimilated
	17:25 32:20	188:13 190:15	214:2
	43:3,10,14,20	203:2,21	

[assistant - basis]

Page 6

assistant 235:18 associate 226:8 associated 192:19 215:10 215:13 association 3:14 6:6,11 40:16 41:13 56:19 70:15 104:18 155:11 155:22 156:23 157:7,19 158:15 160:14 188:3,6 191:8 192:22 194:2 194:12,25 204:13,18 210:25 214:8 219:8,11,21 221:23 223:9 224:22 226:2 226:24 227:20 228:3,14 229:9 229:15 236:18 241:14 associations 157:20 158:3 173:19 224:3 227:25 228:20 228:23 assume 20:6 100:9,18 186:24 193:3 196:12 228:9	assumption 131:2 assure 117:2 attached 6:18 attempted 152:13 attempting 183:3 attention 222:17,18 attenuate 205:21 206:1 attitude 129:14 attorneys 2:3 2:20 audio 77:1 author 17:24 51:8 63:22 64:6 91:25 92:3 95:6 108:18 113:15 113:18 128:1,2 128:2 161:10 161:17 166:25 168:12 204:13 authored 30:4 authoritative 44:6 authors 35:5 36:6 63:6,8,14 63:17,18 64:17 65:2,12 69:12 71:23 77:5 78:3 97:6 109:7 123:18 143:24 150:4 153:13 155:20 156:20	157:6 159:19 160:2,12 164:4 164:8,13 166:16 179:8 185:20 191:13 192:10 198:21 229:1 234:7 automated 71:10 available 15:11 16:20 34:20 149:22 avenues 211:2 average 76:2,7 76:12 111:24 112:3 125:8,15 aware 40:4,8 40:14,20 50:19 50:24 58:16 60:11 63:5,8,25 64:1,3,8,14 81:19 125:24 129:9,11 133:11,17 134:16,19 135:3,9 144:4 144:18,21,24 145:9 187:2 206:15,19 234:13,17 235:3	baby 43:2 47:2 53:9 55:21 231:18 back 9:20,23 12:24 17:1,4 20:9 23:8 44:9 49:15,22 79:18 101:5 106:16 107:15,17 124:23 145:13 174:11 180:2 184:4,24 192:15 197:7 202:13 230:9 background 132:8 balderrama 206:24 ballpark 37:5 ban 17:15 54:23 bankruptcy 217:7,12,17 banning 208:23 based 40:18 43:18 44:4,6 132:7 149:5,9 178:13,16,17 218:9 221:17 223:24 225:18 bases 214:18 basic 220:13 basically 55:9 66:16 73:11 basis 131:1,14 137:4
		b	
		b 3:11 4:3 5:3 6:3	

[bath - camera]

Page 7

bath 176:24 177:7 179:8,10 180:3 182:12 182:24 183:9 183:20 baylen 2:11 bearings 8:11 beasley 125:2,4 125:10 beast 134:8 began 33:22 beginning 52:13 198:11 begun 33:19,21 behalf 7:2 27:14 93:22 97:12,20 206:16 belief 19:4 245:4 beliefs 131:8 believe 16:13 68:12 71:5,19 110:11 113:13 129:1 135:21 136:16,17 137:7 166:6 169:22 199:6,6 199:7 205:11 206:7 215:24 218:5 230:14 230:23 233:5 238:24 240:8 240:15 245:3 believed 84:10 93:18 153:14	bell 38:10 52:8 bellwether 206:17 berg 143:17 144:4,9 best 121:11 219:20 245:4 better 71:10 bias 6:10 164:5 164:15 165:4 165:11,19 167:1 168:1 204:12,17 205:20 237:13 237:24 238:25 239:4,11 240:9 240:10,17,25 241:5,12 biases 167:24 bibliography 10:20 15:17 biden 17:15 big 96:19 bigger 86:1,18 binder 19:19 170:7 binders 10:19 10:22,25 104:3 170:5 biological 210:20 211:2 211:16 231:24 233:7 biomarkers 125:9	biomedicine 157:20 bit 15:4 22:2 54:16 65:3 72:7 74:4 86:9 91:17 131:6 229:25 blank 124:3 blanket 147:23 blockage 154:12 blocked 151:17 154:8 blount 47:13 53:25 54:6 blow 111:7 156:13,15 174:4 blue 11:14 board 214:9 220:14 body 190:22 222:4,20 bold 155:6 bottom 9:13 66:8,19 77:8 83:15 89:20 95:16 105:12 113:24 174:16 174:18 176:22 210:6 230:22 box 18:23,23 137:13 bradford 221:11,13 226:8,10	brain 38:9 237:12,19,20 238:17 239:7 240:10,16 break 53:1,3 82:13 127:20 206:13 227:13 237:8 breast 173:22 bring 10:17 broaden 140:25 brought 10:19 bulk 25:13 bullshit 101:25 bunch 221:2 buried 201:20
			c
			c 2:1 8:23,23 168:20,22 244:1,1 call 37:2 49:23 52:25 56:15 157:15 198:10 called 17:14,20 17:23,25 30:9 30:10 37:15 60:12 137:11 140:19 141:25 147:3 161:14 172:4 calling 105:1 camargo 211:23 212:5,6 camera 7:17,21 111:6 128:11

[camera - cause]

Page 8

128:18 202:20 202:21 205:17 campus 29:16 canada 8:5,8,9 27:15 37:2,6 38:1,15 233:15 233:16 234:7 canadian 27:8 cancer 3:16 4:7 4:10,10,17,22 5:7,9 6:7,11 9:11 17:7 18:1 27:15 30:5 32:25 33:6,17 36:24 37:9,20 39:2,17,23 40:2 40:6,12,15,17 40:24 41:13 58:21,25 59:1 59:12,14 60:1,5 60:13,25 61:22 62:17,21 63:1 70:17 91:4,24 93:3 94:22 95:5 95:5,10,11 97:6 104:17 105:15 108:11,17 113:22 114:3 123:7,16 125:9 127:24 128:5 132:1 133:9,18 133:22 134:17 135:4 136:2,6 137:1,25 138:1 138:21 139:16 140:8 141:14	142:12,21 143:16 149:23 150:6,16,23 151:11 152:6 153:8 155:2,12 155:23 156:24 157:22,25 158:3,7 159:6 159:21 160:15 165:25 166:18 170:15 173:22 173:25 174:20 176:17 177:10 178:2 179:10 188:5 190:23 192:20 194:4 195:2 197:24 204:13,18 205:22 207:10 207:14 210:22 211:1,6,10,18 212:18 215:7,9 215:11,13,14 217:22 218:11 222:5,20 223:10,12,24 224:4,6,9,10,21 225:13,18 231:25 232:22 232:25 233:6 235:19,23 236:1,6,8,12,18 237:3,12,19,20 238:4,17,25 239:8 240:10 240:16 241:24	cancer's 138:12 cancers 5:18 133:14 168:10 168:16 capacity 27:25 28:25 213:18 captioned 244:10 captured 117:25 captures 151:22 capturing 121:16 carcinogeneses 221:21 carcinogenic 213:3 carcinogenicity 32:10 cardiovascular 229:5 care 5:16 168:9 168:15 173:21 199:22,24 200:9 career 131:25 213:14 carefully 73:8 carl 206:24 carolina 126:8 carried 33:10 33:23 36:10 65:20 66:14,17 129:20 211:23 226:12 235:25	carry 152:10 157:12 214:11 carrying 211:25 216:25 226:21 case 21:1 27:8 27:12,13 28:3 33:9,16 64:13 65:8 67:11 73:3 73:14 87:9 92:5 92:7,9 117:2 146:14 147:7 147:25 148:6 148:10 149:7 156:21 188:1 217:11,16 220:15,23 225:18 241:2 cases 20:17 21:24 29:5 69:7 87:7 99:4,6,7 99:20 135:4 207:3,6 catch 164:18 categorize 228:19 229:9 category 173:20 causal 188:5 228:24 causality 226:25 causation 59:15 cause 58:25 63:1 114:7 160:13 210:21
---	---	---	--

[cause - column]

Page 9

212:16,17 215:12 223:6,9 caused 207:13 236:5 causes 231:24 232:22,25 233:5 causing 211:17 222:5 ccr 244:14 cdc 39:19,22,25 40:4 cell 237:11,19 237:20 238:5,8 238:17,24 239:7 240:9,16 cells 98:24 center 57:10 certain 39:10 73:23 120:20 210:10 222:2 certainly 56:5 64:21 103:13 136:19 172:3 209:16 224:13 225:11 certainty 138:6 certificate 244:21 certified 1:11 244:4,6 certify 244:8 certifying 244:25 cfr 209:5	chairman 237:1 challenge 78:10 challenging 153:22 chance 60:1,4 154:17 177:14 225:2 chang 5:20 17:24 168:12 168:18 change 13:8 106:7 178:10 245:6 changed 106:8 137:5 168:6 239:13 changes 11:15 41:22 42:10 135:14,17,22 136:19 139:13 140:18 245:5 changing 136:25 characterizati... 78:8 characterize 53:11 chat 61:7,10 85:11,24 91:8 91:19 95:22 142:15 174:23 175:15 204:22 che 5:19 168:18 check 19:6 65:10,11,14	83:7 206:9 chinese 47:8 choices 82:9 choose 25:20 chose 64:18 82:7 chosen 206:18 chris 7:2,10,13 96:6 194:22 christopher 2:11 chronological 34:17 chrysotile 208:23 cite 47:15,19 cited 214:21 city 120:10 claiming 191:6 clarify 100:12 clarity 51:23 166:2,4 clarke 12:16 class 146:14 147:12,24 clear 42:8 45:13 52:2 105:13 152:15 155:4 188:6 219:12 clearly 46:13 clinical 219:14 close 66:6,9 118:8 122:8 closely 81:10	coached 46:13 coast 8:14,16 coauthor 30:8 235:21 cohort 5:19 73:2,7,13 74:11 147:7,12,24 148:5,10,13,15 148:24 149:8 149:13,21,22 156:22 168:12 168:18 178:17 188:2 220:14 220:23 241:3 cohorts 72:15 146:13 coincidence 114:19 coincidentally 65:19 coins 119:17 colette 4:12 95:12 colleague 33:10 33:24 236:1 colleagues 211:23 collected 122:11 collecting 167:3 collection 34:23 college 132:23 133:4 214:10 color 11:15 column 80:18 173:25 174:18
---	---	--	--

[column - confidence]

Page 10

181:3 193:3,5 216:1 combination 62:10 combinations 39:8 combined 9:11 152:20 combines 159:7 combining 62:12 come 35:8,22 35:24,25 36:5 102:1 138:14 comes 30:1 coming 35:11 107:16 commencing 1:14 comment 74:24 106:25 160:19 172:4 202:1 203:3 commentaries 12:12 commentary 78:12 commenting 41:6 comments 36:3 committee 7:3 237:2 common 122:18 commonly 140:19	communicate 213:24 214:13 214:23 communicating 214:5 communication 213:14 communicati... 88:24 234:22 community 214:3,16 215:3 companies 83:20 137:7,8 216:7 company 131:11 compare 19:8 115:17 compared 11:4 44:5 158:24 159:9 167:21 182:4 224:4 compares 11:4 comparing 99:11 115:22 comparison 159:15 compatible 122:10 compensation 97:4 competent 211:24 competing 92:20,23 93:10	complained 107:11 complete 34:23 90:2,10,21 211:14 completely 66:15 77:3 91:15 130:4,19 130:19 136:3 144:8 220:16 complex 15:5 complicated 71:12 122:3,4 141:3,8 complies 8:21 component 72:9,19 components 67:9 72:14 composition 136:14,20 137:5 139:14 140:18 compositions 140:4,5 comprehensive 50:15 149:12 149:16,21 computer 11:22 175:16 175:22 concepts 226:7 concern 32:9 54:24,25 concerned 235:22	concerning 30:5 32:25 210:15 concerns 39:1 39:16,22 55:1 concise 187:22 concluded 213:2 243:7 conclusion 41:6 155:20 156:6 156:12 187:19 188:9 196:4 212:10 219:3 222:8 conclusionary 101:19 conclusions 156:4 187:24 188:12 222:25 conditions 4:22 123:7,17 conduct 218:19 219:21 conducted 230:2 conference 8:7 confidence 66:11 114:14 114:17 115:8 115:16 116:4 116:13 118:1,3 118:12,15,23 119:3,10,22 120:1,3,24,25 121:14,25 122:7 179:24
--	---	---	---

[confidence - copy]

Page 11

180:5 181:15 181:16 183:19 183:21 184:21 185:7,10,19 187:11 188:13 188:15 190:9 191:24 192:21 192:23,25 193:8,10,12,13 195:9,13 196:20,22 197:1,22 200:11 203:16 203:18 204:6 confirm 22:19 58:1 confirming 68:20 240:21 conflict 57:5 83:14 87:21 92:18 93:6 96:25 97:6,19 109:7 127:3 144:15,22 145:3,8 conflicts 57:21 124:22 126:20 126:25 143:8 conformity 221:10 confused 72:6,7 74:4 confusing 96:2 96:12 confusion 109:12 146:4	190:12,15 conjure 119:18 consensus 60:12,24 consequence 151:19 consider 48:22 73:8 78:22 172:3 236:17 considerable 118:23 considerably 115:18,19,20 116:4,5,7,20 117:16 120:3 183:23,25 185:11,22 204:7 considerations 221:11,14 226:9 considered 14:9,16,21 15:6 15:16 16:17,18 16:18 104:5 129:12 158:1 171:5,8 172:6 218:21 221:15 225:14 241:13 considering 117:22 consistency 225:21 226:11 consortium 4:11 95:6,12	constitutes 224:16 consult 93:14 consultant 29:2 consultation 83:18 84:11 87:12 216:5 consulted 28:19 consulting 28:23 contagion 163:6 contain 210:9 210:17 231:2 contained 15:23 43:3 47:18 48:10 55:5,21,22 containing 210:8,16 213:1 213:3 231:1 contains 44:12 47:3 contamination 53:9 contest 22:18 contested 137:19 context 33:9 56:20 158:11 226:5 239:5,6 contexts 157:17 continue 87:20 145:12 154:2 188:8	continued 4:1,3 5:1,3 6:1,3 15:20 continuous 64:22 contract 130:24 contrast 144:13 147:6,22 149:8 159:2,11,13 contrasting 148:18 contributed 87:7 control 33:9,16 36:6,7 73:3,14 92:5,7,9 146:14 147:7,25 148:6 148:10 149:8 156:22 188:1 220:15,23 241:2 244:24 convention 224:16 conventions 225:7 converse 206:21 convey 79:22 copies 11:1,2 12:25 copy 11:2 60:19 85:11 86:3,6,23 87:1 91:9,11 96:15 124:3 162:17,19 196:7,8 205:6
--	---	--	--

[copy - d2]

Page 12

209:23 corn 137:11,13 137:13,21 correct 8:16 20:5 30:19 39:2 39:3 52:22,23 55:5,8,9 58:21 58:22 72:24,25 76:1 83:23 85:6 85:7 87:16 88:2 90:16,17,19,20 90:22,23 92:1,2 92:15 97:20 98:6,17 99:13 100:1,3,11 112:7,9,9 124:10 125:11 125:13,20 126:14 129:4,5 129:7,8 132:9 133:24 140:1 140:10 144:16 144:23 146:2 149:13,23 160:3,25 161:3 165:13 169:24 169:25 170:1 171:3,11,13 172:18 177:24 180:5,7,11,13 181:4,12,18,22 182:5,10,22,23 182:25 183:7 183:12 184:21 184:22 186:25 187:1 195:25	196:1,14 203:7 203:18 204:7,8 223:20 227:3 231:19,21 233:15 238:6 239:14 245:4 corrected 9:21 correction 9:6 9:24 42:11 correctly 10:14 67:7 97:8 157:2 158:13 210:12 corresponding 127:25 128:2 cosmetic 43:11 93:4 137:23 231:14 counsel 54:2 55:12 88:9,24 89:6 183:4 208:21 215:23 216:13 234:20 235:4 241:25 counsels 53:7 count 66:25 219:6,7,16 220:3 counted 219:19 counting 221:8 countries 226:13 couple 13:22 23:13 35:20 36:11 43:8 48:16 74:2 169:14 211:21	235:21 course 15:13 34:21 55:13 105:6 186:4 208:13 court 1:1,11 7:8 8:19 9:1 18:12 20:14,17,21 21:1,23 31:21 45:16,23 87:7,9 94:9 202:6,10 242:19,22 243:1 244:5,25 covered 47:21 55:24 201:15 232:2 233:24 234:9 covers 116:16 116:17 cox 173:23 cramer 18:10 18:20 112:6 123:20 125:3 125:17 cream 177:8 180:10 creating 109:12 credentials 129:17 233:20 234:2,5,6 credibility 212:1 credible 43:21 220:17 credit 194:22	criteria 135:23 critical 5:6 127:23 128:4 217:21 218:11 criticize 141:24 crr 244:14 ctisi 2:13 cumulative 13:24 67:15 curious 218:18 current 27:1 currently 23:25 24:1 33:4,13 74:8 240:15 cut 189:22 cutpoint 65:5 cutpoints 64:22 65:1,5 cv 30:18 32:23 33:2 133:21 d d 3:1 4:1 5:1 6:1 d.w. 125:3 d.w.c. 110:19 111:9,14 d1 3:14 70:14 d10 5:9 142:11 d11 5:12 162:2 d12 5:16 168:14 d13 5:21 173:8 d14 6:6 194:2 d15 6:10 204:16 d2 3:20 82:18
--	---	---	--

[d3 - davidson]

Page 13

d3 3:22 85:15	12:1,4,5,13	82:14,21 84:2	142:17,20
d4 4:6 91:2	13:2,3,13 14:18	84:15 85:12,19	143:2,6 144:12
d5 4:9 95:8	15:24 16:24	85:22,25 86:4	144:20 145:21
d6 4:14 106:11	17:4,9 18:15,18	86:11,14,19	146:3,8 148:11
d7 4:16 108:9	18:25 19:4,8,14	87:3,4,19 88:8	149:18 150:10
d8 4:21 123:5	19:21 20:24	89:12,17,21,23	150:13 151:5
d9 5:6 128:3	21:3,12 22:7,10	90:25 91:7,12	153:1 154:19
daniel 123:20	22:12 23:24	91:18,21,22	155:19 156:5
data 34:8,20,24	24:13,18,19,25	93:16 94:11,20	156:10,13,18
36:16,18 44:5	25:2,11,18 26:9	95:15,21,24	156:19 158:17
48:23 68:8,8	26:13,24 27:5	96:3,6,9,13,16	159:17 160:1
69:1,4,9,12,17	27:23 28:5,11	96:20,24 97:16	160:10 161:4,7
77:5 78:4,23	28:21 31:3,5,7	100:4,15 101:9	161:14,19,21
92:6 107:17,19	31:15,22 35:16	101:16,24	162:13,20,25
114:15 122:10	36:18,21 38:12	102:4 103:7,10	163:5,7 164:3
153:5,14	40:10,22 41:8	104:22,25	166:5,13 168:7
154:21,24	41:21 43:15	105:6,11,22	168:21 169:17
155:1 156:21	45:2,12,20,22	106:15 107:10	169:22 170:2
178:5,6,12	46:3,8,16,22,24	107:13 108:7	170:12,24
184:16 186:18	47:23 48:2,5,18	108:15,21	171:6,14
188:1 200:4	49:8,17,20,25	109:2,6,17,20	172:24 173:5
211:25 222:6	50:5,18 51:4	109:25 110:7	173:10,15
date 11:12	52:3,24 53:4	111:21,23	174:5,8,12,15
19:25 21:15	54:19 55:10	112:10,17,21	175:4,8,13,16
27:11 52:9	56:8 57:22 58:2	113:1,4,16,19	175:20 176:6,9
60:14 82:25	58:5,8,14 59:5	115:4 123:11	176:13 177:4
245:19	59:19 60:21	123:14 124:4,5	177:17 178:20
dated 244:18	61:2,5,8,12,18	125:14,21	179:1,6 180:8
dates 216:14	62:4,15 63:4	126:18,23	180:14,20
217:1,1	64:2,7,16 67:22	127:10,18,21	181:8,9,19,25
davidson 2:22	68:5,16,21 69:8	128:10 130:14	182:3,9,15,21
3:5,7 7:9,16,20	69:21 70:1,4,11	132:21 134:13	183:6,18 184:3
7:24 8:4,8,10	70:23 72:1 74:6	134:15 135:11	184:9 185:2,4
8:15 9:4,25	75:14,19 76:21	137:3 139:1,11	185:16 186:3,7
10:6,10,12	77:4,24 78:13	139:23 141:9	186:12,14
11:10,18,21	81:14 82:6,11	141:22 142:5,9	188:10 189:2,9

[davidson - deposition]

Page 14

189:14,18,22	103:12,24	declined 134:19	deliver 147:15
189:24 190:2,4	104:11,14	135:1 136:6	243:3,4
190:14,18	106:3,23	defend 130:7	delivery 243:2
191:1,11	107:14,18,25	defendant 2:20	demonstrate
193:17,21	109:18	defendant's	155:4 222:2
194:7,14,20,24	day 58:13 83:2	3:14,20,22 4:5	227:1
195:23 196:3,5	83:3 197:9	4:8,13,15,20	demonstrated
196:18 197:8	242:12 245:22	5:5,8,11,15,21	47:8 211:5
197:20 200:20	days 16:14	6:5,9 70:14	demonstrates
201:3,10 202:8	104:4 219:5	82:18 85:15	210:25 220:18
202:13,17,24	dc 12:25	91:2 95:8	denying 240:21
203:24 204:5	dealt 168:4	106:11 108:9	deodorant
204:21 205:2,9	debunk 146:19	123:5 128:3	176:24 177:7
206:7,12,14	debunked	142:10 162:1	180:9
207:18 208:9	146:11 148:4	168:13 173:7	depend 119:14
208:11,14	debunks 147:11	194:1 204:15	depended 35:2
209:11,14	147:18	defending	dependent
227:11,17	december	96:10,17	158:11
228:2,7,12	35:21	189:10	depending
229:10,20	decide 171:19	defense 87:8	73:16 178:8
230:8,13,16,20	decided 171:17	112:7	depends 100:17
231:22 232:3,7	decision 72:24	define 115:18	145:5
232:19 233:3	73:2	116:6	depose 15:25
234:3,12,18	decisions	defined 67:24	deposed 84:16
235:2,8 236:16	171:22	157:11	87:8 89:5,7
237:5,9,18,22	declaration	definitely 163:1	90:16
238:12 239:12	3:20 82:16,19	definition	deposition 1:8
239:19 240:24	85:5 215:17,25	58:20 64:18	9:20 10:18
241:7,10,15	declared 92:20	definitive 222:2	12:17,23 13:18
242:1,4,7,11,15	decline 134:24	degree 113:21	13:21 15:18
242:21	135:24 136:7	114:3,7 115:23	16:21 31:6,20
davis 4:12 18:7	136:18 139:16	120:20,21	45:14 47:22
94:5,7 95:7,13	139:21 140:8	131:18,21	49:19 50:23
97:24,25	140:16 141:14	138:6	55:25 78:2 89:2
100:19 101:7	141:15	delicate 107:4	96:10,17 101:5
101:21 102:12			101:21 102:5

[deposition - discrepancy]

Page 15

103:20,25	designing 34:2	116:23 117:5	direction 43:9
113:2 128:15	34:2	117:13,20,21	212:10 244:24
189:5,11 232:2	designs 73:3	118:5,11,12,14	directions
234:10 236:15	147:3,21	118:18,21	60:13,24
238:3,21 241:6	desk 38:9	differences	directly 54:25
243:6	despite 26:14	104:17 116:25	disadvantages
depositions	116:24	117:9 167:2	73:14
13:5,9	detected 55:2	different 42:21	disagree 40:23
deposits 210:7	detection 54:10	67:25 81:5,20	41:7,17 72:2,4
210:16 230:25	56:3	81:21 82:2 90:1	73:1,5,12 94:2
231:6,17	determinant	109:9,20 115:1	94:4 167:8
depth 103:14	220:24	115:2,9 116:1	215:14,15
derive 44:3	determine	116:14 118:20	223:16
describe 158:9	61:21 80:9 82:7	130:20 138:15	disagreed 215:7
158:15 203:3	125:16 138:18	166:3 167:23	discern 15:9,15
211:24 223:22	164:8	167:24 184:11	discipline 225:5
228:3 229:14	determines	187:15 188:21	disclose 30:20
described	148:8	205:3 226:12	32:8,8,17 93:19
152:12 225:9	determining	226:13,13,14	97:11 144:1
225:10 228:14	73:9	differs 164:16	disclosed 19:22
describes 65:25	develop 207:14	165:6	29:7 31:9,24
describing	developed 34:5	difficult 15:9	126:19 127:1
155:7	58:24 73:17	77:25 78:9	145:4
description	developing 60:1	138:5 139:25	disclosing 32:2
3:13 4:4 5:4 6:4	151:19 154:7	153:22	disclosure
221:13 228:1	192:20 225:6	dig 171:25	32:14 97:1,19
descriptive	development	dimensional	124:21
163:25	58:21 170:15	71:7	disclosures
descriptor	197:24 224:18	dimensions	110:2,8
158:8 159:15	develops 59:11	71:13 73:9	discovered
descriptors	diagnostic	direct 151:19	225:5
230:7	135:17,22	222:17,18	discovery
design 73:2,7	dial 167:21	239:16 244:24	234:21
designed	differ 114:21	directed 106:23	discrepancy
224:15	difference 68:6	111:20	241:2
	68:13 115:10		

[discussed - dr]

Page 16

discussed 35:18	102:16 105:20	42:14,21 44:8	12:6 13:4 14:12
discussing	106:16 107:4	47:10 48:7,17	16:7 19:24
149:24	107:14,24	49:1,6,10 50:8	22:13 24:20
discussion	110:9 111:20	50:13,15,20,25	25:12 31:8,23
13:25 17:3 57:2	119:20 124:2,6	53:13,15 54:18	45:24 46:5,11
96:23 145:15	139:24 141:24	55:11 207:2	46:18,25 47:4
167:13 168:1	152:9 153:3,25	216:16,18	48:6,19,25
202:12 208:17	155:8 158:18	235:5,9	49:21 50:6 51:6
237:7	160:11 170:3	doing 56:24	51:7 52:4 53:5
discussions	174:25 179:18	92:5 112:23	53:24,25 55:11
13:23	179:25 186:21	131:25 213:21	56:1,9 58:15,16
disease 62:11	187:17 192:17	dollars 23:16	58:19 61:13
79:24 135:15	195:4 196:12	domain 126:4	70:3 74:7,18
135:19 138:5	199:23 200:6	dose 100:20	75:1,3 79:15
141:1 151:19	201:4 209:8	104:11,15	80:24 83:22
224:5,25 229:6	215:16 232:9	105:14 106:3	84:17 89:24
disingenuous	240:4 241:8,11	106:20	97:10 99:2
102:22	doctor's 177:13	double 221:8	101:6,17 102:7
display 116:10	document 41:3	doubt 112:2	103:8,11 112:6
disruptions	41:5 44:14,15	douche 176:25	113:13,20
35:14	44:17,20,25	177:7	125:17,17,23
distinction 44:1	45:6,11 47:4	douching 4:21	125:23 128:11
68:11 170:4	53:20,24,24	5:12 123:6,15	128:17,24
distorted 225:8	54:20,22 55:3	161:8,15 162:2	129:17 130:9
distortion	60:19,23 61:14	162:13 163:14	131:4,18,21
220:7	82:23 175:19	164:1 166:3	132:8,12,22
district 1:1,1	176:5 182:2,17	181:3,12,20	133:3,6,9,12,17
divulge 25:9	208:22 209:7	182:4	134:16 141:10
divulging 25:5	210:6 216:15	download	142:23 143:8
doctor 8:20	216:20	175:7	144:14,14,21
19:16 25:20	documented	downloads	145:2,8,9,24
39:13 61:11	224:1	175:19	157:3 159:18
69:24 75:15	documents	downplaying	162:21,24
77:9,25 78:14	11:4 12:7,9,12	149:7	163:8 164:11
78:17 80:1,16	14:8,15,19 15:6	dr 7:12,14 9:6	166:14 171:7
99:12 101:2	16:1,3,8 38:22	9:17 10:11 12:2	177:6 178:21

[dr - entitled]

Page 17

181:10 182:22	e	effect 115:9	endometriosis
183:1,7 184:10	e 2:1,1 3:1,11	136:23 147:19	4:18 108:12,18
185:7 186:15	4:1,3 5:1,3 6:1	157:15 164:15	113:22,23
189:15 190:5	6:3,12 8:23	165:5 167:2	114:4,6 115:24
196:6 202:25	30:11 83:7	effects 4:16	115:25 116:12
204:10 205:13	168:20 174:22	108:10,16	117:14,14
205:16 206:15	204:18 244:1,1	137:23 157:23	120:15 121:8
208:20 210:5	245:1,1,1	158:1	121:20 122:13
211:7 215:5	earlier 11:16	efficient 213:24	122:16
227:18 237:10	184:11 191:12	egilman 130:22	endorse 180:18
238:22 239:20	205:4 207:22	131:4,6,18	180:25
240:14 241:21	233:12	133:3,6,9,12	ends 214:4
drafted 41:22	early 54:8,9	144:14,21	energetic 131:7
41:25 42:7,13	138:13	145:8,9	enormous
drafting 35:2	earned 21:14	egilman's 130:9	134:8 171:23
drive 153:13	22:21 26:17	eight 23:8	178:10
driven 34:14	earnings 24:9,9	198:16	ensuing 87:6
driving 167:1	24:22 25:13,24	either 22:19	entire 72:12
drop 138:18,20	26:5,5,15	102:6 125:23	77:11 102:5
139:21	ears 110:14	126:13 131:17	147:18,19
dropbox 15:18	easier 86:9	151:16	149:10 177:14
15:20 16:14,16	91:17 193:7	element 64:23	198:11 200:21
16:22 17:12	easily 66:12	elizabeth	201:1
19:5 42:16 58:4	easy 90:14	143:19	entirely 55:7
169:24	141:3	emails 88:18	entirety 41:3
due 25:22 62:14	echeverria 21:1	embodies	149:6
180:22	89:22	120:20	entities 115:22
duly 8:24	editor 130:9	embody 71:14	entitled 1:10
duplicate 11:1	editorial 18:16	employees	3:14 4:5,8,15
duplicative	18:21 130:20	127:5	4:20 5:5,8,11
15:4	editorials 18:8	employment	5:15 6:5,9 9:9
duration	18:10,21	24:1	15:25 16:6
104:16 105:14	editors 36:3	ended 29:6	24:11,24 25:6
dust 236:5	edt 1:14 243:7	endometri	28:2,15,20 45:7
		117:13	60:23 70:15
			91:3 94:15 95:9

[entitled - evidence]

Page 18

108:10 123:6 123:15 125:9 127:23 128:4 142:11 162:2 168:8,14 173:19 194:2 194:12 204:11 204:16 209:4 217:21 218:10 222:19 entry 159:1 environment 4:6 91:3,24 environmental 209:4 236:5 epa 17:13,14 43:22 44:10,11 44:14 46:25 53:23 54:20,22 55:3 208:22 210:9 epi 61:21 epidemiologic 167:25 190:24 214:16 218:20 epidemiologi... 71:6,11 75:7,21 152:3 156:21 196:13 201:5 210:24 219:15 220:17 222:21 229:13 epidemiologi... 211:5 epidemiologist 213:11	epidemiologi... 214:9 epidemiology 125:9 131:19 131:22,25 132:17,24 133:4,7 157:21 157:22 214:10 224:19 225:8 225:15 237:4 epithelial 4:9 94:22 95:4,10 138:9 epstein 2:22 61:4,6 85:21,24 86:17 89:16,19 91:19 109:14 109:19,23 110:6 112:19 113:3,5,10 142:7,15,19 146:1,5 156:7 156:16 173:3 174:3,7,10,14 184:6 193:20 194:19 204:24 equipped 214:11 error 9:22 100:18 164:15 165:4 220:13 errors 115:14 especially 138:3 164:15 165:5 226:11	esq 2:5,5,11,16 2:22,22 established 224:6,11 establishing 64:22 estimate 21:16 22:20 23:7 66:13 88:5 99:22,23,25 120:13,19,20 121:10,11,11 121:15 138:10 170:14 178:11 218:19 estimates 66:3 66:7 82:1 114:13,18,24 116:1 117:5,21 117:23,24 118:3,15,19 119:6,13 120:7 164:15 165:5 167:3 197:22 198:21 199:2 203:4,4 229:16 estimating 22:2 22:15 et 3:19 4:7,12 4:19,24 5:7,10 5:14,20 6:8,12 70:19 80:24 91:5 95:13 108:13 123:9 127:24 128:6 142:13 162:5	168:18 194:5 204:19 evaluate 71:9 evaluated 78:21 236:24 241:1 evaluation 44:4 56:17 103:15 170:11 212:25 212:25 213:2 221:12 239:4 evaluations 214:12 events 79:12 eventual 35:5 everybody 86:22 242:12 evidence 5:10 40:16 41:12,19 41:19 43:8,21 44:2,5 47:17 48:10 64:13 88:18 140:10 140:14,15 141:13,21 142:13,22 144:8 190:24 210:24 215:11 221:22,22 222:9 223:19 223:23 224:17 224:17 225:15 225:17,20,25 226:2,2,6,23 239:7
---	---	--	---

[evil - fact]

Page 19

evil 110:18,18	94:6,10,15 95:1	56:11 57:5	93:11 141:1
ex 59:15 127:12	95:3,8 106:10	60:12,23 63:6,9	161:10,17
exactly 66:18	106:11 108:8,9	63:15,23 84:20	162:4,12,15
130:13 157:13	122:25 123:5	84:22,25 88:10	163:13 167:4
212:9	127:22 128:3	89:8 90:15	170:14 210:11
examination	142:6,8,11	93:19,21	235:23 236:5
3:3 10:9 208:18	145:14,23	106:12,24	241:3
227:16 241:19	146:2,4 161:8	107:6 110:20	exposures
examined 8:24	162:2 168:8,14	110:20 111:15	212:22
49:15 101:7,20	172:25 173:6,7	125:2,3 126:12	express 39:1,22
241:5	193:19 194:2	145:10,14,24	222:14,15
examining	194:19,25	234:14,23	expressed 60:8
241:13	204:11,15	236:19,24	81:4,5 120:22
example 121:21	205:11 209:15	expertise 43:19	146:12
152:17 177:23	209:17,19,25	experts 3:21	expressing
examples	215:24 230:10	51:13 56:16	119:4 120:23
119:17 225:12	230:13	82:20 127:7,14	expression
228:22	exhibits 6:18	explain 59:23	121:25
except 110:14	existing 152:13	119:7 135:24	extent 55:24
exception 67:6	expect 35:22	explained 75:2	174:25 233:22
excess 211:4,5	38:19	explains 51:7	extra 22:2
226:17	expedited	explanation	extrapolate
excuse 84:18	242:16,17	117:11	61:20
96:5,8 189:3	243:1	explicitly 54:25	extremely
190:14 213:12	expedites	57:20	71:12
excused 243:5	242:18	explore 53:20	eyeballing
exhaustively	experience	exploring 29:4	116:18
241:5	118:7 131:10	exposed 9:10	eyes 110:15
exhibit 3:13,14	132:15 133:13	exposure 5:14	174:17
3:20,22 4:4,6,9	214:7	17:25 33:9 34:6	f
4:14,16,21 5:4	expert 4:13	35:10 36:20	f 244:1
5:6,9,12,16,21	27:2,3,6,21,22	40:17 41:14	face 7:25
6:4,6,10,14	28:3,7,16 29:1	59:16 62:14,25	fact 26:14
69:23 70:14	29:7 30:21	67:15,16 79:6	54:24 55:3
82:15,18 85:13	31:10,24 32:4	79:13,23 80:19	65:23 76:14,15
85:15 91:1,2,23	32:11 51:5,6,16	81:22 82:3	

[fact - first]

Page 20

85:3 93:20	familiar 37:14	fibers 43:23	200:19 201:21
106:3 107:16	37:16,25 38:3	47:9,18 48:11	202:3 219:21
107:18 130:22	38:20 39:4,8	79:13 213:1,3	220:5,22
149:11 155:10	40:11 60:22	221:20 222:4,5	229:13
159:18 210:16	61:13,15 70:24	fieldwork 34:2	finding 108:25
211:13 215:8	71:1,18 73:18	34:23	229:25
221:17 237:1	82:22 126:1,2,3	figure 9:16	findings 187:23
factor 37:20	133:25 168:25	17:1 23:10	fine 30:17
40:2,5 114:7	169:3 170:21	62:13 107:22	94:25 95:24
224:19,19	195:3 201:6	112:19 189:7	96:22 112:24
225:2	237:3	199:13,13,18	166:8,8 189:12
factors 4:16	familiarity	figured 184:7	192:16 222:6
38:24 108:10	134:2	filed 215:18	240:1 242:19
108:16 132:2	family 113:21	filibuster 45:21	finish 46:7,8,9
138:5,13,14	114:3,7 143:17	filibustering	64:4 67:5 68:18
188:5,7 207:9	143:18 144:5	45:14 49:19	68:23 153:20
224:5,6,7,11,24	fashion 183:2	102:7	158:21 181:6
225:9,12	fatal 71:14	final 92:3	232:15
factual 76:17	fatally 218:24	113:14 187:19	finished 46:9
factum 76:10	favor 208:12	204:11	46:10
failed 92:21	fda 43:22 47:1	finalizes 17:15	finishing 68:18
faint 166:9,11	53:24 54:13	financial	firm 83:19
fair 10:4 48:4	federal 21:23	143:25	110:21,22
54:1 103:2	127:13	find 38:23	111:15,16
119:1,2 139:2	feel 130:8,13	41:16 57:24	112:1 125:2,4
166:24 217:14	168:3	58:9,10 69:14	125:11 129:21
232:6 240:6	feeling 138:8	95:25 100:19	130:24 131:11
fall 36:15 88:11	166:11 207:23	100:23 106:3	firms 83:19
89:9 137:12	208:5	109:5 117:10	216:6
fallen 134:17	fell 135:4 136:2	142:2 147:1	first 8:24 17:24
135:13	fellow 132:23	158:16 166:16	35:5 36:2 74:24
fallopian 17:8	133:3,10,18	168:24 192:7	93:25 95:6
77:6 78:4,24	felt 130:6 168:3	195:18 196:25	108:18 113:2
79:5 151:17	female 132:1	197:15 198:12	113:21 114:3,7
false 220:16	ferraro 110:21	198:15,20,20	115:23 122:6
	111:15 112:1	199:11 200:9	128:2,17

[first - frustrated]

Page 21

135:15 139:13 140:5 161:10 161:17 168:12 191:25 193:3,4 204:13 218:18 225:5 232:2 238:15 firsthand 137:18 fits 148:9 five 9:12 34:24 35:7 53:1 80:18 139:6 192:6 204:1 flaw 222:12 flawed 218:13 218:25 219:15 flaws 51:7 71:14,15,15 218:8 flipping 119:17 flom 2:21 florida 2:12 fluctuate 119:15 fly 38:9 focus 174:1 follow 69:6 136:7 221:6 following 56:15 59:4 245:5 follows 8:25 font 98:11 footnote 77:9 77:11,13,16,20	foregoing 244:8 245:2 forensic 103:14 forget 85:23 forgive 115:11 115:13,14 forgotten 186:9 186:15 form 13:10 24:10 25:15 34:12 40:7,19 40:25 41:15 43:5 49:4 54:3 57:19 59:2,17 61:24 63:2 68:1 68:9 71:24 73:4 75:9 81:12,23 83:24 84:13 87:17 88:3 93:13 97:13 100:2 112:8 114:9 125:12 125:19 126:15 126:21 127:15 130:11 132:19 136:9 138:23 139:4,19 140:11 141:18 144:17 149:14 157:9 163:17 170:16 172:8 178:24 180:6 180:12 181:5 181:13,23 182:6 183:13 184:1 185:12	196:15 200:15 200:23 201:8 203:19 204:4 207:15 213:1 227:22 228:16 229:17 231:20 232:23 234:16 234:24 235:7 236:14 237:16 237:21 238:10 239:1,15 240:18 forms 24:24 25:5 120:22 formula 62:2 formulation 79:2 formulations 43:11 forth 36:4 131:12 fortunately 163:5 forums 214:2 forward 19:13 78:11 forwarded 16:23 foul 102:13,24 found 9:22 42:19,21 58:16 58:19 66:1,16 66:18 104:11 121:3 150:4 151:25 152:3 165:8,23 178:5	195:20 203:10 218:12 foundation 49:14 143:17 foundational 55:24 four 20:10 31:18 35:7 45:15 50:1 80:17 201:17 fourfold 111:9 frequency 65:7 66:11 67:15,17 67:24 72:16 104:15 105:14 165:20 173:20 frequent 3:15 58:17,20 59:11 59:25 64:19 70:16 frequently 58:24 fresh 103:17 165:15 169:5 front 16:8,11 18:24 19:3 30:25 31:13 39:14 42:6 45:8 57:9 70:8,10 86:7 98:13 129:23 146:7 153:10,11 172:19 194:8 195:25 223:1 frustrated 102:14 207:24
---	---	---	--

[frustrating - going]

Page 22

frustrating 102:9,10	73:20 76:5 138:8 148:5	give 21:17 46:17,20 49:14	128:19,22 145:15 148:17
full 24:1 29:20 77:20,23	214:3	71:23 94:18	148:21 150:1
171:21 193:4	generalizable 120:13	101:4,6,22	152:9 161:4
fulsome 183:14	generally 48:1	107:21 109:4	169:19,20
fund 134:12	62:6 93:11	112:22 123:3	171:24 175:6,9
funded 34:22	103:4 226:1	161:18,20	175:14,21
143:12,16	generated 11:22	162:7 185:1	176:21 180:2
funding 34:1	generic 73:20	204:25 213:15	180:25 184:4
34:16 143:21	120:12 148:5	227:5,6 232:16	187:21 191:5
further 171:24	generous 129:14	given 36:9	193:17 196:3
227:9,15	genetic 158:2	86:25 118:15	201:22 202:8
241:16 242:9	genital 4:9,22	223:11	202:13 206:8
furthermore 104:14	5:12 6:6 41:13	giving 101:24	208:8,9 209:7
future 60:13,24	76:8 94:21 95:4	102:18,21,25	227:7 230:9
88:1,7	95:9 104:16	183:4	237:5 239:24
fuzzy 54:17	105:15 123:8	glad 50:17	241:8,11
g	123:17 151:10	glance 191:25	goes 116:15
g 30:11 168:20	155:12,22	238:15	212:9
168:22	156:24 161:8	glanced 171:17	going 7:17 15:8
gabriel 4:24	161:15 162:3	glancing 171:20	15:15 20:9 23:8
122:25 123:9	162:14 163:14	go 7:17 8:2 9:20	29:12 35:25
123:18 124:3	167:3 188:4	9:25 16:24 17:4	36:5,8 45:10
game 103:2	192:18 194:3	23:22 31:20	46:1 49:22 50:6
gaps 221:19	194:13 195:1	38:23 39:9 44:8	56:22 57:1
222:7,8	gerel 2:4	45:16,22 52:24	85:12 86:7
gather 219:25	110:21 111:16	73:9 81:3 82:11	95:25 101:10
gel 176:24	112:1	83:13 85:8,21	115:18 116:8
177:7 179:8,10	getting 8:11	87:5 94:5 96:3	127:22 150:9
180:4 182:24	35:1 60:4 102:9	96:20 101:10	153:24 172:21
183:9,20	102:10 168:23	101:14 108:21	172:24 176:15
general 20:6	194:9	108:23 109:6	176:16 184:24
40:17 53:19		110:1,5 114:8	186:17,20
		117:10 119:17	194:14,15,15
		124:21 127:18	198:5 199:11
			226:25 242:13

[golomb - hear]

Page 23

golomb 2:15,16 7:7,7 202:4 golomblegal.... 2:18 gonzalez 184:13 good 10:11,12 10:15 46:20 86:24 121:15 135:25 138:4 191:3,4 218:21 227:10 242:11 goodman 5:7 6:12 127:24 128:6,25 131:21 132:12 132:22 133:17 146:12 148:12 204:14,19 217:19,20 218:2,10 220:10,11 221:1 goodman's 129:17 132:8 goodness 102:2 gossett 18:15 18:16 government 127:13 grab 143:1 grabbing 108:6 grade 99:5 grant 34:16 graph 116:16 116:17	graphic 116:10 grasp 138:4 great 10:16 11:10 12:19 13:2 83:11 94:11 96:3 110:15,16 112:23 116:24 136:4 142:17 176:9 194:21 242:11 greater 60:2 154:17 greatly 114:23 grew 64:9 group 92:14 199:8 212:4 groups 159:16 214:16 233:13 growing 47:17 48:9 guarantee 219:20 guess 15:4 21:17 25:16 36:13 76:10 124:15 130:5 132:10 136:11 165:14 177:20 200:17 239:18 guessed 81:24 guessing 126:11 guesstimate 76:16	guide 219:3 guys 102:15 175:8 189:19 194:7 gynecological 39:5 133:13 gynecologists 38:1,15 h h 3:11 4:3 5:3 6:3 168:20,22 245:1 habits 135:17 half 111:13 hancock 233:19 hand 8:20 91:9 113:24 130:21 164:25 190:21 handed 90:5 124:2 handing 91:15 150:25 handle 45:3 handwritten 11:23 12:11 hang 169:13 happen 33:12 36:13 120:10 happened 217:5 224:21 happy 7:18 113:11 179:21 180:23,23 192:9 232:16	hard 86:9 107:1 107:2 138:3 161:12 196:7,8 197:2,4 200:14 200:16 208:16 harlow 18:10 18:20 harmonize 77:7 78:5,24 harmony 79:24 harris 17:15 harvard 131:25 hastily 216:19 216:25 hazard 174:20 176:24 177:9 179:9,24 180:3 181:3,11 182:23 183:8 183:10 192:20 200:7 201:13 203:15 hazards 173:23 head 88:20 heading 142:18 health 36:23,23 37:2,6,7,10,12 73:22,23,24,25 127:6 136:1 233:13,14,16 234:7 hear 70:4 86:5 91:12 110:18 161:12 196:23 208:16
--	--	---	---

[heard - implying]

Page 24

heard 38:4 39:19 153:18 174:11 197:9 206:20,23 213:21 214:23 217:9 229:5	highest 71:23 74:10 highlighted 114:18 highlights 11:14,15 hill 221:13 226:8,10 hill's 221:11 hinted 79:3 hired 236:19 historic 43:24 47:6 164:13 165:3 historical 54:17 historically 47:12 history 49:23 113:21 114:3,8 115:23 165:25 166:18 192:18	hormone 5:17 168:10,16 hours 13:24 31:18,21 45:15 208:21 huh 17:10 42:3 89:21 119:24 146:23 147:4,8 151:6,8 167:16 196:25 199:16 202:17 hundred 122:2 hundreds 172:10,10 hygiene 174:19 177:6 hyperlipidemia 229:6 hypotheses 34:15 hypothesis 222:4,10 hypothetically 121:3 hysterectomy 151:11,17 152:16,19	215:18,19 216:22 236:23 idea 51:2 126:17 127:9 133:5,8 135:21 194:23 231:16 236:4 identical 67:20 114:19 identification 70:20 82:20 85:18 91:6 95:14 106:14 108:14 123:10 128:7 142:14 162:6 168:19 173:9 194:6 204:20 209:21 identify 14:13 19:18 40:5 42:14,22 76:7 95:20 198:6 201:6 imagine 116:9 immunological 188:1 impact 71:16 168:2 implication 73:6 157:13 implications 119:12 implied 9:15 implying 131:16 240:22
hearing 107:2 197:3,4,5 heavy 55:17,19 55:22 held 17:3 96:23 202:12 208:17 237:7 help 11:8 20:22 189:21,23 190:3 230:11 helpful 176:12 239:17 helping 34:1 189:24 hesitate 141:5 hesitating 232:10 hey 113:7 189:9 hi 7:9 high 66:10 99:5 150:6,16,18,23 152:6 153:7,16 154:14,23 155:2 157:6,11 158:18,23,23 159:15,21 160:24 191:14 225:4 229:12 higher 60:5 73:3	hold 44:3,4,6 94:23 162:16 189:18 222:17 honest 166:20 hoops 227:1 hope 136:16 hopeless 220:7 hopelessly 219:15 hopkins 132:11 132:16 hormonal 132:2	i i.e. 151:16 iarc 3:20,22 56:10,15,19 57:1,13,16 58:7 60:11,23 82:17 82:19 85:16 212:11,15,20	

[important - interpret]

Page 25

important 48:20 93:18 104:5 114:20 138:4 170:10 171:18,20 172:2,2 214:24 216:20 217:2 226:20	74:5 81:9 90:18 92:18 124:9,14 124:15 167:25 186:21 212:6 235:20	indicated 24:16 60:10 97:15 230:5	initiated 130:23
imprecise 117:24	including 11:3 43:22 47:7 78:23 132:1	indicating 72:11 121:1 152:22	input 37:3
imprecision 117:23,25 119:5	inclusive 129:14	indicator 219:10	institute 17:7 133:23
impression 149:5,9	income 23:3,7 23:11,15 24:15 24:21,24 25:6,9 25:13,24 26:16	individual 219:1 226:18	institutes 127:6
inaccurate 83:25 85:6 87:16 88:2,5	incontroverti... 226:23	individually 219:2 220:4	insufficient 152:23 215:11
inches 96:12,14	incorrect 216:13	inflammation 4:23 19:3 123:8 123:18	intact 77:6 78:4 78:23 79:5 150:2,4,14,22 152:4 153:6,15 154:6,11,16,22 159:8,13,19
incidence 62:11 135:3,15 136:1 137:1	increase 137:15 160:16 173:20 175:22 176:1 192:19 223:11 236:6	inference 160:9	intake 213:18
incident 5:17 168:10,16 192:20	incredible 229:3	infinite 121:5	intention 33:7 33:12,15 34:6,7
include 32:13 41:5 57:4 72:16 77:5 78:4 93:10 107:25 124:8 124:13,17 167:13 181:17 188:7 212:21 212:22	incredibly 102:14,14	inflammation 4:23 19:3 123:8 123:18	interest 3:20 57:5,21 82:16 82:19 87:21 92:18 93:7,10 97:7,19 124:22 126:20 127:1,3 143:8 144:15 144:22 145:3,8 215:18,25
included 34:5 47:6 66:12 67:8 67:12 72:18	independent 53:12 160:13 223:5,8	influencing 214:4	interested 120:6 201:20
	independently 42:19,25 66:4 66:15	information 20:4 28:15 54:14 76:17 192:3 200:17 200:19 201:20 211:1 213:18 214:1,6 228:19	interesting 9:19
	indicate 116:2 119:12 186:20 226:17	information's 20:5	interestingly 175:21
		informed 56:25	interests 35:3 92:20,24 143:25
		infrastructure 215:2	interpret 221:22

[interpretation - julie]

Page 26

interpretation 160:8 221:10 221:12 interrupt 22:11 31:19 158:25 interrupting 46:3,4 197:11 interval 66:12 118:1 119:22 120:1,24,25 121:14,25 122:7 179:24 180:5 181:16 181:17 184:21 188:15 192:21 192:23 193:9 193:10,12,14 203:16,18 intervals 114:14 115:8 115:16 116:4 116:13 118:4 118:13,16,24 119:3,11 120:3 183:20,21 185:8,11,20 187:11 188:14 190:9 191:25 192:25 195:10 195:14 196:20 196:22 197:1 197:22 200:11 204:7 intervenor 130:23 131:11	interventions 154:13 158:25 interview 120:11 interviewed 75:5,6,20,22 121:6 introduce 7:6 investigation 143:7 investigations 143:11 investigator 33:25 investigators 36:7 226:14 invite 57:1 invited 236:23 invoices 21:8 involve 27:12 involved 33:11 33:25 69:5 83:20 87:23 216:6 235:17 involvement 87:25 88:7 irrelevant 25:7 issue 93:6 122:4 168:4 197:4,13 224:20 issued 60:12 issues 37:13 48:22 56:11 110:14,15 130:20 132:1 214:14	it'll 36:1,1 146:21 iteration 36:2 iterations 36:3 iwona 4:23 123:9,18 j j 1:10 8:23 244:4,14 j&j 49:1,6 50:9 50:13,19 51:13 208:21 j&j's 49:9 51:6 51:17,20 jack 1:8 3:4,22 4:14 46:21 85:16 106:12 243:6 jama 195:2 january 35:21 49:16 50:23 83:18 216:5 jersey 1:1,13 244:8 jessica 2:22 8:3 9:3,19 11:8 12:21 15:2 16:22 19:11 20:23 24:12 26:21 46:15 47:20 50:3 52:1 60:18 68:17 77:2,15 78:10 86:2 101:3,18 101:23 102:3	104:21 105:4 106:25 107:8 108:5 112:24 123:2,23 145:20 146:2 153:17 161:13 162:9 166:1,9 171:5 173:13 174:24 175:12 180:17 182:13 185:23 190:11 194:10 202:20 206:11 208:4 227:6 jessica.davids... 2:24 joan 143:18 job 10:15 112:23 134:11 john 5:10 142:13,22,24 143:4 johns 132:11,16 johnson 1:3,3 137:8,8 143:19 johnson's 43:2 47:2 53:9 55:21 231:18 joke 94:13 journal 36:8 125:8 214:22 journals 112:5 judge 49:24 101:14 julie 5:7 6:12 127:24,25
--	---	---	--

[julie - legitimate]

Page 27

128:5,8,9 204:18 july 83:1 jumping 222:16 june 11:16 jung 5:19 168:18	45:15 50:2,14 51:1,2,14,15 54:18 58:8 61:12 62:25 64:17 67:23 68:2 69:11 71:9 76:2,12,14,15 76:17 77:3 78:20,20 80:5 81:3,8,15 86:15 100:21 102:11 102:17 107:1 111:25 112:5 114:10 116:18 119:9,16,16,18 121:4,7,7 122:18,20 124:13,17 125:10 126:6 126:17 127:5 130:12,21,21 131:6,7,13,14 131:20,23 132:12,16,22 134:21,22 135:1 136:10 136:11,11 142:23 143:5 143:10 152:18 156:16 158:6 159:4 163:15 166:10,19 167:17,22 168:5 170:7 171:23 172:9 173:14,15,15	176:6 178:12 179:12 180:21 185:13 186:18 187:12,13 189:3 195:19 196:13 197:8 200:1,24 201:2 207:5,9 221:25 224:14 225:1 226:5 228:18 229:5,6,11 231:8,10 232:11,21,24 233:2,11 240:15 knowledge 36:11 132:8 215:2 221:20 222:8,9 245:4 known 38:2 39:6 knows 86:21 143:3 korean 212:4 koushik 33:24 92:4 kudos 112:23 kwon 17:24	115:11 130:2,5 150:7,17 160:21 183:23 large 157:15 largely 122:20 larger 69:6 latched 225:6 late 8:17 54:9,9 latency 137:24 138:7,11,15,20 140:22 141:2,6 law 83:19,19 110:21,21 111:15,16 112:1 125:2,4 125:11 131:11 216:6 lawyer 112:22 lawyers 42:17 42:18,24,25 53:16 54:12,15 54:21 56:21 87:8 189:4 layout 98:22 learn 127:11,17 learned 57:1 leeway 101:4 101:23,25 102:18,19,21 102:25 left 9:16 10:1 202:5,5 legal 2:15 87:12 legitimate 25:19
k			
k 2:5 8:23,23 17:23 katie 5:14 6:8 162:5 194:4 keep 19:13 94:13 104:25 197:11 kept 42:20 key 167:11 kim 17:23 kind 21:17 34:1 71:7 120:7 121:17 122:1 163:24 204:22 219:10 224:23 kinds 132:1 167:23,24 knew 116:8 know 15:25 16:6,9 18:22 19:12 20:15,18 21:22 22:25 30:16 32:12 34:9 35:7,12,24 36:1,2 37:19 38:11 39:7 45:9			
		l	
		l 30:11 labeled 58:6 110:25 lack 154:12 language 102:3 102:13 105:3	

[len - looking]

Page 28

len 143:18	line 66:8,19	28:7,25 30:22	46:21,21 47:14
letter 3:22	111:2 245:6	31:10,25 32:4	50:17 53:14,21
57:13,17,18,19	lines 9:12 65:21	32:11 49:2	54:24 63:12
58:6 83:4,6	150:1 151:14	50:20 55:17	64:24 65:4
85:9,13,16 86:7	lisa 4:7 30:12	63:7,23 64:11	69:13,20 73:12
130:9 145:4,5	91:4	83:20 84:12,17	80:5,8,16 88:18
215:19	list 14:10,16,21	87:24 88:25	96:21 99:6
letters 18:21	15:16 16:2,9	93:19 97:5	103:19,24
letting 181:6	17:12,22 18:17	126:13 127:8	104:3,7 108:4
leung 4:7 30:9	19:9 34:18	127:14 133:15	110:8,10 111:5
30:12 32:13,19	35:12 37:19	144:6 145:3,10	112:12 114:13
91:1,5	40:1 42:15	216:7 217:7	114:14 115:1
level 100:8,17	50:15 57:21	236:20 237:11	115:15 132:4
226:19	67:19 78:18	238:5,7	132:13,13
levin 2:10	171:1,8 172:6	little 15:4 49:14	144:25 146:20
levinlaw.com	218:15 221:3	54:16 65:3 72:7	152:13 160:6
2:13	listed 74:12	86:8 91:17	160:11 163:19
liability 1:5	178:23 183:21	101:4,23 107:1	173:24 178:14
license 1:11	listening	116:10 131:6	184:23 187:12
244:15	108:24	174:17 190:12	187:19 192:2,4
life 35:15	lists 174:19	229:25	192:5,9,10
ligation 76:13	literature 62:20	live 14:5	199:11,21,22
151:11 152:17	66:2 211:9	llp 2:4,21	199:24 205:5
152:20	214:18 219:7	lock 152:24	224:5
likely 130:25	220:17 221:14	logical 222:12	looked 37:22
limit 114:17	223:24,25	long 46:12	39:25 101:1
limitations	225:10 235:13	56:18	103:12,23
148:13,16,25	236:11 237:12	longer 69:6	104:4 127:4
limited 46:14	237:17,24	75:22 103:16	163:20 165:11
69:16 78:19	238:25 240:16	longo 17:19	170:10 172:8,9
80:3,3,10,24	241:22	47:4,5 51:6,21	172:10 174:3
81:16 93:12	litigation 1:5	51:23 53:24	175:1 207:1
155:13,23	20:1,14,19	55:11	229:12
156:25	21:15 22:22	longo's 51:7	looking 33:1
linda 123:19	23:4 26:18 27:1	look 23:2 30:15	44:13,13 45:7
	27:7,14,17,25	32:15,23 44:2	48:17 63:13

[looking - mdl]

Page 29

64:25 65:6 70:12 90:4,7 92:16 94:17,24 98:7,25 104:12 106:22 110:11 111:3 113:24 114:1 123:24 143:2 146:22 151:3 164:5 165:17 169:14 174:16 176:22 176:23 177:18 191:22 192:5 193:2,6 196:6 199:7,16,18 242:17 looks 114:5 163:15 205:14 losing 102:23 lost 77:1 103:6 lot 22:1 73:13 119:5 122:19 122:19 low 160:15,16 223:10,11 229:12 lower 98:4,17 99:3,20,22 224:10 lucky 176:20 lunch 161:6 lung 158:7 224:21 235:23 236:1,6 lynch 146:12 148:12	lyons 2:5 7:4 15:19 16:14 58:3,6 113:9,11 176:3,8,11 m m 4:23 5:14 6:8 8:23 17:23 123:9 162:5 194:4 made 12:25 16:14,20 20:18 32:24 57:10 72:24 148:3 160:9 magnitude 157:14 158:9 224:4 226:10 mail 83:7 mailed 174:22 main 134:11 210:23 211:22 majority 25:24 26:1 make 9:5,24 12:20,21 15:10 43:24 44:1 46:19 58:10,12 65:5 85:25 87:1 90:14 106:25 107:4 115:5 118:11 120:12 147:23 148:3 151:15 154:5 155:6,6 171:22 193:7 198:17	220:13 222:7 227:7 238:22 makes 59:7 making 86:17 120:7 136:16 170:5 190:19 manhattan 2:23 manner 183:14 manuscript 36:12,14 113:15,18 march 1:13 244:18 mark 82:15 85:12 90:25 94:6 106:9 108:15 122:25 127:22 161:7 168:8 172:24 173:5 193:18 194:15 204:10 209:14,17 marked 69:23 70:19 82:20 85:18 91:5 95:13 106:13 108:13 123:9 128:6 142:14 162:5 168:19 173:8 190:13 194:5 204:19 209:20,24 markedly 151:18	marker 224:24 markers 158:2 market 2:16 marketing 1:4 marking 91:23 94:14,25 95:3 142:6 205:10 mas 1:2 material 10:20 14:20 66:16 171:24 218:23 materials 10:17 14:9,15 15:6,16 15:20,22 16:12 16:16 19:20 47:1 53:6 54:1 169:23 170:8 171:4,8 172:6 math 19:25 mathematical 117:18,19 mathematics 118:2 matter 1:10 120:18 130:23 244:10 matthew 52:5,7 52:17 maximum 21:17 mcgill 29:10,18 29:24 30:1 md 3:18 70:19 mdl 1:2 17:20 20:1 206:18
---	---	--	--

[meagher - minutes]

Page 30

meagher 2:21	media 214:24	67:14,24 70:18	michelle's
mean 20:9	medical 112:5	149:12,21	189:10
22:18 23:1 26:1	207:2 213:6	212:2 218:19	microphone
27:4 32:5 42:20	214:3	220:1,2 226:22	208:15
44:1 49:6 50:15	meeting 212:20	metals 55:17,19	microscopist
55:18 58:23	meetings 14:4	55:22 56:4	51:17,20
62:1 67:19 75:7	214:1	method 218:25	middle 116:12
75:23 100:8	member 37:17	methodological	147:14 173:25
102:1 105:25	237:1	218:8	174:18 176:17
115:19 116:9	memorized	methodologic...	mill 235:22
119:3 134:22	127:2	218:12	milled 236:3
137:17 140:6	memory 33:2	methods	millers 235:20
140:12 157:12	47:14 90:13	178:18 211:24	mind 12:23
157:17 162:23	103:18 104:8	metric 81:6	20:7 38:11
176:3 181:15	143:18 163:22	micha 5:10	51:15 116:10
219:4 220:22	165:15 216:19	141:25 142:5	130:5 169:6
221:24 225:22	229:4	142:13,22,24	175:6 199:25
meaning 16:17	mentally	143:4,8 144:14	200:2
59:21 151:23	158:22	michelle 2:5	mine 243:4
means 59:24	mention 44:22	7:1,10 12:13	mined 236:3
114:15 120:5	212:19	22:11 31:5,17	mineral 136:21
141:4 157:13	mentioned	31:18 45:2,12	137:10,20
244:23	27:10 39:13	47:24 49:18,25	mineralogist
meant 9:17	42:16 51:21	49:25 57:22	43:19
159:12	53:23 64:20	86:5 91:13	minerals 188:7
measure	129:19	94:16 96:17,18	miners 235:19
219:17	mentor 34:1	101:9,25 102:4	minh 4:18
measured	mercy 65:3	103:3 104:22	108:12
43:23	mesothelioma	107:10 111:21	minimum
measurement	235:24	169:24 176:19	21:17
43:20 164:14	message 114:21	177:18 182:1	minute 16:25
165:4	met 13:14,17	186:13 189:12	53:1 163:21
mechanism	13:19,20	191:2 206:10	197:17 237:6
233:6	meta 3:17 9:9	207:19,22	239:3
mechanisms	18:1 64:9,24	208:11 228:8	minutes 17:2
221:21 222:3	65:25 66:10,24	232:3 242:5	23:13,22 48:17

[minutes - nhs]

Page 31

51:21 74:3 139:6 146:21 169:14 187:21 192:6 198:4,6 198:19 201:12 204:1 206:9 miscellaneous 170:8 missing 169:16 misstates 43:6 48:12 55:6 64:12 144:8 201:9 mistaken 126:8 mixtures 5:16 168:9,15 models 173:23 moderate 224:4 224:14 modern 224:19 moment 14:7 23:20 109:4 123:3,12 145:17 161:18 161:20 204:25 monday 242:21 money 21:14 mono 71:7 monograph 3:23 56:17 58:7 85:17 212:12 212:15,20 month 103:15 months 35:20 36:12 56:14 88:12,14,16,21	88:21 112:22 montreal 29:10 29:19,21 30:1 33:10 moorman 97:3 97:10 moot 226:20 morning 10:11 10:12 207:24 motivations 131:15 mouth 102:24 mouthwash 176:25 177:7 180:10 move 20:23 26:21 78:11 89:11 108:3 112:11 139:14 142:3 204:9 241:9 moved 35:13 140:3,3 167:20 moving 19:13 45:9 109:22 mparfitt 2:7 mph 4:19 108:13 msc 1:9 3:4,18 4:14 8:23 70:19 106:13 243:7 multiple 52:11 52:17 82:9 234:14 myong 17:25	n n 2:1 3:1 4:1 5:1 6:1 30:11 168:20,22 naive 130:4 name 4:4 5:4 6:4 10:13 39:9 132:4 168:25 169:3 233:19 names 54:7 206:20,23 naming 194:23 national 17:7 73:23,24 127:6 133:22 natural 213:23 218:22 nature 197:3 198:12 217:10 nci 39:14,15 60:11,23 133:10,18,22 134:10 213:5 214:17,21,25 near 23:8 necessarily 15:21 104:6 191:20 necessary 205:20 need 31:16 46:21 50:2 52:2 52:24 77:19 102:19 122:4,5 128:19 131:10	178:14 183:15 201:21 212:13 239:24 242:20 needed 63:1 218:23 needs 238:20 neither 72:3 never 9:10 35:24,25 38:4 38:21,21,25 41:20 42:20 71:19,20 75:8 75:23 94:12,13 165:12 172:6 213:14,21 214:20,22 219:21 229:12 new 1:1,13 2:23 2:23 15:11 16:3 33:16 47:2,23 48:3 49:17 50:16 55:4 56:16 129:4 135:4 142:18 187:17 205:15 212:7,8 244:7 newcastle 70:25 73:16 newly 205:15 news 17:14 135:25 newsome 206:21 nhs 68:8,8,12 68:14 69:1,3,9 69:12,17 72:6,9
---	---	--	--

[nhs - objection's]

Page 32

72:19	notation 160:24	68:15 69:5	100:2 112:8
niehs 126:9	note 12:20,21	71:25 72:10,12	114:9 125:12
nine 23:9 56:14	159:19 160:2	72:15 125:23	125:19 126:15
noah 2:22	244:21	149:11,15,19	126:21 127:15
58:10,12 61:2	noted 184:10	154:25 161:11	130:11 132:19
69:21 85:19,22	notes 12:6	161:17 162:5	134:5 135:7
86:15 89:14	206:9	166:3 178:5	136:9 138:23
91:7,18 105:1,2	notice 6:13	184:5,11,16,20	139:4,19
109:8 112:18	114:16 209:20	184:24 185:8	140:11 141:18
112:21 113:1,7	notion 146:12	185:17 189:1	144:7,17
113:17 142:6	147:11	190:21,22	147:13 149:14
145:22 156:5,9	notions 148:4	193:18 194:5	157:9 159:23
156:15 169:18	november 9:7	194:11 195:2	160:4 161:1
173:1,24	11:13 47:5 52:1	202:15 222:19	163:17 170:16
194:16,17	null 9:16	o'brien's	171:12 177:11
204:21	192:22 205:22	165:23	178:24 179:4
noah.epstein	206:1	object 25:5	180:6,12 181:5
2:25	number 69:7	78:7 86:8	181:13,23
non 60:2,6	138:2 151:3	174:25	182:2,6 183:13
185:10 187:3	194:17 209:18	objection 13:10	184:1 185:12
188:16 190:8	209:25 216:3	23:17 24:10,23	196:15 200:15
191:9,18	numbers 109:9	25:15 26:7,11	200:23 201:8
195:10 196:21	119:14 135:10	26:19 28:1,8,14	203:19 204:4
197:25 199:3	135:13 182:8	34:12 38:5 40:7	207:15 227:22
199:15 200:8	201:25 203:14	40:19,25 41:15	228:16 229:17
203:17	203:22,25	43:5 48:12 49:4	231:20 232:1
nonfinancial	216:1 219:22	49:13 50:11,22	232:23 233:21
143:25	219:23	54:3 55:6,23	234:8,16,24
nonsignifican...	numeric 191:23	59:2,17 61:24	235:7 236:14
220:4	numerical	62:8 63:2,24	236:21 237:16
nope 38:6	191:20,24	64:12 68:1,9	237:21 238:10
normal 213:23	nurses 73:22,25	71:24 73:4 75:9	239:1,15
north 126:7	o	76:19 81:12,23	240:18 241:4
notarized 32:7	o'brien 5:14 6:8	83:24 84:13	objection's
notary 1:12	18:10,22 68:11	87:17 88:3	28:13
244:7 245:24		93:13 97:13	

[objective - opinions]

Page 33

objective 131:1 221:17	94:11 98:21 102:2 124:24	113:10,20 114:2 115:5	222:24 223:16 223:22 229:21
obliged 25:8	143:23 146:3	118:17 120:4	233:10 238:18
observe 218:9	150:19 154:14	122:22 124:4	239:25 241:15
observed 105:12,13 167:2	162:25 163:23 175:13 184:10 208:3 242:6	124:21 125:22 127:18 129:3 134:13 141:17	242:22 old 219:5 older 76:18
obstetricians 38:1,14	okay 8:10,18 10:3,6,16 11:11	142:9 144:13 145:12 149:3	once 214:1 oncology 39:5
obstructed 183:4	12:4,10 13:14 14:19 17:10	151:14 156:11 156:18 160:11	ones 12:16 15:5 18:6 42:23,23 50:16 67:20
obvious 141:4	18:5,18,25	164:11,22	104:4,5,6 171:24,25 198:22
obviously 15:22 103:2 148:21	20:13 21:25 22:20 28:22	165:16 166:7 166:12,22,24	ongoing 17:16 33:13
occasion 71:20 237:2	29:3,9,22 30:3 30:16 36:22	167:7,10,19 168:7 170:25	onset 141:1 open 41:18 174:23
occupational 4:6 91:3,24 235:23	44:23 48:19 52:24 53:2 55:11,15 58:2,5	172:17 174:6 174:12,14 175:13 176:21	opining 211:15 opinion 43:2,13 43:17,17,18 47:2 48:8 50:1 55:4,16,18,20 129:12 130:20 135:12 154:3 207:12 231:23 232:8 239:13 239:16
occurred 53:18 224:20	58:15 61:19 64:8 67:2,4	176:22 180:2 181:8,25 184:4	opinions 15:23 37:3 44:3,6,7 48:21 56:6 131:12 132:6 147:23 210:19 213:16,18
odds 116:11	80:15 82:22	184:23 185:2	
offer 56:10,19	83:11,12,16	186:24 187:16	
offered 57:10 81:20 137:9	85:4,14 86:11 87:3,20 88:23	187:18 189:18 190:1 191:3,4	
offering 43:2 43:17,18 55:16 55:20 207:12 232:8	89:11 91:21 92:8,10,16 93:17 94:11,25 95:2,19,20	192:14,14 193:11,16 194:17,20 196:12,19	
office 7:4,15	96:13,18 97:22	199:20 200:13	
oh 10:19 11:24 18:5 22:4 27:19 29:22 30:12 61:9 67:12 70:6 72:9 87:14 89:12 91:14	98:2,21 99:8 106:6 107:7 108:3,22 109:23 110:4,6 111:7,18,22,24 112:3,11,15	202:6,18 204:6 204:9 206:6,12 207:18 208:7 209:3,13 210:5 216:12 217:10 218:1 222:16	

[opinions - page]

Page 34

214:19 218:14 opposite 107:12 optimal 60:6 order 158:4 159:5 200:22 224:12 236:4 organization 37:10,15 134:1 134:4,11 organizations 36:23,24 37:8 37:12 213:6,15 214:4,11,21 215:1 orient 185:25 origin 54:17 original 65:1,2 177:25 224:18 originally 54:6 54:12 124:14 184:12 origins 47:7 ottawa 70:25 oules 21:3,4 89:22 outburst 207:25 outcome 164:16 165:6 outcomes 235:24 outreach 36:22 ovarian 3:16 4:7,10,10,16,21 5:6,9 6:7,11 9:11 17:8 18:1	27:14 30:5 32:25 33:6,16 36:24 37:8,20 39:2,16,23 40:2 40:6,17 41:13 58:21,24,25 59:11 60:1,5,13 60:24 61:22 62:17,21 63:1 70:17 91:4,24 93:3 94:22 95:5 95:5,10,11 97:5 104:16 105:15 108:11,17 113:22 114:3 123:7,16 127:24 128:5 134:17 135:4 136:1,5 137:1 137:25 138:21 139:16 140:8 141:14 142:12 142:21 149:23 150:6,16,23 151:10 152:6 153:7 155:2,12 155:23 156:24 157:22,25,25 158:3 159:5,21 160:14 165:25 166:18 170:15 173:22,25 174:20 176:17 177:10 178:2 179:10 188:4 190:23 192:20	194:4 195:2 197:24 204:13 204:17 205:21 207:10,14 210:21 211:1,6 211:10,17 212:17,17 215:10,13,13 217:22 218:11 222:5,20 223:10,12,23 224:9,10 225:13,17 231:24 232:22 232:25 233:6 236:8,12,18 237:3 238:4 241:23 ovaries 154:10 154:18 222:11 overall 159:4 219:3,11 overlap 114:22 115:8,17,20 116:4,5,6,19,20 116:23 117:16 118:23 119:3 119:10 120:3 122:19 183:22 183:25 185:11 185:22 188:15 193:1,9,13 195:11,13,14 196:22 200:12 204:7	overlapped 66:20,23 68:25 190:9 overlapping 187:11 overlaps 107:18 107:22 108:1 191:24 oversight 124:18 own 7:15 43:19 44:4 53:8,12 65:25 86:21 202:3 p p 2:1,1 4:12 5:10 95:12 142:13 p.a. 2:10 p.m. 243:7 p1 6:14 209:19 page 3:3,13 4:4 5:4 6:4 9:8,13 9:21 89:17,18 95:17 98:7 101:8,20 104:21,24 105:8,19 108:22,23 109:9 110:1,12 142:3 143:21 143:22 145:23 146:24 147:1 150:11 151:2,3 151:4 155:15
---	--	--	--

[page - parfitt]

Page 35

155:17 160:12	81:25 82:9	169:3,11,22	130:10 148:24
164:21 165:9	86:23,25 90:4	170:11,13	153:10 188:21
177:2 179:17	91:1,3 92:5,6	177:22 179:7	192:15,17
179:19 192:10	92:16,25 93:2	180:25 182:19	199:8,10
193:3 196:9	93:11 94:5,7,15	184:5 185:6,14	205:24 206:2
197:15,18	95:9,19 96:1,15	185:17 186:22	212:6,9 221:5
198:1,10,16	96:21 97:24	187:20,20	236:7
199:14 201:25	98:1,13 100:19	188:14,16,22	paragraph
202:14 203:8	100:25 101:2,7	190:7 191:13	105:13 110:24
209:7,10 210:1	103:12,24	192:12,12	111:1 156:12
210:2,6 218:5	104:7,9,11,14	194:2,8,12	156:14 160:23
223:2,2 225:24	106:23 107:14	195:3,8,9,11,25	165:1 193:4
230:14,22,22	107:18 108:6	196:14,20	paragraphs
245:6	108:10 109:1	197:23 198:2,3	127:3 147:5
pages 101:6	109:18 111:11	198:7,9,11,16	201:18
paid 19:25 20:7	112:13,14	198:16,24	paralegal
20:13,16 83:18	113:9 123:1,3,6	199:1 200:3,7,9	174:13
84:11,25 93:19	123:11,15	200:18,22	parameter 65:6
painfully	124:3,6 125:16	201:1,5,13,17	67:18 115:16
219:12	127:3,23 128:4	201:21 203:13	parameterizat...
pair 110:16,16	128:25 129:3,9	204:2,11,16	82:2
panel 212:14	129:19,20	205:10,12	parameters
236:24	130:7 131:5	212:7,8 220:9	62:12 164:1
papantonio	134:14 141:25	220:10,11	parfitt 2:5 3:6,8
2:10	142:11 143:3	229:4,7,13	7:1,1,13,18,22
paper 4:5,8,15	143:13 144:5	230:6 231:5,8,9	8:1,6,9,12,18
4:20 5:5,8,11	144:15,24	231:11 234:7	9:3 10:3,8 11:8
5:15 6:5,9 30:8	145:1,16	235:12,15	11:11,20,24
30:20,24 31:9	146:18,20	paper's 171:19	12:3,20 13:10
31:16,25 32:13	150:21 152:11	papers 32:3	13:14,17 14:12
32:19 35:5,18	153:11 162:2	35:2,8 63:18	15:2 16:11
35:18,25 36:8	163:15 165:23	66:21 80:9,22	17:17 18:3,9,17
63:9,21,22 64:9	166:3,4,6,16	81:9,15,20	18:19 19:2,6,10
64:20 65:17,21	167:14,15,22	104:2 107:22	19:15 20:4,22
66:13 67:9 68:7	167:23 168:8	108:1 111:25	20:25 21:4 22:6
68:7 74:3 80:8	168:14,25	126:24 127:1	22:9 23:17

[parfitt - past]

Page 36

24:10,16,23	106:22 107:8	186:5,10	116:16,17
25:4,15 26:7,11	108:5 111:19	187:15,17	126:5 131:3,4,5
26:19 27:2,21	112:8,24 113:7	190:11,17,19	139:7 209:5
28:1,8,14 30:24	114:9 123:2,12	191:3 194:10	212:24 214:18
31:12 34:12	123:23 124:1	195:21 196:2	215:1 216:23
36:17 38:5,7	125:12,19	196:15 197:2	participants
40:7,19,25	126:15,21	197:10 200:15	98:4,5 99:10
41:15 43:5	127:9,15 128:9	200:23 201:8	participate
44:24 45:4,18	130:11 132:19	202:19 203:19	56:16 236:23
45:21 46:1,7,15	134:5 135:7	204:4,25 205:3	participated
46:17 47:20,25	136:9 138:23	206:11 207:15	37:17
48:4,12 49:4,13	139:4,19	208:3,7,10,13	participating
49:22 50:3,11	140:11 141:18	208:19 209:13	86:25
50:22 51:22	142:3,25 144:7	209:16,22	participation
53:2 54:3 55:6	144:17 145:17	210:4 227:5,12	29:5
55:23 57:25	145:19 147:13	227:14,22	particles 54:11
59:2,17 60:18	149:14 150:8	228:5,16	79:14 154:9,18
61:9,24 62:8	150:12,25	229:17,22	159:1 222:10
63:2,24 64:4,12	152:7 153:17	230:11,15,21	particular 39:8
67:5 68:1,9,17	154:2 155:17	231:20 232:1,5	65:8 73:19 76:4
68:23 69:24	156:9 157:9	232:14,23	76:10 98:22,23
70:2,6 71:24	158:21 159:23	233:21,24	98:24 212:20
73:4 75:9,16	160:4 161:1,12	234:8,16,24	particularly
76:19,23 77:2	161:18,20	235:7 236:14	71:20 150:6,16
77:15 78:7	162:9,23 163:3	236:21 237:16	150:18,22
81:12,23 83:24	163:17 166:1,7	237:21 238:10	152:5 153:7,16
84:13 85:10,14	169:19,25	239:1,15	154:14,23
86:2,6,12,23	170:4,16 171:4	240:18 241:4,9	155:2 157:6
87:17 88:3 90:5	171:12 173:13	241:17,20	158:18,23,23
91:9,14 93:13	174:24 177:11	242:6,9,13,24	159:12,21
94:18 97:13	178:24 179:4	243:2,3	160:24 166:23
100:2,14 101:3	180:6,12,17,24	park 126:9	191:14 207:25
101:18 102:2	181:5,13,23	part 15:17	partly 141:6
103:9,22 104:1	182:6,13,20	16:19 23:11	past 21:8 87:24
104:20,23	183:1,13 184:1	25:16 34:14	118:6 172:12
105:4,9,19	185:12,23	88:5 114:20	

[patent - plaintiff's]

Page 37

patent 69:17 75:4,6,8,22,24 78:19 79:5 80:4 80:12 155:13 155:24 156:25 185:9,10,21,22 187:3,3 188:14 188:16,20 190:7,8 191:8,9 191:14,18,18 192:23 195:10 195:10 196:21 196:21 197:24 197:25 199:2,3 199:14,15 200:8,8 203:5,6 203:15,17 pathologists 135:18 pathway 231:24 233:7 patients 151:10 patricia 97:3 patrick 2:5 7:4 7:10,15 15:19 16:14 58:1 176:6,10,14,15 176:21 209:22 209:24 210:1 230:16,18,19 patterns 5:12 161:9,15 162:3 162:11,14 163:12 payment 111:14	payments 110:19 pdf 194:23 pdq 17:7 39:14 213:5,12 214:17,21,25 pearson 12:16 peer 235:13 236:11 pending 186:8 202:20,22 pennsylvania 2:17 pensacola 2:12 pension 24:6,8 24:22 25:12,23 26:4 29:25 people 8:1 73:17 79:4 120:17 135:5 219:5,6 225:1 230:7 percent 26:1,3 26:5 58:25 59:14 60:5 117:25 121:18 121:22 122:2 122:14 179:24 180:5 181:16 184:21 percentage 23:3,15 24:14 60:9 perfect 209:23 performed 224:1	perineal 3:15 33:8 34:5 35:10 58:24 59:15 61:23 70:16 81:17 93:5,12 162:10 170:14 178:2 197:23 period 69:6 135:23 137:24 138:7,11 140:23 141:2,6 216:23 217:7 217:11,13,15 periods 138:15 permission 9:4 9:5 person 96:7,10 111:24 112:3 125:8,15 132:3 133:1,19 personal 5:16 44:4 168:9,15 173:21 personally 62:22 persuade 43:25 persuaded 41:18 persuasive 212:2 226:6,6 pertaining 33:5 pertains 186:19 ph.d 243:7 ph.d. 1:9 3:4 8:23 29:13	phd 4:14,19 6:8 106:13 108:13 194:5 philadelphia 2:17 phone 237:11 238:24 240:16 phones 237:19 237:20 238:5,8 238:17 239:7 240:9 phung 4:19 108:4,8,13,18 111:10 physicians 135:18 pieces 133:21 140:13 pile 18:8 45:1 piles 63:16 place 38:23 111:4 175:11 places 203:9 plaintiff 2:3 7:3 144:6 plaintiff's 6:13 30:21 31:10 53:6,16 54:2,21 55:12 57:5 63:6 63:22 88:9,24 89:6 145:9 207:6 209:17 209:19,25 230:9,13 234:14,20,22 235:3
---	---	--	---

[plaintiffs - presence]

Page 38

plaintiffs 7:8 32:4 57:12 63:10 112:6 206:17 207:3 207:10 234:19 plan 233:4,8 planning 232:20 plausibility 210:21 211:3 211:17 plausible 115:20 play 138:14 played 136:25 please 10:8 31:19 49:19 58:10 74:14 77:25 78:11 95:16 105:2 145:22 153:19 154:2 205:1 plug 118:3 plyons 2:8 point 21:16 43:9 44:25 56:24 98:24 99:22,23,25 101:19 104:20 104:24 105:8 107:4 114:17 114:24 116:1 117:10,20 118:3,15,18 119:6,13 120:19 124:16	130:7 147:10 148:2 172:1 178:10 186:18 192:8 195:16 197:22 198:9 198:20 202:2 221:18,19,19 225:23 226:19 227:19,24 229:16 pointed 89:1 114:25 115:1 192:6 218:16 points 131:17 policy 32:2,6,7 pollution 158:6 population 62:12 121:3,4,5 164:2 populations 226:13 portion 26:15 position 43:4 237:14,25 positive 126:10 155:11,21 156:23 157:7 157:19 188:3 possibility 29:4 41:10 79:24 136:24 239:10 possible 79:13 116:21 117:8 122:9 152:18 168:2 214:12 214:13 235:24	241:13 possibly 140:3 potential 35:18 53:8 56:10 57:21 124:22 159:1 210:10 211:2 236:17 potentially 167:1,9 240:20 potentially's 167:11 powder 1:4 3:15 4:9 5:9 6:6 9:10 40:18 43:3 47:2 53:9 55:21 70:16 79:9 83:21 94:21 95:4,9 104:16 105:15 136:7 136:13,13,18 136:20 137:5 138:19 139:13 139:15,22 140:4,16,20 141:15 142:11 142:21 150:5 150:15 151:10 152:5,17 153:7 153:15 155:12 155:22 156:24 159:20 160:14 167:4 188:4 190:22 192:19 194:3,12 195:1 207:7,13 211:17 212:16	215:10,12,20 216:8 222:20 223:9,23 225:17 231:19 practice 37:11 practices 1:4 135:22 pre 6:13 209:20 preamble 99:15 99:17 precipitous 136:7 139:16 140:8 precipitously 136:2,6 precise 121:15 215:4 precision 120:21,21 predict 71:13 prefer 25:10 prejudiced 131:14 premise 240:7 preparations 43:24 prepare 13:5 13:15,18,21 216:15 prepared 11:19 preparing 103:20,25 preprint 162:18 163:19 presence 29:15 47:9
--	---	---	--

[present - published]

Page 39

present 60:7 210:10 221:2 222:6 presentation 163:25 presented 199:10 president 214:8 pretty 7:25 120:1 171:2,10 prevent 211:15 prevention 125:10 133:10 133:18 previous 11:5 79:3 132:15 167:2 previously 19:22 65:4 primary 212:21 principal 33:24 34:15 principle 71:8 print 175:9,10 printed 10:24 prior 13:5,9 15:17 47:22 133:14 152:19 239:16 241:6 priorities 34:14 35:3 priority 34:18 private 127:7 129:21 130:24 probability 121:18,22	122:14 probably 15:8 34:19,24 56:14 64:25 73:11 76:9 103:16 129:13 149:4,5 229:25 problem 7:22 7:23 79:1 108:7 108:8 109:17 128:14 161:21 221:1,8,9 problems 45:5 218:15 procedures 34:3 proceed 9:2 16:10 proceeding 206:18 process 14:1 228:19 proclaimed 137:9 produce 57:13 220:1,2,3 produced 12:14 15:17 49:1,7 50:9,19,25 57:23 83:21 140:13 216:7 product 5:16 165:20 168:9 168:15 173:21 products 1:4,5 3:16 47:6,7,17	48:10 49:12 50:10 53:19 54:11 55:1,2 56:4 70:17 83:21 136:22 137:10,21 140:6,19 174:19 177:6 216:8 231:17 professional 133:13 207:25 244:5 professor 29:18 29:20,23 program 49:11 50:10 132:17 programming 125:1 pronounce 10:13 proper 93:9 97:18 properly 74:4 proponent 131:8 proportional 173:23 proposed 37:3 188:6 proposition 220:18 prospective 5:19 168:11,17 prospectively 167:5	protection 209:4 proves 220:18 provide 24:17 57:12 84:20,22 provided 16:13 42:17,18 53:6 54:2,12,15,20 55:12 83:18 84:19 87:1 125:1,3 199:2 216:5 provides 82:1 187:2 211:2 providing 84:11 125:18 public 1:12 32:24 36:23 37:7,10,12 136:1 214:6,14 225:10 233:13 244:7 245:24 publication 6:13 168:5 177:25 209:20 227:19 228:13 publications 30:4 32:9 77:7 78:5,18,25 126:4 213:25 227:24 235:21 publish 29:13 33:15 34:8 published 18:2 30:13 32:18 34:10 35:7,9
--	--	---	---

[published - rate]

Page 40

95:7 113:14	q	177:12 180:22	215:17,21
124:6 149:12	qualified 100:7	181:1 183:15	216:1,10 227:9
149:16,20	qualifier	185:5 186:2,8,9	227:15 241:16
178:1 195:2	167:11	186:16,19	242:10
199:8 205:15	quality 70:21	187:15,17	quick 52:25
212:6 226:15	71:6,9 73:10	188:18 190:16	227:8 241:17
229:13 235:12	74:10 131:16	193:11 195:7	quickly 19:18
236:10 241:23	148:9 218:21	195:15 198:13	44:25
publishers 93:9	220:24	198:15 199:23	quite 66:6
publishes 212:8	quantitative	200:22 202:19	72:17 101:19
pull 15:7	6:10 204:12,16	202:22 203:1	129:1 132:18
113:11 173:4	quebec 235:20	203:11,21	132:20 158:1
pulled 86:16	236:3	205:25 215:5	218:13 235:1
109:10	question 14:14	217:23,24	quote 47:17
purpose 205:18	14:25 19:11	223:13 228:7	146:11 147:11
purposes 64:10	25:3,20 28:2	228:10 232:13	227:21 228:15
177:16 216:16	31:13 37:6	232:18 233:1	r
purview 213:20	39:12 46:20	235:1 238:19	r 2:1 244:1
put 9:17 37:2	50:7 60:10 66:2	239:22 240:5,7	245:1,1
42:16 61:6,10	68:22 69:2	241:25	rack 90:13
69:21 85:10	71:18 73:6 74:8	questioning	rafferty 2:10
86:7 89:13,14	74:9,13,16,17	103:2	raise 8:20 39:16
91:7,8,19 105:2	75:11,13,15,18	questionnaire	153:24
105:9 119:1,2	78:2 79:16,18	34:4 72:17	ran 122:16
131:12 142:15	79:19,21 80:1	questions 34:5	range 21:18
145:22 149:2	80:14 83:11	45:10,25 46:6	115:20 120:5
156:5 161:22	90:1,11 98:15	46:12,19 72:16	121:1,23 122:8
169:17,21	99:18,19	74:2,15 78:12	138:2,9 224:8
172:21 173:18	100:12 101:11	79:3 102:16	225:13
176:15,16	102:6,8 117:15	104:7 135:16	ranges 116:20
204:22 209:11	135:19 139:25	164:5 173:16	122:14,16,17
217:2 230:17	140:9 141:6,7	178:19 180:24	122:19
230:17	141:11,12,20	182:16,18	rarity 223:12
puts 194:16	146:9 147:14	207:19,20	rate 73:2 135:4
putting 85:20	158:12 165:18	208:22 209:1	
173:11 226:21		211:11 213:4,8	

[rates - recognizes]

Page 41

rates 134:17 136:6 137:1 138:21 139:16 141:15	72:18 77:18,19 79:17 83:14 96:25 97:8 98:12 110:13 111:6 124:7 137:17,19 140:14 143:12 143:15 157:2 162:21 163:8 165:2 169:7,10 170:3,19,20 171:2,10,15,16 172:7 186:11 186:24 188:11 196:13 197:6 197:15,17 198:4,8,11 200:2,3,18,21 201:4 203:12 204:1 210:12 228:13 230:6 230:21 231:7 242:14 245:2	real 44:25 227:8 realize 153:21 really 42:22 79:7 107:1 111:13 114:15 120:6 121:7 131:9 166:9,11 178:18 202:2 208:16 213:17 228:17 realtime 244:6 reason 57:3,3 70:5 91:13 107:25 109:8 135:21 184:15 reasonable 138:10 reasons 117:8 recall 6:10 13:12 21:11,11 30:23 31:4,8,23 32:1,22 33:1 48:7,15,15 51:10,12 52:19 63:20 65:9 69:15,16,18 72:20,24 76:9 79:19,20,21 88:20 89:10 92:21 93:17,23 93:25 94:1 97:17 100:24 103:13 104:8 104:10 125:25 126:25 129:18	129:22,24 132:14 142:1 148:21,23 149:1 164:4,5,7 164:9,10,16 165:5,11,19,22 166:25 167:1,6 169:7,10 191:16 198:24 199:1,4 203:21 204:12,16 205:20 206:3,5 208:20,25 215:4 228:17 229:2,7 230:5 237:13,24 238:25 239:4 239:11 240:9 240:10,17,25 241:5 recalled 164:14 165:4 recalls 31:16 received 22:16 97:4 recent 44:14 54:23 212:3 recently 35:13 51:18 56:11 103:17 163:20 171:2,10 208:23 recognize 68:4 recognizes 210:9
rather 93:11 113:14 157:5 157:16			
ratio 58:16,19 59:12 60:7 82:8 116:11 174:20 177:9 179:9,24 180:3 181:3,11 182:24 183:8 183:10 184:11 184:18 185:8 190:6 192:21 200:8 203:15			
ratios 65:11,16 81:9,21 176:24 178:22 187:3 198:6 201:7,13			
rausa 206:21			
raw 66:16			
reach 37:12 56:9	reader 199:25		
reached 37:1,7 38:25 39:15,21 174:10 213:11 213:15 234:14	reading 51:10 51:12 53:13 74:3 77:11,15 77:22 87:11 111:12,25 125:8,15 130:5 149:6 152:11 171:21 188:8		
reaching 48:21 154:10,18 213:5	reads 112:4,4		
read 16:18,19 18:3 38:21 40:21 53:20 56:2,7 61:14	ready 10:6 36:14 208:7 218:6		

[recollecting - remote]

Page 42

recollecting 126:10 217:4	56:3 126:5	74:16 79:6	163:13 164:16
recollection 14:6 21:7 44:16 44:19,21 92:17 104:19 107:17	referencing 216:3	87:12 97:4	165:6
record 16:25 17:3,5 18:4 23:22 28:13 52:2,25 76:23 82:12 96:4,21 96:23 101:22 111:19 124:1 127:19 128:19 161:5 175:10 202:9,11,12,14 206:8 208:17 237:6,7 239:24	referring 51:25 81:7 185:24 187:6,7,10 189:16 197:16 198:23 200:4 228:5	123:8,17 207:2 235:5 236:8	reliance 15:21 16:2,9,12 42:15 170:25 171:5
records 207:1,2	refers 20:20 227:20 228:10	relates 59:15 140:7 141:15	relied 48:8 177:15
red 11:14	reflect 101:22 111:20 124:2	relation 75:10	rely 214:16 216:16,18 218:24
redirect 232:4	reflected 65:17	relationship 79:8 100:20 104:15 106:4 210:20 211:16	relying 47:1,11 47:13 56:6
redline 11:18 11:22 42:5 124:8	reflects 80:24 81:1	relative 59:22 59:24 60:7 62:10 66:3,6,10 66:12 80:23 114:13 115:21 120:8,9,14 121:2,12,16,19 122:9,13 157:23,24 158:4,10 159:4 159:7 160:15 178:3,7 187:10 203:4 218:20 223:10 224:7 224:12,22,24 225:4,14 228:23	remember 10:1 26:16 27:10 42:5 50:12 53:17 56:24 63:18 64:21 67:7 74:15 88:17 99:14 124:12 131:24 159:3,3 166:20 166:20 167:17 170:9,22 202:25 204:3 211:11 212:4 213:7 215:21 215:23 216:9 217:23,24 223:13 226:4 229:4 241:25
redlined 42:11	refresh 33:2 92:17 104:19 163:22	relatively 212:8	remembering 54:7
reduced 151:18 154:7,9	refusing 178:21 179:2	release 17:14	remind 47:21
reevaluated 212:22	regard 97:5 101:7 135:18 208:22 210:19 215:17 216:13 241:22	relevant 32:17 48:23 79:22 143:24	remote 1:8 45:18 153:22 197:3
refer 47:16	regarding 53:8 211:9 221:20 225:20	reliability 5:13 161:9,16 162:4 162:12,15	
reference 9:14 160:24 214:22	registered 244:5		
referenced 44:10	regular 243:2		
references 44:17,20 53:14	reinforces 212:10		
	related 4:22 32:3 62:20		

[reorienting - result]

Page 43

reorienting 98:22	200:11 201:16 212:3 218:2,5	represented 216:12	researcher 213:19
repeat 57:15 98:15 149:17 193:11	222:18 225:16 227:3,25 228:21 232:12	reproduction 244:22	researchers 213:21 219:14
report 4:14 9:7 9:23 10:21 11:3 11:5,12,16 15:23 16:5 17:13,19,20 27:10 37:3 41:23 42:1,9,10 47:14,15,24 48:3,9 49:18 51:5,9,11,16,19 51:21,23 52:1 52:10 54:16 60:12 65:22,23 65:24 84:20,22 85:1 88:10 89:3 89:8 90:15 97:6 101:11,12 102:12,18,20 103:1 105:24 106:2,8,9,12,16 106:24 107:6 107:15 124:9 124:10 126:5 129:4,7,10,20 129:23 141:25 145:14,25 146:7,10 149:4 150:2,11 153:4 153:10 167:14 167:23 168:4,6 170:13 186:22	232:15 233:25 reported 5:13 113:21 161:10 161:16 162:4 162:15 163:13 184:13,19 185:20 188:14 188:16 190:7 191:14 195:11 197:1,23 198:21 201:13 203:14 214:24 reporter 1:11 8:19 9:1 18:12 94:9 202:6,10 242:19,22 243:1 244:5,6,6 244:25 reporting 165:19,24 166:17 167:25 reports 42:22 47:13 51:12,13 51:14 52:5,12 52:17 87:7 110:19 111:9 111:14 124:7 196:20 200:7 224:2 representation 78:10 215:9	reproductive 79:5 150:3,5,15 150:22 152:4 153:6,15 154:6 154:11,16,22 155:14,24 157:1 159:8,14 159:20 191:9 203:5 reputations 126:2 request 8:22 130:25 require 115:3 229:3 required 136:15 requires 220:20 226:25 research 29:13 33:19,20,22 37:13 38:23 53:7,12 60:13 60:25 126:8 129:16,21 134:12,12 137:17,18 143:16 152:23 214:3,12,13 222:2 233:20 234:1,5,6 235:17	resided 236:2 resituate 238:1 239:6 respect 25:22 134:9 165:12 180:22 respected 134:4 134:10 respond 74:14 responded 74:21 144:14 responding 130:9,25 responds 51:6 response 51:20 74:16,23 100:20 104:11 104:15 105:14 106:3,20 147:15 179:5 responsibility 214:5 responsible 211:4 rest 231:7 restate 238:18 restated 60:3,4 238:20 result 66:8,19 71:16 73:10 178:1 214:24

[resulting - robust]

Page 44

resulting 218:13	218:11 219:7	142:16 145:20	138:13,13
results 9:9	221:7 223:24	156:1,7 157:2,8	151:18 154:7,9
98:19 99:4	223:25 225:18	159:22 164:21	157:6 158:10
100:23 172:3	237:2	164:25 165:1	158:18 159:4,7
187:8,13	reviewed 16:1	169:12 172:14	160:15,15,16
188:19,20	16:4 48:25 49:9	176:23 179:14	160:25 170:13
191:7,17,21,24	50:8 51:5,16	183:22,25	178:3,7,22
192:7,8 195:17	52:4,18,19	184:13,16	184:11,18
195:20 197:16	65:10 80:8	186:5,22 187:4	185:8 187:3
198:16 199:9	175:2 235:13	194:21 195:4	190:6 191:14
199:14 200:24	236:11	195:22 201:23	194:4,13 195:1
205:21 213:17	reviewers 36:4	203:8,14	198:6,20 199:2
219:23 220:22	reviewing	208:10 210:14	201:6 203:3,4
220:25 221:10	50:12 100:24	211:13 216:14	207:9 218:20
226:12	171:23	218:4 227:5	223:10,11
retained 26:25	reviews 211:22	238:4,14	224:5,5,7,11,19
27:6,17,24 28:3	rgolomb 2:18	239:17	224:19,22,24
28:16,25 93:20	richard 2:16	rigorous 230:3	225:2,4,9,12,14
93:21	7:5,7,9	ring 38:10 52:8	226:17 236:6
retire 24:3	right 9:18 10:2	risk 4:7,9,16,21	risks 80:23
retired 24:2	10:3 15:7 16:24	6:7 37:20 38:24	115:21 121:2
retrospectively	20:2,12 23:1,9	40:1,5 58:16,19	122:9 132:1
167:4	27:16 48:15	59:12,13,22,24	150:6,16,23
revenue 23:7	57:6,7 58:2,17	60:2,7,8 61:22	152:6 153:7,16
24:12	61:8 68:2,8,8	62:10,14 65:11	154:15,23
review 3:17 5:6	76:21 80:1	65:16 66:3,7,10	155:2 157:23
13:4 15:21	82:11,15 85:8	66:13 81:9,20	157:24 158:4
51:19 62:19	87:9 89:19	82:1,8 91:4,25	159:21 187:11
70:18 127:23	91:14 94:12,14	94:21 95:4,10	211:4,5 224:7
128:4 171:18	100:20 106:17	104:17 105:15	224:12,24
171:20 177:14	106:20 108:25	108:10,16	228:23 235:19
191:19 211:9	109:16 111:3	114:7,13 120:8	236:2
211:14 212:11	112:18 113:24	120:9,14	rls 1:2
212:13 215:20	117:15 124:7	121:13,17,19	road 2:6
217:21 218:9	125:18 128:1	121:21 122:14	robust 49:2,10
	133:23 136:2	123:7,16 138:4	50:9

[role - seeing]

Page 45

role 20:16 28:6 room 7:11 8:5,7 rough 242:17 roughly 52:13 140:23 roughs 242:18 rpr 244:14 rrs 9:15 rule 53:20 ruzzo 143:18 running 94:12 163:1	120:2 122:12 129:22,24 137:4 139:8 157:5 166:25 191:10 240:12 says 16:7 45:7 83:1,17 87:5,23 97:1,3 110:13 110:17,19 111:14 124:25 150:14,21 151:9,15,24 152:2,11 154:11 155:3 179:14,23 192:18 210:7 230:25 scale 70:25 71:18 73:17 scales 71:8 scattered 10:21 scientific 48:22 111:25 131:8 213:6,13,25,25 214:18,22 215:3 scientifically 224:15 scientist 43:20 48:21 233:17 233:18 scientists 43:23 127:12 214:15 214:23 score 71:23	scream 176:25 screen 69:22 85:20 86:10,13 86:15,22 90:8 91:8,20 96:19 98:10,11 105:10 111:6 145:23 161:22 164:23 169:18 172:22 173:12 173:19 179:16 196:9 204:23 205:5 209:12 scribbles 12:8 12:14 script 74:22 scrolling 195:21,24 sean 3:18 70:18 search 230:1,2 searching 211:25 second 4:13 94:19 106:12 108:20 123:23 145:24 156:11 165:1 168:24 185:1 193:6 202:7 seconds 118:6 227:7 section 9:8 102:12 147:18 147:19 151:9 156:4 167:22 222:25 223:1	sections 201:19 secured 16:15 see 7:24 8:2 18:7 32:16,16 40:1 41:2 45:1 47:14 72:18 77:8,14 78:3,6 78:14,16,16 80:20 86:9 92:19 97:14 98:18 105:17 109:5 110:18 110:23 111:17 114:15 116:19 117:18 123:21 124:20,24 125:5 132:14 143:20,22 144:2,3 145:12 146:16,17 148:18 150:7 150:17,19 160:7,17,18,20 160:22 162:16 162:18 174:4 174:21 175:7 175:24 179:25 180:1 188:17 188:19,20 191:22 192:1 196:10,10 199:11,13 227:8 231:3,4 seeing 109:14 126:25 175:14 206:3
s			
s 2:1 3:11 4:3 5:3 6:3 8:23 245:1 s4 5:21 172:14 172:16,25 173:2,8,11,18 176:16 sales 1:4 sample 120:9 120:16 121:10 121:12,15 122:8 sanchez 52:5,7 52:17 savant 19:1,2 saw 54:15 132:4 177:21 saying 11:7 22:4,14 74:20 93:23 115:7,15 118:10,12,14 118:19 119:25			

[seen - siemiatycki]

Page 46

seen 15:12 36:16,17 41:20 43:8 61:16 76:6 140:15,17 169:13 205:12 205:24 206:2 212:3 214:20 229:8 self 5:13 130:23 161:10,16 162:4,12,15 163:13 seminary 2:6 send 12:25 senior 63:21 64:6 sense 20:7 21:13 65:5 122:18 151:15 154:5 sensitive 5:17 168:10,16 sent 15:19 16:15 42:23,24 95:21 169:23 215:19 sentence 9:14 47:23 48:3 77:13,19 78:6 78:14,16 79:2 88:6 111:12,13 147:11,17 149:10 151:22 151:23,24 152:2 154:10 165:1,9 167:12	193:2 196:23 223:5 231:9,12 231:15 sentences 151:21 201:19 separately 199:14 september 30:6 30:13,19 32:20 sequence 79:11 152:16 155:5 sequitur 75:11 series 208:25 213:7 216:9 serious 71:14 71:15 seriously 218:14 serve 127:7,13 served 28:6 services 57:11 83:18 84:11 216:6 serving 145:2 set 171:25 seven 81:20 several 23:4 25:14,25 26:6 27:18 81:19 174:19 199:8 201:18 208:21 215:16 224:1 228:22 sgo 39:6 213:5 213:11 214:17 234:15,21	235:4 share 60:20 176:4,5 210:2 235:9 shared 85:24 234:19,20 shaving 176:25 177:7 180:10 shift 137:20 shorten 44:24 shorthand 119:11 show 14:8 83:6 116:22 117:3 146:18 147:20 150:20 153:5 153:14 154:21 155:1 156:2 158:13 170:17 177:9 179:21 182:8 187:5 191:20 209:3 216:2 219:8 showed 178:3,6 179:22 showing 116:11 175:5 178:13 191:7 shown 14:14 157:24 210:8 210:17 225:3 231:1 shows 42:6 181:20,21 182:4 219:11 226:22	shriek 50:4 sic 162:21 side 93:21 97:11,20 112:18 125:16 126:13 siemiatycki 1:9 3:4,22 4:14 7:12,14 9:17 10:11 12:2,6 13:4 14:12 16:7 19:24 22:13 24:20 25:12 31:8,23 45:24 46:5,11,18,25 48:6,19,25 49:21 50:6 52:4 53:5 56:1,9 58:15 61:13 70:3 74:7,18 75:1,3 79:15 83:22 84:17 85:16 89:24 99:2 101:6,17 103:8,11 106:13 113:13 113:20 128:11 128:24 134:16 141:10 142:23 145:2 157:3 159:18 162:24 163:8 164:11 166:14 171:7 177:6 178:21 181:10 182:22 183:1,7 184:10
--	---	--	--

[siemiatycki - sort]

Page 47

185:7 186:15	significantly	slate 2:21	41:24 44:18
189:15 190:5	118:20 134:17	slightly 122:3	59:3 65:14
196:6 202:25	134:22 183:22	small 98:12	66:22 67:10
204:10 205:13	similar 27:13	119:14 120:16	69:10 70:1,6
205:16 206:15	66:17 137:23	120:17 155:11	71:3 72:22
208:20 210:5	simple 45:24	155:21 156:23	76:25 77:10,10
211:7 215:5	46:5,12 90:11	157:7,10,16,18	84:5 86:4 87:10
227:18 237:10	181:1 188:18	158:14 188:3	88:15 89:13
238:22 239:20	simpler 238:23	219:22,22	93:1 94:7,9
240:14 241:21	simplistic 71:11	smaller 157:24	95:2,21 97:2
243:6	simply 70:7	society 37:25	98:8,11,18
siemiatycki's	single 138:2	38:14,16 39:4	102:13 103:6
9:6 102:7	173:21 229:7	39:11 40:12,15	104:22,23
128:17 145:24	sister 5:18	40:24 215:7,9	109:19,21
sign 242:14	163:24 168:11	soft 107:11	110:10 112:20
signature	168:17 177:24	sogc 38:2,4	115:23 119:7,9
244:12 245:19	178:1,4,6,17	sold 83:21	119:20 123:25
significance	184:12,19,19	216:8	128:13,23
100:13 210:15	sitting 15:9	solicitation	130:16 134:25
210:18 218:25	23:14,20 26:16	131:10	137:11 139:5
219:16,17	32:12 48:6 68:3	solicited 130:7	146:3,3 149:15
220:8	72:20,23	solid 138:9	149:16 155:16
significant 98:6	141:12 190:6	somebody	156:2,17
99:25 100:1,7	199:4	59:10 229:1	161:13,19
104:17 116:25	six 81:20 88:20	someone's	162:25 163:2
117:4 118:9,13	190:18 206:16	28:18,19	166:10 169:2,8
118:22 177:10	sixth 80:18	somewhat	170:20 173:3
178:23 179:11	size 120:19	158:10	174:7 185:13
180:4,16 181:2	skadden 2:21	soon 194:16	186:12 195:12
181:11,15	skadden.com	sophisticated	197:6 198:25
183:9,11	2:24,25	219:13	205:17 227:23
184:20 219:3,8	skeptical 71:8	sophistication	234:25 237:15
219:24 220:4,6	skim 201:1	220:20	238:1 239:23
225:19,21,25	skimmed	sorry 11:6	sort 11:4 12:12
226:3,19	103:16	13:16 18:5,12	29:12 32:6
		21:10 33:14	34:17 35:15

[sort - stenographic]

Page 48

42:11 48:21	specification	started 10:7	states 1:1 9:14
53:21 57:17	80:18	34:19 35:1	39:5 121:5
62:9 103:14	specifications	36:10,13 117:7	134:9
113:24 116:10	81:21	153:19 225:6	stating 239:22
117:17 119:18	specifics 148:7	235:18	statistical
131:24 138:17	specify 231:5,9	starting 8:16	100:13 116:22
152:24 216:24	231:11,12,15	163:19 202:23	119:5 120:19
221:8	speculate 117:8	starts 89:21	122:4 125:1
sought 234:21	speculated	156:14 223:5	212:1 218:25
sound 20:2	139:12 140:1	state 1:12 7:8	219:16,17
168:25 169:3	speculating	20:14,16,21	220:8
sounds 20:11	138:22 139:3	21:1 77:5 78:3	statistically
61:15	speculation	148:13,14,24	98:6 99:24
source 24:21	139:9,18,20	155:21 160:12	100:1,6 114:22
sources 24:12	speeches	164:13 192:11	117:4 118:9,13
25:9 43:21	182:16	244:7 245:25	118:19,22
241:12	spend 48:16	stated 34:15	177:10 178:23
south 2:11	74:2	40:15 44:11	179:10 180:4
span 226:15,16	spoke 139:5	104:14 144:25	180:16 181:2
spanish 110:4	233:16	216:4 225:16	181:11,14
spans 223:1	spoken 89:5	240:8	183:9,11
speak 57:14	125:22	statement	184:20 219:2,8
89:6 213:11	sponsored	40:21 41:10,11	219:24 226:19
233:13,14	144:5	49:18 68:18	statisticians
specific 149:10	spot 109:16	83:13 85:5	219:13
198:9,10	stage 138:13,13	87:15 92:18	status 121:8
206:17 207:13	standalone	94:3 97:1 109:7	152:21 164:16
239:5 241:3	12:11	122:1 147:24	165:6 167:4
specifically	standing 182:1	155:6 164:17	stayed 217:16
69:18 132:4	stands 228:8	165:7,10	steam 163:1
195:17 197:19	starch 137:13	187:23 210:15	steering 7:3
209:6 210:6	137:13,21	210:19 216:17	stenographer
215:6 216:1,3	start 26:3 76:3	223:17,18	79:17
217:20 218:1	76:7 77:22	statements	stenographic
222:24	179:8 229:24	32:24 149:1	244:10
		180:19	

[steps - sure]

Page 49

steps 77:22	74:11 76:6 80:2	168:17 177:24	substantial
stick 141:11	80:6,9 82:4	178:1,4,6,17	26:15
stimulus 53:21	120:17 146:13	184:12,19	substituted
stop 49:19,22	146:15 147:7	187:8,14	9:22
stopped 84:10	147:12,24,25	191:17,21	subsumed
stotz 1:10 244:4	148:5,6,13,15	218:10 220:19	122:20 221:4,5
244:14	148:18,22,24	220:21,23	suggest 102:21
strain 174:17	149:8,9,13,21	221:2 236:1	115:9
strategy 45:13	149:22 151:25	studying	suggesting
street 2:11,16	152:3,13	235:19	130:1
strength 225:21	154:21,24	subject 207:18	suggests 156:22
226:1,10	155:1 156:22	subjective	188:2
strengths 147:6	156:22 167:3	117:17 131:15	suite 2:6,16
147:20 220:19	167:25 188:2,2	157:16 158:10	summarized
220:21	205:22 213:19	221:16	71:7
strictly 32:7	218:21 219:1,2	subjects 178:15	summary
122:2	219:7,16,19,22	219:23	190:23 222:20
strong 132:17	219:25 220:3	submission	summer 217:4
132:20 158:1	220:14,15	36:15	superior 69:4
224:14,16	221:3,5,15	submit 36:8	147:25 148:6
225:3 226:24	226:12,18	submitted 16:4	220:15
227:21 228:4	240:9,11 241:2	21:8 51:20	supplemental
228:15 229:2	241:3	53:15 57:13	5:21 17:20
229:14	study 5:18 33:9	82:16 83:3,4,8	84:20,21 173:1
strongly 225:14	33:16,23 34:2	88:11,13 89:4,8	173:8
stuck 172:13	34:21 35:9 68:4	90:15	support 40:16
stud 107:19	69:5 71:22,25	subpoenaed	41:5,12 55:4
student 236:1	72:6,12,15	235:4	125:1 215:12
students 29:12	73:23,24,25	subscribed	222:4
35:4	74:10,11 75:7	245:21	supported
studies 33:5	75:21 76:4	subsequent	225:15
61:21 65:2 66:1	78:22 92:7,9,11	225:8	supposed 14:2
66:20,23 67:19	143:15 147:3	subsets 178:16	14:24
68:25 71:6,10	148:8,8 150:24	substances	sure 7:19 11:6
71:12 72:8	151:1 163:24	137:22 236:25	11:14 15:15
73:13,15,19,22	165:11 168:11		16:15 17:12

[sure - talc]

Page 50

18:6 20:20,24 28:9 32:5 38:16 49:5 53:10 54:13 58:11,12 60:16 72:17 73:24 77:1 79:9 82:3 83:5 87:1 87:10 108:22 113:17 115:5 118:11 124:20 124:20 126:11 131:20,23 132:3 139:6 147:2 190:20 196:16 198:17 199:9 205:2 209:16 217:2 225:23 227:7 227:11 surgery 79:10 surgical 154:13 158:24 surprise 69:19 133:20 229:11 229:18,19 230:4 surprised 38:17 38:19 127:11 127:17 133:2 susan 143:17 144:4,9 suspect 130:22 suzanne 1:10 186:11 202:4,8 242:13 244:4 244:14	switch 192:17 208:14,15 switched 192:15 sworn 8:24 245:21 system 216:22 systematic 3:16 62:19 70:17 211:9,14 223:25 225:18 systems 150:3,5 150:15,22 152:4 153:6,16 154:6,12,17,22 159:20 t t 3:11 4:3 5:3 6:3 8:23 244:1 244:1 245:1,1 table 5:21 9:15 65:23,24 67:13 68:16 69:22 70:12,13,22 72:11 76:22 78:18 80:3,17 81:16 89:15,16 89:24 90:2,7,9 90:19,21 97:23 98:3,9,24 100:22 112:12 112:16 113:5 113:25 151:7 172:14,16,25 173:2,8,11,18	175:20 176:16 176:17 177:18 177:20 182:8,8 182:11 183:8 183:22 185:15 185:23 186:18 187:5,7,9 195:17,19 198:10 199:17 199:21 200:5 201:25 203:23 tables 106:17 106:19 107:15 108:1 196:11 201:7 take 12:24 23:12,21 53:1 95:25 101:14 123:13 124:11 134:13 146:21 163:21 168:23 184:6 197:17 198:3,5,19 201:12 210:23 218:13 236:7 242:24 taken 1:9,13 53:3 82:13 127:20 156:14 156:20 161:6 187:25 206:13 227:13 237:8 takes 34:21 talc 3:23 4:21 5:6,8,12 6:11 9:10 20:1,17,19	21:15 22:21 23:4,11 24:9,22 25:13,23 26:4 26:14,17 27:17 27:19 30:5,21 31:10,25 32:3,9 32:20,25 33:5,8 33:16 34:6 35:10 36:19,24 37:8,19 39:1,16 39:22 40:1,5,18 43:11,24,24 44:11,17,20,22 47:6,7,17 48:10 49:2,11 50:10 50:21 53:19 54:11,24,25 55:2,4,21 56:4 56:6,11,17 58:17,20,24 59:1,11,15 61:23 62:16 75:8,23 76:3,8 79:6,13,13 80:19 81:9,17 81:21 85:17 87:13,24 93:2,5 93:11,12 97:5 123:6,16 126:4 127:23 128:4 137:10,21,23 140:6 142:11 142:21 144:6 145:10 149:23 151:20 152:4 152:18,20
--	---	--	---

[talc - thank]

Page 51

154:9 157:21 157:25 159:1,5 161:8,15 162:3 162:10,14 163:14 164:1 165:24 166:17 170:14 177:2,2 177:3,8,8 178:2 180:10,11 181:21 182:5 182:24 183:11 183:20 188:7 190:22 197:23 204:12,17 205:21 210:7,8 210:10,16,17 210:21 211:1 212:17,19,21 212:25 213:2 217:21 218:11 222:5,19 224:9 225:13 228:6 228:11 230:25 231:1,13,14,24 232:21,25 233:5 235:5 236:24 237:3 238:4,17 241:23 242:8 talcum 1:4 3:15 70:16 83:21 136:7,13,13,18 136:20 137:5 138:19 139:13 139:15,22 140:4,16,19	141:15 150:5 150:15 152:5 153:6,15 159:20 207:6 207:13 211:17 212:16 215:10 215:12,20 216:8 223:23 225:17 talk 15:14 79:4 153:19 182:14 189:9 talked 14:3 28:18 205:4 talking 22:3 48:1 51:22 60:16 100:14 111:10 140:2 145:21 153:18 153:23 166:2,5 185:14,15,18 186:13 187:10 188:21,23 189:4,5,7 190:20 192:16 193:4 194:11 200:25 201:2 224:8 231:13 231:17 tally 42:20 220:20 tallying 219:1 taught 133:6 team 178:5 211:24 235:18	teams 226:14 technically 62:1 157:11 tell 14:2 23:14 46:22 56:21 63:14 64:6 78:17 96:19 104:13 118:8 178:22 179:2 190:5 196:19 196:24 200:6 201:12,25 213:16 218:6 telling 45:20 48:2 121:17 122:7 173:17 tells 121:14 temper 102:24 103:6 temporal 79:8 79:11 152:15 155:5 ten 33:22 63:17 80:2 tend 153:5 154:21 155:1 221:21 tenor 46:18 term 100:6 117:16 128:1 141:3 terminology 225:7 terms 60:9 157:10,14 200:7 224:14	terry 67:8,8,12 test 100:18 117:3,6,18,19 117:20 118:4,7 222:21 testified 8:25 20:25 43:1 87:9 97:11,18 175:1 177:13 181:24 191:12 195:6 233:12 237:10 237:23 238:13 testify 232:20 233:4,9 testifying 93:17 238:16 testimony 43:6 48:13 55:7 84:3 84:6 100:16 107:24 110:20 111:15 125:2,3 125:18 172:5 201:9 206:16 239:17 245:2 testing 49:2,11 50:9,21 51:7 tests 116:22 text 86:20 thank 8:2 9:1 10:4,8 21:4 46:23 53:2 55:15 61:19 76:1 80:14 90:24 95:2 96:22 97:22 99:8,16 100:5
---	--	---	---

[thank - together]

Page 52

100:10 105:4	56:23 57:18	186:6,17,19	81:2,6,10
107:8 111:21	65:24 66:9 67:3	thoughts 238:2	190:18 234:15
113:10 122:22	67:6 72:10,13	thousand 23:16	timing 51:9
122:24 129:2	74:9,12,25	201:18	79:22
141:23 149:25	75:16 79:4	thousands	tisi 2:11 7:2
161:4 169:20	84:14 90:6	50:20 51:1	13:15,18 95:18
176:18 183:19	94:10 109:11	three 16:13	95:23 96:2,5,8
184:7 185:3	117:7 120:25	20:10 36:2	96:11,14,18,22
206:11 208:1,3	121:24 122:7	80:17 87:6,24	108:20,24
208:6 209:9,23	122:22 124:19	88:4 104:4	109:4 162:7,11
210:3 227:12	124:24 126:7	112:22 170:5	162:16 175:6
227:14 230:19	128:1 131:23	201:17 206:8	175:11,14,18
242:14,22,25	136:4 137:8,19	threefold 111:8	175:24 184:25
thanks 156:9	138:2 139:14	time 13:20	185:3 188:22
190:2	140:6,12	21:11 23:21	189:6,12,16,20
theirs 66:9	147:14,17	24:1 27:1,1	189:23 190:1
theme 79:20	151:3,22	33:25 35:17	title 164:6
theories 131:9	163:10 167:20	42:20 45:17,23	titled 173:12
theorizing	169:14 171:16	46:14 71:13	titus 123:19
115:3	171:17 177:21	75:4,6,21,23	tobacco 224:21
thing 38:18	188:21 190:11	78:15 83:9 84:8	today 10:18
130:18 157:17	192:5 203:2	84:9 88:6 89:8	13:6 14:20
179:12 218:22	205:14 207:24	95:25 101:1	15:10 23:15
225:5 226:20	216:20 217:1	103:12 107:21	25:21 26:16
things 79:8	224:3 227:9	123:13 129:15	31:19 32:12
114:12 191:25	228:7 235:16	135:23 136:12	42:16 48:7
213:22 216:24	239:2,9 240:6	140:18 148:21	52:22 53:23
217:5	240:19 241:12	197:3,5 200:18	72:21,23 84:3,6
think 10:25	thinking 133:1	202:4,5 207:20	103:5 110:16
12:14 13:23	133:20	208:2 211:7	141:13 149:24
15:8,24 17:11	third 17:20	216:24 217:8	199:5 206:16
17:14 19:18	78:15 91:25	225:2 227:15	208:2 237:25
20:11 22:13	111:1 221:1	230:17 240:13	together 12:19
23:9 26:21 27:9	thorough 230:3	times 60:2	140:7 156:15
27:9 29:8 33:3	thought 56:17	64:18 65:13,18	156:21 187:25
35:8 44:15 54:5	72:5 154:3	67:25 80:25	219:25 226:21

[told - under]

Page 53

told 56:23 68:3 107:5	transmission 215:2	162:7 184:25 185:25 189:7	115:15,21 116:3,13,19
took 23:21 130:19 191:21	transport 221:20 222:3	189:20,20,23 201:11 238:1	117:5,22,23,24 118:5 119:5,13
tool 71:11,11	transported 222:11	239:5	120:2 122:17
top 38:10 69:13 88:19 160:12 179:17,19 223:2	trend 219:11	tubal 76:13 151:11 152:16 152:19	122:19 148:17 148:22,23 159:16 203:22 204:6 229:15 229:16
topic 44:14 53:18,18 65:25 138:25 152:24 172:11 211:22 221:8 241:4,23	trial 206:18 232:21 233:4	tubes 75:4,6,8 75:22,24 77:6 78:5,19,24 79:5 80:4,12 151:18 185:9,10,21,22 192:23	type 148:7 types 9:11 147:21 typically 35:4 64:24 233:13
topics 172:11 213:20 214:12	triggered 160:8	tumors 17:8 138:9	u
total 20:15,19 21:15 22:5,21 23:7,11 51:3 121:3,4	trouble 54:7	tung 4:18 108:12	u 30:11 u.s. 5:18 43:22 168:11,17
touch 38:21	true 115:21 120:8 121:1,12 121:16,18,21 122:9,13,16 136:3 148:1 149:19 167:9 180:9 217:18 244:9 245:3	turn 68:16 76:22 91:16 95:16 97:23 112:17 145:13 172:14 177:1 202:14 205:17 206:10 207:21 209:7,10 218:4 222:25	uh 17:10 42:3 89:21 119:24 146:23 147:4,8 151:6,8 167:16 196:25 199:16 202:17
toward 140:4	truths 148:5	turned 59:12	umbrella 148:10
towns 236:2	try 69:14 74:14 107:22 141:10 195:18 198:12 200:19	two 13:5,9,24 14:4 17:1 21:23 51:24 64:18 65:13,18 66:14 66:21 67:25 77:22 80:17,25 81:2,6,10 114:24 115:7	unable 152:15 155:4
track 94:13	trying 24:13 48:14 65:4 69:2 75:17 78:1 79:21 90:12 115:17 117:10 120:12 142:25 147:15 148:2 152:7 153:9,12 158:13,19		unaware 133:16 144:10 145:11
tract 4:23 79:6 123:8,17			uncited 48:9
tracts 155:14 155:24 157:1 159:8,14 191:9 203:5			under 36:6 87:12 99:20
transcript 6:18 244:9,22 245:3			
translates 160:16 223:11			
translocation 222:3			

[under - value]

Page 54

148:9 244:23 underarm 177:2,8 180:10 underlying 115:21 120:8 121:1,12,16,18 121:21 122:9 160:13 188:5 223:6,8 understand 11:7 24:14,18 33:14 47:25 59:8,9 75:13,18 79:11,12 90:12 95:23 96:11 100:16 115:6 118:11 119:12 145:7 153:9,12 158:12 175:4 177:17 178:15 180:21 181:8 181:25 198:14 198:18 201:11 201:24 208:5 216:22 235:1 238:16 239:21 239:22 understanding 35:11 73:21 79:23 217:6 understood 109:2,3 undertake 53:7 undertaken 53:11	unedited 91:16 unfair 78:9 united 1:1 39:5 121:5 134:9 units 81:5 university 24:2 29:10,14,19,21 29:24 30:1 35:14 unreliable 221:16 unsong 218:20 unstable 119:13 updated 16:2 212:5 upper 114:16 ups 221:6 usage 140:16 207:6 use 3:15 4:9,21 5:12,13,15 6:6 36:24 37:8,20 58:17,20 59:1 61:23 64:19 65:7,13,18 67:17,25 68:14 69:3 70:16 71:20 80:24 81:2,9,17 82:8 94:21 95:4,9 104:16 105:15 117:16 119:10 123:6,16 130:4 136:8,13,18 138:19 139:22	141:3,16 151:10,20 152:17,21 155:12,22 156:24 157:18 158:9,14 160:14 161:8,9 161:15,16 162:3,3,10,14 162:14 163:12 163:14 164:1 164:14 165:3 165:12,12,20 165:24 166:17 168:8,14 170:14 173:21 178:2 183:21 183:23 188:4 192:19 194:3 194:12 195:1 197:23 207:13 210:25 219:9 223:9 230:7 used 58:23 62:2 65:1,12,16 66:1 66:3,7 67:18,21 68:7,8,11,12,14 68:24 69:1,4 71:2,4,19 72:6 72:8,11,12 75:8 75:23 79:9 80:23 99:15 150:3,5,15 152:5,19 153:6 153:14 158:15 159:20 183:23	219:5,6 229:8 useful 56:18 176:19 user 59:11,25 60:2 users 60:6 66:11 uses 17:16 210:10 229:14 using 71:10 76:3,7 92:6 173:22 218:25 226:4 229:2 usually 7:20 76:18 81:25 107:12 uteri 151:16 uterine 173:22 v v 2:11 vacation 105:1 vaginal 177:2,8 180:11 181:21 182:5 183:10 183:20 vaguely 169:5 valid 146:14 147:12 180:19 validity 73:10 131:16 132:6 149:7 220:15 220:24 value 9:16 122:16
--	---	--	--

[variability - winded]

Page 55

variability 116:24 117:22	volume 171:24	79:25 119:1,2,4	went 74:21
variable 82:3	volunteer 56:16	120:23 126:16	77:2 187:20
variables 64:22	w	129:13 130:8	202:20,21
various 47:7	wait 68:17	130:13 152:14	wentzensen
53:13 74:11	94:23,23 95:19	167:21 172:13	125:23 145:15
120:22 131:25	108:20 229:22	174:4,5 213:13	145:19 149:11
132:2 163:25	229:22 232:14	213:24 219:20	149:20 150:21
venture 177:20	waiting 12:15	225:8 230:3	150:24 151:1
verbal 115:14	105:7 186:1	232:21,24,25	152:11 153:13
verifications	want 7:24 8:2	233:2,11	154:25 155:7
216:25	19:13 61:6,9,10	ways 66:18	156:6 160:12
verifying 67:10	61:12 77:17	138:15	162:21 184:5
version 11:3,5	85:10 86:14	we've 185:18	184:24 185:17
42:12 90:5	101:14 108:21	192:13,16	186:22 187:14
113:12,14	108:22,23	weak 160:15	188:24,25
146:24 163:19	109:6 110:1	223:10,19	190:20,22
versions 109:21	113:12 119:17	224:14,17	192:3 203:13
versus 99:10	123:13 140:24	weaknesses	222:19
147:7 167:4	141:5,7 160:19	147:6,21	west 2:23 8:14
185:9 190:8	170:17 174:23	220:19,21	8:15
197:25 199:2	175:9,9 176:3,5	web 109:10	when's 101:1
200:8 231:13	176:21 182:13	website 37:22	white 98:5,17
videoconfere...	182:19 188:8	40:1,9	99:3,12,21,25
2:4,10,15,21	190:3 195:16	websites 214:25	105:16
view 130:7	195:16 197:6	wednesday	who've 206:17
131:15,17	197:14,18	1:13	wide 5:18
views 32:18	198:17 199:21	week 64:18	119:21,25
virginia 2:6	199:23 207:21	65:13,18 67:25	120:1 168:11
visible 179:20	208:1 240:14	80:25 81:2,6,11	168:17
vitonis 123:19	242:15,16	weeks 13:23	widely 140:22
124:25 125:17	wanted 10:23	weight 40:15	width 120:24
vocabulary	204:10	41:12	william 47:5
137:12	watch 102:3	weighted 73:17	123:19
voice 107:11	way 9:23 37:18	weird 110:3	win 101:15
153:25	60:6,8 73:20	welch 123:19	winded 46:12

[wish - work]

Page 56

wish 9:24	136:10 138:24	245:19	191:8,15,18
222:13	139:5,20	witnesses	192:22 195:10
witness 8:21	140:12 141:19	126:13 189:5	195:10 196:21
13:11 14:17	143:5 144:10	woman 58:23	197:25,25
17:6,18 18:5	144:18 145:18	59:25 74:18	199:2,3,15
19:1,17 21:10	146:6 147:16	75:3,5,20 92:4	200:8 203:5,5
23:19 25:8,16	149:15 150:24	203:15	203:17 207:13
26:8,12,23 27:3	151:2 152:10	woman's 59:14	226:14 236:2
27:22 28:9 31:1	154:1,4 155:18	women 4:11,17	women's 61:21
34:13 36:19	157:10 158:22	27:14 69:17	143:16 152:20
38:6,8 40:8,20	160:6 161:3	76:3,7,13 77:6	210:25
41:2,16 43:7	163:18 168:20	78:4,19,23 79:9	wondering
46:23 48:14	169:16 170:9	80:3,10 92:14	237:25
49:5 50:12,24	170:19 171:13	95:5,11 98:3,16	woolen 3:18
54:5 55:8 56:2	177:19 178:25	98:17,20 99:3,3	58:16,19 59:12
59:3,18 61:16	180:7,13,18	99:9,12,20,21	63:6,9,21,22
62:1,9 63:3,25	181:14 182:7	99:24 100:1	64:9,17 65:11
64:5,14 67:6	183:17 184:2	105:16,16	65:17,21 66:4
68:2,10,19,24	185:13 186:1	108:11,17	66:13 67:18
70:9,21 71:25	187:16,18	115:22,23,24	68:7 69:9,11,12
73:5 75:10,17	188:25 191:6	115:24 116:11	69:22 70:19
76:20,25 77:17	194:9 196:16	120:10,15	71:22 76:24
78:8 81:13,24	197:14 200:16	121:6,19	78:21 80:24
83:25 84:14	200:24 202:16	122:13 136:18	82:7
87:18 88:4	202:18 203:20	140:2 150:2,4	woolen's 73:2
91:11 93:14	205:7 207:16	150:14,21	word 99:15
94:16 97:14	208:6 227:23	151:16 152:3	124:11 158:8
100:3 105:7,21	228:9,17	153:5,14 154:5	158:14,16
107:7 111:22	229:18,24	154:21 155:13	167:12 226:5
112:6,9 114:10	231:21 232:16	155:23 156:25	229:2,14 240:6
123:24 125:13	232:24 233:23	158:24 159:8,9	words 39:9
125:20 126:16	234:1,11,17,25	159:13,16,19	92:13 137:12
126:22 127:16	236:22 237:15	163:14 185:9,9	157:18 201:18
128:8 130:12	237:17 238:11	185:20,21	229:8
132:20 133:14	239:2 240:19	187:3,4 188:15	work 29:9,11
134:7 135:9	242:3 243:5	188:16 190:7,8	97:4 126:6,7

[work - zooming]

Page 57

127:12 217:11 217:15 workers 235:22 working 33:4 works 213:14 216:23 worries 163:3,4 163:4 worry 172:22 write 33:8 171:18 writing 36:12 129:25 written 10:21 32:7,19 47:4 107:20 wrong 110:1 217:5 wrote 83:14 84:7,8,9 129:10 191:13 216:24	94:18 97:25 98:10,11 109:14 110:5 112:19 115:13 116:9 123:22 130:3 133:21 137:14 147:16 147:16 154:1 155:18 158:20 163:1 164:24 172:23 173:3 175:18 194:15 196:8 203:22 230:15,24 year 36:15 56:14 60:15 61:1,2 120:11 172:12 226:15 226:16 years 20:10 23:5,9 25:14,25 26:6 27:18 33:22 34:24 43:9 50:1 52:16 65:21 66:5 73:18 87:6,24 88:4 134:18 136:2,5 138:10 138:21 140:23 140:24 184:16 199:9 217:15 yesterday 13:19 14:5 york 2:23,23	z zoom 13:22 14:4 86:19,21 156:17 163:6 175:17,21 176:4 zooming 184:8
x		
x 3:1,11 4:1,3 5:1,3 6:1,3 xeroxed 87:2		
y		
y 8:23 yeah 8:6 14:1,7 19:10,15,23 20:9 30:12,12 30:18 31:1 54:22 55:14 57:18 58:3,8 70:9,22 77:10 85:4 87:14 90:4		

Federal Rules of Civil Procedure

Rule 30

(e) Review By the Witness; Changes.

(1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:

(A) to review the transcript or recording; and

(B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.

(2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY. THE ABOVE RULES ARE CURRENT AS OF APRIL 1, 2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS

COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted

fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.